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General introduction and outline of the thesis
A new era has commenced for the disease group referred to as thrombotic microangiopa-
thy (TMA). TMAs are associated with significant morbidity and mortality, including end 
stage renal disease. Early recognition is important to allow rapid initiation of therapy. 
This holds in particular for a rare but severe form of TMA, the atypical hemolytic uremic 
syndrome (atypical HUS; aHUS). The elucidation of the role of complement in aHUS 
and the introduction of anti-complement therapy has greatly improved the outcome 
of aHUS. However, this particular therapy is accompanied with a high burden in costs. 
Optimizing differential diagnosis and treatment of the TMAs poses many challenges, 
and controversies remain.
Thrombotic microangiopathy
TMA is a heterogeneous group of disorders, characterized by vascular occlusion of cap-
illaries due to thrombus formation, leading to thrombocytopenia, mechanical hemolytic 
anemia (low hemoglobin level together with high lactate dehydrogenase, schistocytes 
and undetectable haptoglobin) and ischemia of end organs.1 Due to the immense network 
of capillaries intertwining the kidney, the kidneys are highly susceptible for the conse-
quences of endothelial damage and vascular occlusion as result of the TMA.2 Despite the 
fact that acute renal failure due to TMA can be often found, TMA is not solely restricted 
to the kidneys and other organs such as central nervous system are also often affected. 
The term TMA is a pathological description based on various characteristics found in 
a renal biopsy: fibrin and platelets rich thrombi in arterioles and capillaries, thickening 
and inflammation of the vascular wall, swelling and detachment of endothelial cells, 
reduplication of the capillary wall and subendothelial widening.2 
In recent years advances have been made in unraveling this heterogeneous group 
of TMA. Yet, discrimination between the different causes of TMA remains challenging. 
Roughly, TMA can be divided into four subcategories, of which thrombotic thrombocyto-
penic purpura (TTP) and shiga toxin producing Escherichia coli (STEC) HUS are the most 
prevalent conditions (Figure 1.1).
Yet, clear differences can be noted between TTP and HUS. TTP is, besides the clas-
sical features of hemolytic anemia and thrombocytopenia, characterized by primarily 
neurological involvement instead of acute kidney injury. TTP originates from a defective 
cleavage of ultralarge von Willebrand factor multimers by ADAMTS13.2,3 This defective 
cleavage can either result from pathogenic mutations in the ADAMTS13 gene or via 
acquired auto-antibodies directed against ADAMTS13. Due to this impaired cleavage, 
microvascular thrombi arise, mainly consistent of von Willebrand factor and aggregated 
(unactivated) platelets. Treatment comprises plasmatherapy in combination with immu-
nosuppressive drugs in case of auto-antibodies against ADAMTS13. 
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This in contrast to STEC-HUS and aHUS, in which the cascade leading to TMA com-
mences through endothelial injury, leading to platelet activation and fibrin deposition. 
Hence, kidney injury characterized by fibrin-rich thrombi is the predominant manifes-
tation. The scope of this thesis comprises both STEC-HUS as aHUS and these diseases 
are extensively discussed below. Besides these relatively frequent encountered forms of 
TMA, TMA also occurs secondary to a broad range of systemic disorders such as malig-
nant hypertension, pregnancy, malignancy, infections (e.g. S.pneumoniae associated HUS), 
inherited disorders (e.g. Cobalamin C deficiency HUS) or intoxication. The mainstay of 
treatment is to treat the underlying disease causing TMA.4,5
Scope of this thesis
The diagnosis and treatment of STEC-HUS and aHUS are the main scope of this thesis. 
The most prevalent form of HUS is STEC-HUS, seen in over 90% of pediatric patients who 
present with HUS.6 Only a small proportion (<10%) of patients presenting with HUS has 
aHUS. Yet, increasing awareness for aHUS has been raised over the last decade. Defining 
the role of complement and especially complement dysregulation as the cause of aHUS, 
can be appointed as a watershed moment.7 By unraveling the pathophysiology of aHUS, 
new complement targeted therapies are emerging, ultimately leading to the golden age 
for complement therapeutics, pursuing the success of the first complement inhibitor: 
eculizumab.8,9 The clinical presentation of STEC-HUS and aHUS shows a high degree of 
resemblance. Moreover, since aHUS is a diagnosis per exclusionem but treatment comprises 
the highly expensive orphan drug eculizumab, establishing STEC infections, as well as 
other causes of TMA, with high accuracy is indispensible.10 As treatment of STEC-HUS is 
still supportive, these divergent treatment options underline the need for differentiation. 
The thesis is divided into two parts, both new aspects of pathophysiology and diag-
nosis of STEC-HUS as well as treatment of aHUS will be discussed within this thesis. 
In Part I of this thesis we focus on the clinical conundrum of differentiating between 
STEC-HUS and other forms of TMA like aHUS. Although STEC-HUS is one of the most 
common causes of acute kidney injury in children, the exact pathogenesis leading to 
TMA and the high diversity in clinical severity is still only partially understood. Besides 
endothelial injury caused by among others Shiga toxins derived from STEC, other fac-
tors could contribute or enhance the process leading to TMA. Secondly, the current gold 
standard to detect STEC infection consists of fecal diagnostics. However, sensitivity of 
fecal diagnostics is limited due to the natural course of the disease. The aim of this part of 
the thesis is to further elucidate pathophysiology and improve diagnostics of STEC-HUS.
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In Part II we focus on strategies to personalize treatment in aHUS patients. After 
the introduction of eculizumab in 2011, a worldwide debate arose regarding the optimal 
treatment dose and duration. Initial guidelines suggested lifelong treatment with a fixed 
dose for all patients. However, there is no evidence to support this strategy, raising the 
question if one could taper or even discontinue eculizumab therapy in aHUS patients. 
Furthermore, little is known regarding the pharmacokinetic and pharmacodynamic prop-
erties of eculizumab, indicating a gap in the knowledge to optimize eculizumab treatment 
in patients with aHUS. The aim of this part of the thesis is to study the ability to taper 
and withdraw eculizumab therapy in aHUS patients. Furthermore, pharmacological data 
are gathered to individualize treatment, ultimately achieving tools for tailored patient 
care and hereby personalize treatment in patients with aHUS.
14   |   Chapter 1
Figure 1.1 Differential diagnosis of thrombotic microangiopathy
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Figure 1.1 A heterogeneous group of diseases can lead to thrombotic microangiopathy (TMA). Thrombotic trom-
bocytopenic purpura (TTP) and Shiga toxin producing Escherichia coli (STEC) hemolytic uremic syndrome 
(STEC-HUS) are the most prevalent conditions associated with TMA. It is highly important to differentiate between 
different causes of TMA to start the appropriate treatment. ADAMTS13; a disintegrin and metalloproteinase with 
thrombospondin type 1 motif member 13, aHUS; atypical hemolytic uremic syndrome, CFH; complement factor H, 
STEC; Shiga toxin producing E.Coli, Stx; shiga toxin
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Shiga toxin producing E. coli-HUS (STEC-HUS)
Epidemiology
Transmission of STEC occurs via a wide variety of contaminated food (among others 
undercooked beef and raw products), contaminated water and directly via per-
son-to-person transmission. In particular, cattle is a well known STEC resevoir. STEC is a 
non-invasive pathogen. Gastro-intestinal infections caused by STEC are usually sporadic 
cases, although large outbreaks have been reported, with the German outbreak in 2011 
as most noted example.11,12 Overall, the incidence is about 0.6-0.8/100,000 in children 
and adolescents.5,6 In the Netherlands, this accounts for approximately 20 new cases of 
STEC-HUS annually.13 There are many STEC serotypes known to cause HUS. Although 
the distribution of STEC serotypes causing HUS has changed considerably, O157 remains 
the most prevalent serotype and accounts for 50% of the STEC-HUS cases. Common non-
O157 serotypes are: O26, O103, O111 and O145.14 
Clinical presentation
In all children presenting with HUS, over 90% can be related to STEC infection. Typically, 
young children (boys and girls equally affected) between six months to five years of age 
present with STEC-HUS (50% of all STEC-HUS cases).15,16 After ingestion of the STEC 
bacteria, with an incubation period of three days (ranging from 2-12 days), patients start 
to develop symptoms (Figure 1.2).17 The prodomal phase usually begins with abdominal 
cramping and non-bloody diarrhea (˜90%), often accompanied by vomiting (˜50%) and 
fever (˜30%).6,18 Typically, after a couple of days, the diarrhea becomes bloody (>80%) after 
which patients seek medical attention. Approximately 15% of the patients with an STEC 
infection will develop TMA (5-10% of sporadic cases and about 20% during outbreaks), 
usually 3-13 days after the start of the symptoms.6 Diarrhea stops usually within one week. 
Moreover, 10% of the patients with STEC-HUS does not report diarrhea as preceding 
symptom. Besides the typical features of hemorrhagic colitis and renal failure, the central 
nervous system is often involved (˜20%). Furthermore, extra-renal manifestations such 
as pancreas involvement resulting in diabetes mellitus, cardiac involvement and in rare 
cases skin, eye, or pulmonary involvement have been reported.6,18
Diagnosis
Since aHUS is a diagnosis per exclusionem, making the correct diagnosis of an STEC infec-
tion has major implications for treatment, the more after the introduction of the orphan 
drug eculizumab as treatment for aHUS. A rapid and accurate diagnosis of STEC infection 
in patients with HUS is highly important considering appropriate public health response, 
treatment and outcome. 
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Currently, fecal diagnostics is the gold standard to diagnose STEC infection, which 
comprises both polymerase chain reaction (PCR,) to detect genes encoding for Shiga 
toxins (Stx) and in addition the attaching and effacing protein, intimin, and feces culture 
using a Sorbital MacConkey agar plate.19 To improve STEC detection, an enrichment step 
is often needed.20 However, in up to 30% of the patients with strong clinical suspicion 
of STEC-HUS, fecal diagnostics remains negative.21-23 Hence, the discrimination between 
STEC-HUS and other causes of TMA like aHUS, based on clinical course of the disease 
can be challenging.
Various factors could explain this high number of negative fecal diagnostics, most 
having to do with the interval between presentation and the onset of symptoms (Figure 1.2). 
Most patients (and/or caregivers) seek medical attention when the bloody diarrhea 
starts, usually two to three days after the onset of symptoms. However, the bacterial 
load decreases quickly after a few days and some STEC bacteria could even lose their Stx 
during some stage of infection or upon subcultivation.24,25 Moreover, only a low inoculum 
is needed to cause disease, making detecting of STEC in feces by either PCR or culture 
more difficult even in the first few days. Collection of feces could also be difficult since 
the diarrhea prodrome has often ceased at time of presenting with HUS. Even new tech-
niques like whole genome sequencing depend on culture of the strain, hereby limiting 
the diagnostic yield.20 Other diagnostic assays have been described, such as the detection 
of Stx concentration in blood, either bound or free, yet need to be further validated.26-28
To complement diagnostics and to enhance detection of STEC infection, serology 
against different STEC serotypes has been recommended.29-31 By determining the presence 
of Immunoglobulin M (IgM) antibodies against different STEC serotypes, STEC-HUS 
can be verified. IgM can be detected after 3-5 days up till two months after start of the 
symptoms and hereby broadens the time window to detect STEC infection (Figure 1.2).
In CHAPTER 2 we study the added value of serology to detect antibodies against 
STEC serotype O157 in combination with fecal diagnostics. Yet, this lipopolysaccharide 
enzyme-linked immunosorbent assay (LPS-ELISA) appeared to have various drawbacks. 
The most prominent one is the potential cross-reactivity between different gram nega-
tive bacteria and between different STEC serotypes. Recently, a new serological antibody 
assay (glyco-iELISA) has been developed, tackling various limitations of the old assay.32 
In CHAPTER 3 we discuss the advantages of this new sensitive serological method to 
detect STEC-HUS. We compare the LPS-ELISA with glyco-iELISA in a single center cohort 
comprising pediatric patients with STEC-HUS, as well as in nationwide cohort of patients 
with TMA. Yet, even with the introduction of serology, only a limited amount of sero-
types can be detected. Fecal diagnostics with molecular methods, which takes advantage 
of whole genome sequencing to detect STEC isolates, are increasingly performed and 
provide additional data regarding sporadic and outbreak isolates.20,33
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Due to improved diagnostic assays, more knowledge is gathered the non-O157 STEC 
serotypes causing HUS. In CHAPTER 4 we describe a case of a 16 month-old boy with 
STEC-HUS, caused by an unusual Stx2d producing STEC O80:H2 which resulted in an 
unusual and highly severe disease course. Our case emphasizes the importance of ade-
quate use of STEC diagnostic tests in all children with HUS, including those with an 
atypical presentation, and emphasizes the importance of molecular and serotyping assays 
to estimate the virulence of an STEC strain.
Pathophysiology
After oral ingestion, STEC colonizes the gut by translocation of their own receptor, Tir, 
into the gut epithelium. Subsequently, the formation of attaching and effacing lesions is 
stimulated.34 Within a few days, STEC will express and release various virulence factors. 
One of the most important virulence factors is the Stx, a toxin composed of a single A 
subunit and a pentameric B subunit. The intact Stx is translocated across the epithelium 
into the blood via multiple routes including transcellular and paracellular transport.35 
There are two types of Stx, Stx1 and 2 respectively, each with various subtypes (Stx1a, 
Stx1c, Stx1d, Stx2a, Stx2b, Stx2c Stx2d, Stx2e, Stx2f, Stx2g).36 However, in the evolvement 
of STEC infection to HUS, Stx2 plays a prominent role due to its higher degree of patho-
genicity. 
When Stx is released into the bloodstream, it can bind to several circulating cells 
(e.g., monocytes, erythrocytes and platelets), serving as Stx carriers to target organs. 
Upon binding, cells are activated and shed microvesicles which are pro-inflammatory 
and pro-thrombotic.37 With its B subunit, Stx can bind to target cells via the globotriaosyl 
ceramide (Gb3) receptor on the cell membrane. Depending the density of Gb3 on cells, 
various tissues have different degrees of susceptibility. Especially the endothelium of the 
kidney, but also intestine and brain express the Gb3 receptors, explaining the characteris-
tic symptoms of STEC-HUS with acute renal failure, hemorrhagic colitis and neurological 
involvement in some patients.6 After binding to its receptor, retrograde transport of the A 
subunit through the Golgi apparatus to the endoplasmic reticulum occurs. Subsequently 
leading to inhibition of protein synthesis in the ribosome, resulting in the end in cell 
death, as such initiating the cascade leading to TMA.35,37
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Only 15% of all patients infected with STEC will develop HUS, which can most 
likely be explained by a complex interplay between pathogen, host and environment, 
ultimately resulting in TMA. Various contributing pathogenic mechanisms have been 
described influencing the cascade leading to TMA. Enhancement of the effect of Stx 
release leading to TMA possibly occurs via various pathways like the interaction of Stx 
with von willebrand factor, hereby decreasing ADAMTS13 mediated cleavage resulting in 
a pro-thrombotic state.38 Also, signs indicative of increased complement activation have 
been described in STEC-HUS. However, the contribution of complement activation in the 
pathophysiology of STEC-HUS remains controversial and a topic of discussion.6,39-42 We 
hypothesized that the noxious molecule heme, as released during extensive hemolysis in 
the acute phase of disease, could enhance TMA in patients with STEC-HUS. In CHAPTER 5 
we describe the contribution of systemic heme levels in the evolvement of STEC-HUS.
Treatment & outcome
STEC-HUS is considered a relative benign disease when compared to aHUS, and is 
self-limiting. Patients are merely treated symptomatically. Nevertheless, 30% of the 
patients have chronic sequelae such as proteinuria, hypertension and/or diminished esti-
mated glomerular filtration rate at five years follow up.23 Overall, only a small proportion 
(<5%) of patients will progress to end stage renal disease and death is reported in up till 
3% of the patients in the acute phase.23 
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Atypical HUS
Clinical presentation
Atypical HUS is an orphan disease, with an estimated incidence of 1-2 cases per million.10,43 
Unlike STEC-HUS, aHUS is known for its relapsing and hereby chronic character. The first 
onset of aHUS appears slightly more often during childhood (60%). Within the pediatric 
patients, half of the patients experience their first episode before the age of seven years. 
This corresponds with the typical age to develop STEC-HUS, making differentiation based 
on age less favorable.6,44
Atypical HUS is usually preceded by a triggering event leading to complement 
dysregulation. In 84% of the children with onset of aHUS a trigger could be identified. 
Gastro-intestinal symptoms were reported most frequently in 74% of the patients, with 
diarrhea in 25% of the patients. Respiratory tract infections were reported in 45% of the 
patients.44 Pregnancy is a frequently reported trigger during adulthood. Moreover, clinical 
differentiation between different etiologies of TMA can be highly difficult, since aHUS 
can also be triggered by among others infections, malignant hypertension, vaccinations, 
malignancy, drugs, each also associated with secondary TMA (Figure 1.1). 
Extra-renal manifestations are also seen in aHUS. Neurological involvement is 
frequently observed in 10-48% of the patients and usually comprises seizures and uncon-
sciousness.45 Pancreatitis (8%) is a common complications and elevated liver enzymes are 
observed frequently (>40%). Cardiovascular (10%) and respiratory involvement (7%) are 
less common.46 In rare cases, gangrenous lesions of fingers and toes have been reported.45
Diagnosis
In 5-10% of the aHUS cases serological auto-antibodies against complement factor 
H (CFH) could be detected to diagnose aHUS.47 These auto-antibodies can bind to 
circulating CFH and are mainly directed against the C-terminal part of CFH hereby 
inhibiting cell surface protection against complement activation. The first onset 
is usually at 5-15 years of age and mimicks the typical presentation of aHUS.47 Fur-
thermore, genetic analysis should be performed (Table 1.1). With the use of more 
comprehensive genetic screening tools, new mutations associated with development 
of aHUS are still discovered. For example, with the use of multiplex ligation-depen-
dent probe amplification (MLPA) various hybrid genes of CFH have been discovered, 
associated with aHUS.48,49 Still, at present in only 60-70% of the patients with aHUS, 
a genetic cause or presence of auto-antibodies can be found explanatory for aHUS. 
Most aHUS cases are sporadic, but in approximately 10-15% of the patients present-
ing with aHUS, there is a family history of aHUS.10 Moreover, incomplete penetrance 
of mutations has been reported, indicating the need for additional triggers (either 
environmental or genetic) to develop disease manifestation. Patients who have 
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both a pathogenic mutations and are homozygous for one of the known haplotypes 
described in CFH or membrane cofactor protein (MCP), have an increased penetrance 
of approximately 50% to 70%.50
However, genetic analysis to screen for pathogenic mutations in complement genes 
can take weeks and consequently cannot inform therapeutic decisions. More research to 
discover potential biomarkers to diagnose and monitor disease activity in patients with 
aHUS is needed. C3 levels in plasma can be both normal as decreased during the acute 
phase of disease. The C3d/C3 ratio could help to differentiate between STEC-HUS and 
aHUS, yet needs to be further evaluated.42 Therefore, despite the sharp increase in knowl-
edge regarding the complement system, the mainstay to diagnose aHUS is to exclude 
other forms of TMA. 
Pathophysiology
With over 40 soluble and membrane bound proteins, the complement system is an 
important part of innate immunity and facilitates the elimination of pathogens.51,52 Via 
respectively the classical pathway (CP), the lectin pathway (LP) and the alternative path-
way (AP), the complement system exerts its function (Figure 1.3). 
Following a specific trigger (e.g. antibodies and mannose residues in resp. CP and 
LP), complement proteins are activated. All pathways converge at complement com-
ponent C3. With help of C3 and C5 convertases, splicing products of C3 (C3a and C3b) 
and C5 (C5a and C5b) are generated.51,52 Ultimately leading to three major functions 
of the complement system: opsonisation of pathogens/cells (via C3b), chemotaxis 
(C3a and C5a) and cell lysis (via assembly of C5b, C6, C7, C8 and C9 to form the lytic 
pore C5b-C9). In contrast to the other two pathways, the AP is permanently active at 
low levels. It is mainly the dysregulation of this latter pathway which is the culprit 
in aHUS.51,52
Due to spontaneous hydrolysis of C3 (known as the tick-over) resulting in formation 
of C3 convertases, the AP has the ability to create an amplification loop and produce an 
excess of C3 convertases. To prevent complement overactivation or dysregulation, the 
complement system is tightly controlled by various regulators (Figure 1.3). Most regu-
lators have a role in the AP, and exists both in fluid phase as well as membrane bound 
to host cells.51,52 Various mutations in (regulator) complement proteins of the AP are 
associated with development of aHUS (Table 1.1).
 
Treatment
Once diagnostic bloodsamples have been gathered, it is highly important to start treat-
ment as soon as possible to reduce chronic sequelae. Plasma exchange (PE) was considered 
the cornerstone of treatment in aHUS since the early nineties. The complement balance 
could be restored with PE by removal of auto-antibodies or mutant overactive proteins 
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and delivery of nonmutant complement proteins via plasma infusion.6,57,58 Nowadays, PE 
in combination with immunosuppressive drugs is only recommended for aHUS patients 
with proven auto-antibodies directed against CFH to reduce the titer of antibodies.57 
With the introduction of the first complement inhibitor eculizumab in 2011, the 
prognosis of aHUS changed dramatically. Based upon two prospective, open label studies, 
eculizumab became the fist-line treatment for aHUS.8 
Eculizumab is a monoclonal antibody directed against complement component C5, 
blocking the splicing of C5 into C5a and C5b, and subsequently the formation of the 
terminal complement complex C5b-C9 (Figure 1.3). Eculizumab is administrated intra-
venously every two weeks to maintain complement blockade. However, the necessity of a 
fully blocked complement, maintained with lifelong treatment to prevent aHUS relapse, 
need yet to be established. Furthermore, surprisingly little is known regarding pharma-
cological characteristics of eculizumab. In CHAPTER 6 we describe serum eculizumab 
trough levels in relation to complement blockade in 11 aHUS patients during standard 
therapy and tapering. In CHAPTER 7 we review current knowledge on pharmacokinetics 
and pharmacodynamics of eculizumab and we discussed the potential of therapeutic drug 
monitoring to improve treatment and reduce costs.
Of note, eculizumab is one of the most expensive orphan drugs on the market. Fol-
lowing the introduction of eculizumab, a worldwide debate arose regarding the optimal 
treatment duration, particularly in view of the high costs and potential side effects of 
eculizumab. Some case reports suggested that a restrictive treatment regimen was feasi-
ble. In CHAPTER 8 we describe a cohort of 20 aHUS patients, treated with a restrictive 
eculizumab regimen. In CHAPTER 9 we review the current literature and focus on the 
safety, efficacy and feasibility of restrictive use of eculizumab. 
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Table 1.1 Mutations in complement (regulator) proteins involved in development of aHUS
Mutation in gene encoding for* Type of mutation Function of protein Prevalence 
in aHUS
Typical characteristrics 
clinical presentation
Ref
Factor H (CFH) Loss-of-function · Competes with CFB for binding to C3b (to 
form C3 convertase; C3bBb)
· Cofactor for CFI to inactivate C3b
· Accelerates decay of C3 convertase
20-30% - 53,54
Factor H related proteins 1-5 (CFHR1-5) Complement regulatory activities Unknown
Homozygous CFHR3-1 deletion Deficiency of CFHR 3 and 1 - 3-10% 87% of patients with auto-
antibodies against CFH has 
this deletion
49,55
Homozygous CFHR1-4 deletion Deficiency of CFHR 4 and 1 - Unknown Associated with auto-
antibodies against CFH
49
Factor H/CFHR1 hybrid Genetic rearrangement Due to formation CFH/CFHR1 hybrid, normal 
CFH binding to cell surface is inhibited
3-5% - 6,49
Factor H/CFHR3 hybrid Genetic rearrangement Due to formation CFH/CFHR3 hybrid, normal 
CFH binding to cell surface is inhibited
Unknown - 49
Membrane cofactor protein (MCP; CD46) Loss-of-function Cofactor protein for CFH to inactivate C3b 5-15% Usually first presentation 
during childhood with median 
age of 5 years
53,54,56
Factor I (CFI) Loss-of-function Inactivation of C3b which is no longer able to 
bind CFB
4-10% - 53,54,56
C3 Gain-of-function Central complement component, needed to 
build convertases and produce C3a and C3b
2-10% - 53,54
Factor B (CFB) Gain-of-function By binding of CFB (Bb part) to C3b, C3 
convertases are build
1-2% Almost always low serum C3 53,54
NA; Not applicable, Ref; Reference 
* Besides these mutations in complement genes, other mutations have been described in relation to aHUS. 
However, these mutations in the genes DGKε, trombomodulin, plasminogen and inverted formin 2 are not described 
here since there role within complement dysregulation is not yet known.
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Dutch guideline regarding diagnosis and treatment of TMA
In the Netherlands, a unique initiative was undertaken by a group of experts assembled 
in the national aHUS working group. In 2016, a new national guideline regarding diag-
nosis and treatment of patients who present with TMA, funded on the same principles 
as described in chapter 9, was implemented by this working group.4 This working group 
consists of one nephrologist and one pediatric nephrologist from every university medical 
center in the Netherlands. Together they discuss all patients treated with eculizumab 
and explore options to taper or withdraw therapy. Simultaneously with the implementa-
tion of this new guideline, which advocates a restrictive treatment regimen, eculizumab 
had to be reimbursed by the National Healthcare Institute. After careful consideration 
and reviewing all data present, the Ministry of Health, Welfare and Sport decided to no 
longer reimburse eculizumab when administered following the pharmaceutical treatment 
scheme; every fortnight as lifelong treatment. Yet, they decided to temporary reimburse 
eculizumab for the indication of aHUS when administered according the new Dutch 
guideline, for another four years. 
In the Netherlands several criteria must be met before orphan drugs can be (re)
imbursed. A so called orphan drug arrangement was implemented with the aim to guar-
antee healthcare access for everyone, promote efficient and purposeful usage of orphan 
drugs, and to optimize 
(cost-)effectiveness of orphan drugs like eculizumab. The first criteria is the presence 
of an indication committee, such as the national working group aHUS. Secondly, there 
have to be clear start and stop criteria, as described in the new guideline. Finally, these 
patients have to be monitored in a registry to evaluate efficacy of the drug and to perform 
a cost-effectiveness analysis.60
In CHAPTER 10 we describe the protocol of the national observational study to mon-
itor and evaluate this new guideline concerning treatment of aHUS, called CUREiHUS. 
With this study, all aHUS patients treated according to the new guideline are monitored 
in a database. Furthermore a cost effectiveness analysis and budget impact analysis will 
be conducted at end of the study. The study estimated end date is December 2020. Con-
sequently, treatment with eculizumab is reimbursed by the National Healthcare Institute 
for four years, with the restriction that all patients (when possible and after informed 
consent) are included in the CUREiHUS study. 
Finally, CHAPTER 11 provides a summarizing discussion together with future per-
spectives regarding the research described in this thesis. 
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New aspects of 
pathophysiology 
and diagnosis 
in STEC-HUS

“It is far more important to know what person the disease had, 
than which disease the person had” 
Hippocrates
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Fecal diagnostics in 
combination with serology: 
best test to establish STEC-HUS
Abstract
Background
In the majority of pediatric patients, the hemolytic uremic syndrome (HUS) is caused by 
an infection with Shiga toxin-producing Escherichia coli (STEC), mostly serotype O157. It is 
important to discriminate between HUS caused by STEC and complement-mediated HUS 
(atypical HUS) due to differences in treatment and outcome. As STEC and its toxins can 
only be detected in the patients stool for a short period of time after disease onset, the 
infectious agent may go undetected using only fecal diagnostic tests. Serum antibodies 
to lipopolysaccharide (LPS) of STEC persist for several weeks and may therefore be of 
added value in the diagnosis of STEC
Method
All patients with clinical STEC-HUS who were treated at Radboud university medical 
enter between 1990 and 2014 were included in this retrospective single-center study. 
Clinical and diagnostic microbiological data were collected. Immunoglobulin M (IgM) 
antibodies against LPS of STEC serotype O157 were detected by a serological assay (ELISA).
Results
Data from 65 patients were available for analysis. Fecal diagnostic testing found evidence 
of an STEC infection in 34/63 patients (54%). Serological evidence of STEC O157 was 
obtained in an additional 16 patients. This is an added value of 23 % (p < 0.0001) when 
the serological antibody assay is used in addition to standard fecal diagnostic tests to 
confirm the diagnosis STEC-HUS. This added value becomes especially apparent when 
the tests are performed more than seven days after the initial manifestation of the gas-
trointestinal symptoms
Conclusion
The serological anti-O157 LPS assay clearly makes a positive contribution when used in 
combination with standard fecal diagnostic tests to diagnose STEC-HUS and should be 
incorporated in clinical practice.
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Introduction
Hemolytic uremic syndrome (HUS) is diagnosed when the characteristics of hemolytic 
anemia, thrombocytopenia, and acute renal failure are present.17 There are different etiol-
ogies leading to HUS, with the Shiga toxin-producing Escherichia coli (STEC) HUS and 
complement-mediated atypical HUS (aHUS) being the most prominent ones. In more 
than 90% of cases, HUS follows a gastrointestinal infection with STEC. Additionally, 
over 50% of STEC-HUS cases are due to STEC serotype O157, although other serotypes, 
such as O26, O103, O145, and O111, are increasingly associated with HUS as well.6,30,61,62 
With symptomatic treatment, patients with STEC-HUS often recover spontaneously, 
with only a small number progressing to end-stage renal disease (ESRD) In contrast, 
aHUS generally has a poor outcome, with 2–10% mortality among patients in the 
acute phase of the disease and up to 50% of patients progressing to ESRD.43
It is therefore vital to be able to distinguish between STEC-HUS and aHUS, as 
this has major consequences in terms of treatment possibilities (for example, the use 
of the expensive orphan drug eculizumab, which is currently the standard treatment 
for aHUS) and outcome.63 However, it can be challenging to differentiate clinically 
between these two entities due to their similar symptoms. For example, in 6–10% of 
children with STEC-HUS there is no (bloody) diarrhea, whereas aHUS is preceded 
by diarrhea in 25% of the cases.43,44 As aHUS is often diagnosed per exclusionum pro-
viding proof for the presence of STEC forms the basis for differentiation between 
aHUS and STEC-HUS.6 In most laboratories, an STEC infection can only be confirmed 
by an examination of fecal material, mostly through simultaneous testing of stool 
culture, shiga toxins immunoassays, and/or polymerase chain reaction (PCR) assays 
for the detection of shiga toxin (Stx) genes.19 With stool cultures, the presence of an 
STEC can only be established in a limited number of patients (approx. 30–69%) with 
clinical signs and symptoms of HUS.30,64 The additional use of PCR for detection of 
Stx genes increases the odds of finding evidence of an STEC infection up to 70%.21,22 
However, the presence of STEC in the intestines declines rapidly during the first week 
of the illness19,65, whereas the average time between the first day of diarrhea and the 
development of HUS is 5–13 days.6,17 
Over two decades ago, Chart et al. described the use of serological assays to 
detect antibodies against, among others, serotype O157 lipopolysaccharide (LPS) as a 
diagnostic tool to establish an STEC infection.29,66-68 A few studies have subsequently 
shown that in patients with clinical signs and symptoms of HUS, for whom only a 
limited number of the stool cultures were positive, the results of serological testing 
for STEC were positive in 60–94% of the patients.30,64,69 The most important explana-
tion for this low number of positive stool cultures next to the low inoculums of the 
bacteria is the small time window when STEC can be detected in the feces. In con-
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trast, the antibody response, composed of immunoglobulin M (IgM), can be detected 
from five days up to two months after the onset of the symptoms.70,71 
Based on these characteristics, a broad application of serological assays for STEC 
may be expected. Additionally, in most of the microbiological studies conducted to 
date, various diagnostic techniques have been compared, using conventional and 
molecular methods; however, all of these methods depend on the presence of fecal 
material.21,33 Hence, only limited data have been published on the combined use of fecal 
diagnostic testing and the serological antibody assay in patients with STEC-HUS. A 
review of the literature and discussion with colleagues suggested to us that interest 
in the serological antibody assay for the detection of an STEC infection has been 
largely neglected in past years.
In the study reported here, we assessed the added value of the serological anti-
O157 antibody assay in combination with fecal diagnostic testing in pediatric patients 
with a clinical STEC-HUS. We also examined the time window between the onset 
of symptoms and testing for STEC using fecal diagnostic tests and a serological 
antibody assay.
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Material and Method
This was a retrospective single-center study which included all patients who presented 
with a clinical pattern of STEC-HUS between 1990 and 2014 to the Pediatric Nephrology 
department of the Radboud University Medical Center Amalia Children’s Hospital. All 
available clinical and diagnostic data were collected. The diagnostic data included the 
results of all fecal diagnostic tests [stool cultures, cell cytotoxicity assays [free fecal Stx 
test (FStx), used in our center until June 2011] and PCR analyses for Stx genes (from June 
2011 onwards). An enzyme-linked immunosorbent assay (ELISA) was used as the serolog-
ical assay for IgM antibodies against O157 LPS.66
A clinical pattern of STEC-HUS was defined as signs of a thrombotic microangiopa-
thy, hemoglobin level below the lower limit of normal for a specific age, signs indicative 
of hemolysis, acute renal failure, thrombocytopenia of <150 × 109/l, and (bloody) diarrhea 
or family members with diarrhea. Clinical data at presentation and follow-up were col-
lected from the medical records. Hypertension was defined as repeated blood pressure 
measurements above the 95th percentile for sex, height, and age.72 Anuria was defined 
as a urine production of <0.1 ml/kg/h for at least 12 h, and oliguria was defined as a urine 
output of <0.5 ml/kg/h. Neurological involvement was indicated by apathy, irritability, 
reduced consciousness, seizures, paralysis, encephalopathy, and coma, and signs of pancre-
atic involvement included pancreatitis and diabetes mellitus. The estimated glomerular 
filtration rate (eGFR) was calculated with the Schwartz formula (k-coefficient = 36.5).73 
Extent of renal impairment was based on guidelines from Kidney Disease: Improving 
Global Outcome.74 The onset of disease was defined as the first day of diarrhea. The onset 
of disease was defined as the first day of diarrhea. The time window of the fecal diagnostic 
tests and serological antibody assay was defined as the time between the onset of the 
symptoms and the collection of feces and/or serum.
Fecal diagnostics
Feces were collected as soon as possible after admission to the hospital. In cases where 
feces could not be obtained, a rectal swab was done. Fecal material was plated on Sorbitol 
MacConkey agar containing 1% sorbitol and on blood agar. After 24 hours of incubation, 
non-sorbitol fermenting colorless colonies were tested for agglutination with anti-O157 
O-antigen serum. Until 2011, fecal samples were also tested for the presence of FStx using 
cell cytotoxicity assays as previously described by Karmali et al.75,76 In June 2011, the PCR 
assay for the detection of Stx1, Stx2 and virulence genes, E. coli attaching and effacing gene 
(eae), and enterohemorrhagic E. coli hemolysin (hly) in feces replaced the time-consuming 
cell cytotoxicity assays as a standard test, in addition to the stool cultures. Nowadays, 
when a patient is suspected of HUS the feces is first tested for the presence of STEC with 
a PCR assay. When the assay results are positive, indicating STEC infection, a stool culture 
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on Sorbitol MacConkey agar plates is performed. To further determine all strains, we send 
all isolates to the Dutch National Institute for Public Health and Environment (RIVM).
Anti-O157 LPS assay
Serum was obtained from all patients and stored at −80 °C until analysis. Sera were 
screened for antibodies against the LPS serotype O157 with an ELISA as previously 
described by Chart.66 In brief, the ELISA plates were coated with LPS from E. coli O157:H7 
[List Biological Laboratories Inc., Campbell, CA; product code 206, diluted in carbonate 
buffer (pH 9.6) to a concentration of 20 ug/ml]. After incubation overnight at 4 °C, the 
plates were blocked, and diluted serum was added to the plate together with predeter-
mined positive and negative control sera. After addition of the antibody goat anti-human 
IgM (Sigma-Aldrich, St. Louis, MO; product code A0420, diluted 1/500 with phosphate 
buffered saline with bovine serum albumin) and substrate (p-nitrophenyl phosphate 
tablets in diethanolaminebuffer), the absorbance was measured at 405 nm. A positive 
IgM reaction was defined by a mean absorbance of >0.800; values of <0.400 were to be 
considered negative and values between 0.400 and 0.800 were considered to be dubious 
and as such taken to be negative for the purpose of this study.
Statistics
All available clinical variables for each patient were included in the analysis. Clinical 
values were expressed as valid percentages for categorical variables and as the mean and 
standard deviation or median and 25–75 percentile (interquartile range; IQR) for con-
tinuous variables, as appropriate. Values for the serological assays, stool cultures, FStx, 
or PCR that were inconclusive or missing were classified as a negative test result. The 
Chi-square test was performed to compare categorical data and the two-sided t test or 
Mann–Whitney U test was used to compare continuous data. To compare positive and 
negative test results in relation to the time since onset of disease, we used binary logistic 
regression analyses, and dummies were computed for the categorical variables. P values 
of <0.05 were considered to be statistically significant.
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Results
Patient characteristics
During the period between 1990 and 2014, 72 children with a clinical pattern of STEC-HUS 
were seen in the Radboud University Medical Center Amalia Children’s Hospital. Seven 
patients were excluded because no data on feces and serology were available for further 
analysis. The patient characteristics of the 65 children with a clinical pattern of STEC-
HUS are described in Table 2.1. The majority of patients (79%) presented with STEC-HUS 
before the age of six years. All but two children had diarrhea at presentation (97%), which 
was generally bloody diarrhea (79%). One patient died in the acute phase of the disease 
from a systemic inflammatory response syndrome combined with severe STEC-HUS, as 
proven by positive results for both the fecal diagnostic tests and the serological assay. 
Another patient, with proven STEC-HUS based on fecal and serological tests, did not 
show any recovery of renal function and subsequently was placed on hemodialysis before 
undergoing kidney transplantation.
Serological assays in addition to fecal diagnostic tests
Evidence of an STEC infection was found in 50 patients (77%) of the 65 patients with a 
clinical pattern of STEC-HUS. Fecal diagnostic tests identified STEC in 34/63 patients 
(54%); in 26 of these 34 patients a STEC strain could be isolated with culture. Serological 
evidence of an STEC O157 infection was found in an additional 16 patients, which is an 
added value of 23% (p < 0.0001) when fecal diagnostic tests are combined with the sero-
logical antibody assay to confirm the diagnosis of STEC-HUS (Figure 2.1, Table 2.2). 
Among those patients with negative stool cultures, the PCR assay was positive for STEC-
HUS in three patients and the cell cytotoxicity assay (FStx) was positive for STEC-HUS 
in five patients. Since implementation of the PCR assay in 2011, Stx genes have been 
detected in nine (69%) of the 13 patients who presented with HUS. Of these nine STEC 
infections, seven were also detected by serological assays. Three additional patients who 
tested negative for Stx genes in repeated PCR assays showed serological evidence of an 
STEC infection (Table 2.2).
Two additional serotypes, serotypes O26 (n = 3) and O5, were detected in fecal spec-
imens from three and one patient, respectively, sent to the RIVM for further testing.
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Table 2.1 Patient characteristics of 65 pediatric patients with clinical STEC-HUS
Parameter All patients
Male 52%
Age of onset in years 2 (1 - 4)
   0-24 months (n=18)
   2-6 Years (n=33)
17 (10 - 20)
3 (2 - 4)
   ≥ 6 Years (n=14) 11 (9 - 12)
Symptoms at presentation
Fever 27% 
Diarrhea, total 97% 
   Of which bloody 79% 
Oliguria 
   Duration in days (n=5)
29% 
5 (3 - 8)
Anuria 
   Duration in days (n=26)
59%
8 (7 - 10)
Blood pressure
   < p95 34%
   ≥ p95 66% 
Neurological involvement 34% 
Pancreas involvement 3% 
Biochemical evaluation at presentation  (reference range)
Hemoglobin 
   (6.0 – 9.0 mmol/l)
5.8 (4.8 - 6.7) 
White blood cells 
   (5.0 - 13.0 x 109/l)
15.3 (10.9 - 22.3) 
Platelet count 
   (210 - 430 x 109/l)
47 (30 - 73.5) 
Haptoglobin 
   (0,3-1,6 g/l)
<0.08 (0.05 - 0.08) 
LDH 
   (<250U/l)
3720 (2325 - 5809)
eGFR
   (>90 ml/min.1.73m2)
15 (10 - 24)
Treatment
Dialysis 63% 
   Duration of dialysis in days 10 (7 - 15) 
Erythrocytes transfusion 80% 
   ≥ 3 transfusions 11% 
Follow up
eGFR at discharge (ml/min.1.73m2)
eGFR<60 after 5 years follow up (n=8) (ml/min.1.73m)
55 (43 - 66)
4 (6%) 
Received Kidney transplantation 1 (2%)
Diseased 1 (2%) 
Categorical values are expressed as absolute number and percentage of total and for continuous variables the median 
with interquartile range (IQR) is expressed. The numbers of patients for whom data were available are reported in 
parentheses. P95: percentile for age and height.
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Table 2.2 Proportion of positive serology for serotype O157 in relation to the fecal diagnostics
Diagnostics Positive Serology Negative Serology Total (%)
Serology 38 (63%) 22 (37%) 60
   Missing 5
Fecal diagnostics 63
   Missing serology 4 (6%)
   Positive 22 (65%) 12 (35%) 34 (54%)
   Negative 15 (60%) 10 (40%) 25 (40%)
   Feces culture 63
      Missing serology 4 (6%)
      Positive 18 (69%) 8 (31%) 26 (41%)
      Negative 19 (58%) 14 (42%) 33 (53%)
   FStx, until 2011 33
      Missing serology 1 (3%)
      Positive 10 (59%) 7 (41%) 17 (52%)
      Negative 9 (60%) 6 (40%) 15 (45%)
   PCR, since 2011 13
      Missing serology -
      Positive 7 (78%) 2 (22%) 9 (69%)
      Negative 3 (75%) 1 (25%) 4 (31%)
Table 2.2 Test results from all 65 patients with clinical STEC-HUS where serology and fecal diagnostics were per-
formed to confirm an STEC infection. The percentage of patients with positive or respectively negative serology 
is reported in parentheses. In a few patients, only fecal diagnostics are performed, the missing serology values are 
presented in the table.
Time window between onset of disease and sample collection
The median time between onset of disease and the collection of feces and serum was 7 
(IQR 5–9) and 8 (IQR 5–12) days, respectively. The added value of serology became more 
evident when the fecal and serological diagnostic tests were run on specimens collected 
≥7 days after the start of the symptoms (Table 2.3). Within seven days after the first 
manifestation of the symptoms, 14 patients had negative fecal diagnostic test results; of 
these, 5 (36%) had positive results on the serological assay, confirming a STEC infection. 
However, of the 12 patients with negative fecal diagnostic test results based on fecal 
specimens collected ≥7 days after the start of the disease, eight (67%) were found to test 
positive for O157 on the serological assay. 
Hence, when feces and serology specimens were collected ≥7 days after the start of 
the symptoms, the serological antibody assay had an added value of 33%, which is signifi-
cantly higher than the 14% added value when the specimens for testing were collected 
within seven days (p = 0.024).
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Discussion
Various fecal diagnostic tests are recommended in the literature to establish an STEC infec-
tion as the cause of HUS including stool cultures, Stx immunoassays, cell cytotoxicity 
assays, and PCR for Stx genes. 19 However, limited data are published on the benefits of 
combining fecal diagnostic with serodiagnostic testing in patients with STEC-HUS. The 
results of our retrospective study show that the serological anti-O157 antibody assay is of 
additional value to the fecal diagnostic tests used in patients with a clinical STEC-HUS. 
In our study, use of the standard fecal diagnostic tests resulted in a STEC infection being 
detected in half of the HUS patients; in comparison, evidence of an STEC infection was 
detected in 77% of the 65 patients when serological testing was used in combination with 
the standard fecal diagnostic tests. The added value of serological testing further improves 
when the specimens for testing were collected ≥7 days after the start of the symptoms.
Figure 2.1 Serological anti-O157 antibody assay in addition to the standard fecal diagnostics.
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Figure 2.1 Test results from all 65 patients with clinical STEC-HUS where serology and fecal diagnostics were per-
formed to confirm an STEC infection. When the fecal diagnostics (stool culture, cell cytotoxicity assay and/or PCR) 
are combined with the serological antibody assay, 77% of the patients has a confirmed STEC infection (p<0.0001).
Our results are in line with the study of Espié et al. who studied 900 children with 
HUS and tested for STEC by stool culture, PCR assay for Stx genes, and serological assays 
for multiple serotypes. 30 In 232 (37%) children, The presence of a STEC was confirmed in 
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232 (37%) children with a stool culture and in 37 patients Stx was detected with the PCR 
assay. STEC infection was confirmed in 518 (60%) patients based on positive serological 
results, of which 85% of patients had serotype O157. The combined use of fecal diagnostics 
and serology provided evidence of a STEC infection in 590 (66%) patients. Unfortunately, 
no further information on the time window was provided by the authors.
Table 2.3 Added value of serology in relation to the time window between onset of symptoms 
and collecting material
Diagnostics Proven STEC infection
Total <7 days ≥ 7 days
Fecal diagnostics 54% (34/63) 44% (11/25) 62% (20/32)
Serology 62% (38/61) 45% (9/20) 69% (25/36)
Combined: Fecal diagnostics & Serology 77% (50/65) 58% (7/12) 95% (20/21)
Added value of Serology 23%  14% 33%
Table 2.3 Collection of diagnostics in the first six days after the start of the symptoms are compared with seven days 
or more since onset and the influence on the detection of STEC infection is compared. The added value of serology 
becomes more evident as of seven days (p=0.024).
The fecal diagnostic tests (stool culture, cell cytotoxicity assay, and/or PCR) 
detected STEC in only half of our patients with a clinical pattern of STEC-HUS. A few 
factors may explain this low number of positive stool cultures, all of which are linked to 
the time of presenting in relation to the development of the disease. First, the isolation 
rate of STEC in feces declines quickly after the first manifestation of the gastrointesti-
nal symptoms, and most parents seek medical attention after the first signs of bloody 
diarrhea (which is after approx. three days). Secondly, there is a low inoculum whereby 
the odds of finding a STEC in the feces is also limited during the first seven days. The 
third and final factor is that the diarrheal prodrome has often ceased before the onset 
of HUS, making detection of the pathogen or its toxins rather difficult when the fecal 
speciment is collected at the time of presenting with a HUS.17 Frequent stool collec-
tions may be considered one option to increase the chance to detect a STEC infection. 
Furthermore, new and promising techniques have been developed for the detection 
of STEC infection since the start of this retrospective study, as illustrated by the PCR 
assay for Stx genes, but also more recently by the molecular approach to assess the 
virulence profile and serotyping of STEC strains. In comparison to the other standard 
fecal diagnostic tests (e.g. stool culture and PCR), molecular testing is generally only 
performed in reference laboratories, as this approach is mostly used for epidemiological 
analysis.19,20 The PCR assay for Stx genes was introduced only a few years ago in our 
hospital, and data on this assay were only available for a minority of patients in our 
study, although results are promising. Even though these techniques are more precise 
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in terms of detecting the presence of STEC, they still require fecal material for testing. 
Therefore, in cases without stool production, besides a rectal swab that is highly rec-
ommended, it may still be difficult to detect STEC. 
In 15 (23%) of the 65 patients enrolled in our study, the results of the serological assay 
and the fecal diagnostic tests were negative for a STEC infection. One explanation may be 
that the techniques used were not sufficiently sensitive, especially because the majority of 
the specimens were tested before the implementation of the PCR assay. Another possible 
explanation is the timing of sampling, even though the time between the onset of symp-
toms and the collection of fecal specimens in our cohort is comparable with those of other 
studies.30,77 In our study, only a serological antibody response against O157 was tested. O157 
currently accounts for 30–80% of STEC-HUS cases in the Netherlands, and our serological 
assay could not detect other important serotypes.15,23,30 Also, the serum samples may have 
been collected too early in the disease course—that is, prior to seroconversion. When these 
explanations appear to be unlikely, other causes of HUS, such as aHUS, should be taken into 
account. However, during follow up, none of the 15 patients with negative fecal diagnostic 
and serological test results presented with a relapse indicative of aHUS or showed signs of 
permanent complement dysregulation.
Our results clearly show that a patient with HUS in the absence of positive fecal diag-
nostic test results is not equivalent to one with aHUS. Moreover, it may very well be a STEC 
infection that is causing the HUS despite the negative fecal diagnostic test results. The need 
for regular serological antibody assays in patients with HUS becomes even more important 
with the introduction of the new and very expensive complement inhibitor eculizumab as 
a treatment for aHUS. We recommend that this assay be performed centrally in specialized 
laboratories per country to guarantee the quality and reliability of the assay and thereby 
ensure its feasibility and affordability in general clinical use.
The added value of the serological assay in relation to the time window has not been 
studied previously. Our results show that this added value becomes more evident (14 vs. 
33% before and after seven days, respectively) when the specimens are collected >7 days 
after the first manifestation of symptoms. The number of patients in Table 2.3 is quite 
small due to missing data on the time window. In addition, feces were collected within 
seven days in 11 patients, whereas the serum was collected >7 days after the start of the 
symptoms, presumably due to negative fecal diagnostic test results. We anticipated the rise 
in positive serological assay results after seven days, as IgM is detectable approximately 
five days after the onset of the symptoms.70 In contrast, the rise in positive fecal diagnostic 
test results after seven days was not expected considering the awaited rapid decrease of 
STEC in the feces. The high percentage of positive results for the fecal diagnostic tests is 
partly explained by the inclusion of the cell cytotoxicity tests (FStx) and PCR assays, both 
of which are highly sensitive tests, even after seven days, as compared to stool culture 
techniques.33 However, these techniques all rely on the availability of fecal material. We 
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recommend testing for the presence of STEC with fecal diagnostic tests and serological 
test concurrently in HUS patients at admission because the time course of the disease at 
presentation is often unclear. In the case of negative fecal diagnostic and serological test 
results for specimens tested within seven days after the start of the symptoms, our advice 
would be to retest for antibodies after ≥7 days since the onset of disease.
Based on our results, the serological antibody assay seems to be indispensable to estab-
lish a diagnosis of STEC-HUS; however, the role of serological antibody detection in healthy 
controls remains unclear and needs further exploration. In one study, 22 of the 606 tested 
healthy controls with high exposure to cattle carrying STEC had positive serological test 
results for O157. However the antibodies found were mainly IgG, which could be indica-
tive of repeated exposure. Presumably, the IgM antibody response we test in this study is 
more indicative of an acute infection.78 There is one important limitation of the serolog-
ical anti-O157 antibody assay—namely, the possibility of cross-reaction with subsequent 
false negative results. Cross-reaction has been reported for pathogens such as as Brucella 
abortus, Yersinia enterocolitica, Vibrio cholera, Escherichia hermanni, Citrobacter freundii, 
Citrobacter sedlakii, and Salmonella.29 However, these pathogens are rarely associated with 
the onset of HUS.
One limitation of our study is its retrospective nature. All information had to be gath-
ered from medical records, thereby increasing the odds that the information would be 
difficult to interpret or even be missing. Furthermore, serological data from the antibody 
assay were available only on serotype O157; although serotype O157 is still the main sero-
type associated with HUS in the Netherlands, other STEC serotypes associated with HUS 
are being increasingly detected. However, it was not the purpose of this study to investi-
gate the epidemiology of STEC, rather to evaluate the added value of the serological assay, 
which has been perform in our hospital since 1990, in addition to the fecal diagnostic tests 
to determine a STEC. STEC serotype O157 is still the cause of HUS in over 50 % of the 
cases in the Netherlands. The remaining serotypes are more scattered; for example, the 
second most prevalent serotype associated with HUS, serotype O26, accounts for <20% 
of the HUS cases.15,23,30 In our cohort, four patients had a confirmed STEC infection with a 
non-O157 serotype (tested by RIVM)—serotypes O26 and O5. To increase the detection of 
the pathogens causing HUS, we are currently updating the serological antibody assay for 
other important serotypes as well.
In conclusion, the serological O157 antibody assay is an important additional test for the 
confirmation of STEC, especially when the fecal diagnostic test results are not sufficient to 
establish a STEC infection. Moreover, it is essential to take the time window into account: 
when patients present ≥7 days after the start of the symptoms, the serological antibody 
assay could be indispensable to establish a diagnosis of STEC-HUS. We recommend the 
implementation of the serological antibody assay as standard diagnostic method in combi-
nation with the fecal diagnostic tests for all patients who present with a clinical STEC-HUS.
“Misschien zijn alle draken in ons leven eigenlijk prinsessen die alleen maar zitten te 
wachten op het moment waarop we eindelijk, mooi en moedig, in actie schieten. 
Misschien is datgene waar we bang voor zijn in zijn blootste essentie 
iets wat hulpeloos onze liefde zoekt.” 
Rainer Maria Rilke.
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Abstract
Background
Providing proof of the presence of Shiga toxin-producing E. coli (STEC) infection forms 
the basis for differentiation between STEC - hemolytic uremic syndrome (HUS) and atyp-
ical HUS. As the gold standard to diagnose STEC-HUS has various limitations, the use 
of ELISA to detect serum antibodies against the lipopolysaccharides (LPS) of STEC has 
proven its additional value. Yet, the conventional LPS-ELISA has its own drawbacks, with 
as most important limitation the presence of cross-reactivity due to the conserved lipid 
A part of the LPS. The newly described glyco-iELISA tackles this issue by using modified 
LPS with elimination of its lipid A part. In this retrospective study the incremental value 
of glyco-iELISA compared to LPS-ELISA is assessed.
Materials and Methods
A retrospective study was performed, which included all pediatric patients (n=51) who 
presented with a clinical pattern of STEC-HUS between 1990- 2014 in our hospital. Subse-
quently, the diagnostic value of glyco-iELISA was evaluated in a retrospective nationwide 
study (n=264) of patients with thrombotic microangiopathy. LPS- and glyco-iELISA were 
performed to detect IgM against STEC serotype O157. Both serological tests were com-
pared with each other and with fecal diagnostics.
Results
The glyco-iELISA is highly sensitive and has no cross-reactivity. In the single center 
cohort, fecal diagnostics, LPS-ELISA, and glyco-iELISA identified STEC O157 infection in 
43%, 65%, and 78% of patients, respectively. Combining the glyco-iELISA with fecal diag-
nostics STEC infection due to O157 was detected in 89% of patients. In the nationwide 
cohort, 19 additional patients (8%) were diagnosed with STEC-HUS with glyco-iELISA. 
Conclusion
In conclusion, this study shows that the glyco-iELISA to detect IgM against STEC sero-
type O157 has a clear benefit compared to the conventional LPS-ELISA, contributing to 
optimal diagnostics in STEC-HUS. 
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Introduction
Providing proof of the presence of Shiga toxin (Stx) producing Escherichia coli (STEC) 
infection forms the basis for differentiation between STEC - hemolytic uremic syndrome 
(HUS) and atypical HUS (aHUS). Both important causes to bear in mind in patients who 
present with signs indicative of thrombotic microangiopathy (TMA); hemolytic anemia, 
thrombocytopenia and acute renal failure. The current gold standard to detect STEC 
infection involves fecal examination by culture and detection of Stx encoding genes by 
polymerase chain reaction (PCR).22,30,79 However, detection of STEC in the feces is limited 
due to the natural course of the disease. Furthermore, due to low inoculums, detection of 
STEC in the feces becomes increasingly difficult as the disease progresses. Despite new 
and upcoming fecal diagnostic techniques, like molecular serotyping, solely use of fecal 
diagnostics is not yet sufficient in establishing STEC infection.20
As the gold standard diagnostics of STEC-HUS has various limitations, the use of 
enzyme-linked immunosorbent assay (ELISA) to detect serum antibodies against the 
lipopolysaccharides (LPS; LPS-ELISA) of STEC has proven its value.30,31,80 As previously 
shown, the combination of fecal diagnostics with the LPS-ELISA to detect Immunoglob-
ulin M (IgM) against STEC serotype O157 has clearly an added value in the detection of 
STEC-infection as cause of HUS.80 Yet, the conventional LPS-ELISA, in which plates are 
coated with purified LPS, has various drawbacks. The most important limitation is the 
presence of cross-reactivity caused by the conserved lipid A part of the LPS molecule. 29,31,81 
The LPS structure consists of a lipid A part, an outer and inner core and a O-antigen, of 
which the latter has the highest immunogenic activity. Since the lipid A is also present in 
other strains of STEC and even other gram negative bacteria, this could lead to cross-re-
activity and ultimately lead to false positive results.29,82,83 Although O157 antigen remains 
the most prevalent serotype associated with STEC-HUS, other non-O157 strains (such as 
O26, O103, O104, O111, O55) are increasingly detected. Differentiation between the different 
STEC serotypes is important considering the variation in clinical presentation, course of 
the disease per serotype and the epidemiological consequences.30,32,80 
To tackle the aforementioned issues, the group of J.E. Ugalde and D.J. Comerci 
exploited a new ELISA technique, the indirect glycoprotein-based ELISA (glyco-iELISA) 
for the detection of STEC infection in HUS patients.32,81 This glyco-iELISA takes advantage 
of a bacterial glycoengeneering technology to develop and produce recombinant serotype 
specific glycoproteins consisting of the O157 polysaccharide attached to the protein car-
rier acceptor AcrA (O157-Acr), in absence of the lipid A part. As shown by Melli et al. the 
glyco-iELISA was able to diagnose STEC in HUS patients even in patients where fecal 
diagnostics failed.32 More importantly, due to the absence of the lipid A structure of LPS in 
the glycoprotein-constructs used in this assay, potential cross-reactivity is counteracted. 
Thus, glyco-iELISA appears to be a highly sensitive and specific assay.81
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Up till now, differentiation between STEC-HUS and aHUS remains a clinical conun-
drum which can be tackled with the introduction of the glyco-iELISA.84 Although 
STEC-HUS and aHUS require a completely different treatment approach and clinical 
outcome is divergent, discrimination in the acute phase remains challenging.5,85 Whereas 
diarrhea is the clinical hallmark of STEC-HUS, in up to 30% of the patients with aHUS, 
a gastro-intestinal infection has been found.5,85 Moreover, aHUS is treated with one of 
world’s most expensive orphan drugs: the humanized monoclonal antibody, eculizumab.8 
In contrary, the treatment of STEC-HUS is merely symptomatic and eculizumab is not 
indicated for the treatment of STEC-HUS.5,85 Hereby underlining the importance of dis-
criminating between both types of HUS and limit the unnecessary use of eculizumab 
in STEC-HUS. 
With this retrospective study the clinical utility of the glyco-iELISA compared to 
LPS-ELISA is accessed in two cohorts. The first cohort comprises pediatric patients of a 
single center with strong clinical suspicion of STEC-HUS, of which all clinical data were 
gathered. The second cohort is nationwide cohort of patients with signs indicative of 
TMA of which STEC infection could be a potential cause. 
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Materials and methods
A retrospective single-center pilot study was performed, which included all pediatric 
patients who presented with a clinical pattern of STEC-HUS between 1990 and 2014 to the 
Pediatric Nephrology department of the Radboud University medical center (Radboudumc) 
Amalia Children’s Hospital. A clinical pattern of STEC-HUS was defined as signs of a throm-
botic microangiopathy (TMA) together with (bloody) diarrhea or a family member with 
diarrhea. Signs of TMA were classified as: signs indicative of hemolysis (low hemoglobin, 
elevated LDH, depleted haptoglobin), acute renal injury and thrombocytopenia of <150 x 
109/l. Fever at presentation was defined as body temperature above 38.2 Celsius as reported 
by patients and/or parents. Anuria was defined as a urine production below 0.1ml/kg/
hour for at least twelve hours, The estimated glomerular filtration rate (eGFR) was calcu-
lated with the Schwartz formula (k: 36.5).73 According to the pediatric Risk, Injury, Failure, 
Loss, End-stage renal disease (pRIFLE) criteria, renal injury is defined as a increased cre-
atinine x2 or decreased eGFR > 50%. Renal failure was defined as an increased creatinine 
x3 or decreased eGFR>75%.86 The first day of illness was defined as the first day of diarrhea 
reported by the patient and/or parents. All available clinical and diagnostic data of these 
patients were collected in the STEC-HUS registry – an online web based database. Residual 
material (serum), received during standard care, was used to detect IgM antibodies against 
serotype O157 with the LPS-ELISA as well as the glyco-iELISA. This single center study 
comprised the same patient cohort as previously described by Wijnsma et al.80
Subsequently, the diagnostic value of glyco-iELISA in STEC-HUS diagnosis was eval-
uated in a retrospective nationwide study. Since Radboudumc Amalia Children’s Hospital 
is the expertise center for HUS patients in the Netherlands, the LPS-ELISA for serotype 
O157 is only performed at the Translational Metabolic Laboratory in Radboudumc. This 
study included all residual sera samples from both pediatric as adult patients with signs 
of TMA. Of note, TMA was defined as thrombocytopenia, hemolytic anemia and organ 
damage, yet the underlying disease leading to the development of TMA was unknown at 
time of sampling. Samples of these patients were sent to Radboudumc Amalia Children’s 
Hospital, between 2007 and 2014, from other university medical centers throughout the 
Netherlands for the performance of LPS-ELISA to diagnose or exclude STEC-HUS. All 
these residual sera samples were additionally tested for the presence of IgM antibodies 
against STEC O157 with glyco-iELISA. In addition, serum of 19 healthy adult controls were 
collected to determine specificity of the assays and determine cut-of values for the assay.
This study doesn’t fall within the remit of the Medical Research Involving Human 
Subjects Act (WMO). The study has been reviewed by the ethics committee on the basis 
of the Dutch Code of conduct for health research, the Dutch Code of conduct for respon-
sible use, the Dutch Personal Data Protection Act and the Medical Treatment Agreement 
Act. The ethics committee has passed a positive judgment on the study.
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Index test: glyco-iELISA
The glyco-iELISA was performed as described by Melli et al.32 In brief, a microtiter plate 
was coated with recombinant glycoproteins (O157-AcrA) and incubated overnight at 4°C. 
The following day, the plate was blocked with PBS-0.1% Tween20 (PBST) + 0.5% skim 
milk for 1 hour at room temperature (RT). Subsequently, diluted human serum samples 
(dilution of 1:800) were added and incubated for 1 hour at RT. Next the plate was washed 
and goat anti-human IgM (HRP-conjugated) antibody added and incubated for 1 hour at 
RT. Hereafter, 3,3’,5,5’-tetramethylbenzidine (TMB, Sigma Aldrich) reagent as a substrate 
for HRP was added. Finally, the enzymatic reaction was stopped with 0.16 M sulfuric acid 
(H2SO4) and the absorbance measured at 450 nanometer (nm) with a spectrometer-based 
microtiter plate reader. Patients were considered positive when an optical density (OD) 
above 0.5 was observed.
Cross-reactivity was tested by adding sera of predetermined positive patients with 
various STEC serotype infections (resp. O26, O55, O103, O111, O145) together with pre-
determined positive and negative patients, to an ELISA plate coated with glycoprotein 
serotype O157.
To study the effect of multiple freeze-thawning cycles on the patient blood samples, 
we freeze-thawed different previously determined positive samples, taken from three 
STEC-HUS patients, on five subsequent days. In the end we had a sample of one up till 
five freeze-thawn cycles of each patient.
Reference standard: Fecal diagnostics and LPS-ELISA
Feces and serum from suspected STEC-HUS patients were collected as soon as possible 
after admission to the hospital. In cases where feces could not be obtained, a rectal swab 
was done. Serum was received from all patients during standard care and stored at -80 °C 
until analysis. Fecal diagnostics and LPS-ELISA were performed as previously described.80 
Fecal diagnostics were considered positive when either PCR for Shiga toxins 1 and/or 2, the 
presence of fecal free shiga toxin by using the verocell assay, or the fecal culture (using 
Sorbitol MacConkey agar plate) was positive for STEC. In case of dubious test results, 
we considered the result as negative. After 2007, it became possible to send the STEC 
strains, isolated from the feces, to the Dutch National Institute for Public Health and 
Environment (RIVM) for further determination of the serotype both O157 and non-O157. 
Within the LPS-ELISA patients were considered positive when an optical density (OD) 
above 0.8 was observed. This cut-off was previously determined in close collaboration 
with Chart et al.87
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Assay characteristics
The response of both LPS-ELISA as glyco-iELISA was established by determining the 
lowest signal to detect positive sample. In each setup of the plate, 1 previously determined 
positive and negative patient for the presence of antibodies against O157 antigens were 
diluted with different concentrations. Positive/negative ratio’s (P/N ratios) were calcu-
lated by dividing the OD’s obtained for each specific concentration. Subsequently, the 
coating antigen concentration was also taken into account when the sensitivity of the 
assays was compared. 
Statistics
For each assay, the mean, standard deviation (SD), and coefficient variation (CV) were 
calculated. Furthermore, for the glyco-iELISA assays with patient screening, cut-off values 
were established using the following formula: mean of optical densities of control sera 
±2 times the SD. 
Clinical values were expressed as valid percentages for categorical variables and as the 
mean and SD or median and 25-75 interquartile range (IQR) for continuous variables, as 
appropriate. The Chi-square test was performed to compare categorical data. P values of 
<0.05 were considered statistically significant. All graphs were performed using GraphPad 
Prism software version 5. For statistical analyses, SPSS software (version 22.0) was used. 
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Results
Patient characteristics
As previously published, during the period between 1990 and 2014, 65 patients with a 
clinical pattern of STEC-HUS presented in the Pediatric Nephrology Department of Rad-
boudumc Amalia Children’s Hospital. Unfortunately, of the 65 patients, 14 patients had 
to be excluded of this analysis due the absence of residual material to test glyco-iELISA. 
The patient characteristics of the 51 STEC-HUS patients are described in Table 3.1. One 
patient with a highly severe presentation of STEC-HUS died due to a systemic inflam-
matory response syndrome. STEC infection was proven with both fecal diagnostics as 
serology.
During the period between 1990 and 2017, a total of 264 serum samples were sent to 
the laboratory of the HUS expertise center of the Radboudumc Amalia Children’s Hospi-
tal of patients with acute TMA. Of the 264 serum samples of this nationwide cohort, 212 
samples were collected from 206 patients with TMA and 52 samples from 50 relatives of 
these patients. The median (range) age of the patients was 6 (0-73) years. The majority 
of the relatives was a parent (n=42), five siblings were tested and three grandparents. 
Unfortunately, no clinical data were available from these patients as the samples were 
obtained from different hospitals in the Netherlands.
Table 3.1 Characteristics of pediatric patients with STEC-HUS in a single center cohort
Parameter All patients (n=51)
Male 47%
Age of onset in months 36 (23 – 65)
Symptoms at presentation
Fevera 22% 
Diarrhea, totalb 96% 
   Of which bloody 78% 
Anuria (defined as <0.1 ml/kg/h) 57%
Blood pressure
   < p95 44%
   ≥ p95 56% 
Neurological involvement 12% (n=6)
   Convulsions 8% (n=4)
   Coma 0%
   Miscellaneousc 10% (n=5)
Pancreas involvement 4% 
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Table 3.1 Continued
Parameter All patients (n=51)
Biochemical evaluation at presentation  (reference range)
Hemoglobin (mmol/l)
   (6.0 – 9.0 )
5.3 (4.0 - 6.3) 
White blood cells (x109/l)
   (5.0 - 13.0)
14.5 (10.97 - 22.5) 
Platelet count (x109/l)
   (210 - 430)
45 (32 - 76) 
Haptoglobin (g/l)
   (0,3-1,6)
<0.08 (0.04 - 0.10) 
LDH (U/l)
   (<250)
3929 (2525 - 5817)
Creatinine (µmol/l)
   (strongly depending age and bodymass)
307 (190.5 – 430)
eGFR (ml/min.1.73m2)d
   (>90)
13 (8 - 23)
Treatment
Dialysis 65% 
   Duration of dialysis in days 10 (7 - 14) 
Erythrocytes transfusion 92% 
   ≥ 3 transfusions 20% 
Categorical values are expressed as percentage of total and for continuous variables the median with interquartile 
range (IQR) is expressed. Neurological involvement included areflexia, coma, epilepsy and signs indicative of 
encephalopathy (decreased consciousness, abnormal behavior, amnesia, desorientation for time/person/place, 
disturbed speak, apraxia, hyperreflexia). P95: percentile for age and height88.
a Fever, defined as body temperature above 38.2 Celcius, was reported by patients and/or parents
b Of note, we report two patients suspected of STEC-HUS without diarrhea. In one patient, STEC infection could 
be established by both fecal diagnostics (with rectal swab) as well as serology. In the second patient, serology for 
STEC O157 was negative and PCR was repeatedly reported as dubious. STEC-HUS seemed very likely, also in the 
light of good clinical recovery with minimal sequelae (mild proteinuria) and no recurrence after 6 years.
c Either in combination with convulsion or as solo presentation. Other neurological symptoms reported were 
decreased consciousness (n=3), ataxia (n=1) and apathy (n=1)
d All patients had signs indicative of renal injury according to the pRIFLE criteria. In total, 46 patients had renal 
failure based on the pRIFLE criteria.
Assay characteristics of glyco-iELISA 
Since some samples were stored for quite some years, we accessed the stability of antibod-
ies in our samples. However, freeze-thawning cycles up till five times did not seem to have 
an effect on determined OD values in the glyco-iELISA (data not shown). Furthermore, in 
contrary to LPS-ELISA, glyco-iELISA shows low intra- and inter-assay variation (CV<20%).
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The discrimination capacity to detect a positive and negative signal of LPS-ELISA 
and glyco-iELISA were determined for serological antibodies against O157 antigen and 
compared to each other (Figure 3.1). Higher Positive/Negative (P/N) ratio’s were obtained 
with the glyco-iELISA, especially when using 1250 ng/ml glycoprotein with 800 times 
serum dilution (P/N ratio of 6.6) compared to LPS-ELISA. Furthermore, no cross-reac-
tivity was observed for STEC serotypes O26, O111, O145, O103 and O55 antigens in the 
glyco-iELISA (Figure 3.2). 
Sensitivity of glyco-iELISA
In total, 51 STEC-HUS patients with serology and clinical data were available and included 
in the analysis. Since the PCR for Shiga toxin (Stx) genes was introduced in our hospital in 
2011, in only 12 patients PCR was performed to detect the presence of Stx genes. In total, 
nine patients had a proven STEC infection based on PCR for Stx, of which seven were 
also confirmed with glyco-iELISA O157. The remaining two patients had a proven STEC 
infection with serotypes O55 and O26, explaining the negative glyco-iELISA result (see 
Table 3.2). 
Figure 3.1 Response of LPS-ELISA versus glyco-iELISA
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Figure 3.1 The response of both assays was accessed by determining the lowest signal at which a positive sample 
could still be detected for both LPS-ELISA as glyco-iELISA for STEC serotype O157. One previously determined 
positive and negative sample were diluted with different concentrations. Positive/negative ratio’s were calculated 
by dividing the optical density obtained for each specific concentration. Subsequently, the coating antigen con-
centration was also taken into account when the accuracy of the assays was compared. LPS; lipopolysaccharide, 
P/N; positive negative ratio.
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Figure 3.2 No cross-reactivity was observed with the glyco-iELISA for different STEC serotypes
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Figure 3.2 No cross-reactivity with different STEC serotypes was observed with the O157 glyco-iELISA. After coating 
with glycoprotein O157,pooled sera of various healthy negative controls (NC) and 4 separate NC together with 
sera of patients (P) with predetermined STEC infection with resp. STEC serotypes O26, O55, O103, O111, O145 and 
O157 were added. Every bar represents one patient with STEC-HUS due to the serotype as indicated. The dotted 
bar represents the cut-of value of 0.5 optimal density (OD). Only the patients with STEC-HUS with serotype O157 
were determined as positive, indicating no cross-reactivity. 
Furthermore, in 17 patients further determination of STEC serotype took place based 
on fecal diagnostics and yielded 14 STEC infections with isolated strain serotype O157. All 
these patients had also serology for O157 tested with the glyco-iELISA. This compared to 
serology tested by LPS-iELISA in which two patients tested negative.
Time window to perform glyco-iELISA
In eight patients of our single center cohort, serum was collected on various time points 
after the onset of diarrhea. These samples were used to examine the production of serum 
IgM antibodies (tested with the glyco-iELISA) during the disease course of STEC-HUS 
(Figure 3.3). A clear positive result for STEC O157 was observed after already one day after 
the start of diarrhea. However, there is a strong variation between individuals. Patient 3 
had no antibodies against STEC O157 on day 1, however when tested on day eight and 14 
antibodies could be detected. Patient 4 (with negative serology on day 1) had a positive 
antibody response up to 23 days after which the signal dropped significantly. Patient 5 
had even persisting antibodies until 51 days after the start of diarrhea.
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Table 3.2 Comparison between fecal diagnostics and glyco-iELISA for antibodies against STEC 
O157 antigen in patients with STEC-HUS in single center cohort
Assays Positive 
glyco-iELISA O157
Negative 
glyco-ELISA O157
Total number 
of patients
Positive fecal diagnostics* 18 4 22
   Feces culture  15 2 17
   Free fecal toxin (verocell assay) 8 3 11
   PCR 7 2 9
Negative fecal diagnostics 22 7 29
   Feces culture 9 8 17
   Free fecal toxin (verocell assay) 11 5 16
   PCR 2 1 3
Total number of patients 40 11 51
* Patients can be positive for each fecal diagnostic assay separate as well as all combined. 
PCR; Polymerare chain reaction
Figure 3.3 Time window to perform glyco-iELISA to detect IgM against STEC O157
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Figure 3.3 From eight STEC-HUS patients multiple serum samples collected after the onset of diarrhea on different 
days during the course of their disease, have been tested by using the glyco-iELISA for the presence of antibodies 
against serotype O157. The dotted line represents the cut-off value of 0.5 optical density (OD) after which samples 
are categories as positive for antibodies against serotype O157in the glyco-iELISA.
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Single center cohort of STEC-HUS patients
Of the 51 STEC-HUS patients, 22 (43%) had a positive fecal diagnosis for STEC, 33 (65%) 
had positive serology based on the LPS-ELISA against O157, and 40 (78%) had positive 
serology based on the glyco-iELISA (see Table 3.3 and Figure 3.4). In total, three patients 
appeared positive in O157 LPS-ELISA whereas they were negative with glyco-iELISA. In 
two of these patients fecal diagnostics revealed STEC infection with serotype O26 and 
O55, explanatory for the negative glyco-iELISA result and indicating a false (due to cross 
reactivity) positive result in the LPS-ELISA. In the third patient, the STEC strain was not 
further determined. Overall, the glyco-iELISA yielded 10 patients that were previously 
negative with LPS-ELISA. In conclusion, glyco-iELISA yielded significantly more patients 
positive for the presence of STEC when compared to fecal diagnostics (p<0.0001) and 
LPS-ELISA (p=0.04). Moreover, when combining fecal diagnostics with glyco-iELISA, 
STEC was detected in significantly (86% , p=0.03) more patients than when combined 
with LPS-ELISA (73%).
Table 3.3 Comparison between LPS-ELISA and glyco-iELISA for antibodies against STEC O157 
antigen in single center cohort
Assays Positive 
glyco-iELISA O157
Negative 
glyco-iELISA O157
Total
Positive LPS-ELISA O157 30 3* 33
Negative LPS-ELISA O157 10 8 18
Total amount of STEC-HUS patients 40 11 51
HUS; hemolytic uremic syndrome, LPS; lipopolysaccharide, STEC; Shiga toxin producing Escherichia coli
* Fecal diagnostics revealed: O26 strain (n=1), O55 strain (n=1), and no further determination of serotype was 
performed (n=1)
Nationwide cohort of patients with TMA
The 264 serum samples of the nationwide cohort of patients with TMA, send in for STEC 
O157 serology, were tested with both LPS-ELISA and glyco-iELISA and outcome differed 
significantly (p<0.0001). When the 212 samples from the patients with TMA suspicion 
were tested using LPS-ELISA, 48 (23%) samples were diagnosed as positive, and 164 (77%) 
as negative (Table 3.4). When tested with glyco-iELISA, 60 (38%) samples of patients 
with TMA were confirmative for STEC O157 infection. 
Subsequently, the 52 serum samples from the relatives of patients with TMA were 
tested with LPS and glyco-iELISA as well (Table 3.4). Interestingly, 10 were positive 
with the glyco-iELISA indicative of STEC infection. Of these relatives, in all but one the 
index patient tested positive for STEC infection as well. In this patient, mother tested 
positive for STEC O157, however the patients tested negative with both glyco-iELISA as 
well as LPS-ELISA.
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In total, of all patients with clinical suspicion of STEC-HUS (n=206 with 212 samples), 56 
(27%) patients tested positive for STEC O157 infection with glyco-iELISA. Overall, using 
the glyco-iELISA, 19 (7.2%) patients with TMA that were previously diagnosed as negative 
with LPS-ELISA could be diagnosed as STEC O157 positive (p<0.001).
Figure 3.4 Proportion of pediatric HUS patients from single center cohort tested positive for 
STEC-infection with different diagnostic tools
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Figure 3.4 The percentage of STEC-HUS patients in the single center cohort per diagnostic test is described, given in 
percentages from the total of 51 patients. The proportion of respectively positive (white bar) and negative patients (black 
bar) are depicted for fecal diagnostics(STEC detection by stool culture, free fecal shiga toxin by verocell assay, PCR for 
shiga toxin genes),LPS-ELISA and glyco-iELISA for STEC serotype O157 (respectively LPS-O157 and Glyco-O157) and 
combined. When glyco-iELISA is combined with fecal diagnostics the percentage of positive STEC patients increased up 
till 86%.FD; fecal diagnostics, LPS; lipopolysaccharide, STEC; Shiga toxin producing Escherichia coli
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Table 3.4 Comparison between LPS-ELISA and glyco-iELISA in nationwide cohort of patients 
with TMA of unknown etiology
Assays Positive 
glyco-iELISA O157
Negative
glyco-iELISA O157 
Total
Total number of patients/relatives 
with positive LPS-ELISA O157
51 0 51
   Patients 48 0 48
   Relatives 3 0 3
Total number of patients/relatives with 
negative LPS-ELISA O157
19 194 213
   Patients 12 152 164
   Relatives 7 42 49
Total number of patients/relatives 70 194 264
HUS; hemolytic uremic syndrome, LPS; lipopolysaccharide, STEC; Shiga toxin producing Escherichia coli
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Discussion
Differentiation between different etiologies of HUS is highly important regarding treat-
ment and outcome. Since aHUS is a diagnosis per exclusionem, proving proof of STEC 
infection in a ‘typical’ STEC-HUS is essential. However, fecal diagnostics, the gold stan-
dard to diagnose STEC-HUS has some major drawbacks, most importantly due to the 
natural course of disease and low inoculums. Serological diagnostics like anti-O157 LPS 
antibodies has proven its added value to fecal diagnostics although this diagnostic assay 
has a different bottleneck; potential cross-reactivity and limited sensitivity. Here we show 
that the novel glyco-iELISA, to detect anti-O157 antibodies, is highly sensitive and spe-
cific and its use in STEC diagnostics led to more patients displaying positive STEC-O157 
infections causing HUS. More importantly, using glyco-iELISA STEC O157-infections 
could be detected for a long period of time after start of the disease.
With this study the clinical utility of the glyco-iELISA was assessed. Melli et 
al. were the first to publish their findings regarding this novel glyco-iELISA using 
bacterial engineered glycoproteins for serotype O157, O145 and O121.32 In a cohort of 
71 samples taken from pediatric patients (comprising both STEC positive patients 
and STEC negative patients with clinical suspicion of STEC-HUS), they showed that 
the glyco-iELISA was highly sensitive and specific. Furthermore, no cross-reactivity 
between the previous serotypes was observed, confirming our results. The same group 
published a second article in 2017 by Castillo et al. where they further investigated 
cross-reactivity between different STEC serotypes (resp. O111, O103, O45, O26, O104) 
and other gram-negative bacteria (salmonella, Brucella abortus, Yersinia enterocolitica 
O9). Again no cross-reactivity was observed.81 This in contrast to LPS-ELISA, where 
clear cross-reactivity between different serotypes has been reported.29 Overall, with 
access to the glycoproteins, the glyco-iELISA is an easily implemented and performed 
assay with stable results.
Ideally, one would calculate sensitivity (proportion of patients with STEC-HUS in 
which the glyco-iELISA is positive) and specificity (proportion of patients with TMA 
caused by other conditions than STEC in which the glyco-iELISA remains negative) for 
an assay like glyco-iELISA. However, various problems arised when attempting to do so. 
The most prominent one has to do with the accuracy of the gold standard to diagnose 
STEC-HUS. Since fecal diagnostics are not sufficient to diagnose all STEC-HUS patients, 
no optimal gold standard is present to calculate sensitivity and specificity. Moreover, 
serology should not replace fecal diagnostics, but should be used in addition, to comple-
ment the microbial diagnostics and broaden the time window to detect STEC. Hence, 
accurate estimation of sensitivity and specificity is not feasible. Although, in our cohort, 
all patients with proven O157 in the feces were positive with glyco-iELISA in contrast 
to LPS-iELISA, indicating high sensitivity (100% in our cohort). Furthermore, in patients 
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with proven STEC infection with non-O157 serotype, glyco-iELISA for O157 remained 
negative in contrast to LPS-ELISA for O157, indicating high specificity.
As stated previously, cross-reactivity between LPS of different Gram-negative bac-
teria is a known problem due to the conserved lipid A part of the LPS molecule. We 
hypothesized that cross-reactivity, as observed in LPS-based ELISAs, can present as a false 
positive test result in the O157 LPS-ELISA. This may be due to the presence of antibodies 
against other non-O157 STEC serotypes or even other gram-negative bacteria, which to 
some extent are able to bind to the lipid A part of STEC serotypes. Interestingly, using 
the highly specific and sensitive glyco-iELISA, we observed an increase in the detection 
of STEC infections, rather than a decrease due to false positive results. Different explana-
tions could explain this better performance. Primarily, STEC serotype O157 is still a highly 
prevalent serotype causing HUS in the Netherlands. Therefore not much cross-reactivity 
could be found, since non-O157 serotypes causing HUS are less common. Furthermore, 
as shown in our single center cohort, the glyco-iELISA is able to detect all patients with 
confirmed O157 serotype in the feces, and remains negative in patients with a confirmed 
infection with other serotypes. Hence, the negative result obtained with the glyco-iELISA 
seemed accurate indicating that the LPS-ELISA is probably a false positive result due to 
cross-reactivity between different STEC serotypes, as this was found to be the case in two 
of our patients. Other methods to detect serology have been reported such as line blot 
immunoassay and immunoblotting, however all use purified LPS to detect antibodies, 
hence potential cross-reactivity remains present.29
Interestingly, of the 52 samples of relatives without clinical HUS features, 10 (19.2%) 
had antibodies detected with the glyco-iELISA, indicating STEC O157 transmission person 
by person or intake of same contaminated food. In all except one, the index patient tested 
positive for STEC infection. Although we have no clinical information about relatives in 
our study, we could show that family members of STEC-HUS patients with no or mild 
signs of gastro-intestinal infection can develop antibodies against O157. These results are 
in line with Ludwig et al. who reported that 17% of the household contacts (symptomatic 
as well as asymptomatic) of STEC-HUS patients had LPS IgM antibodies against STEC 
serotype O157.71 The exact rate of IgM antibodies against STEC serotypes in healthy pop-
ulation is still unknown. However, to exclude potential false positive results, one could 
consider to only test for presence of IgM and not include IgG, since IgG can be present for 
years after infection. Yet, we would recommend to test family members of patient with 
STEC (with fecal diagnostics and serology), especially in patients who tested negative for 
STEC infection. By providing proof of STEC infection in household contact, the diagnosis 
STEC-HUS in the index patient despite negative diagnostics becomes more likely. 
We found IgM antibodies against STEC O157 up to 55 days after onset of the disease. 
These results are in line with previous reported kinetics of IgM (LPS based assay) against STEC 
by Chart et al.70 Hence, in contrast to fecal diagnostics in which the isolation rate declines 
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quickly after the initial symptoms (within one week), serology (both LPS- and glyco-iELISA) 
broadens the time window to diagnose STEC infections. Furthermore, when serum is col-
lected too early in the course of the disease, serology could be negative due to yet incomplete 
seroconversion, as was the case in two of our patients. In case of a negative serology result 
tested in serum collected within seven days after disease onset, the advice would be to collect 
and test serum again after seven days for a re-evaluation. As described previously, the added 
value of serology increased even more seven days or more after the start of the symptoms.80
Limitations of this study are the retrospective nature and the lack of clinical data of 
the national TMA cohort. Serological detection of STEC infection by detection of anti-
O157 antibodies in serumis advised in the national guideline of diagnostic work-up for 
TMA at presentation. Presumably, quite some patients in the national cohort had a differ-
ent diagnosis that not only comprised STEC-HUS , but also aHUS or other causes of TMA. 
Concerning the single center cohort of pediatric patients, STEC infection could not be 
detected in seven patients with clinical suspicion of HUS. Yet, aHUS as diagnosis is highly 
unlikely regarding the clinical presentation with bloody diarrhea in all seven patients 
Although, aHUS can present in 30% of the cases with gastro-intestinal infection, bloody 
diarrhea is seldom reported in aHUS. Also, follow up data showed no disease recurrence, 
making aHUS highly unlikely in this single center cohort. In three patients, genetic analy-
sis was performed and showed no pathogenic mutations in complement genes associated 
with aHUS. Furthermore, in most patients serology was only tested at one timepoint. 
Seroconversion takes 3-5 days, hence patients who were seen early in the course of dis-
ease could be false negative. Furthermore, we focused on the still most prevalent STEC 
serotype O157 causing HUS in our country, however nowadays non-O157 serotypes are 
increasingly detected as cause of HUS. The relatively high number of patients with STEC 
O157 infection in our cohort could be explained by the substantial amount of STEC-HUS 
patients who were included in the late nineties, when serotype O157 was then and still 
now the main serotype to cause STEC-HUS. Nowadays, the amount of non-O157 serotypes 
causing HUS are increasingly detected, partly explained due to the new and improved 
diagnostic assays. In this study, non-O157 STEC serotypes were not detected.20,30 It would 
be very worthwhile to examine the 14% of clinical STEC-HUS patients who were nega-
tive in fecal and serological diagnostics with glyco-iELISA for other STEC serotypes in 
the near future. Hence, future plans are to expand the glyco-iELISA to detect multiple 
serotypes. Melli et al. described already the use of glyco-iELISA for STEC serotype O145 
and O121 with comparable results regarding absence of cross-reactivity and sensitivity of 
the assays.32 Furthermore, to it is highly important differentiate between STEC-HUS and 
aHUS as soon as possible, to start appropriate treatment. Since the current glyco-iELISA 
takes at least 24 hours to perform, future studies should focus on improving this assay 
for bedside use. For example, with by using lateral flow technology one could develop a 
point of care test for patients presenting with TMA.
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In conclusion, serological assays for STEC O-antigens have a place in the diagnostic 
work up plan of patients with TMA. Moreover, since aHUS is a diagnosis per exclusionem 
it is highly important to diagnose STEC-HUS. Therefore, we advocate to always combine 
fecal diagnostics together with serological diagnostics to achieve optimal diagnostics and 
prevent unnecessary use of the highly expensive orphan drug eculizumab. The optimal 
assay to determine serological antibodies against STEC serotype O157 is the glyco-iELISA.
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Unusual severe case of 
hemolytic uremic syndrome
due to Shiga toxin 2d producing 
E.coli O80:H2
Chapter 4
Abstract
Hemolytic uremic syndrome (HUS) is one of the most common causes of acute renal 
failure in children, with the majority of cases caused by an infection with Shiga tox-
in-producing Escherichia coli (STEC). Whereas O157 is still the predominant STEC serotype, 
non-O157 serotypes are increasingly associated with STEC-HUS. However, little is known 
about this emerging and highly diverse group of non-O157 serotypes. With supportive 
therapy, STEC-HUS is often self-limiting, with occurrence of chronic sequelae in just a 
small proportion of patients. In this case report we describe a 16-month old boy with a 
highly severe and atypical presentation of STEC-HUS. Despite the presentation with 
multi organ failure and extensive involvement of central nervous system due to extensive 
thrombotic microangiopathy (suggestive of atypical HUS), fecal diagnostics revealed 
an infection with the rare serotype: shiga toxin 2d producing STEC O80:H2. This report 
underlines the importance of STEC diagnostic tests in all children with HUS, including 
those with an atypical presentation, and emphasizes the importance of molecular and 
serotyping assays to estimate the virulence of an STEC strain.
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Background
Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in 
children and diagnosed when the features of hemolytic anemia and thrombocytopenia 
are present simultaneously.6 In over 90% of pediatric cases, HUS follows a gastro-intes-
tinal infection with Shiga toxin-producing Escherichia coli (STEC), previously known by 
the name of post-diarrheal or typical HUS, because of its main characteristic of (bloody) 
diarrhea.6 Whereas O157 is still the predominant STEC serotype, non-O157 serotypes are 
increasingly associated with STEC-HUS.30 However, in contrast to STEC O157, little is 
known about this emerging and highly diverse group of non-O157 serotypes. Thrombotic 
microangiopathy (TMA) causing HUS predominantly affects the renal vasculature. Nev-
ertheless, especially in non-O157 STEC serotypes, extra renal involvement such as central 
nervous system involvement is described.89 If symptomatic treatment is started in time, 
the recovery of STEC-HUS is often spontaneously with minimal chronic sequelae.90
Here we present a case of a 16-months-old boy with an unusual presentation and rare 
STEC serotype resulting in a very severe course of STEC-HUS. 
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Case report
A previously healthy 16-month old boy presented at the emergency department of a 
general hospital with convulsions and impaired consciousness. He had a two-day history 
of coughing, vomiting and lethargy, without signs of fever. Three months prior, he had a 
period of non-bloody diarrhea for over a week after visiting a biological farmer. A detailed 
medical history of the patient and family revealed no ingestion of unpasteurized milk or 
cheese nor a visit to a foreign country. On physical examination he exhibited fluctuating 
levels of alertness. Respiratory rate was 29/minute with oxygen saturation of 97%. Body 
temperature (36.4°C) and blood pressure were normal (98/60 mmHg) with mildly elevated 
pulse rate (138 beats per minute). Examination of the heart, lungs and abdomen was unre-
markable. Skin examination revealed a pale looking patient with petechiae at lower limbs. 
Based on clinical suspicion of meningitis or non-convulsive status epilepticus, ceftri-
axone and midazolam were administered and the patient was transferred to our hospital. 
Initial laboratory evaluation showed hyperglycemia and the triad of HUS (Table 4.1). 
In the first hours, consciousness further decreased and the patient was transferred to 
the pediatric intensive care unit (ICU), where peritoneal dialysis was initiated due to 
persistent anuria. Blood and feces samples to determine the presence of an STEC infec-
tion were obtained. Blood cultures were performed repeatedly and remained negative 
during admission. Thrombotic thrombocytopenic purpura (TTP) was excluded with a 
normal ADAMTS13 activity (Table 4.1). Atypical HUS (aHUS), caused by complement 
dysregulation, was considered because of severity of the presentation, mainly neurolog-
ical presentation, no recent history of (bloody) diarrhea, and young age of the patient. 
Consequently, the patient received 600mg of eculizumab. Later incoming results of addi-
tional complement and DNA diagnostics showed no abnormalities (Table 4.1).
The following day, fecal diagnostics revealed an STEC infection, indicating STEC-
HUS; real-time polymerase chain reaction (PCR) was positive for Shiga toxin 2 (Stx2) and 
attaching and effacing (eae) genes. In addition, molecular serotyping using whole genome 
sequencing revealed the rare STEC serotype O80:H2, which contained the Stx2d gene and 
the rarely in human seen eae ξ gene variant (Table 4.1).91 
In the course of admission, the patient developed multiple signs of severe, extra 
renal manifestations of TMA. Due to the severe neurological symptoms, with convulsions 
and decreased consciousness, brain magnetic resonance imaging (MRI) was performed, 
showing diffusion restriction of the deep white matter (Table 4.1). 
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Table 4.1 Multi-organ involvement 
Test At 
admission
Most 
abnormal 
value 
At 
discharge
Normal 
value or 
range
Differential 
diagnosis
TTP
STEC-HUS
Blood culture
ADAMTS13 activity (%)
Serology
O157 IgM / G / A
O26 IgM / G / A
PCR Stx1 gene
 Stx2 gene
 eae gene
WGS Serotype
 Isolate
 Sequence type 
Virulence factors
 Stx1gene
 Stx2gene
 eae 
 aggR
 aatA
Negative
91%
Negative 
Negative
Negative
Positive
Positive
O80:H2
Stx2d, eae ξ 
variant
ST301
Negative
Positive
Positive
Negative
Negative
 Negative
Negative
Negative
Negative
>65%
 aHUS Complement
 C3 (mg/l) 874 NA NA 900-
1800 
 C4 (mg/l) 71 NA NA 150-400 
Anti factor H 
autoantibodies
Negative
DNA analysis
 Factor H No pathogenic 
variation
 Factor I No pathogenic 
variation
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Table 4.1 Continued 
Test At admission Most 
abnormal 
value 
At 
discharge
Normal 
value or 
range
 aHUS
(Continued)
 Factor B No pathogenic 
variation
 C3 No pathogenic 
variation
 MCP No pathogenic 
variation
 CFHR 1-5 No pathogenic 
variation
 DGKε No pathogenic 
variation
 THBD No pathogenic 
variation
 MLPA Factor H operon No aberrations
Hematological Hemoglobin (mmol/l) 4.5 3.3 7.3 6.8-8.6
Platelet count (x109/l) 22 18 872 210-430 
WBC count (x109/l) 15.5 29.0 12.9 5.0-17.0 
Schizocytes (%)
Haptoglobin (g/l)
>5
Hemolytic
>5
Hemolytic
NA
1.85a
<0,5
0.3-1.6 
LDH (U/l) 2285 6521 908 <250 
Kidney Creatinine (µmol/l) 167 444 (PD) 470 (PD) 15-45 
eGFR(ml/min/1.73 m2) 17 anuria anuria 80-120 
BUN (mmol/l) 43.9 44.2 22.4 2.5-7.0 
Brain MRI Diffusion 
restriction 
of the deep 
white matter 
consistent 
with metabolic 
encephalopathy
NA NA
EEG No epileptic 
activity
NA NA
Heart CK (U/l) 2743 8390 139a <170 
Ntpro-BNP (pg/ml) NA >180,000 NA <320 
Troponin T levels (ng/l) 557 23,444 508 a <14 
Echo NA Left 
ventricular 
dysfunction
Normal left 
ventricular 
functiona
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Table 4.1 Continued 
Test At admission Most 
abnormal 
value 
At 
discharge
Normal 
value or 
range
Pancreas Amylase (U/l) NA 1933 42 a <105 
Glucose (mmol/l) 9.9 30.7 6.2 4.0-5.6 
Triglycerides (mmol/l) NA 14.17 4.92 0.8-2.0 
Liver AST (U/l) 163 1020 114 <35 
ALT (U/l) 62 480 144 <45 
Gamma-GT (U/l) 6 1810 824 <55 
Alkaline phosphatase 
(U/l)
205 1529 401 <115 
Direct bilirubin 
(µmol/l)
Ultrasound
Biopsy
4 326
Edema 
around 
and sludge 
inside 
gallbladder
Cholestasis
35 <5 
aatA; necessary for translocation of dispersin (Aap), ADAMTS13; a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif; member 13, aggR; transcriptional regulator aggR, aHUS; atypical hemolytic uremic 
syndrome, ALT; alanine transaminase, AST; aspartate transaminase, BUN; blood urea nitrogen, CFHR; comple-
ment factor H related proteins, CK; creatine kinase, DGKε; diacylglycerol kinase epsilon, eae; E. coli attachment 
effacement gene (intimin), EEG; electroencephalogram, eGFR; estimated glomerular filtration rate based on 
Schwartz estimation with k-value of 36.5, gammaGT; gamma-glutamyl transferase, IgA; immunoglobulin A, IgG; 
immunoglobulin G, IgM; immunoglobulin M, LDH; lactate dehydrogenase, MCP; membrane cofactor protein, MRI; 
magnetic resonance imaging, NA; not available, Ntpro-BNP; N-terminal of the prohormone brain natriuretic pep-
tide, PCR; polymerase chain reaction, PD; peritoneal dialysis; STEC; Shiga toxin producing Escherichia coli, Stx1; 
Shiga toxin 1, Stx2; Shiga toxin 2, THBD; thrombomodulin, TTP; thrombotic thrombocytopenic purpura, WBC; 
white blood cell count, WGS; whole genome sequencing. aTwo months after presentation
On day four of admission, the patient was resuscitated twice due to post-intubation 
hypotension and bradycardia, with rapid recovery of cardiac output. Cardiac biomarkers 
were elevated, and retrospectively elevated troponin T levels and creatine kinase were 
already present. Echocardiogram revealed a mildly dilated and dysfunctional left ventri-
cle. Eventually, follow up demonstrated a significant improvement in cardiac biomarkers 
and function. 
Pancreas involvement was noticed based on a gradual rise in serum glucose and 
elevation of serum amylase and triglyceride concentrations without clinical signs of 
pancreatitis. Insulin treatment was needed for two weeks.  
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After two weeks, jaundice was observed in combination with elevated bilirubin levels, 
without signs of ongoing hemolysis. Progressive elevation of transaminases was mea-
sured, with normal levels of clotting factors but low serum albumin (Table 4.1). Liver 
biopsy showed extensive signs of cholestasis without microthrombi, most likely due to 
sludging or drug related effects (Figure 4.1). 
Figure 4.1 Liver biopsy
Figure 4.1 Light microscopy on the liver biopsy (with hematoxylin and eosin staining) revealed hepatocyte swelling 
and extensive signs of cholestasis.
Eventually, our patient was hospitalized for over three months. Only minimal signs of 
neurological improvement were observed and over time the patient developed spastic 
dystonia. Furthermore, he exhibited persistently decreased levels of consciousness with 
frequent periods of severe agitation. The patient remained anuric for which dialysis was 
continued. Nine months after initial presentation the patient died due to peritoneal- and 
hemodialysis failure combined with progressive liver failure and further neurological 
impairment. 
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Discussion
In this report we describe a 16-month-old boy with an unusual, severe presentation 
and course of STEC-HUS due to the rare Stx2d producing E.coli O80:H2. STEC-HUS is a 
common cause of HUS in childhood and in more than half of the cases results from an 
STEC infection with serotype O157. However, non-O157 serotypes are increasingly associ-
ated with HUS in recent years, most likely due to improvement of diagnostics.6,30 Usually, 
the majority of STEC-HUS resolves with no or minimal chronic sequelae.
STEC infection with serotype O80:H2 resulting in HUS was rarely described up to 
recently.30,92-94 To our knowledge, up till now this serotype was only found in patients with 
HUS in France and this report is the first describing a case in the Netherlands. In addition, 
one study from Spain already described the finding of this serotype in cattle over ten 
years ago. Interesting to note is that there is no direct geographic connection between 
the different areas. Hence, the source of the O80 serotype remains of unknown origin.94
STEC strains can produce different shiga toxins, respectively Stx1 and Stx2. Within 
these genotypes, especially the Stx2 gene, there is a wide variety of Stx subtypes, such as 
Stx2d which we describe in this case report.20 Moreover, the Stx2d gene is known to cause 
a more severe course of disease. This together with the rare eae ξ and the plasmid of the 
O80:H2 STEC, which showed high resemblance with the previous described plasmid 
associated with extra intestinal virulence, resulted in an increased association with HUS.94 
Only recently, Soysal et al. described the STEC serotype O80 as a new therapeutic chal-
lenge in patients with STEC-HUS due to its capacity to cause a bacteremia. Furthermore, 
Espié et al. described an outbreak of STEC serotypes O26 and O80 co-infection related 
to unpasteurized cheese.92 However, our patient had no bacteremia and no indication of 
co-infection, tested with both fecal diagnostics and serological antibody assays against 
both O157 and O26 lipopolysaccharide (Table 4.1)
Mariani-Kurkdjian et al. described the case of an adult male with a severe episode 
of HUS caused by STEC O80:H2 containing both Stx2d and the rare eae ξ variant like 
the strain described above.93 Similar to our case, the adult male patient presented with 
afebrile convulsions followed by coma and, after a few weeks, he developed bacteremia. 
This raised the question if the O80 serotype may not be cleared rapidly, in contrast to 
most other serotypes. Such a slow clearance would make it more likely that the STEC 
found in our patient could be the consequence of the gastro-intestinal infection three 
months prior to presentation.94,95
Nowadays, in the majority of laboratories, STEC diagnostics comprises PCR, cul-
ture and/or enzyme immune-assays. Obviously, these approaches could have missed the 
identification of the O80:H2 strain. Using additional molecular and serotyping assays 
allows the detection of virulence factors and typing of the Stx genes, both important to 
estimate the virulence of the strain. Such additional diagnostic tests are relevant both 
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for individual patients as for public health to monitor new or rare serotypes that cause 
severe HUS and emerge into the population.20
It can be challenging to clinically differentiate between STEC-HUS and aHUS due to 
similarity of symptoms. Similar as in our patient, in 6-10% of the children with STEC-HUS 
there is no (bloody) diarrhea, whereas aHUS is preceded by diarrhea in 25% of cases.44 
Since aHUS is merely a diagnosis per exclusionem, it is essential to proof the absence of 
an STEC infection.6,80 Even in cases without (bloody) diarrhea and atypical presentations 
such as young age of the patient, it is highly recommended to perform both fecal and 
serological diagnostics in every HUS patient to exclude STEC-HUS.80 
The treatment of STEC-HUS is merely symptomatic. A topic of discussion remains 
the use of antibiotics to eradicate STEC infection. Increased transcription, production and 
release of shiga toxins, possibly aggravating HUS, can be induced by antibiotics.96 Soysal 
et al. studied in vitro effects of different antibiotics on Stx production. Ceftriaxone, which 
our patient received at presentation, seems to have no effect on Stx production.94 Another 
controversial topic in patients with STEC-HUS is the use of eculizumab. Eculizumab, a 
monoclonal antibody directed against complement C5, is nowadays the standard treat-
ment in patients with aHUS.97 Some case series, among others Pape et al., reported better 
outcome of STEC-HUS after eculizumab administration, particularly in neurologically 
affected STEC-HUS patients.89,98 However, Pape et al. also described the use of eculizumab 
in patients with multi-organ failure, where it seems to be associated with a less favorable 
outcome.98 Well-designed and well-powered randomized controlled trials are needed to 
shed light on the effect of eculizumab in STEC-HUS.
Extra-renal manifestations of TMA are not uncommon in HUS. In 25% of HUS cases 
neurological involvement is noted, other organs are affected less frequently.6,89 Although 
severe multi-organ failure and especially liver failure is rarely described in STEC-HUS, 
the highly severe disease presentation in our patient could partially be explained by the 
(extraintestinal) virulence factors of this O80 strain. However, in our patient jaundice 
and liver failure evolved two weeks after one dose of eculizumab possibly indicating 
hepatotoxicity. This was recently described in five pediatric aHUS patients.99 Transient 
liver enzyme derangement was noticed in these children 10-29 days after the first dose 
of eculizumab with spontaneous resolution. The time pattern in our patient as described 
above, cannot rule out the hypothesis that administration of eculizumab could have 
contributed to liver failure in our patient. 
In conclusion, we describe a severe case of STEC-HUS caused, by an unusual Stx2d 
producing STEC O80:H2. This resulted in an unusual and severe disease course, com-
plicated by multi-organ failure and central nervous system involvement. This case 
emphasizes the importance of molecular and serotyping assays to estimate the virulence 
of an STEC strain.
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Heme as contributing factor 
in the evolvement of Shiga 
toxin Escherichia coli induced 
hemolytic uremic syndrome
Abstract
Although Shiga toxin (Stx)-producing Escherichia coli hemolytic uremic syndrome (STEC-
HUS) is one of the most common causes of acute kidney injury in children, the exact 
pathogenesis still remains elusive. Stx-mediated endothelial injury initiates the cascade 
leading to thrombotic microangiopathy (TMA). Yet, there is wide variability in clinical 
presentation and outcome. One explanation for this could be the enhancement of TMA 
through other factors. We hypothesize that heme, as released during extensive hemolysis, 
contributes to the development of TMA. Plasma levels of heme and its scavenger hemo-
pexin and degrading enzyme heme-oxygenase 1 (HO-1) were measured in 48 STEC-HUS 
patients. Next, the effect of these disease specific heme concentrations, in combination 
with Stx, were assessed on human primary glomerular microvascular endothelial cells 
(HGMVECs).
Significantly elevated heme levels up to 21.2 µM were found in STEC-HUS patients 
compared to controls (median of 1.8 µM). These elevated heme levels inversely correlated 
with plasma hemopexin levels (R2 -0.74). Furthermore, heme is internalized and led to a 
significant increase in reactive oxygen species production. We observed heme-induced 
nuclear translocation of NFκB together with increased cell surface tissue factor expres-
sion. Interestingly, upregulation of the cytoprotective enzyme HO-1 was impaired by Stx. 
In conclusion, we are the first to show elevated heme levels in patients with STEC-
HUS. These increased heme levels promote endothelial injury, thus may contribute to 
the cascade leading to TMA. Moreover, the impaired upregulation of HO-1 by Stx in 
endothelial cells leads to a decreased protection against injurious heme and contributes 
to Stx-mediated TMA.
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Introduction
Typically, the cascade leading to thrombotic microangiopathy (TMA) is explained as a 
cause-effect relationship. This cascade commence via a specific trigger causing endothe-
lial injury, leading to the formation of thrombi in the small vessels, subsequently leading 
to thrombocytopenia, hemolytic anemia and acute kidney injury.2,5 The most common 
cause of TMA in children is a gastro-intestinal infection with Shiga toxin (Stx)-producing 
Escherichia coli (STEC). In the majority of cases STEC hemolytic uremic syndrome (STEC-
HUS) has a prodromal phase characterized by (bloody) diarrhea.5,6 Stx produced by STEC 
is known to be the most important factor leading to HUS. However, only approximately 
15% of all patients with STEC infection develops HUS, suggesting other factors may be 
involved as well.17
The exact pathogenesis of STEC-HUS is only partially understood.85 It is thought that 
endothelial cell injury is caused by the Stx, an AB toxin, secreted from the STEC bacteria. 
Stx can enter the bloodstream and binds to its receptor, the glycolipid globotriaosylcer-
amide (Gb3) present on endothelial cell surfaces. After the transport of the A subunit of 
Stx intracellularly, cellular activation and damage is caused together with the promotion 
of a pro-inflammatory and pro-thrombotic state.89 Yet, there is wide variability in clinical 
presentation and outcome in STEC-HUS ranging from no chronic sequelae to hyperten-
sion, proteinuria, end stage renal disease or even death.5 One possible explanation for 
this broad range of clinical outcome could be the enhancement of TMA through other 
additional factors.
One of these additional factors could be heme, as released during extensive hemo-
lysis such as present in STEC-HUS patients.100 Heme is known for its noxious effects 
and primarily causes oxidative stress, together with the release of pro-inflammatory 
and pro-thrombotic molecules.100-103 Furthermore, it has the unique ability to intercalate 
in the membrane of red blood cells, thereby enhancing hemolysis.104 To prevent the 
accumulation of heme and limit the heme-mediated toxicity, heme is normally directly 
scavenged extracellularly by hemopexin, and degraded intracellularly by heme-oxy-
genase 1 (HO-1).102,104,105 When the extracellular heme scavenger hemopexin is saturated, 
heme will bind to less potent scavengers present in the blood like albumin or lipopro-
teins, hence remaining (partly) bioreactive.106,107 In addition, heme proteins could get 
trapped in the kidney where they can release their free heme group.108 Even more inter-
estingly, Bitzan et al. described the ability of Stx to inhibit HO-1 expression in human 
renal carcinoma-derived tubular epithelial cells. To our knowledge, no studies have 
been published regarding the effect of heme and Stx2 on HO-1 regulation in primary 
glomerular endothelial cells.109
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Unfortunately, very little is known about the (patho)physiological levels of extracel-
lular heme in case of hemolysis in STEC-HUS patients. Knowledge regarding accurate 
and representative heme levels as present during hemolysis in vivo is necessary to study 
the possible noxious effect of heme levels in vitro. We hypothesize that extracellular 
accumulation of bioreactive heme can initiate and amplify the cascade leading to TMA. 
In this study we measured plasma levels of heme in STEC-HUS patients, during the acute 
phase and assessed in vitro the effects of these disease specific heme concentration, in 
combination with Stx2, on primary human glomerular microvascular endothelial cells.
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Methods
Patient cohort
All patients who presented in the Radboud University Medical Center (Radboudumc) 
Amalia Children’s hospital between 1990-2016 with signs indicative of STEC-HUS were 
included. A clinical pattern of STEC-HUS was defined as; hemoglobin level below the 
lower limit of normal for the specific age and signs indicative of hemolysis, acute renal 
failure, thrombocytopenia < 150 x 109/l, and (bloody) diarrhea or family members with 
diarrhea. STEC-HUS was diagnosed by fecal diagnostics and serology. Both plasma and 
serum were collected on admission (acute phase) and stored at -80°C. Clinical data were 
collected retrospectively from medical records. In addition, 24 plasma samples of healthy 
adult controls and 26 samples of age matched controls were included after informed 
consent was obtained. Exclusion criteria for this control group were: fever, bacterial/viral 
infection in the past few weeks, chronic illness, inborn or acquired immune disorders and 
the use of immunosuppressive drugs. The ethics committee (CMO Arnhem-Nijmegen) 
has passed a positive judgment on the study (2017-3490).
Methods in supplemental data 
Hemopexin and HO-1 were measured with enzyme-linked immunosorbent assay (ELISA), 
the method is described in the supplemental data. For detailed description of flow 
cytometric apoptosis assay, reactive oxygen species (ROS) measurement, quantitative 
polymerase chain reaction (qPCR), western blot and statistic analysis, see supplemental 
data.
Colorimetric heme quantification assay
Plasma heme was measured using 1-Step™ Turbo 3,3’,5,5’-Tetramethylbenzidine (TMB)-
ELISA Substrate (Thermofisher scientific). This method is based on the oxidation of 
TMB by the pseudoperoxidase activity of heme. For this assay, hemin chloride porcine 
(designated as heme, Sigma-Aldrich) was diluted in 0.1M NaOH (Merck) and the pH was 
adjusted to 7.8-8.2.110 Subsequently, this solution was filtered through 0.2 µm pore size 
membrane (Whatman). Hereafter, serial dilutions (4.0 - 2.0 – 1.5 – 1 – 0.5 – 0.25 – 0 µM) 
of an 2 mM heme stock were made in 20 mM HEPES (Sigma-Aldrich) + 1% bovine serum 
albumin (BSA, Millipore), pH 7.4. Next, plasma samples (patients 10x, controls 2.5x) were 
diluted in 20 mM HEPES + 1% BSA, pH 7.4, where after 20 µL of every sample and 80 µL 
of the turbo TMB substrate was added to a microtiter plate (Greiner Bio-One™) and 
incubated for 10 minutes in the dark. The reaction was stopped with 100 µL 2 M sulfuric 
acid (Sigma-Aldrich) and absorbance was read at 450 nanometer (nm) with Victor 3 V 
multilabel plate reader (Perkin elmer).
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Cell culture 
Human glomerular microvascular endothelial cells (HGMVECs) were isolated and cul-
tured as described previously by van Setten et. al.111 Cells were cultured 24 hours prior to 
the experiments in serum free conditions to avoid the effect of serum in experiments. 
Immunofluorescence imaging
Confluent monolayer of HGMVECs cultured on 1% gelatin (Fluka) coated round glass 
coverslips Ø 1 cm (VWR) were stimulated with 25 or 50 µM heme and/or Zn(II) Mesopor-
phyrin IX (ZnMP; Frontier scientific) for 6 hours. After stimulation, cells were fixed with 
4% paraformaldehyde (PFA; Sigma-Aldrich) for 15 minutes at RT and subsequently stained 
with appropriate antibodies (CD31(mouse IgG1; Sanquin, monoclonal mouse α-human 
NF-kB p65 (F-6; Santa Cruz)). Subsequently, secondary antibody alexa fluor goat α-mouse 
IgG (Thermofisher scientific) and DAPI was added. Finally, stained cells on the coverslips 
were mounted on microscopic slides (Thermofisher scientific). Slides were viewed with a 
Zeiss fluorescence microscope or by Olympus FV1000 confocal microcopy.
Tissue factor (TF) measurement
With a cell-based ELISA, TF expression on the surface of HGMVECs were assessed. Con-
fluent monolayer of HGMVECs on gelatin coated 96-well tissue culture plate (Corning 
® Costar ®) were stimulated with 25 and 50 µM heme for 6 hours. Subsequently, the cells 
were fixed with 0.025 % glutaraldehyde (Merck), where after cells were incubated with 
biotinylated goat anti-human coagulation factor III detection antibody (DuoSet ELISA, 
R&D systems) diluted in M199-10% FCS. Next, diluted streptavidin-HRP (DuoSet ELISA, 
R&D systems) was added. Signal was visualized with TMB (Sigma-Aldrich)substrate at 
450 nm using Viktor 3 V multilabel plate reader.
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Results
Patient characteristics
In total, 48 patients were diagnosed with STEC-HUS from 1990 to 2016 in the department 
of Pediatric Nephrology of Amalia Children’s Hospital Radboudumc of which medical 
information was present. Patients characteristics on admission are shown in Table 5.1. 
Patients showed signs of (mechanical) hemolytic anemia, based on low hemoglobin and 
increased lactate dehydrogenase (LDH) levels with decreased and often depleted hapto-
globin levels. Dialyses was started in majority of the patients. 
Increased plasma heme levels
Plasma levels of heme in STEC-HUS patients in acute phase were significantly higher 
(p<0.0001) when compared to healthy controls. A median (range) of 3.2 (0.5-21.2) µM heme was 
found in STEC-HUS patients compared to 1.8 (0.6-3.8) µM in healthy controls (Figure 5.1A). 
Of note, no difference between pediatric and adults controls was observed. In total, 12 
patients had heme levels above the 75 quartile range (6.3 µM) up till 21.2 µM. Median (IQR) 
time between hospital admission and sample collection was 3 (1-11.3) days. Furthermore, 
when samples were collected later on in the disease course, the risk of measuring lower 
heme levels was OR of 0.79 (95% CI 0.64 – 0.99, p=0.49).
Plasma levels of heme neutralizing proteins: hemopexin and HO-1
STEC-HUS patients in the acute phase had significantly lower plasma hemopexin levels 
compared to healthy controls with median (range) of 0.4 (0.01-1.2) g/L and 0.9 (0.2-1.3) g/L 
respectively (p<0.0001, Figure 5.1B). Hemopexin was depleted (<0.1 g/L) in 15 patients with 
a heme median (IQR) of 11 (6.5-12.8) µM. Moreover, a strong inverse correlation between 
measured heme levels and hemopexin levels was observed with R2 of -0.74 (Figure 5.1B). 
Of the 12 patients with high heme levels, nine had depleted hemopexin (<0.01 g/L), and 
the remaining three patients had hemopexin levels below 0.1 g/L.
HO-1 levels in plasma were significantly elevated in STEC-HUS patients with median 
(range) of 163 (2.57 – 789) ng/ml compared to 23.7 (6 - 70) ng/ml in healthy controls 
(p<0.001). Interestingly, especially patients with high heme levels (n=12, heme levels 
above 75 quartile range) had high plasma HO-1 levels with median of 332.5 (86-720) ng/
ml (p=0.008, Figure 5.1C).
Clinical outcome in relation to plasma heme levels
As heme is known for its toxic effect, we hypothesized that high heme levels would be 
associated with a more severe clinical presentation (Figure 5.2). Therefore we performed 
a binary logistic regression to look at the risk of developing various clinical parameters 
in light of increasing heme levels (by 1 µM). The risk for the need of erythrocyte infusion 
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seems to increase (OR 1.8 with 95% CI 0.86-3.8, p=0.116) with higher plasma heme levels, 
although the results were not significant. This corresponds with the fact that heme is 
mainly released from red blood cells. Surprisingly, the risk for intensive care admission, 
dialysis and multiorgan involvement decreased when higher heme levels were observed.
Table 5.1 Patient characteristics
Parameters STEC-HUS (n=48) 
Age at disease onset, in years 3 (1-4) 
Female 50% 
Time between first day of illness and day of 
admission at academic hospital, in days 
7 (5-8) 
Clinical presentation 
Diarrhea 98% 
   Of which bloody diarrhea 75% 
Fever defined as >38.2 Celsius 29% 
Blood pressure ≥ 95 percentile for age and height 55% 
Multi organ involvement 31% 
Duration hospital admission, in days 16 (11-21) 
Biochemical evaluation at presentation (reference range)
Hemoglobin (mmol/l)
   (6.0 – 9.0 )
5.5 (4.6-6.0) 
Platelets (x109/l) 
   (210 - 430)
47 (32-69) 
Haptoglobin (g/l) 
   (0,3-1,6)
0.1 (0.1-0.14) 
Leukocytes (x109/l)  
   (5.0 - 13.0)
15 (11-22) 
eGFR (ml/min/1.73m2) 
   (>90)
11 (8-19) 
LDH (U/l) 
   (<250)
4255 (2609-6290) 
Treatment 
Dialysis 75% 
Duration dialysis, in days 10 (7-15) 
Need for erythrocyte transfusion 86% 
Proven STEC infection 85% 
Results show percentages or median with interquartile range (IQR). LDH; lactate dehydrogenase, eGFR; esti-
mated glomerular filtration rate, n; number of patients of which data was available, STEC; Shiga toxin producing 
Escherichia coli.
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Endothelial cells internalize heme
As heme levels are elevated in STEC-HUS patients, we next aimed to characterize the 
functional consequences of disease-relevant heme levels on primary HGMVECs. Exposure 
of HGMVEC to 25 and 50 µM auto fluorescent heme analog, ZnMP caused a detectable 
red fluorescent signal in the cells, with no reciprocal difference between both concentra-
tions (Figure 5.3A middle panels). To confirm whether heme and not only its analogue 
ZnMP is internalized by endothelial cells, endothelial cells were next exposed to 25 and 
50 µM ZnMP and heme simultaneously. A decreased ZnMP signal in endothelial cells 
was observed due to competitive uptake of ZnMP and heme (Figure 5.3A, right panels). 
Finally, to confirm that ZnMP was truly internalized by the endothelial cells rather than 
sticking to its outer membrane, the ZnMP signal in endothelial cells by confocal micros-
copy was established. By co-staining the outer membrane with CD31 (green fluorescence), 
we confirmed that the ZnMP signal was indeed within the HGMVEC (Figure 5.3B). In 
sum, these data indicate that human glomerular endothelial cells have the capacity to 
internalize heme. 
Heme causes oxidative and inflammatory stress 
To assess whether the exposure of endothelial cells to disease-relevant heme levels causes 
endothelial cell activation and cell stress, we analyzed reactive oxygen species (ROS) pro-
duction by HGMVECs either in the absence or presence of heme. Treatment of HGMVECs 
with heme (25 or 50 µM) resulted in significantly increased ROS generation after 1 hour 
(Figure 5.4A). Furthermore, ROS generation led to a profound nuclear translocation of 
the pro-inflammatory transcription factor NFκB (Figure 5.4B). HGMVECs exposed to 
heme (25 or 50 µM) for 24 hours showed increased necrosis, yet this was not observed 
after 48 hours (Figure 5.4C). Despite NFκB translocation and increased ROS production, 
exposure to heme did not result in apoptosis (Figure 5.4C).
Heme promotes a pro-thrombotic state 
As the pro-thrombotic state, present during TMA caused by STEC infection, is an import-
ant feature of STEC-HUS, we assessed the effect of heme on tissue factor, the key initiator 
of the coagulation cascade. A significantly increased cell surface tissue factor expression 
was observed on HGMVECs following incubation with 25 or 50 µM heme, indicating 
that heme may enhance the pro-thrombotic state in STEC-HUS patients (Figure 5.4D).
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Figure 5.1 Plasma levels of heme, hemopexin and HO-1 in STEC-HUS patients
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Figure 5.1 A. Significant higher heme levels were observed in STEC-HUS patients compared to and healthy controls 
(p<0.001) B. Heme levels in STEC-HUS patients inversely correlated with plasma hemopexin levels with (R2 -0.74) 
C. HO-1 levels in plasma were significantly elevated in STEC-HUS patients compared healthy controls (p<0.001). 
Interestingly, especially patients with high heme levels (n=12, heme levels above 75 quartile range) had high plasma 
HO-1 levels (p=0.008) HO-1; Heme oxygenase 1, STEC-HUS; Shiga toxin producing Escherichia coli hemolytic 
uremic syndrome
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Stx2 inhibits the expression of heme degrading enzyme HO-1
HO-1 is the most important intracellular heme degrading enzyme and provides resis-
tance to heme-induced oxidative stress and cell injury. Stx2 has previously been shown 
to enter endothelial cells and interfere with protein translation. We therefore assessed 
HO-1 regulation in endothelial cells in response to heme in the presence or absence of 
Stx2 both on mRNA and protein level. HO-1 mRNA expression was found upregulated 
in HGMVECs in response to 25 or 50 µM heme after 6 hours (Figure 5.5A). Interestingly, 
in the co-presence of Stx2, HO-1 mRNA upregulation was even more pronounced. In 
contrast, protein levels of HO-1 were severely reduced in the co-presence of Stx2 com-
pared to conditions in which Stx2 was absent (Figure 5.5B). Altogether, these data 
indicate that HO-1 mRNA expression is upregulated in response to heme, but that its 
translation into heme-degrading proteins is impaired by Stx2.
Figure 5.2 Correlation between clinical severity and plasma heme levels
     
    
    
    
    

   
 

 
 
    
 
Figure 5.2 Odd ratios for different clinical parameters in relation with rise of plasma heme levels is depicted. 
With every rise in plasma heme of 1 µM the estimated risk of erythrocyte transfusion, development of multiorgan 
involvement, dialysis and ICU admission is calculated with binary logistic regression. CI; confidence interval, ICU; 
intensive care unit, OR; odds ratio
88   |   Chapter 5
Fi
gu
re
 5
.3
 E
nd
ot
he
lia
l c
el
ls
 in
te
rn
al
iz
e 
he
m
e
A 
GMVEC 
25 µM 50 µM 
DN
A 
   
 Z
nM
P 
   
 C
D3
1 
DN
A 
   
 Z
nM
P 
B 
- 
+ 
+ 
- 
- 
+ 
Zn
M
P 
He
m
e 
Fi
gu
re
 5.
3 A
.E
xp
os
ur
e o
f H
GM
VE
C 
to
 25
 or
 50
 µM
 of
 re
d-
flu
or
es
ce
nt
 Z
nM
P 
fo
r 4
 ho
ur
s y
iel
ds
 in
cr
ea
se
d s
ig
na
l in
te
ns
ity
 (m
id
dl
e p
an
els
), 
wh
ich
 is
 de
cr
ea
se
d w
he
n s
am
e c
on
ce
nt
ra
tio
ns
 
of
 h
em
e i
s s
im
ul
ta
ne
ou
sly
 a
dd
ed
 to
 ce
ll 
cu
ltu
re
 (r
ig
ht
 p
an
els
). 
B.
 C
on
fo
ca
l m
icr
os
co
py
 co
nfi
rm
s e
nd
ot
he
lia
l u
pt
ak
e o
f r
ed
-fl
uo
re
sc
en
t Z
nM
P. 
Sc
al
e b
ar
s: 
10
 µ
m
. H
GM
VE
C;
 h
um
an
 
gl
om
er
ul
ar
 m
icr
ov
as
cu
la
r e
nd
ot
he
lia
l c
ell
, Z
nM
P;
 zi
nc
 m
es
op
or
ph
yr
in
, C
D
31
; e
nd
ot
he
lia
l c
ell
 m
ar
ke
r.
CH
A
PTER 5
Heme as contributing factor in STEC-HUS   |   89
Figure 5.4 Heme causes endothelial cell injury and promotes a pro-thrombotic state
Figure 5.4 A. Exposure of HGMVEC to 25 or 50 µM heme resulted in increased reactive oxygen species generation 
(ROS) (n=3). B. HGMVEC exposed to 25 or 50 µM heme showed nuclear translocation of NFκB p65 (200x mag-
nification). C.HGMVEC exposed to 25 or 50 µM heme for 24 and 48 hours showed no apoptosis, however necrosis 
was increased after 24 hours (n=3). D. HGMVEC expressed membrane-bound tissue factor in response to 25 and 
50 µM heme after 6 hours (n=3). 
*** p < 0.001, * p < 0.05, compared to control unless specified otherwise. Scale bars: 10 µm. HGMVEC; human glomer-
ular microvascular endothelial cell, ROS; reactive oxygen species, A.U; arbitrary units, 4-NQO; 4-nitroquinoline 
1-oxide (positive control for apoptotic cell death).
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Discussion 
Although STEC-HUS is one of the most common causes of acute kidney injury in chil-
dren, the exact pathogenesis and the high diversity in clinical severity is only partially 
understood. In general, extensive hemolysis leads to release of the noxious molecule 
heme. To our knowledge, we are the first to show elevated heme levels in patients with 
STEC-HUS. These increased levels of extracellular heme are associated with depleted 
hemopexin and increased levels of HO-1 in plasma. Furthermore, when applied in vitro 
on primary HGMVECs, these heme concentrations caused ROS production and stimu-
lated both a pro-inflammatory (e.g. nuclear translocation of NFκB) and pro-thrombotic 
state (e.g. increased TF expression). Moreover, the cytoprotective effects of HO-1 against 
the noxious effects of heme are largely abrogated by the HO-1 inhibiting effects of Stx2. 
Consequently, heme released during mechanical hemolysis could contribute, amplify 
and even drive the detrimental cascade leading to TMA. This heme-mediated effect is 
even more profound in STEC-HUS since Stx2 inhibits the induction of the protective 
HO-1 enzyme.
Previous literature regarding pathogenic heme levels refer mostly to one article of 
Muller-Eberhard et al. published in 1968.112 As one of the first, they described free heme 
levels, determined with the use of pyridine hemochromagen assay, in patients with vari-
ous hemolytic diseases in correlation with hemopexin levels.112 From 6 µg/ml (˜10 µM) of 
heme onwards hemopexin levels were depleted, and heme levels up to 30 µg/ml (˜50µM) 
were measured.112
Since then, accumulating studies demonstrate that heme can contribute to the eti-
ology of a wide variety of diseases as exemplified below.108,113 Some studies report heme 
levels, mainly measured in patients with sickle cell disease, where heme levels around 4 
(up to 20) µM were measured.114 Heme was found to strongly contribute to the pathogen-
esis of sickle cell disease, whereas hemopexin and HO-1 protect against heme-induced 
detrimental effects.103,115,116 Reported heme levels in patients with severe malaria are similar 
with median of 10 (IQR 4-22) µM and strongly contribute to its pathogenesis.117,118 Similarly, 
heme has been shown to augment the severity of sepsis.119 These previously reported heme 
values correspond well with the values we found in STEC-HUS patients. 
Measurement of free heme in polar solvents is considered challenging due to its 
poor stability. Furthermore, heme easily reacts with various proteins, with the highest 
affinity for hemopexin, but is also known to bind to other proteins like albumin and 
lipoproteins.104,105 However, only hemopexin and HO-1 are capable of fully neutralizing 
the noxious effect of heme, so in case heme is bound to for example albumin it remains 
partly bioreactive.107 To measure these bioreactive levels of heme, we used an assay which 
takes advantage of the Fenton reaction of heme. When bioreactive heme comes in contact 
with the TMB substrate, this is oxidized resulting in a color which can be spectropho-
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tometrically quantified. This assay has been used previously to measure heme levels in 
different patient cohorts and has been proven simple and sensitive when compared to 
assays using for instance toxic substances such as pyridine.110,112,114,117 The measured plasma 
heme levels in our study reflect most likely the circulating levels of bioreactive heme. 
These levels could be even higher when measured in the microcirculation where heme is 
trapped in blood clots (over 350 µM) such as also is present in TMA.120 The observed heme 
levels are supported by the inverse correlation between low hemopexin levels and mea-
sured heme levels. Moreover, in 15 patients hemopexin was undetectable with a strong 
correlation with high heme levels. This in contrast to haptoglobin, used as marker of 
hemolysis, which was undetectable in almost all patients. Hereby making hemopexin 
a reliable marker for high heme levels. Subsequently, significantly elevated HO-1 levels 
were observed in STEC-HUS patients compared to the healthy adult controls. HO-1 is 
known to be upregulated in response to various triggers like ischemia, inflammation 
and heme.107 Besides intracellular upregulation of the degrading enzyme HO-1, it is also 
released in the bloodstream of patients in increasing amounts. However, in comparison 
to the well described extracellular scavengers like hemopexin, albumin and lipoproteins 
(all measured in g/L), concentrations of extracellular HO-1 are considerably lower (ng/
ml). Most likely, HO-1 mainly exhibits its protective function intracellularly, however, we 
cannot exclude that it acts as a heme scavenger in serum. 
We assessed the relation between measured heme levels and clinical severity. How-
ever, if any, higher heme seems to be associated with lower disease severity (lower risk of 
ICU admission, dialysis and multiorgan involvement). One possible explanation for this 
could be that a high red blood cell count, pointing to severe dehydration, is associated 
with worse outcome in STEC-HUS, hence interfering with our results.121,122 In contrast, 
with every unit heme increases (1 µM) the chance for erythrocyte transfusion increases 
with approximately 80%, although this was not statistically significant. One could explain 
this by the fact that heme is mainly derived from red blood cells, hence a lower eryth-
rocyte count is associated with more decay. Hence, higher heme and more erythrocyte 
transfusions. Another explanation could be that high heme levels amplify hemolysis as 
described previously.104,106,123 A correlation between higher heme and worse outcome could 
still be present, but larger cohort studies are needed to confirm this.
Various studies have assessed the effect of heme in vitro, however using broad range 
of heme levels, up till 100 µM.109,124 In our study, we used primary HGMVECs as these are 
the main target cell in the pathogenesis of HUS. By using a fluorescent heme analogue, 
ZnMP, we showed that heme is internalized by these endothelial cells. The mechanisms 
by which heme is internalized remains unknown. Various hypothetical theories of heme 
internalization have been proposed. First of all, heme possesses a highly lipophilic nature 
and therefore may have the ability to intercalate into the hydrophobic phospholipid 
bilayer of cell membranes.104 Although we did not observe cellular injury upon exposure 
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to relatively low amounts of heme, we previously demonstrated that heme can cause 
cellular injury and death.104,125 A role for heme transporters is perhaps a more plausible 
explanation for the observed internalization and efflux of heme. 
Figure 5.5 Stx2 induces transcription, but inhibits protein expression of the heme-degrading 
enzyme HO-1
Figure 5.5 A.HGMVEC showed upregulated HO-1 mRNA levels in response to 25 or 50 µM heme, which was ampli-
fied by the co-presence of 100 pM Stx2 . B. Western blot analysis of HO-1 showed that the co-presence of Stx2 reduces 
HO-1 protein levels. The mRNA expression of HO-1 was plotted as relative value to the expression of GAPDH. 
GAPDH; Glyceraldehyde 3-phosphate dehydrogenase, HGMVEC; glomerular microvascular endothelial cell, HO-1; 
heme-oxygenase 1, mRNA; messenger ribonucleic acid, Stx2; Shiga toxin 2
To assess the effect of disease specific heme levels we choose a concentration of 25 
and 50 µM, taking into consideration our measurements of heme in our STEC-HUS cohort 
(levels up till 25 µM ) and values measured by Muller-Eberhard et al. (levels up till 50 µM 
).112 When exposing HGMVECs to these heme levels, we observed increased ROS produc-
tion together with induction of a pro-thrombotic and pro-inflammatory state. These 
results are in line with previous published studies.102 The generation of free radicals by the 
Fenton reaction is to date still considered the major form of ROS generation by heme and 
an important mechanism of heme-induced cytotoxicity.104 Moreover, we demonstrated 
that heme induced nuclear translocation of NFκB, which is associated with tissue factor 
expression on the surface of the endothelial cells, facilitating vascular obstruction. 
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As previously proposed by Bitzan et al. Stx2 could inhibit HO-1 levels, when tested 
on human renal carcinoma-derived tubular epithelial cells.109 Since STEC-HUS is mainly 
a glomerular disease we assessed HO-1 expression in HGMVECss with co-stimulation 
of Stx2. The presence of Stx2 caused an upregulation of HO-1 on mRNA level, however 
protein expression was inhibited. Most likely this could be explained by the known effect 
of Stx2 to inhibit protein synthesis via the ribosome. In line with these findings, HO-1 
protein expression was altered by Stx2. Via a negative feedback mechanism this could 
explain the increased HO-1 at the mRNA level. Since HO-1 is important for degrading 
heme, inhibition of HO-1 activity through Stx2 would even further enhance heme-in-
duced cytotoxicity in STEC-HUS patients. Furthermore, due to a polymorphism at the 
promoter region of HO-1, there is a wide variety between individuals in their ability to 
upregulate HO-1 expression. Individuals with longer repeats have reduced HO-1 activity 
and, as a consequence, are more susceptible to acute kidney injury.126 These could partly 
explain the individual susceptibility to develop TMA.102,125 For this purpose, it may be 
beneficial to screen individuals for HO-1 polymorphisms.126 
Measurement of heme levels is considered quite difficult. By using the TMB assay our 
measured heme levels could be influenced by additional factors like free hemoglobin, also 
present during extensive hemolysis. However, free hemoglobin levels did not correlate 
with TMB results (data not shown). Haptoglobin is the scavenger of free hemoglobin, 
however in contrast to the strong correlation between hemopexin and heme, no cor-
relation was found between haptoglobin and the presumed heme levels, indicating that 
the heme levels obtained with TMB seem specific for bioreactive heme. Hence, these 
observations could also be explained by interactions between heme and Toll-like recep-
tor (TLR) 4.127,128 As TLR4 is highly expressed on endothelial cells, and as ligation to TLR4 
does generally not result in receptor-mediated endocytosis but rather in activation of 
pro-inflammatory signaling pathways, it is plausible that the internalization of heme is 
not required for the observed (pro-inflammatory) events in endothelial cells. As shown by 
Belcher et al. heme activates TLR-4 signaling leading to vaso-occlusion due to degranu-
lation of Weibel-Palade bodies and expression of vascular adhesion molecules in models 
of sickle cell disease.127
Although STEC-HUS is merely treated symptomatically up till now, our findings 
suggest several potential future therapeutic candidates. One strategy could be to supple-
ment the depleted scavengers like haptoglobin, to capture hemoglobin and prevents its 
decay into heme, or more naturally hemopexin to neutralize heme.106,129 Various studies 
have already been conducted to study the effect of hemopexin infusions with promising 
results.129 As the production of ROS is implicated in pro-thrombotic (TF expression) and 
(pro-inflammatory) NFκB-dependent signaling, it would be important to investigate 
whether ROS scavengers are able to prevent the TF expression or/and the nuclear trans-
location of NFκB in heme-treated endothelial cells. Furthermore, in a murine model 
94   |   Chapter 5
of STEC-HUS, the administration of anti-oxidants was shown to counteract important 
pathogenic events (e.g. platelet activation, renal damage) and ameliorate disease pathol-
ogy.130 Thus, ROS scavengers may protect against the detrimental effects of heme in 
HUS. Furthermore, by providing a higher amount of heme and hemoglobin scavengers, 
hemopexin and haptoglobin, one could prevent increased levels of bioreactive heme 
and consequently endothelial cell injury mediated by heme.105,131 Various animal stud-
ies have been performed to look at the effect of therapeutic hemopexin administration 
with promising results.105,132 In contrast to hemopexin, haptoglobin is already present as 
orphan drug. Hypothetically, by administrating haptoglobin, free hemoglobin would be 
bound and therefore could not be oxidized and release heme, hence no heme would be 
present.106 Although up till some extent damage is already caused at time of admission, 
most patients still have active disease with ongoing TMA at presentation.
In conclusion, heme might be a contributing and driving factor in the pathogenesis 
of STEC-HUS and could potentially amplify the cascade leading to TMA. In this study 
we have provided evidence that elevated heme levels are present in STEC-HUS patients. 
Moreover, the observed heme levels have a strong inverse correlation with hemopexin 
levels, making hemopexin a reliable biomarker for toxic levels of heme present in vivo. 
Moreover, these disease relevant elevated heme levels promoted oxidative, pro-inflam-
matory and thrombotic stress in vitro. Importantly, via Stx2 inhibited HO-1 induction 
exacerbates these events by decreased protection against heme-induced insults and may 
promote development towards TMA. 
Acknowledgements
This work was supported by the Sengers Stipendium, granted from the Foundation for 
Pediatric Research, of Radboudumc Amalia Childrens Hospital, to LvdH, NvdK, KW and 
SV. ZonMw, “Goed Gebruik Geneesmiddelen” (project number: 836031008) to NvdK and 
Dutch Kidney Foundation (13OI116) to EV. Furthermore, we want to thank dr. R.P.L. van 
Swelm for her help with setting up experiments and interpretation of the data.
CH
A
PTER 5
Heme as contributing factor in STEC-HUS   |   95
Supplemental data: Methods
Hemopexin measurement
Hemopexin was measured in enzyme-linked immunosorbent assay (ELISA) setting. A 
microtiter plate (Greiner Bio-One™) was coated with 500 ng/mL anti-human hemopexin 
capture antibody (Bioporto) at 4°C overnight. Subsequently, standard dilutions of hemo-
pexin from human plasma (0-50 ng/mL, Sigma-Aldrich) as wells as diluted samples were 
added to the plate. Next 100ng/ mL of the detection antibody biotinylated anti-human 
hemopexin (Bioporto) was added to the plate followed by 1:1000 dilution of streptavi-
din-HRP (RPN1231V GE healthcare). Subsequently, TMB Substrate (Sigma-Aldrich) was 
added and the absorbance was measured at wavelength of 450 nanometer (nm) with 
Victor 3 V multilabel plate reader (Perkin elmer).
Heme-oxygenase 1 measurement
Plasma HO-1 levels were determined by a sandwich ELISA using the human HO-1 matched 
antibody pair kit (Abcam) according to the manufacturer’s instructions.
Flow cytometric apoptosis assay
Confluent monolayers of HGMVECs on gelatin (fluka) coated 48-well tissue culture plate 
(Corning ® Costar ®) were stimulated with 4-nitroquinoline 1-oxide (4NQO; Sigma-Aldrich) 
or 25 and 50 µM hemin chloride porcine (designated as heme, Sigma-aldrich) prepared 
from 10 mM stock solution for 24 and 48 hours. Subsequently, cells were detached with 
0.25 % Trypsin-EDTA (Gibco™) and collected into 1.5 mL eppendorf tubes( Eppendorf). The 
cells were taken up in Annexin V-buffer and stained with FITC-labeled Annexin V and 
propidium iodide (Sigma-Aldrich) according to the manufacturer’s protocol (BioVision). 
All samples were analyzed on a FC500 flow cytometer with CXP software (Beckman 
Coulter). The flow cytometry data were analyzed with Kaluza Flow Analysis Software 1.3 
(Beckman Coulter).
Reactive oxygen species (ROS) measurement
The production of intracellular ROS was measured using the fluorescence probe reagent 
CM-H2DCFDA (Thermo Scientific) as described previously by Wilmer et al.133 Briefly, con-
fluent monolayers of HGMVECs on gelatin coated 96-wells tissue culture plate were 
stimulated with 25 and 50 µM heme (prepared from 10 mM stock solution) or 50 µM 
hydrogen peroxide (H2O2; Merck). ROS formation was measured by fluorometry (exci-
tation/emission 464/530 nm) after 1 hours at 37°C with the Victor 3 V Multilabel Plate 
reader.
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Quantitative polymerase chain reaction (qPCR) and western blot
HGMVECs were seeded on gelatin coated 6-wells tissue culture plate (Corning ® Costar 
®) and grown to confluent monolayers. HGMVECs require inflammatory mediator tumor 
necrosis factor α (TNFα) to upregulate the Gb3 receptor on their cell surface. 111,134 There-
fore, in the conditions where the effect of Stx2 in the presence or absence of heme was 
assessed, HGMVECs were preincubated with 10 ng/mL TNFα (Sigma-Aldrich) for 24 hours 
at 37 °C with 5 % CO2. Subsequently, 100 pM Stx2 (Phoenix lab) was added to HGMVECs 
and incubated for 8 hours at 37 °C with 5 % CO2. Next, 25 and 50 µM heme was added and 
incubated for additional 16 hours at 37 °C with 5 % CO2. 
The total RNA was extracted using TRIzol reagent (Ambion life technologies) and 
RNA isolation kit according to the manufacturer’s instructions (NucleoSpin® RNA II from 
Macherey-Nagel). From the total RNA, 200 ng served as a template for cDNA synthesis 
in a reaction using a mix consisting of milliQ, reverse transcriptase buffer 5x ( RT buffer 
5x; Invitrogen), random primers (Promega), oligo dT (promega), dNTP’s (self made), dith-
iothreitol (DTT; Invitrogen), recombinant RNasin® ribonuclease inhibitor (Invitrogen), 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT; Invitrogen). For 
qPCR analyses, a SYBR® Green master mix including primers (respectively forward and 
reverse primers for GAPDH were 5’-TCC AAA ATC AAG TGG GGC GA-3’ and 5’-GGA 
CTG TGG TCA TGA GTC CT-3’ and HMOX1 5’-AGA CAC CCT AAT GTG GCA GC-3’ and 
5’-CTG AGC CAG GAA CAG AGT GG-3) was made. qPCR was performed using the Bio-Rad 
CFX96™ Real-Time PCR Detection System. Experiments were performed in duplicate and 
the values were normalized to GAPDH using delta-delta Ct method.
Protein was isolated with standard RIPA buffer (0.15M NaCl (Sigma-Aldrich), 0.012M 
Sodium Deoxycholate, 0.1% nonidet P-40 (NP40), 0.1% SDS (Sigma-Aldrich), 0.05M Tris 
(Sigma-Aldrich) pH 7.5 and protease inhibitor cocktail (Sigma-Aldrich)). The concen-
tration of extracted protein was determined with BCA protein assay according to the 
manufacturer’s protocol (Thermofisher Scientific). For HO-1 protein expression, 1 ug/mL 
protein was boiled in Laemmli buffer (Biorad). Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) analysis was carried out using 10 % resolving gels and 
4 % stacking gels. Subsequently, protein were transferred to polyvinylidene difluoride 
(PVDF; Merck) membranes. Blots were blocked with PBS-5 % skim milk (Merck) for an 
hour and incubated with primary antibodies, rabbit anti-heme-oxygenase-1 polyclonal 
antibody (Enzolifesciences) or anti- β-actin (Novus biological) for 1 hour at RT. Proteins 
were detected with HRP-conjugated goat-anti rabbit IgG antibody (Dako). Blots were 
developed using SuperSignal West Pico Chemiluminescent substrate according to the 
manufacturer’s instructions (Thermofisher scientific). The visualization of the bands were 
done with Biorad image lab software (Biorad). 
Statistical analysis
Values are expressed as valid percentages for categorical variables and as median and 25 
- 75 interquartile range (IQR) for continuous variables. Log transformation was applied 
when data were not normally distributed to reduce skewed data. Regression analyses, 
with coefficient of determination R2, was performed to determine degree of correlation 
between to variables. Binary logistic regression analyses was preformed to look at the 
risk (odds ratio: OR) of heme levels in relation to clinical parameters. Chi-square test was 
performed to compare categorical data and Mann-Whitney U test was used to compare 
continuous data. Heme levels were categorized with quartile ranges. In case a value was 
above the 75 IQR, the level was classified as high heme level. P values less than 0.05 were 
considered statistically significant and 95 confidence intervals were reported. All graphs 
were performed using GraphPad Prism software version 5. For statistical analyses, SPSS 
software (version 22.0) was used. 
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Abstract
Recent studies indicate that eculizumab is often given in excess to aHUS patients. Indi-
vidualization of treatment is thus highly requested, however, data on pharmacokinetics 
and pharmacodynamics of eculizumab remain limited. We analyzed 11 patients during 
induction (weekly), maintenance (2-weekly) and tapering (every 3-8 weeks) phases of 
treatment.
The trough eculizumab levels increased with each additional dose during the 
induction phase (depending on body weight). During maintenance, high eculizumab 
concentrations of up to 772 µg/ml were observed. The levels decreased with each follow-
ing dose during tapering (3- and 4-week intervals), however three patients maintained 
target eculizumab levels over long time periods (30-48 weeks). At intervals of 6-8 weeks 
target eculizumab levels were no longer attained. Serum samples with eculizumab con-
centrations ≥50 µg/ml showed adequate complement blockade.
Our data provide essential insight for optimization of eculizumab dosing schemes 
and lessening of therapy burden for the patients and cost of the treatment. 
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Introduction
Hemolytic uremic syndrome (HUS) is a severe form of thrombotic microangiopathy 
(TMA) characterized by hemolytic anemia, thrombocytopenia and acute renal failure. 
The majority of cases are caused by an infection with Shiga toxin producing Escherichia 
coli (STEC). However, 5-10% of HUS occurs without a preceding STEC infection and is 
attributed to complement dysregulation.1,10,43,54,58,59 Currently, alternative complement 
pathway aberrations are identified in 50-60% of atypical HUS (aHUS) patients. Genetic 
variants affecting complement factor H (CFH), complement factor I (CFI), membrane co-fac-
tor protein (CD46), C3, complement factor B and thrombomodulin as well as autoantibodies 
against CFH (anti-CFH) are associated with aHUS pathogenesis.135-147 More recently, 
genetic rearrangements resulting in CFH/CFH-related hybrid proteins have also been 
described.49,148,149
Eculizumab is a humanized monoclonal complement inhibitor that binds to C5 and 
prevents its cleavage and activation into C5a and C5b, blocking formation of the ter-
minal complement complex C5b-9. Eculizumab is currently approved by the Food and 
Drug Administration and European Medicines Agency (EMA) for the treatment aHUS 
and has proven to be highly efficient in the treatment of this disease.8,58,150-153 The current 
international guidelines recommend life-long treatment with eculizumab. However, the 
resulting life-long complement blockade may increase the risk of meningococcal infec-
tion, and eculizumab treatment is associated with extreme costs.154,155 There are no studies 
that would support the necessity of a life-long treatment in all aHUS patients. Before 
eculizumab has become available, plasma therapy was a main-stream approach for the 
treatment of aHUS. The guidelines for plasma therapy in aHUS advised individualized 
regimen and withdrawal in patients that have reached remission.156,157 Therefore, many 
nephrologists use a restrictive approach for eculizumab treatment in aHUS and discon-
tinue therapy when patients reach remission.158-165 A subset of patients that discontinued 
eculizumab in these reports experienced relapse, and the therapy had to be reinitiated. 
This underscores the need for close monitoring of these patients for signs of relapse.
The recommended concentrations of eculizumab for efficient complement blockade 
are 50-100 µg/ml, however in the past our and other studies demonstrated that eculi-
zumab levels in patients, that receive the drug every two weeks exceed this reference 
by up to ten fold.158,166-168 Thus, optimization of dosing regimen in eculizumab therapy is 
urgently needed, however, pharmacokinetic and pharmacodynamic data to guide such 
personalized treatment schemes remain limited. 
In this study, we followed patients who were treated with standard and extended 
infusion intervals, and analyzed eculizumab concentrations and complement blockade 
in these patients. 
104   |   Chapter 6
Methods
Patient cohort
The 11 patients, described in this study were diagnosed with aHUS and received treatment 
at the Radboud university medical center, Nijmegen, The Netherlands. Eculizumab was 
administered in the dosages that are recommended by the current EMA guidelines.169 The 
current treatment schedule is split into two phases: the initial phase (weekly infusions for 
up to 4 weeks for patients ≥40 kg body weight), followed by the maintenance phase (life-
long infusions every two weeks). For pediatric patients (<18 years old, <40 kg), the dosage 
regimen is adjusted to body weight. The other patients (pediatric and adult) receive the 
drug according to the schedule for adults. 
In this report, in patients who have reached remission (normalized hematological 
parameters and improved/stable renal function), the therapy was reevaluated and inter-
vals between infusions were gradually extended (while keeping maintenance infusion 
doses unchanged) or therapy was discontinued (Table 6.1). In two patients, eculizumab 
treatment was discontinued without extension of dosage intervals beyond two weeks 
due to an allergic reaction (patient 8 (P8)) and severe pneumonia (P11). In nine patients 
≥40 kg, the eculizumab dose was 1200 mg in the maintenance/tapering phase and for the 
two children with body weight of 15 kg (P2) and 11 kg (P9), the dose was 300 mg.
During tapering/discontinuation of therapy, all patients and/or their caregivers were 
strictly instructed to contact their physician in case of any signs of infections, generalized 
malaise, fever, hematuria, edema, oliguria, paleness or other signs indicating recurrence of 
aHUS. In case of signs of aHUS recurrence (which did not take place during the described 
period), eculizumab would be restarted immediately.
Collection of blood samples
Blood samples from healthy adult controls and patients just before each eculizumab 
infusion were collected and placed immediately on ice (ethylenediamineteraacetic acid 
(EDTA) blood) or allowed to clot for 30-40 minutes (min) at room temperature (whole 
blood). EDTA plasma and serum samples were collected by centrifugation (10 min, 2000 
x g, 4°C), aliquoted and stored at -80°C. 
Assay for detection of serum eculizumab concentration
Eculizumab detection was performed using in-house enzyme-linked immunosorbent 
assay (ELISA). To capture eculizumab, 96-well plates (Greiner Microlon® 600 High Bind-
ing, Sigma-Aldrich, Zwijndrecht, the Netherlands) were coated with 0.5 µg/well of purified 
C5 (Calbiochem®, San Diego, CA, USA) diluted in carbonate buffer (pH=9.6) overnight at 
4˚C. The wells were washed with phosphate buffered saline (PBS) supplemented with 
0.05% Tween-20 (PBST) (Sigma-Aldrich) after this and following steps. The plates were 
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blocked with SuperBlock (PBS) Blocking Buffer (Thermo Fisher Scientific, Waltham, MA, 
USA) 30 min at room temperature (RT) and then 45 min at RT with PBS, supplemented 
with 1% bovine serum albumin (PBS/BSA). Serum samples were diluted in PBS/BSA and 
dose response standards were prepared by adding eculizumab (Alexion Pharmaceuticals, 
Cheshire, CT, USA) to PBS/BSA. Samples and standards were added to the wells and 
incubated for 2 hours (h) at RT. Eculizumab detection was performed using incubation 
with Peroxidase AffiniPure Goat Anti-Human IgG (H+L) ( Jackson ImmunoResearch Lab-
oratories Inc., West Grove, PA, USA) diluted in PBST for 2 h at RT, o-phenylenediamine 
dihydrochloride tablets (Dako, Hevelee, Belgium) were added as a substrate. The reaction 
was stopped with 2M H2SO4, and samples were measured in a 96-well microtiter plate 
reader at 490 nm. Dilution linearity of the test was analyzed by measuring serum contain-
ing 383 µg/ml eculizumab and had coefficient of variation (CV) of 10.5% over the range of 
a standard curve. The detection limit of an assay was 8 µg/ml for undiluted samples. The 
assay showed variation coefficients of 2.9% (intra-assay, 352 µg/ml) and 5.2% (inter-assay, 
328 µg/ml). Recovery was determined in 20 control samples spiked with 50 µg/ml (68 ± 
31 %), 75 µg/ml (66 ± 25%) and 150 µg/ml (74 ± 17%).
C5 assay
C5 concentrations were measured in available sera or EDTA plasma, that were collected 
from 10 aHUS patients in acute phase, before the start of eculizumab therapy and from 
nine healthy volunteers. The C5 levels were measured using Human Complement C5 
ELISA Kit (Abcam, Cambridge, UK), according to manufacturer’s instructions.
Complement assays
The concentrations of fluid phase terminal C5b-9 complement complex (sC5b-9) in seven 
available EDTA plasma samples were quantified using ELISA, as previously described in 
detail by Bergseth et al.170 International complement standard two was used for quantifi-
cation of sC5b-9 in complement activation units per ml (CAU/ml).
Complement activity was accessed in serum samples by determining the activity 
of classical complement route (CH50) using an ELISA method adapted from.171 Briefly, 
polyclonal goat (affinity purified) anti-human IgM (Cappel, Bioconnect Life Sciences, 
Huissen, The Netherlands) was coated in 96-wells plates (Nunc Maxisorb plates, Nunc, 
Roskilde, Denmark) at a concentration of 0.2 µg/well in carbonate buffer (pH 9.6), over-
night at 4˚C. The plates were washed with Tris buffered saline (TBS) containing 0.05% 
Tween-20 (TBST) after each step. Residual binding sites were blocked by incubation with 
10 mM TBS containing 1% gelatin (BD Difco™, Franklin Lakes, New Jersey, USA) for 1 h 
at RT. After blocking, 0.25 µg/well IgM (Fitzgerald Industries International, Acton, MA, 
USA) diluted in TBST was added and incubated for 1 h at RT. Next, standards (human 
pooled serum) and patient serum samples diluted in cold buffer containing 10 mM Tris, 
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84 mM NaCl, 0.5 mM MgCl2, 2 mM CaCl2 and 0.1% gelatin (pH 7.5), were added per well 
and incubated for 1 h at 37˚C. Complement binding was detected using a monoclonal 
mouse-anti-human C5b-9 antibody (Dako) diluted in TBST and incubated for 1 h at RT. 
After washing, alkaline phosphatase labeled goat anti-mouse IgG (Dako) in TBST was 
added for 1 h at RT. Alkaline phosphatase activity was revealed following incubation with 
4-nitrophenyl phosphate disodium salt hexahydrate as a substrate (Sigma-Aldrich). The 
reaction was stopped with 2 M NaOH, and samples were measured in a 96-well microtiter 
plate reader at 450 nm. The reference value of CH50 of 67-149% was calculated with the 
results of 50 healthy donors.
Statistical analyses
GraphPad Prism 5 for Windows (GraphPad Software Inc.) was used to plot eculizumab 
levels against treatment intervals, and sC5b-9 complex concentrations and CH50% 
against eculizumab levels. If a patient did not reach the minimal target level of 50 µg/ml 
eculizumab ≥ 1 time in a treatment interval, he/she was considered not to have attained 
the target level for that interval. Following, the percentages of patients not reaching the 
eculizumab target level were plotted against treatment interval. To evaluate changes in 
eculizumab concentrations by the number of infusions within a treatment interval, we 
used IBM Statistics 22.0 for Windows (IBM SPSS Inc.). For each treatment interval, we 
plotted eculizumab levels against infusion number and estimated the increase or decrease 
in eculizumab level per infusion with 95% confidence intervals (CI), using linear mixed 
models with infusion numbers as fixed and patients as random effects. Body weight (in 
kg) and age (in years) were included in these models as potential confounders. 
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Results
Patient cohort
In total, five pediatric and six adult patients diagnosed with aHUS treated with ecu-
lizumab were included in this study (Table 6.1). In nine of these patients, pathogenic 
variations in the complement genes were found. One aHUS patient (P3) had anti-CFH 
and in one other patient (P9) no genetic abnormalities or anti-CFH were detected. In nine 
patients, the intervals between eculizumab infusions were extended for up to eight weeks 
after stable remission was achieved. In one of these patients (P1), eculizumab treatment 
was discontinued completely. Serum samples of this patient were continuously collected 
through week 26 after the last eculizumab dose (Table 6.1), no disease recurrence was 
observed during the study period. In two patients, eculizumab treatment was discontin-
ued without extension of dosage intervals beyond two weeks due to an allergic reaction 
(P8) and severe pneumonia (P11).
Serum eculizumab concentrations in aHUS cohort
The eculizumab trough concentrations (lowest drug concentration in blood between two 
consecutive infusions) that were measured in 11 patients are depicted in Figure 6.1A. The 
detected values were 36-459 µg/ml (n=27) and 40-772 µg/ml (n=90) during the induction 
and maintenance phases, respectively. During tapering, concentrations of 61-367 µg/ml 
(n=38), 11-256 µg/ml (n=38) and 13-161 µg/ml (n=6) were measured at 3- , 4- and 5- week 
infusion intervals. At intervals of 6-8 weeks (n=10), the concentrations were 0-41 µg/ml. 
For infusion intervals of 1-5 weeks, attainment of the minimal target level of 50 µg/ml 
was found in 75-91% of patients (Figure 6.1B).
Serum eculizumab concentrations in individual
patients during infusions with standard and extended intervals 
In the induction phase, the eculizumab levels gradually increased with each following 
1-week interval by on average 73.1 (95% CI: 56.2-90.0) µg/mL, adjusted for body weight 
(Table 6.2). Two adult patients (P10 and P11) did not attain the target eculizumab level 
after the first infusion, but did so after the second dose (Figure 6.2A). Figure 6.3 shows 
that patients P10 and P11 had the lowest trough eculizumab concentrations one week after 
the first eculizumab infusion and the highest sC5b-9 complex levels measured before the 
first infusion. The serum C5 levels in patients in acute phase before start of therapy were 
52-136 µg/ml, while values obtained from nine healthy controls were 80-107 µg/ml. Serum 
eculizumab concentrations did not change with each following dose at 2-week intervals 
(Figure 6.2B, Table 6.2), whereas the concentrations decreased on average by -11.8 (95% 
CI: -7.1- -16.6) µg/ml and -3.6 (95% CI: -1.1- -6.2) µg/ml with each following dose in the taper-
ing phase of the 3- and 4-week intervals, respectively (Figure 6.2C and 6.2D, Table 6.2). 
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Table 6.1 Characteristics of aHUS patients
Patient aHUS 
pathogenic change
Gender
(F/M)
Age at 
start of the 
observation 
(years)
Body 
weight 
(kg)
Studied 
dose 
intervals 
(weeks)a
Total 
observation 
period 
(months)
P1 CFH: c.1778T>A, 
p.Leu593Stop
F 28 61 1-6, 8, 14, 
20, 26
15.5
P2 CFH: c.3572C>T 
(p.Ser1191Leu); CFH: 
c.3590T>C (p.Val1197Ala)
M 2 15 2-4 24
P3 Anti-CFH M 9 50 1-4 28.5
P4 CFH/CFH1 hybrid protein M 11 45 1-4 30.5
P5 CFH: c.2572T>A 
(p.Trp858Arg)
F 22 114 2-7 12
P6 CFH: c.2120delC F 45 71 1-6 7
P7 C3: c.481C>T (p.Arg161Trp) F 62 56 1-3, 8 8
P8b C3: c.481C>T (p.Arg161Trp) F 11 46 1, 2 2.5
P9 No changes found M 1.3 11 1-5 11.5
P10 CFH: c.1520-1G>A (splice 
site)
F 44 53 1-7 23.5
P11b CFI: c.685T>C (p.Cys229Arg) F 21 85 1, 2 2
a All patients with body weight ≥ 40 kilo were treated with four weekly infusions of 900 mg at start of therapy, after 
that, starting from week five the patients were treated with 1200 mg. For P2 and P9 pediatric dosage was applied 
(600 mg infusion at first week, 300 mg at week 2 and further). Samples were taken after the indicated intervals since 
last eculizumab infusion. 
b Eculizumab treatment in these patients was discontinued during the study due to allergic reaction (P8) and severe 
pneumonia (P11).
However, only three patients had a follow-up with five or more infusions at 3- and 
4-week intervals. At 3-week intervals, the eculizumab levels remained relatively high in P4 
and within/slightly above the target range of 50-100 µg/ml throughout the observed peri-
ods of 10 and 11 intervals (30 and 33 weeks) in P2 and P3, respectively. At 4-week intervals, 
the eculizumab levels remained within the recommended range throughout 12 intervals 
(48 weeks) of therapy for P4 only. 
Body weight had a small effect on eculizumab level in the induction period only -3.9 
(95% CI: -1.8 - -6.0) µg/ml per kg, while age did not have an effect in any of the intervals. 
The number of available data points at 5-week intervals did not allow statistical analysis. 
However, four of the five patients analyzed still attained the eculizumab target concentra-
tion after the first 5-week interval and P10 also attained the target range after the second 
5-week interval (Figure 6.2E).
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Figure 6.1 Serum eculizumab concentrations in aHUS cohort
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Figure 6.1 A. Eculizumab trough levels in 11 patients in the induction (weekly), maintenance (2-weekly) and tapering 
(every 3-8 weeks) phases of therapy (Table 6.1). From one patient (P1), samples were also collected after discontin-
uation of treatment (at 14, 20, 26 weeks). The dashed lines indicate the recommended range of eculizumab levels 
of 50-100 µg/ml. B. Percentages of patients that attained the trough eculizumab level of 50 µg/ml in all measured 
samples in an interval are indicated in white, whereas percentages of patients with a value < 50 µg/ml in at least one 
sample are indicated in gray. Total numbers of patients analyzed for each interval are shown above the columns.
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Figure 6.2 Eculizumab concentrations in individual patients during infusions with standard 
and extended intervals
Figure 6.2 Eculizumab trough levels in 11 patients before next eculizumab infusion in the induction (1- week intervals, 
A. maintenance (2-week intervals, B. and tapering (3-, 4- and 5-week intervals, C, D and E. phases of therapy. The 
dashed lines indicate the recommended range of eculizumab levels of 50-100 µg/ml. Observed effects (*) of each 
following infusion or weight of a patient (kg) on eculizumab concentration as presented in Table 6.2 are indicated. 
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Complement inhibition under eculizumab treatment 
All samples that were measured in our study and reached the eculizumab target level of 
50 µg/ml had a CH50 value ≤ 12% (detection limit 10%) (Figure 6.4).
Table 6.2 Estimated effects of number of infusions on eculizumab concentration in serum 
per treatment interval
Number of 
patients in 
treatment 
intervala
Range of 
samples 
per 
patient
Estimated 
mean 
eculizumab 
level (µg/ml)
95% 
CI
1-week intervals
At start of interval 7 131.1 53.6 208.6
Increase/decrease per infusion 9 1 - 4 73.1b 56.2 90.0
2-week intervals
At start of interval 10 271.9 176.9 366.9
Increase/decrease per infusion 11 2 - 20 2.3 -0.7 5.3
3-week intervals
At start of interval 8 285.0 212.4 357.6
Increase/decrease per infusion 9 1 - 9 -11.8 -16.6 -7.1
4-week intervals
At start of interval 6 158.2 80.8 235.6
Increase/decrease per infusion 8 1 - 11 -3.6 -6.2 -1.1
a At the start of each interval, data were not collected from all patients
b Adjusted for patient’s body weight (kg); weight and age did not influence the other estimates. 
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Figure 6.3 sC5b-9 complex concentration at baseline and trough eculizumab levels after the 
first infusion 
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Figure 6.3 Seven patients (P1, P3, P4, P7, P9, P10, P11) of whom EDTA plasma was available were included. The 
dashed lines indicate the recommended range of eculizumab levels of 50-100 µg/ml. Patients that did not attain 
the recommended eculizumab level after first infusion are indicated (P10 and P11).
Figure 6.4 Complement inhibition during eculizumab treatment in aHUS patients
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Figure 6.4 Complement activity (CH50%) data of the samples included in the study are presented as percentage 
of activity of normal human pooled serum. The dashed lines indicate the recommended range of eculizumab levels 
of 50-100 µg/ml.
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Discussion
In this report we, to our knowledge, for the first time performed a systematic analy-
sis of eculizumab levels in patients, receiving the drug with various (standard and 
extended) infusion intervals. In the induction phase (1-week intervals) we have observed 
a weight-dependent increase in eculizumab concentration with each following infusion, 
which is consistent with the half-life of eculizumab in aHUS patients reported as 7.8-19.5 
days.167 In two patients with high initial sC5b-9 levels, the values were below the target 
range one week after the first infusion. Previous report investigating efficacy of eculi-
zumab treatment in patients with TMA after hematopoietic stem cell transplantation 
indicated that patients with higher levels of sC5b-9 complex before treatment have faster 
initial eculizumab clearance.172 Interestingly, recent study indicated that eculizumab is 
able to bind to sC5b-9 in vitro, which suggests that part of the drug may be scavenged 
into a complex with sC5b-9 at first infusion.168 Elevated sC5b-9 is a known biomarker 
in aHUS and thus should be taken into consideration in design of future personalized 
eculizumab protocols.173,174
In the maintenance phase (2-week intervals) the levels of eculizumab had reached 
extremely high values of up to 772 µg/ml. Considerable excess of eculizumab in patients 
was also previously reported by our and other studies.158,166-168 Interestingly, one of the 
patients (P11) who had a severe pneumonia did not attain minimal target value of eculi-
zumab and complete complement inhibition at the second infusion at 2-week interval. 
The reason of this is not clear, however, since levels of sC5b-9 have been shown to influ-
ence eculizumab pharmacokinetics, inflammation and increased rate of complement 
activation may have caused lower eculizumab concentration in this patient. 
Although most patients attain eculizumab levels far above the recommended range 
at 2-week intervals, P11 illustrates that in some patients with ongoing active disease stan-
dard eculizumab dosing may be not sufficient for complement blockade and this should 
be taken into consideration when applying extended eculizumab regimen. 
Interestingly, P11 developed severe pneumonia while having sub-therapeutic ecu-
lizumab levels. Although it was not a meningococcal infection, for which the terminal 
complement pathway is especially important, this case emphasizes the need to evaluate 
how much of residual complement activity is necessary to decrease risk of infection and 
how much of this activity may be safely allowed without risk of an aHUS relapse.
No significant correlation between eculizumab levels and number of received infu-
sions was observed in the maintenance phase. Previously in another study, weight of the 
patient was correlated to the median trough concentration in a small group of aHUS 
patients (n=7), which was not reproduced in our study.167 Nevertheless, with the exception 
for P11, all other patients attained target eculizumab levels at all 2-week infusion intervals 
that were analyzed. 
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During tapering of the treatment with extended intervals of 3- and 4- weeks, sta-
tistically significant decrease in eculizumab concentration was observed with each 
infusion. This indicates, that complement blockade may remain adequate at the first 
infusions of the extended intervals, but diminish overtime. However, at 3-week interval, 
in two patients (P2, P3) eculizumab recommended range of 50-100 µg/ml was attained 
and complement was efficiently blocked throughout the observed period of 10 and 11 
intervals (30 and 33 weeks), respectively. At 4-week interval for one other patient (P4), 
the eculizumab levels remained within the recommended range and complement was 
completely blocked throughout 12 intervals (48 weeks) of therapy. Interestingly, of the 
three pediatric patients, who were able to sustain optimal eculizumab concentration 
in extended intervals, two (P3, P4) were treated with a standard adult dosage (1200 mg) 
and one (P2) with standard pediatric dosage (300 mg) per infusion based on their body 
weight (Table 6.1). These three cases illustrate how monitoring of eculizumab con-
centrations and complement inhibition allows to establish optimal infusion intervals 
which can be maintained over a long period of time for patients on adult and pediatric 
regimen. 
Furthermore, our data indicate that at 5-week intervals attainment of target eculi-
zumab range is possible at least for one or two infusions. 
Overall, quite high inter-patient variability has been observed. In our manuscript we 
analyzed influence of body weight and age on the eculizumab levels in individual patients. 
Moreover, levels of the sC5b-9 complex may play a role in eculizumab clearance after the 
first eculizumab infusion and may contribute to variability. To facilitate individualized 
treatment options, inter-patient variability should be investigated further in the future. 
Our findings suggest that C5 concentrations vary considerably among the patients, more 
than among the controls. Our previous data using C5 deficient serum indicated that even 
a 1-2% of unblocked C5 in serum may already lead to measurable complement activity.158 
Thus, when fine-tuning the eculizumab therapy based on patient’s needs, C5 concentra-
tion may be important to take into account.
In our previous work, we measured eculizumab-C5 complexes in patients, which in 
the situation of substantial eculizumab excess, as was observed in that study, provided 
a good indication of C5 levels. The data indicated some fluctuation of eculizumab-C5 
complexes during the course of therapy.158 Relevance of these findings for personalized 
treatment should be investigated further.
In this study only dosing intervals have been varied. However, in the future also 
options for the adjustment of the administered eculizumab dosage should be investi-
gated. To this end, proportionality across the recommended dosing range of 50-100 µg/ml 
should be addressed at various diseases stages. Current knowledge on pharmacokinetics 
and pharmacodynamics indicates that eculizumab is bound to C5 and sC5b-9 in vitro.168 In 
vivo deposition on other ligands, including surface of blood cells, endothelium, etc. is also 
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possible. It may interfere with drug’s complement inhibiting activity and thus should be 
taken into account when lowering the treatment dose.
In this study three samples with 93-250 µg/ml of eculizumab and residual 11-12% 
activity in CH50 assay were observed (Figure 6.4). These findings are in line with previ-
ous work, where the authors also observed several samples with eculizumab >99 µg/ml 
(which they use as a target reference) and CH50 >10 %.172 Interestingly, recent data point 
out that eculizumab inhibition of complement may not always be complete and even high 
drug levels would not always completely block complement in an in vitro assay.175 Clinical 
importance of such residual complement activity in aHUS should be further investigated.
Thus, in this study we performed a thorough analysis of data of patients who 
were treated with eculizumab and where standard and extended intervals between 
infusions were applied. Our data indicate that eculizumab accumulates in the body 
during 1-week intervals (depending on the body weight and possibly initial sC5b-9 
concentration) remains stable at 2-week intervals, and diminishes during 3- and 4- week 
intervals. Importantly, extended 3- and 4- week intervals may be optimal for complete 
complement inhibition in a considerable subset of pediatric and adult patients, as 
shown in this study. Our data indicate that even at 5-week intervals at least some of 
the patients were able to sustain optimal eculizumab concentration and complement 
inhibition, at least for a short time. As our study included a relatively limited number 
of patients, further optimization of treatment intervals in aHUS should be evaluated 
in a larger patient cohort. 
The results of this study have laid the base to formulate the Dutch guideline for the 
restrictive treatment regimen of aHUS patients that is currently being introduced in the 
Netherlands. In the future, it will help to design correct individualized dosing schemes 
for patients in acute aHUS that require continuous complement blockade, as well as for 
patients in remission for whom therapy is being discontinued by using gradual exten-
sion of intervals. That will help to save costs and make this efficient medication more 
accessible to the patient.
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“Twee zusjes zitten voor het raam. Eén leest. De ander luistert. 
Haar handje schuifelt door het haar. 
Er is nog even samenhang maar dan ontgaat haar het verhaal. 
De duim blijft steken tussen mond en kin. 
De oudste leidt met zachte dwang haar zusje weer het sprookje in.” 
Neeltje Maria Min
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Abstract
Eculizumab is the first drug approved for the treatment of complement mediated diseases. 
Current dosage schedules result in large inter-individual drug concentrations. This review 
will give insight into the pharmacokinetic and dynamic properties of eculizumab, both 
for reported on- (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syn-
drome, generalized myasthenia gravis) and off-label indications (hematopoietic stem cell 
transplantation associated thrombotic microangiopathy). Furthermore, we will discuss 
the potential of therapeutic drug monitoring to individualize treatment and reduce costs. 
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Introduction
With orphan drug status in 2003 and approval in 2007, eculizumab (Soliris) was the first 
drug targeting the complement system, specifically complement component C5.176-178 Since 
the approval of eculizumab, many trials have been conducted and various drugs targeting 
different proteins of the complement system are in the pipelines.9 Up till now, marketing 
authorization for eculizumab has been obtained for the treatment of paroxysmal noctur-
nal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and refractory 
generalized myasthenia gravis (gMG).8,176,179 Noteworthy is the off-label use of eculizumab 
in broad spectrum of other diseases (Table 7.1).180 
Like other orphan drugs, costs as high as €500,000 per patient per year are asso-
ciated with eculizumab therapy.181 Consequently, eculizumab is considered one of the 
world’s most expensive drugs. Secondly, the burden for the patients is considerable, since 
eculizumab has to be administrated intravenously, every fortnight, potentially lifelong. 
Thirdly, there are large inter-individual variations in pharmacokinetics.167,182 And lastly, 
treatment is not without risks. The most prominent risk is the susceptibility to infection 
with Neisseria meningitidis (meningococcus).183 Furthermore, evidence is accumulating 
regarding the potential (long-term) adverse effects of eculizumab like hepatotoxicity.99,184
Taking this into consideration, the infinitesimal data regarding dose adaptations 
guided by either measuring drug concentration or efficacy markers (complement system) 
is striking. In this review we give insight into the PK and PD of eculizumab both for reported 
on- and off-label use. Furthermore, pharmacokinetic targets within different diseases are 
discussed to optimize dosing. To conclude, the possibility, and above all necessity, of dose 
individualization will be discussed together with the tools to achieve tailored patient care.
The complement system
The complement system is an important part of innate immunity and consists of three 
different pathways, all converging at C3, the central complement component (Figure 7.1). 
The classical pathway (CP) and lectin pathway (LP) are, respectively, triggered by antibodies 
(such as the case in gMG) and mannose containing sugars on pathogens. The alternative 
pathway (AP) is unique since spontaneous auto-activation is always present and can be 
further triggered by bacterial components such as lipopolysaccharide and bacterial toxins. 
When activated, an amplification loop is generated.228 Activation of each pathway leads to 
the formation of the C3 convertase (C3bBb) which can cleave C3, leading to chemotaxis and 
opsonization with respectively C3a and C3b. Generation of large amounts of C3b results in 
the formation C5 convertase (C3bBbC3b). On its turn, C5 convertase can cleave C5, hereby 
producing the second anaphylatoxin C5a, and C5b which can bind complement proteins 
C6, C7, C8 and C9 to form the end product of the complement system, the membrane attack 
complex or C5b-C9 (C5b-C9), which causes cell lysis (Figure 7.1). 
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Table 7.1 Reported use of eculizumab in light of pharmacokinetic and pharmacodynamic data
Disease Pharmacokinetic 
data availablea
Pharmacodynamic 
data availableb
References
Atypical hemolytic uremic syndrome Yes Yes 8,158,165-168,182,185-
194
Paroxysmal nocturnal hemoglobinuria Yes Yes 176,177,195-208
Refractory generalized Myastenia Gravis Yes Yes 179,209,210
Shiga toxin producing E. Coli hemolytic 
uremic syndrome
No No 211,212
Multifocal motor neuropathy Yes Yes 213
Antibody mediated kidney rejection No No 214,215
C3 glomerulopathy (including dense 
deposit disease)
Yes No 216,217
Age related macular degeneration Yes No 218,219
AQP4 IgG positive Neuromyelitis optica Yes 220
Systemic lupus erythematosus Yes Yes 221
HSCT – TMA Yes Yes 172,222,223
Guillain Barré No No 224
Psoriasis Yes No 178
Rheumatoide arthritis Yes Yes 178,207,225
Dermatomyositis Yes No 226
Idiopathic membranous glomerulopathy Yes Yes 178,207
Demyelinating neuropathy with CD59 
p.Cys89Tyr mutation
No No 227
HSCT-TMA; Hematopoietic stem cell transplantation associated thrombotic microangiopathy
a Data on serum eculizumab (trough) levels was considered sufficient for pharmacokinetic data
b Data regarding serum eculizumab levels in relation to complement blockade
Normally, the complement system is tightly controlled by regulatory proteins pres-
ent both in fluid phase and on the cell surface. The most important soluble factor is 
considered complement factor H, followed by complement factor I. In addition to these 
blood derived regulators, the human body has various regulators bound to the membrane 
of host cells. Examples of important bound regulators on cells are respectively decay 
acceleration factor (DAF;CD55) and CD59 on among others erythrocytes, platelets and 
endothelial cells en membrane cofactor protein (MCP; CD46) on among others platelets 
and endothelial cells.228,229
CH
A
PTER 7
Pharmacology of eculizumab   |   121
Figure 7.1 The complement system
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Figure 7.1 The complement system consists of three pathways which all converge at C3. The classical pathway is depicted 
in the left upper quadrant, the lectin pathway is depicted in right upper quadrant and the alternative pathway is 
depicted in the middle on the right. Each pathway is activated by a trigger such as antibodies which will be bound 
to C1q, mannose containing sugar which will be bound to mannose binding lectin (MBL) or ficolin, or spontaneous 
hydrolysis of C3 to C3a and C3b and hereby the potential to activate or enhance complement activation via alterna-
tive pathway. By formation of C3 convertases (C2aC4a or C3bBb) and subsequently C5 convertases (C2aC4bC3b or 
C3bBbC3b) the lytic pore and end product of the complement system is formed (C5b-C9) causing lysis of the cells. The 
complement system is tightly controlled by various complement regulators such as factor H and factor I. Eculizumab 
is a chimeric monoclonal antibody which consists of both human and murine regions (depicted as dark and red bars 
in Fab arms). Eculizumab is able to bind 1 or 2 C5 molecules, hereby preventing the cleavage of C5 into C5a and C5b, 
hence blocking formation of C5b-C9. Fb; factor b, MAC; membrane attack complex, MBL; mannose binding lectin
Pathogenesis of complement mediated diseases
Together with our growing knowledge of the complement system and its role in differ-
ent diseases, evidence has emerged for complement blockage with drugs. Eculizumab 
was approved by the European medicines agency (EMA) and food and drug administra-
tion (FDA) as standard treatment for PNH, aHUS and gMG in respectively 2007, 2011 and 
2017.8,169,176,197 Eculizumab administration is reported in two disease situations: primarily in 
diseases resulting from complement dysregulation (e.g. PNH and aHUS) and subsequently 
in diseases with extensive complement activation with inflammation (e.g. gMG).152,172,211,216-
218,222,223,230-234 For the purpose of this review, the most prominent diseases with reported 
eculizumab therapy will be described, in light of sufficient PK and PD data available.
Paroxysmal nocturnal hemoglobinuria 
PNH is a rare form of acquired hemolytic anemia with an estimated incidence of 
respectively 1-2 cases per million. PNH is caused by a non-malignant clonal expansion 
of hematopoietic stem cells containing a somatic mutation in a gene located on the 
X-chromosome called phosphatidylinosital glycan complementation class A.177 As a result, 
affected stem cells are deficient of glycosyl phosphatidylinositol anchored proteins. In 
patients with PNH, clonal expansion results in the production of cells, like erythrocytes, 
granulocytes and platelets, that lack the expression of glycosyl phosphatidylinositol 
anchored complement regulatory proteins CD55 and CD59. Due to the absence of comple-
ment regulators CD55 and CD59, erythrocytes are susceptible for complement activation 
on the cell surface, in particular causing hemolysis and thrombosis 229
PNH usually affects adult patients with an average onset at the age of 30 years, and is 
associated with increased mortality and morbidity.199,235 PNH is characterized by chronic hemo-
lysis due to complement activation. As a consequence, free hemoglobin is released which 
depletes nitric oxide and impairs vasodilatation. Clinical manifestations include abdominal 
pain, dysphagia, erectile dysfunction, pulmonary hypertension and chronic kidney disease. 
The most feared complication of PNH is thrombosis. Before the era of eculizumab, thrombosis 
accounted for up to 65% of the deaths with thrombosis incidence of 29-44%.235 
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Atypical hemolytic uremic syndrome
Atypical HUS is a rare and severe form of thrombotic microangiopathy (TMA) resulting in 
mechanical hemolytic anemia, thrombocytopenia and acute kidney injury.1 Atypical HUS 
results from an uncontrolled overactivation of AP due to pathogenic mutations of or acquired 
auto-antibodies directed against, complement regulatory proteins. Overactivation of the AP 
causes excessive generation of respectively C3 and C5 convertases, leading to excessive depo-
sition of C5b-C9 on endothelial cells. This causes endothelial activation and injury, resulting 
in platelets aggregation, formation of thrombi and scattering of erythrocytes when squeezed 
through these narrowed microvessels in mainly the glomeruli of the kidney. 
Atypical HUS has an estimated incidence of 1-2 cases per million and affects all ages 
with a slightly higher incidence in childhood when compared to adults.1,6 Although TMA 
affects predominantly the renal vasculature, extra-renal involvement of central nervous 
system (10-15%), heart (3-10%), pancreas, liver, intestines, lungs, and skin is reported.1,6 
Before the implementation of eculizumab, mortality was as high as 25% in the acute 
phase of the disease and over 50% of the patients reached end state renal disease after 
their first presentation. 
Refractory generalized myasthenia gravis
Generalized MG is a rare and acquired form of neuromuscular auto-immune disorder. 
It occurs in the presence of antibodies, in up to 80% directed against the acetylcholine 
receptor at the postsynaptic membrane of the neuromuscular junction. Antibodies com-
posed of IgG1 and IgG3 isotypes are known to activate CP, ultimately leading to C5b-C9 
deposition on the postsynaptic membrane and consequently disruption of the acetylcho-
line receptors. Due to chemotaxis and cell lysis associated with complement activation, 
the postsynaptic membrane becomes less sensitive to the released acetylcholine, hence 
nerve impulses will be inhibited.209,236-238
Generalized MG has an estimated incidence up to 10 per million. Patients suffer from 
progressive muscle weakness and fatigue, starting usually with ocular muscle weakness. 
However, when generalized, it affects bulbar, axial, limb and respiratory muscles as well. 
Due to respiratory failure patients are frequently admitted to the intensive care unit and 
in case of delayed intervention, eventually this can lead to death.209,236
Hematopoietic stem cell transplantation associated thrombotic microangiopathy
Secondary TMA is frequently seen in patients after hematopoietic stem cell transplan-
tation (HSCT).172 Mimicking aHUS, the complement system seems to play a crucial role 
in developing severe HSCT-TMA.172,222,239 Especially in patients presenting with severe 
HSCT-TMA, the mortality rate and severity of chronic sequelae are high. Severe TMA 
affects 20-30% of the HSCT recipients and is characterized by proteinuria and elevated 
levels of sC5b-C9 in addition to TMA.
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Pharmacokinetic properties of eculizumab
Eculizumab (Soliris, Alexion Pharmaceuticals, Inc.) is a humanized chimeric monoclonal 
antibody consisting of a human framework build of IgG2 and IgG4 composed with vari-
able regions of murine origin (Figure 7.1). The eculizumab dose depends on the indication 
and weight of the patient. Pharmacokinetics of eculizumab in healthy subjects have not 
been studied.240 At the end of the previous century, phase I studies were performed in 
rheumatoid arthritis (RA, C97-001-01) and systemic lupus erythematosus (SLE, C97-002-
01) patients. Phase II multiple dose studies were conducted in patients with RA (C01-004), 
idiopathic membranous glomerulopathy (IMG, C99-004) and PNH (C02-001) Pilot studies 
have been performed in patients with dermatomyositis (C99-007) and psoriasis (C99-007) 
as well.208,214,220,221,225,226,241 
Eculizumab is administrated as an intravenous infusion in 25-45 minutes, with a max-
imum of two hours in patients above 12 years of age and four hours in children less than 12 
years of age (see Table 7.2 for different dosage regimens per disease).240 After intravenous 
administration, eculizumab is primarily distributed in blood plasma. Limited distribution 
in cerebrospinal fluid has been described, with concentrations 5000-fold lower than in 
plasma.220 Distribution to other tissues has not been described in human studies. In vivo 
animal studies and in vitro studies with normal human tissues showed intracellular dis-
tribution to a wide variety of cells, consistent with expected C5 localization. 
The specific metabolism of eculizumab has not been described. As described for other 
monoclonal antibodies, they are catabolized via the mononuclear phagocyte system con-
sisting of monocytes, macrophages, Kupffer cells and histiocytes. By either endocytotic 
digestion or binding to the Fcγ-receptors on phagocytic cells, monoclonal antibodies will 
be degradated by lysosomes to peptides and amino acids. Eculizumab contains no known 
active metabolites.240,242,243 It has an average half-life of approximately 11.3 days (standard 
deviation of ±3.4).178 Due to the molecular size, eculizumab is not excreted in urine, except 
in patients with heavy proteinuria where eculizumab concentrations as high as 56 µg/
ml have been detected. 158,168
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Table 7.2 Dosage scheme in different patient populations
Patient group Induction Maintenance
PNH 600mg, every 
week, for 4 weeks 
900mg in fifth week, every 14 days 
thereafter
aHUS – gMG 900mg, every 
week, for 4 weeks 
1200mg in fifth week, every 14 days 
thereafter
   Pediatric population PNH & aHUS <40 kg
   30 to < 40 kg 600mg, every 
week, for 2 weeks 
900mg in third week, every 14 days 
thereafter
   20 to < 30 kg 600mg, every 
week, for 2 weeks 
600mg in third week, every 14 days 
thereafter
   10 to < 20 kg 300mg once 300mg in second week, every 14 
days thereafter
   5 to < 10 kg 300mg once 300 mg in second week, every 21 
days
HSCT-TMA 900mg, second 
dose when* 
1200 every 2 weeks, when steady 
CH50 suppression is achieved and 
TMA parameters together with 
sC5b-C9 levels normalize
   Pediatric population <40 kg
   30 to < 40 kg 600mg second 
dose when*
900mg every 2 weeks, when 
steady CH50 suppression is achieved 
and TMA parameters together with 
sC5b-C9 levels normalize
   20 to < 30 kg 600mg second 
dose when*
600mg every 2 weeks, when 
steady CH50 suppression is achieved 
and TMA parameters together with 
sC5b-C9 levels normalize
   10 to < 20 kg 600mg second 
dose when*
300mg every 2 weeks, when 
steady CH50 suppression is achieved 
and TMA parameters together with 
sC5b-C9 levels normalize
 5 to < 10 kg 300mg second 
dose when*
300mg every 2 weeks, when 
steady CH50 suppression is achieved 
and TMA parameters together with 
sC5b-C9 levels normalize
aHUS; atypical hemolytic uremic syndrome, CH50; classical pathway inhibition, gMG; generalized myasthenia 
gravis, HSCT; Hematopoietic stem cell transplantation, PNH; paroxysmal nocturnal hemoglobinuria, sC5b-C9; 
soluble C5b-C9, TMA; thrombotic microangiopathy
* Within 72h when sC5b-C9 is > 244ng/mL, when CH50 was no longer suppressed or after seven days. In case of 
remaining complement activity (CH50>10% and elevated sC5b-C9, dose should be increased by 300mg/dose to 
maximum of 1200mg/dose.
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Eculizumab pharmacokinetics. 
The eculizumab concentration in serum depends on various factors. The adequate dosage 
is based upon weight of the patient and the underlying disease. 
To identify the optimal dose of eculizumab necessary to block complement, six single 
dose studies were performed in patients with RA (C97-001-01) and SLE (C97-002-01).178 
Patients were infused with a single dose, ranging from 0.1 mg/kg up till 8mg/kg of eculi-
zumab in 30 minutes (Table 7.3 and Table 7.4). As reported in the scientific discussion of 
the EMA, these single dose studies in RA patients yielded a mean clearance (CL) of 0.26 
ml/kg/hr with a central volume of distribution (Vd1) of 15 ml/kg and peripheral volume 
of distribution (Vd2) of 20 ml/kg.208 The estimated Vd at steady state was calculated at 35 
ml/kg. With this Vd, the estimated half-life was 93 hours (3.9 days). The area under the 
curve (AUC) was calculated at 24467.6 µg.hr/ml. One highly interesting observation was 
the presence of a second peak after two days post dose, however no further information 
regarding this observation was published. Two-fold increase of the eculizumab dosage from 
4 to 8mg/kg in respectively RA and SLE yielded an increase of 60% and 15% in mean maxi-
mum concentration (Cmax) (Table 7.3). The AUC increased by 70% and 103% in RA and SLE 
respectively (Table 7.3). Both distribution and half-life are dose dependent (Table 7.3).178,208
Multiple-dose studies were conducted in three patient groups with RA (C01-004), 
IMG (C99-004) and PNH (C02-001). With the use of a two-compartment model, PK 
parameters were calculated (see Table 7.4). At therapeutic doses, eculizumab shows 
linear pharmacokinetics, indicating saturation of the drug target.208 
The population pharmacokinetics of eculizumab in PNH patients have previously 
been described using a one-compartment model (Table 7.4). Clearance was estimated 
to be 0.3 ml/kg/hr with Vd of 110.3 ml/kg which was slightly larger than estimated serum 
volume of patients.178 Elimination rate (K) of 0.0028 1/h which resulted in a half life of 
approximately 271.7 hours (11.3 days). In PNH, eculizumab trough concentration (Ctrough) 
measured at week 26 were 97 ± 60 µg/ml. Ctrough levels remained stable during maintenance 
phase (see Table 7.2 for dosage regimen).178,194 During follow-up of patients in both pivotal 
trials (extension study, E05-001), Ctrough concentrations below 35 µg/ml were repeatedly 
observed in 10% of the patients. This was correlated with rapid eculizumab CL above 0.4 
ml/kg/hr or a shorter half-life < 130 hours. In half of the patients the breakthrough hemo-
lysis was successfully treated with decreasing the eculizumab dosing interval. Overall, 
10% of the patients needed frequent changes in dosing interval to sustain remission.203
In the group of aHUS patients, pharmacokinetics were best described with a one-com-
partment model. In total, 57 patients from C08-002A/B, C08-003 A/B and C09-001r were 
included in the analysis (see Table 7.3 and Table 7.4). Clearance was estimated at 0.2 ml/
kg/hr and Vd was 87.7 ml/kg. Ctrough concentrations measured at week 26 in aHUS were 
242 ± 101 µg/ml with an estimated half life of 291h (12.1 days).194 Pharmacokinetic data of 
both prospective trials (C08-002 A/B and C08-003 A/B) showed Ctrough levels of respec-
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tively 93 and 113 µg/ml in adults and 104 and 109 µg/ml in adolescent patients. The AUC 
during maintenance phase in both trials were 77,693 µg/hr/ml and 104,228 µg/hr/ml in 
adults and 104,228 µg/hr/ml and 99,956 µg/h/ml in adolescents respectively. Observed 
Cmax were up to 431 µg/ml.
194
Pharmacokinetic properties of eculizumab in gMG were best described using a 
two-compartment model (see Table 7.4).179,237,244 Patients from two studied were included, 
with resp. 14 participants of double-blind placebo-controlled randomized cross-over trial 
(C08-001) and 126 participants of a double-blind placebo-controlled randomized trial (ECU-
MG-301). Clearance was estimated at 0.09 ml/kg/hr with Vd1 of 27.6 ml/kg and Vd2 of 30 
ml/kg (median weight of 80kg in eculizumab arm). Eculizumab Ctrough concentrations were 
approximately twofold different at steady state comparing both studies. Following a main-
tenance dose of 1200mg, Cmax and Ctrough levels reported at week 26 were 738 ± 288 µg/ml and 
341 ± 172 µg/ml. Interindividual variability was high, CL up to 42% and Vd up till 24%.179,244
Finally, a study assessed PK properties in patients with HSCT-TMA. Eculizumab 
clearance ranged from 0.23 to 3.39 mL/kg/hr during induction phase. Important to note 
is the high number of erythrocyte and platelets transfusions due to severe and per-
sistent gastro-intestinal bleeding explaining the high clearance. At the fifth week CL was 
decreased to mean CL (±SD) of 0.35 ml/kg/hr (± 17.7). Pharmacokinetic modeling with one 
compartment model of eculizumab therapy in HSCT recipients showed high variability 
of eculizumab clearance of 1.4 ml/kg/hr (relative standard error of 9%), especially within 
the first weeks of treatment.172 
Factors influencing eculizumab concentrations
Several covariates have been identified to impact pharmacokinetics of eculizumab. Next 
to age and weight, these are C5 concentrations, C5b-C9 concentration, human anti-hu-
man antibodies (HAHA), plasma exchange therapy, and pregnancy. The impact of these 
covariates will be discussed in the next paragraphs. 
Effect of age and weight
The most important covariate between different populations is the difference in weight. 
Since weight influences the clearance and volume of distribution of eculizumab the 
dosage is weight based.167 Eculizumab pharmacokinetics in children have been investi-
gated in two open label studies in both PNH (n=7) and aHUS (n=22) patients.166,204 In the 
open label phase I/II study (M07-005) conducted in seven PNH patients ranging from 
11-17 years, patients received eculizumab according the standard protocol (600mg weekly 
for 4 weeks, followed by 900mg at week 5 and every 14 days thereafter). Eculizumab 
concentrations reached a plateau after 4 weeks. After 12 weeks median (range) Ctrough 
concentrations were 192.5 (124.2-321.1) µg/ml with median Cmax of 425.4 (220.5-556.1) µg/
ml.204 No data regarding CL and Vd were described. 
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Based on population PK analysis of the three pivotal trials of aHUS (C08-002, C08-
003 and C09-001r), (±SD) per weight category (>40kg, 30-40kg, 20-30kg, 10-20kg, 5-10kg) 
was estimated at respectively 15.1 (± 6.5), 7.6, 6 (± 1.46), 5.49 (± 0.24) and 3.6 (± 1.3) ml/kg/hr, 
resulting from an allometric relationship between weight and clearance.194 Furthermore, 
in the prospective open-label non-randomized single arm C10-003, 22 pediatric aHUS 
patients above 1 month and 4.9 kg, were included.166 Median weight was 20 kg (range 7 – 
95 kg). Patients received eculizumab in different dosage with interval of 14-21 days based 
on weight as described in summary of products.193 Clearance and Vd were 10.4 ml/hr and 
5230 ml. Overall, patients had a Cmax of 515.4 µg/ml (range 264.7-1094.4) and Ctrough of 256.7 
µg/ml (50.2-531.1), which is higher than in the adult population. The elimination half-life 
was 290 hr (12 days). The parameters AUC, Cmax and Ctrough were different between different 
age groups. Overall, patients had a median AUC (range) of 141,741.4 µg.ml/hr (43,652.9 – 
261,814.4) at steady state. Power function of body weight was estimated at 0.715 (95% CI: 
0.59-0.84). Eculizumab appeared safe and effective in pediatric patients.166
Soluble C5b-9 levels
Recently, three articles were published which suggested that soluble C5b-9 (sC5b-C9) 
levels may impact eculizumab exposure.168,172,182 Since eculizumab is not only capable of 
binding C5 but also sC5b-C9 with lower affinity, it physiologically plausible that increased 
levels of sC5b-C9 at initiation of therapy correlate with lower eculizumab concentrations. 
Jodele et al. even showed that pre-treatment measured sC5b-C9 levels correlated with 
eculizumab clearance. 172 
Intravenous administration of immunoglobulins
Monoclonal antibodies can be cleared via non-specific endocytosis in various phagocytes, 
however are protected intracellular from degradation by the neonatal Fc receptor. This 
receptor is mainly present in endothelial cells and proximal renal epithelial cells. In case 
of saturation of this neonatal Fc receptor, due to, for example, a high load of immunoglob-
ulins, increased elimination of monoclonal antibodies can occur.242 A study performed in 
patients with multifocal motor neuropathy, who were treated with eculizumab accord-
ing to PNH protocol, and concomitant intravenous immunoglobulins (IVIg), showed 
significantly lower eculizumab Ctrough. In patients who received IVIg therapy, eculizumab 
concentrations were measured with a median (interquartile range; IQR) of 79 (55-108) 
µg/ml versus 120 (96-147) µg/ml in patients who did not receive IVIg.213 No statistical 
significance was observed in hemolytic complement activity, although more patients 
with IVIg had detectable total complement activity above 20%.213 
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Human anti-human antibodies
As with any humanized antibody therapy the risk of developing (neutralizing) human 
anti-human antibodies (HAHA) is present. Analysis of a cohort of 75 PNH patients with 
median of 7.5 years of eculizumab therapy revealed no HAHAs.245 In the TRIUMPH trial 
one patient developed HAHAs, however it seemed not to effect eculizumab therapy.176 
One aHUS patient, 30 months old, was reported with HAHAs. The patient had inadequate 
Ctrough (17.1 µg/ml) ongoing hemolytic activity, together with nonresponsive TMA after the 
start of treatment.166
Plasma infusion and exchange 
As expected, plasma exchange and plasma infusion have a clear influence on clearance of 
eculizumab and subsequently lead to a marked reduction of the half-life (see Table 7.3). 
Clearance was measured in aHUS patients with plasma exchange and increases from 
14.6 ml/hr to 3660 ml/hr with an estimated half-life of 1.26 hours. Therefore, it is recom-
mended to supplement an extra dosage (600mg, unless patient received only 300mg in 
maintenance phase, then only 300mg suppletion) of eculizumab within 60 minutes after 
plasma exchange. In case of infusion of fresh frozen plasma, it is recommended to give 
300mg in addition to normal dosage, 60 minutes prior to infusion. 240,244 
Effect of pregnancy
No formal pharmacokinetic studies have been performed for pregnant women receiving 
eculizumab. Different articles and case reports describe the use of eculizumab in pregnant 
women with either PNH or aHUS.200,246-251 Kelly et al. reported therapeutic concentrations 
of eculizumab measured in two out of three PNH patients, without detectable eculizumab 
in cord blood and breast milk.200 Servais et al. described five pregnancies in respectively 
three aHUS patients receiving eculizumab. Similar as reported by Kelly et al. no eculi-
zumab was detected in cord and neonatal blood. However, eculizumab dosage had to be 
increased in two patients, as high as 1800mg every fortnight, to maintain complement 
blockage. Both patients showed signs of partial blockage already in the first trimester 250 
In contrast to the previous discussed studies, in a cohort of 61 pregnant PNH patients, in 
35% of the cord blood samples eculizumab concentrations were detectable, ranging from 
11.8 to 21.2 µg/mL. This in contrast to the breast milk samples where eculizumab was not 
detectable.251 Moreover, pregnancy was associated with lower and even inadequate Ctrough 
levels of eculizumab. Of the 61 patients evaluated, half of the patients needed increased 
dosage of eculizumab.251
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Table 7.3 Non-compartmental analysis 
Population Number
of 
participants
Eculizumab 
dosage
Clearance 
(ml/hr)
± SD
Central 
volume of 
distribution 
(ml) ± SD
Peripheral 
volume of 
distribution 
(ml) ± SD
AUC∞ (µg.hr/ml) 
± SD
Cmax 
(µg/ml) 
± SD
Ctrough
(µg/ml)
± SD
Half-life
(hr)
± SD
Reference
RA (C97-001) 6 4 mg/kg  16.2 ± 7.2 7500 ± 4700 NA 22,200± 13,700 111 ± 53 unknown 281 ± 298 178
RA (C97-001) 6 8 mg/kg  20.3 ± 7.2 5000 ± 3600 NA 37,800 ± 5900 182 ± 19 unknown 197 ± 198 178
SLE (C97-002) 3 4 mg/kg  19.3 ± 5.2 4200 ± 1500 NA 15,600 ± 5000 139 ± 25 unknown 162 ± 88 178
SLE (C97-002) 3 8 mg/kg  19.1 ± 8.1 3900 ± 1800 NA 31,600 ± 9100 160 ± 10 unknown 141 ± 6 178
aHUS patients with PT (C08-003, C09-001r) 48 See table 7.2 3660 unknown unknown unknown unknown unknown 1.26 208
Pediatric aHUS patients (C10-003) 22 See table 7.2 10.4 5230 NA Median 141,741.4 (range 
43,652.9 – 261,814.4)
515.4 (range 
264.7-1094.4)
256.7 (50.2-531.1) 290 166
aHUS; atypical hemolytic uremic syndrome, AUC; area uder the curve, Cmax; maximum concentration, Ctrough; 
trough concentration NA; not applicable, PNH; paroxysmal nocturnal hemoglobinuria, 
PT; plasmatherapy, RA; rheumatoid arthritis, SD; standard deviation, SLE; systemic lupus erythematosus
Table 7.4 Population pharmacokinetic analyses
Population Nr. of 
participants
Clearance 
(ml/hr/
kg ± SD)
Central volume 
of distribution 
(ml/kg ± SD)
Peripheral 
volume of 
distribution 
(ml/kg  ± SD)
Intercompartment 
clearance 
(ml/hr/kg)
Elimination 
constant 
(1/hr)
Half-life
(hr) ± SD
Effect weight 
on Vd
Reference
RA (C97-001) 10 0.262 15.04 20 unknown unknown 92.9 NA 208
RA (C97-001) 121 0.3 ± 0.12 12.7 ± 8.54 42.3 ± 9.7 0.54 ± 0.16 unknown unknown NA 207
SLE (C97-002) 6 0.3 ± 0.11 18.7 ± 4.8 20.6 ± 10.84 0.59 ± 0.56 unknown unknown NA 207
RA (C01-004) 111 0.230 12.5 44.4 unknown unknown 131.33 NA 208
IMG (C99-004) 71 0.41 ± 0.14 64.9 ± 31.5 149.5 ± 44.92 0.21 ± 0.17 unknown unknown NA 207
PNH (C02-001) 11 0.25 ± 0.069 32.5 ± 16.5 26.5 ± 7.37 0.21 ± 0.06 unknown unknown NA 207
PNH (C04-001) 40 0.311 ± 0.13 110.3 ± 17.9 NA NA 0.0028 ± 0.0008 271.7 ± 81.6 NA 207
gMG (ECU-MG-301, C08-001) 75 7.37 ml/kg [6.62-
8.2 95%CI]
2210 ml [1940-2530 
95%IC]
2400 ml [2040 
– 2820 95% IC]
1820 ml/hr [73.3- 45.4 
95% CI]
unknown unknown 0.634 [0.494 - 
0.774 95% CI]
179
aHUS (C08-002, C08-003, C09-001r) 57 0.208 87.7 NA NA unknown 291 NA 193
HSCT-TMA 18 1.4 (RSE of 9%) 81.7 (RSE of 21%) NA NA unknown unknown NA 172
aHUS; atypical hemolytic uremic syndrome, gMG; generalized myasthenia gravis, HSCT-TMA; Hematopoietic 
stem cell transplantation associated thrombotic microangiopathy, IMG; idiopathic membranous glomerulopathy, 
NA; not applicable, PNH; paroxysmal nocturnal hemoglobinuria, RA; rheumatoid arthritis, RSE; relative standard 
error, SD; standard deviation, SLE; systemic lupus erythematosus
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Table 7.3 Non-compartmental analysis 
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Eculizumab 
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Clearance 
(ml/hr)
± SD
Central 
volume of 
distribution 
(ml) ± SD
Peripheral 
volume of 
distribution 
(ml) ± SD
AUC∞ (µg.hr/ml) 
± SD
Cmax 
(µg/ml) 
± SD
Ctrough
(µg/ml)
± SD
Half-life
(hr)
± SD
Reference
RA (C97-001) 6 4 mg/kg  16.2 ± 7.2 7500 ± 4700 NA 22,200± 13,700 111 ± 53 unknown 281 ± 298 178
RA (C97-001) 6 8 mg/kg  20.3 ± 7.2 5000 ± 3600 NA 37,800 ± 5900 182 ± 19 unknown 197 ± 198 178
SLE (C97-002) 3 4 mg/kg  19.3 ± 5.2 4200 ± 1500 NA 15,600 ± 5000 139 ± 25 unknown 162 ± 88 178
SLE (C97-002) 3 8 mg/kg  19.1 ± 8.1 3900 ± 1800 NA 31,600 ± 9100 160 ± 10 unknown 141 ± 6 178
aHUS patients with PT (C08-003, C09-001r) 48 See table 7.2 3660 unknown unknown unknown unknown unknown 1.26 208
Pediatric aHUS patients (C10-003) 22 See table 7.2 10.4 5230 NA Median 141,741.4 (range 
43,652.9 – 261,814.4)
515.4 (range 
264.7-1094.4)
256.7 (50.2-531.1) 290 166
aHUS; atypical hemolytic uremic syndrome, AUC; area uder the curve, Cmax; maximum concentration, Ctrough; 
trough concentration NA; not applicable, PNH; paroxysmal nocturnal hemoglobinuria, 
PT; plasmatherapy, RA; rheumatoid arthritis, SD; standard deviation, SLE; systemic lupus erythematosus
Table 7.4 Population pharmacokinetic analyses
Population Nr. of 
participants
Clearance 
(ml/hr/
kg ± SD)
Central volume 
of distribution 
(ml/kg ± SD)
Peripheral 
volume of 
distribution 
(ml/kg  ± SD)
Intercompartment 
clearance 
(ml/hr/kg)
Elimination 
constant 
(1/hr)
Half-life
(hr) ± SD
Effect weight 
on Vd
Reference
RA (C97-001) 10 0.262 15.04 20 unknown unknown 92.9 NA 208
RA (C97-001) 121 0.3 ± 0.12 12.7 ± 8.54 42.3 ± 9.7 0.54 ± 0.16 unknown unknown NA 207
SLE (C97-002) 6 0.3 ± 0.11 18.7 ± 4.8 20.6 ± 10.84 0.59 ± 0.56 unknown unknown NA 207
RA (C01-004) 111 0.230 12.5 44.4 unknown unknown 131.33 NA 208
IMG (C99-004) 71 0.41 ± 0.14 64.9 ± 31.5 149.5 ± 44.92 0.21 ± 0.17 unknown unknown NA 207
PNH (C02-001) 11 0.25 ± 0.069 32.5 ± 16.5 26.5 ± 7.37 0.21 ± 0.06 unknown unknown NA 207
PNH (C04-001) 40 0.311 ± 0.13 110.3 ± 17.9 NA NA 0.0028 ± 0.0008 271.7 ± 81.6 NA 207
gMG (ECU-MG-301, C08-001) 75 7.37 ml/kg [6.62-
8.2 95%CI]
2210 ml [1940-2530 
95%IC]
2400 ml [2040 
– 2820 95% IC]
1820 ml/hr [73.3- 45.4 
95% CI]
unknown unknown 0.634 [0.494 - 
0.774 95% CI]
179
aHUS (C08-002, C08-003, C09-001r) 57 0.208 87.7 NA NA unknown 291 NA 193
HSCT-TMA 18 1.4 (RSE of 9%) 81.7 (RSE of 21%) NA NA unknown unknown NA 172
aHUS; atypical hemolytic uremic syndrome, gMG; generalized myasthenia gravis, HSCT-TMA; Hematopoietic 
stem cell transplantation associated thrombotic microangiopathy, IMG; idiopathic membranous glomerulopathy, 
NA; not applicable, PNH; paroxysmal nocturnal hemoglobinuria, RA; rheumatoid arthritis, RSE; relative standard 
error, SD; standard deviation, SLE; systemic lupus erythematosus
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Pharmacodynamic properties of eculizumab
Formal dose and concentration response studies were not performed in any of the patient 
groups reported below. Data of various clinical trials were used to assess efficacy and 
exposure-response of eculizumab. Only the data published regarding PD in relation to 
PK will be described here. 
Monitoring of eculizumab therapy
In all trials conducted by the pharmaceutical company, hemolytic activity was used to 
determine PD properties of eculizumab.8,166 Hemolytic activity reflects total comple-
ment activity (reported as CH50) by testing the capacity of patient serum to lyse sheep 
or chicken erythrocytes coated with antibodies. In case of a functional complement 
system, the CP will be activated, subsequently leading to C5b-C9 deposition on the 
erythrocytes thus causing hemolysis. CH50 levels correlated with eculizumab serum 
trough levels and a completely blocked complement (no hemolytic activity measured) 
was the aim of treatment. 
It is important to realize that besides the classical hemolytic assay based on lysis of 
erythrocytes, various other assays have been introduced to measure CH50 and AP50. A 
well-known and characterized assay is the so called “Wieslab” test. In this ELISA CH50 
and AP50 can also be detected, however instead of hemolysis the readout is C5b-C9 for-
mation, detected using a C9 neoantigen. However,the Wieslab ELISA is less sensitive252
Exposure-effect relationship of eculizumab
The exposure-effect relationship in the phase I and II trials in respectively RA, SLE and 
IMG patients was mainly evaluated using the serum hemolytic activity to assess com-
plement inhibition.178 The results of the single dose studies in RA (C97-001) and SLE 
(C97-002) showed a concentration-dependent inhibition of hemolytic activity with 
inverse relationship between eculizumab concentration and C5 complement blockade. 
Hemolytic activity was completely blocked within 15 minutes, in almost all patients 
who received a 2.0 mg/kg dose, but hemolytic activity reappeared within two days. By 
increasing the dose to 4 or 8mg/kg complement activity was completely suppressed for 
respectively 7-14 and 11-21 days. Complete blockade of complement hemolytic activity 
was measured at eculizumab concentrations as low as 29- 55 µg/ml and 11- 35 µg/ml in 
respectively RA and SLE patients.178
Maximum PD effect was modeled using an Emax model with the above described 
data from RA patients pooled with data of IMG, and PNH patients with an half maximal 
effective concentration (EC50) of 43 µg/ml (95% CI: 39.04-47.78 µg/ml). Since eculizumab 
concentrations are reported in both bound to C5 and unbound proportion of eculizumab, 
this could indicate an overestimation of the required eculizumab concentration for com-
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plement blockade.207 The EMA scientific report with pooled data from all single and 
multiple dose studies (performed in various patient populations) suggested that an ecu-
lizumab serum concentration of 35 µg/ml is sufficient to completely block complement 
activation. Hence, the dosing schedule of 600mg in the initiation phase followed by 
900mg every fortnight was selected as most optimal dosing regimen to suppress com-
plement inhibition in almost all PNH patients (Table 7.2).178,208 
In aHUS patients, higher eculizumab concentrations of 50-100 µg/ml for complete 
complement blockade are recommended. This higher target exposure was based on 
meta-analysis of data of 177 PNH patients. In this cohort, some patients (up to 10%) 
had remaining complement activity.197,203 It was expected that this residual activity could 
result in clinical manifestations in the aHUS patient group. The main expected clinical 
manifestations reported was the potential rapid loss of kidney function in case of insuf-
ficient blockage with ongoing active TMA.193 In the FDA approval package an analysis is 
shown which described the necessity of minimal eculizumab concentration of 50 µg/ml 
to achieve more than 90% decrease in free C5.194 
Paroxysmal nocturnal hemoglobinuria 
Different trials, C02-001 (n=11), TRIUMPH (n=43) and SHEPHERD (n=97), and the exten-
sion trial comprising all previously reported patients (E05-001) reported efficacy of 
eculizumab in PNH.176,177,198 To assess pharmacodynamic properties, serum hemolytic activ-
ity was evaluated. Unfortunately, both the TRIUMPH as SHERPERD trial mention the use 
of the serum hemolytic assay, however no values were reported.176,197 Only in the extension 
trial, eculizumab concentrations in relation to hemolytic activity were described. In total 
43 patients of the TRIUMPH trial and 97 patients of the SHEPHERD trial were included. 
In total, 36% of the patients had eculizumab concentrations below 35 µg/ml after the first 
infusion of eculizumab.203 Of these 36%, 74% exhibited hemolytic activity (>20%). During 
follow up, Ctrough concentrations below 35 µg/ml were repeatedly observed in 14 (10%) 
patients. In half of them complement activity was blocked with decreasing the interval 
between the administrations. In total, 21 patients of the whole population experienced a 
median of 22 decreases in dosing interval.203
Reiss et al. described the results of a phase I/II study in seven pediatric PNH patients, 
all above 11 years of age. Eculizumab concentrations above 124 µg/ml correlated with 
complete complement blockade. The Cmax and Ctrough concentration together with AUC 
of eculizumab was associated with change in LDH.204 
Latour et al. assessed efficacy of eculizumab in 22 PNH patients.253 The association 
between CH50 and LDH was assessed with linear mixed model with intercept and slope 
for therapy duration. The association between CH50 and eculizumab was analyzed using 
generalized linear models with logistic link function. They reported suboptimal eculi-
zumab concentrations (< 35µg/ml) in 5% of the samples. Ctrough varied from 18-643 µg/ml 
134   |   Chapter 7
and half-life was highly variable ranging from 4-21 days. Furthermore, CH50 measured in 
these patients (median follow up of 13 months with a minimum of 6 months treatment) 
showed a CH50>10% in 49% of the patients prior to the next eculizumab administration. 
Complete blockade of complement (CH50 <10%) was associated with lower LDH levels 
(longitudinal Tobit regression model). An increase of CH50 by 1.4% per 100 U/l (95% CI 
0.03-2.7) increase of LDH was observed. All patients with eculizumab serum levels above 
150 µg/ml never experienced breakthrough hemolysis. Inter-patient variation was broad 
with T1/2 ranging from 4-21 days.
253
Atypical hemolytic uremic syndrome
To analyze efficacy of eculizumab in aHUS, free C5 is used as read out. In both prospec-
tive studies (C08-003 and C08-003) a median reduction of 50 and 62% respectively was 
observed in C5 activity and eculizumab Ctrough levels above 50 correlated with decrease of 
free C5 by >90%.194 CH50 levels were reduced or undetectable after seven days of therapy.194 
After 24 weeks, they report complete inhibition of complement activity in all participants. 
However, no specific values are reported regarding complement activation and eculi-
zumab concentrations.8,185 The prospective study in pediatric aHUS patients (C10-003) did 
not report complement inhibition data, only that all patients showed signs indicative of 
complement inhibition after 24 hours.166
Gatault et al. described a concentration-effect relation in seven aHUS and two PNH 
patients treated with eculizumab. With regression technique (A=20.6 x exp (-0.083 x C) 
the relation between hemolytic activity and pharmacokinetics was described. No lysis 
was detected when Ctrough levels were above 20 µg/ml, using a CH50 SPAPLUS kit which 
measures liposome lysis. However, they state this assay is less sensitive, hence not rec-
ommended. They also used and ELISA kit to measure C9, to detect low to moderate 
depression of complement activity which corresponds with CH50. Complement activity 
was detected with this assay when Ctrough levels were below 59 µg/ml.
167
Other populations. 
No exposure effect studies have been conducted in HSCT-TMA patients. Like HSCT-TMA 
patients, pharmacodynamic data are sporadically reported for gMG. EMA assessment 
report describes the population pharmacokinetic/dynamic analysis with free C5 as target 
engagement and hemolytic activity for proof of pharmacology.179 
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Covariates for eculizumab pharmacodynamics
In some patient with PNH or aHUS population a suboptimal (defined as persistent disease 
activity) response to eculizumab is described despite adequate eculizumab concentra-
tions and suppression of CH50. Although CH50 is suppressed, sC5b-C9 levels can remain 
elevated, indicating ongoing complement activation. One possible mechanism for this is 
residual C5 activity despite adequate eculizumab levels, especially during strong comple-
ment activation. Careful characterization and monitoring of these patients is necessary 
to understand this mechanism.175 
Nishimura et al. described 11 PNH patients (3.2% of the PNH population receiving 
eculizumab) with a poor response to eculizumab.254 Despite adequate Cmax and Ctrough con-
centrations patients had ongoing hemolysis. All had a single missense C5 heterozygous 
sequence variant c.2654GàA which corresponds to the polymorphism p.Arg885His. This 
genetic variant prohibits the binding of eculizumab to C5, and subsequently C5 capacity 
to form the lytic C5b-C9 remains present. Further screening revealed the same prevalence 
of this variant among healthy controls in Japan.254 Separately, an Asian PNH patient with 
poor response to eculizumab had a c.2653CàT mutation in C5 which predicts p.Arg885Cys. 
Both mutation were not found in a cohort of 220 Chinese PNH patients and 259 healthy 
controls.255 Schatz-Jakobsen et al. investigated the structural changes in C5 as a conse-
quence of these mutations. Due to the replacement of arginine by histidine or cysteine, 
the arginine binding pocket is too small, hence eculizumab cannot bind to C5.256
136   |   Chapter 7
Incremental value of therapeutic
drug monitoring of eculizumab therapy
We have reviewed the basic pharmacology of eculizumab in all diseases for which this 
drug is currently licensed. Next we described the pharmacokinetic and pharmacoki-
netic-dynamic relations as well as covariates that impact both pharmacokinetics and 
dynamics. We conclude, that there is high diversity between the different patient groups. 
As a consequence, both set Ctrough targets as the pursued effects are different per indication. 
However, not only between but also within patient groups large variations are noted. We 
advocate for an individualized approach, to provide the best tailored care.
We hypothesize that by performing Therapeutic Drug Monitoring (TDM) one could 
adjust the dose and/or dosing intervals and hereby maximize treatment response and 
reduce treatment costs. As an illustration, we performed a simulation study of the effect 
of TDM of eculizumab in PNH patients. We simulated a population of 1000 virtual 
patients based on the population pharmacokinetics and pharmacodynamics of eculi-
zumab in PNH patients.207 We simulated the pharmacokinetics of eculizumab at steady 
state (after eight weeks of standard treatment including induction phase) and applied a 
protocol for TDM based on the measurement of the steady state Ctrough, with the following 
algorithm: the absolute dose at each administration (900 mg) remained the same, but 
the dosing interval was adjusted, based on the measured Ctrough levels. When Ctrough levels 
were below the target of 30 µg/ml, we decreased the dosing interval from two weeks to 
one week. When the Ctrough was between 30-90 µg/ml the usual two week interval was 
maintained. At higher exposure, the dosing intervals were extended: a Ctrough of 90-120 
resulted in a three week dosing interval, a Ctrough between 120-210 µg/ml resulted in a 
four week interval and a Ctrough above 210 µg/ml resulted in interval of five weeks. The 
results of the simulation are presented in Figure 7.2, where the predicted Ctrough and 
associated inhibition of C5 activity are shown before and after the TDM intervention. 
Without TDM, large inter-individual variation in predicted exposure can be observed, 
with median (range) Ctrough level of 76 (4 to 362) µg/ml when using standard dosage reg-
imen. By using TDM, median Ctrough levels decrease to 58 (30-131) µg/ml (Figure 7.2A). 
Furthermore, simultaneously with decreasing the range of Ctrough levels, a decrease in the 
variation of C5 inhibition could be observed with more patients reaching target attain-
ment (Figure 7.2B). Moreover, with our TDM regimen an overall cost reduction of 11% 
in 1000 simulated patients was achieved by diminishing eculizumab administrations. 
We calculated the costs of eculizumab administrations alone per patient for one year 
of treatment and compared this with standard treatment (patients who are treated one 
year according to treatment scheme described in Table 7.2). Every patient received eight 
weeks of standard therapy after which TDM was applied with adjustment of the interval 
between eculizumab administrations. Obviously, costs largely depend on the cumulative 
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dose per patient, ranging from €211,618 per patient per year with five weekly interval to 
€726,524 per patient per year with one weekly interval. 
In conclusion, we would like to stress the potential of TDM for the use of eculizumab 
in various diseases. To fully determine efficacy of therapy, we advise to monitor both 
eculizumab serum levels as well as complement blockade by CH50. One could argue that 
eculizumab levels alone would be sufficient since there seems to be a clear correlation 
between Ctrough and complement blockade. In our opinion, CH50 is especially important 
in the case of clinical deterioration despite adequate exposure. 
Figure 7.2 Effect of therapeutic drug monitoring in PNH
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Figure 7.2. A. Large variations are observed in Ctrough levels when simulated in 1000 PNH patients according compar-
timent model as described by pharmaceutical company. A substantial amount of patients does not reach the target 
of 35 µg/ml (depicted as red dottet bar) and in contrast some patients even reach Ctrough levels up till 362 µg/ml. B. By 
applying therapeutic drug monitoring the distribution can be largely diminished, with almost all patients reaching 
target attainment and adequate inhibition of C5 activity as measured by a serum complement hemolytic activity.
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Discussion
Eculizumab is known as one of the most expensive orphan drugs worldwide. Despite 
multiple studies in various patient populations, little is known regarding the potential 
for TDM in patients receiving eculizumab. In this review we extensively discussed PK 
and PD parameters in various patient populations (PNH, aHUS, gMG and HSCT-TMA) 
treated with eculizumab. Furthermore, strategies to target optimal Ctrough levels via TDM 
with preserving adequate complement blockade are discussed. 
Although CH50 is used as PD outcome in most of the articles, one should realize 
the high diversity in the assays used. Taken together with the uncertain concentration 
of both bound and unbound proportion of eculizumab measured in the assay, we would 
advocate to set up a close collaboration with national reference laboratory in each coun-
try. Furthermore, the potential influence of high soluble C5b-C9 levels on eculizumab 
levels should be further evaluated. 
Eculizumab was first approved for PNH patients, with a set Ctrough target level of 35 
µg/ml based on multiple-dose studies performed in PNH patients. However, long-term 
studies revealed breakthrough hemolysis during maintenance therapy and half of all 
patients had insufficient blockage of complement prior to the next infusion.253 Different 
etiologies could be the cause of this ongoing hemolysis. The most prominent ones are 
considered C3 opsonisation of erythrocytes, making them more vulnerable to hemolysis, 
and insufficient C5 blockage by either inadequate Ctrough levels or in case of strong com-
plement activation.175,257 Multiple studies have described ex vivo detection of hemolytic 
activity, indicating ongoing complement activation, despite eculizumab treatment with 
adequate Ctrough levels. Besides discordant results between different assays used in the clin-
ics, remaining hemolytic activity could persist in light of strong complement activation.175 
On the other hand, the determined Ctrough target level of 50-100 µg/ml in aHUS 
patients is based rather on assumptions than on PK modeling. Taking into account the 
breakthrough hemolysis in PNH patients with a Ctrough of 35 µg/ml, and the risks of ongo-
ing TMA in aHUS patients, the Ctrough target was set at 50-100 µg/ml. Especially in patients 
with aHUS, the duration of eculizumab treatment is a highly debated topic. Important 
to note is the trend towards withdrawal of eculizumab in patients with aHUS and only 
reinitiate treatment at recurrence of disease.5,192,258 Of note, most studies focused on com-
plete complement blockade to prevent ongoing disease activity. However, it is unknown if 
complete blockage is necessary to prevent disease progression in acute and/or remission 
phase. Ardissino et al. recently described eculizumab treatment in aHUS patients with 
impaired instead of fully blocked complement activity.259 With CH50<30% instead of 
completely suppressed no recurrences were observed. 
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Only recently, eculizumab was approved for the treatment of gMG. Striking is the 
lack of data correlating complement inhibition to clinical deterioration in patients with 
gMG. Furthermore, no relation between eculizumab concentration and primary efficacy 
endpoint was seen. Hence, monitoring complement inhibition while on eculizumab ther-
apy needs to be evaluated. Future (extension) studies should provide more data regarding 
eculizumab treatment in gMG. Since IVIgs are used as therapy in gMG one should realize 
that eculizumab Ctrough levels could be influenced hereby. During trials patients had a 
washout period before receiving eculizumab.
In conclusion, to minimize unnecessary use of the highly expensive orphan drug 
eculizumab, and to assess the optimal treatment scheme, TDM may be performed using 
eculizumab Ctrough levels. Furthermore, disease activity should be monitored to look for 
possibilities to taper treatment. Treatment algorithms should be developed to explore the 
possibility of individual dosing regimens based on set Ctrough levels together with CH50. 
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Safety and effectiveness 
of restrictive 
eculizumab treatment 
in atypical hemolytic uremic 
syndrome
Abstract
Background
Atypical hemolytic uremic syndrome (aHUS) is a rare, but severe form of thrombotic 
microangiopathy, as a consequence of complement dysregulation. Atypical HUS has a 
poor outcome with high mortality and over 50% of patients developing end stage renal 
disease. Since the end of 2012, these outcomes have greatly improved with the intro-
duction of eculizumab. Currently, the duration of treatment is debated. Most guidelines 
advise lifelong treatment. However, there is no hard evidence to support this advice. 
Historically, a substantial number of aHUS patients were weaned of plasma therapy, 
often without disease recurrence. Moreover, the long-term consequences of eculizumab 
treatment are unknown. In this retrospective study we describe 20 patients who received 
a restrictive treatment regimen.
Methods
All aHUS patients who presented in the Radboudumc, Nijmegen, the Netherlands, 
between 2012-2016, and who received eculizumab are described. Clinical, diagnostic and 
follow up data were gathered and reviewed. 
Results
Twenty patients (14 adults, 6 children) with aHUS have received eculizumab. Eculizumab 
was tapered in all and stopped in 17 patients. Atypical HUS recurrence occurred in five 
patients. Due to close monitoring, recurrence was detected early and eculizumab was 
restarted. No clinical sequela such as proteinuria or progressive kidney dysfunction were 
detected subsequently. In total, eculizumab has been discontinued in 13 patients without 
aHUS recurrence, of which five are event free for over a year now. With this strategy 
approximately €11.4 million has been saved.
Conclusions
A restrictive eculizumab regimen in aHUS appears safe and effective. Prospective studies 
should further evaluate the most optimal treatment strategy.
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Introduction
Atypical hemolytic uremic syndrome (aHUS), is a severe form of thrombotic microangi-
opathy (TMA). Atypical HUS is considered the consequence of complement dysregulation 
caused by mutations in complement genes or acquired auto-antibodies against com-
plement regulatory proteins such as complement factor H (CFH).260 Atypical HUS can 
occur at any age and, before the era of eculizumab, outcome was very poor with up to 
10% mortality in the acute phase and up to 50% of patients developing end stage renal 
disease (ESRD).43,261
In 2012, the new orphan drug, eculizumab, was approved for the treatment of aHUS. 
Initiation of eculizumab treatment in the acute phase of aHUS resulted in significant 
recovery of renal function and hematological remission of TMA occurred in almost all 
patients.8,166 According the Summary of Product Characteristics (SPC) of eculizumab pub-
lished by the European Medicines Agency (EMA), treatment with eculizumab consists of 
weekly infusions in the initial phase (up to four weeks) followed by eculizumab infusions 
every 14-21 days depending on the body weight of the patient, potentially their entire 
life.240 
Currently, the duration of treatment is debated. There is no strong evidence in favor 
of a lifelong treatment. Historically, plasmatherapy (PT) was the only available treatment 
option, but failed in a number of aHUS patients, leaving them dependent on dialysis. 
In contrast, in some patients who developed complete remission, PT could be tapered 
and stopped. Thus, only a small proportion of aHUS patients remained on chronic PT.1,262 
It is noteworthy that there are no studies that provide strong evidence in favor of life-
long treatment with eculizumab. This together with the high expenses of eculizumab 
has stimulated a debate regarding duration of treatment. Eculizumab is not only one of 
world’s most expensive drugs, the burden of lifelong treatment is substantial.8 Patients 
have to return to the hospital every fortnight. Also, the long-term consequences of eculi-
zumab treatment are unknown. The most prominent risk is the development of a severe 
meningococcal infection. Other adverse outcome include: the possibility of developing 
(neutralizing) human antihuman antibodies (HAHAs) 166,203, or immune-mediated drug 
reactions. Other side effects are not yet fully understood. For example, only recently a 
study was published about the potential hepatotoxicity of eculizumab.99
Even though the outcome of patients with aHUS has improved greatly with the 
implementation of eculizumab, the costs of treatment are striking. The costs effective-
ness of eculizumab, considering the price per quality adjusted life year, is a matter of 
international debate. For example, one important requisite for the approved funding of 
eculizumab by the National Institute for Health and Care Excellence in the United King-
dom is the exploration of dose adjustment or discontinuation of eculizumab treatment.263 
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These findings underline the need for studies that evaluate optimal dosage and dura-
tion of eculizumab therapy. A growing number of case reports have emerged that suggest 
that eculizumab therapy can be reduced or discontinued in patients with aHUS.158,160-
162,165,190,192,264,265 
Eculizumab therapy became available in the Netherlands in November 2012. In view 
of the limited evidence for lifelong therapy, the high expenses and the yet unknown 
side-effects of long-term eculizumab therapy, lifelong treatment of aHUS patients was 
considered unnecessary and undesirable. Eculizumab was tapered or stopped, as early as 
three months after initiation of treatment, in patients who had reached stable remission. 
In this retrospective study we describe 20 patients who received eculizumab according 
our local practice between 2012 and 2016.
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Materials and Methods
In this descriptive study, we provide information on all pediatric and adult patients with 
aHUS who were treated with eculizumab, from November 2012 until October 2016 at the 
Radboud university medical center (Radboudumc), Nijmegen, the Netherlands. Medical 
ethical committee approval was waived, according Dutch law, since the study was observa-
tional and retrospective. Patients were followed regularly by one of the treating physicians 
(NvdK is the treating physician for the pediatric patients and JW for adults patients). 
Patients were coded, and clinical and laboratory data were analyzed anonymously. 
TMA was defined as: signs of hemoglobin level below the lower limit of normal for 
the specific age together with signs indicative of hemolysis, thrombocytopenia < 150 x 
109/l, and acute renal failure. To exclude the presence of Shiga toxin producing Esche-
richia coli causing HUS (STEC-HUS) at presentation, fecal diagnostics and serological 
antibody assay for O157 serotype were performed. These test were obligatory in children 
and performed on indication in adult patients. The ADAMTS13 (a disintegrin and metal-
loproteinase with a thrombospondin type 1 motif, member 13) activity was determined 
to exclude thrombotic thrombocytopenic purpura (TTP). Medical history was reviewed 
for signs of previous (suspected) aHUS episodes. Possible triggers such as drugs or malig-
nant hypertension causing TMA and specific aHUS triggers such as pregnancy or (viral) 
infections were reviewed. In cases where aHUS was suspected, the presence of auto-an-
tibodies against CFH were determined in serum. Simultaneously, DNA was collected for 
genetic screening of mutations in complement genes. Initially, patients were screened 
for mutations in: complement factor H (CFH), complement factor B (CFB), complement factor 
I (CFI), complement component C3, and membrane cofactor protein (MCP/C46). In case no 
explanatory mutation was found, patients were further screened for mutations in: factor 
H related proteins 1-5 (CFHR1-5), diacylglycerol kinase-ε (DGKε), thrombomodulin (THBD) and 
plasminogen (PLG). Multiplex ligation-dependent probe amplification (MLPA) was used 
to screen for possible rearrangements in CFH/CFHR region. Hypertension was defined as 
the use of antihypertensives, blood pressure repeatedly measured above 140/90 millimeter 
of mercury (mmHg) in adult patients or blood pressure above the 95th percentile for sex, 
height and age, in pediatric patients.
Eculizumab treatment
Eculizumab was started in adult patients with a (suspected) diagnosis of aHUS in the 
native kidneys, who did not respond to PT, or remained PT dependent. In children and 
in patients with recurrent aHUS after kidney transplantation, eculizumab therapy was 
started immediately without PT. The dose of eculizumab in the initial and maintenance 
phase was dependent on the body weight of the patient.240 All patients received antibiotic 
prophylaxis and vaccination as appropriate. Clinical remission was defined as normalized 
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platelet count, normalized hemoglobin level without signs of hemolysis, and improved 
and stable kidney function.
When clinical remission was reached, eculizumab treatment was evaluated. In adult 
patients who received eculizumab, and who had: improved and stable kidney function, 
well controlled blood pressure and no evidence of ongoing TMA after three months, eculi-
zumab was withdrawn. In patients with aHUS after kidney transplantation, or in patients 
who needed retreatment because of a relapse after eculizumab withdrawal: treatment 
interval was first gradually extended when clinical remission was reached. In pediat-
ric patients the interval was extended, and patients were observed with eculizumab at 
extended intervals with suppressed titers of total hemolytic complement activity (CH50). 
However, in case of stable disease (no signs of TMA), eculizumab was gradually further 
extended and finally stopped. When the treatment interval was eight weeks and no signs 
of TMA were present, eculizumab was stopped. 
In case of therapy discontinuation, patients were closely monitored for any signs of 
disease recurrence. Patients were seen frequently within the first year of discontinuation 
for blood and urine workup, initially in the first four months with an interval of two 
to four weeks, and every two months thereafter. Blood was drawn to look for signs of 
hemolytic anemia (values determined: hemoglobin, haptoglobin, lactate dehydrogenase), 
thrombocytopenia and renal impairment. Furthermore, urine was collected to screen for 
proteinuria and hematuria. 
Patients were advised to measure their blood pressure at home, and in case of 
increased blood pressure to contact their physician. All patients and their caregivers 
were strictly instructed to pay close attention to any signs of disease recurrence and were 
advised to contact their physician in case of any signs of infections, generalized malaise, 
fever, hematuria, edema, oliguria, paleness or other signs indicating recurrence of aHUS. 
In case of aHUS recurrence, eculizumab was restarted immediately.
All kidney transplant recipients were treated according the protocol as described by 
Verhave et al.266 To prevent endothelial damage and hereby lowering the risk of aHUS 
recurrence, among others, patients were strictly monitored to prevent high calcineurin 
inhibitor levels, had aggressive blood pressure control, preferably with ACE inhibition, and 
were prescribed statins. In patients with aHUS in their native kidneys, we also adhered to 
tight blood pressure control. However, patients with well controlled blood pressure and 
low cholesterol levels did not necessarily receive ACE inhibitors or statins. 
Statistical analysis
Clinical variables were expressed for the total number of patients of whom data were 
available. Values were expressed as absolute numbers and percentages given in paren-
thesis for categorical variables and as mean and standard deviation (SD) or median and 
25 - 75 interquartile range (IQR) for continuous variables, as appropriate. 
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Results
Patient characteristics
Between 2012 and 2016 a total of twenty patients, both adult (n=14) and pediatric (n=6) 
patients, received eculizumab as treatment for aHUS, in the Radboudumc, Nijmegen, the 
Netherlands (Table 8.1).
The median (IQR) age at first presentation with aHUS was 24 (7 - 40) years and 13 
(65%) patients were female. Five patients had a history of kidney transplantation. In 11 
(55%) patients a pathogenic mutation in complement genes or auto-antibodies against 
CFH were found and 7 (35%) patients had a mutation of unknown significance (Table 8.1). 
Of the 20 patients who received eculizumab treatment between 2012-2016, four patients 
(patient 1, 3,16, 17) already received treatment for aHUS when eculizumab became avail-
able in the Netherlands in November 2012. Patient 3, 16 and 17 were PT dependent before 
they were switched to eculizumab and patient 1, previously PT dependent, continued 
eculizumab therapy after the clinical trial conducted by Alexion Pharmaceuticals, Inc 
ended. (Table 8.1). Since November 2012, 16 patients presented with a new TMA episode 
of which seven patients initially received PT. However due to either PT dependency 
(n=2) or PT resistance (n=5), eculizumab therapy was initiated. Nine patients received 
eculizumab without PT.
All pediatric patients reached remission with initiation of eculizumab. Of the 14 
adult patients, all but one showed signs of aHUS remission after initiation of eculizumab. 
Patient 7, with a history of chronic renal failure e causa ignota for over ten years, did not 
show a renal response after eculizumab initiation. At presentation this patient had a high 
blood pressure, signs of TMA and further decline of renal function. Renal biopsy showed 
signs of mainly chronic TMA. Eculizumab was started immediately, but did not result 
in improvement of renal function, most likely due to the chronic condition. Therefore 
eculizumab was stopped. 
In the 19 responding patients the median (IQR) time until recovery of creatinine, and 
thrombocytes was respectively 39 (19 - 74) days and 5 (2 - 6) days (Table 8.2). 
Withdrawal of eculizumab therapy
Adults:
Thirteen of the fourteen adult patients have responded to eculizumab therapy. Therapy 
has been discontinued in all but one patient (Figure 8.1). Patient 6, who received a kidney 
transplant, has been treated with eculizumab for many years now. Treatment with eculi-
zumab at extended intervals resulted in low grade TMA for which therapy recently was 
intensified. Of the twelve patients where therapy was discontinued, three experienced 
TMA recurrence at respectively two weeks, three months and twelve months after ecu-
lizumab withdrawal. Immediate initiation of eculizumab was effective and no clinical 
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sequelae such as more severe proteinuria or decline of kidney function were observed 
(Table 8.3). In patient 3 eculizumab was again withdrawn after a period of receiving ecu-
lizumab with an extended interval. The median (IQR) duration of initial therapy was 3.8 
(2.8 - 5.8) months. The median (IQR) time of follow up after start of eculizumab therapy 
was 27.4 (7.8 - 42) months.
Children: 
In total, eculizumab therapy was given to six pediatric patients between 1 - 11 years of age. 
Until now, eculizumab treatment has been discontinued in four patients. In the remain-
ing two patients the dosing interval was prolonged (Figure 8.1). Patient 19 experienced 
a relapse at twelve months after eculizumab withdrawal, which was treated successfully 
for a period of three months with eculizumab (Table 8.3). After reaching remission ecu-
lizumab was again withdrawn. The pediatric patients had a median (IQR) time of follow 
up after start of eculizumab therapy of 31.3 (18.5 – 42.3) months.
Relapses
In total, five patients experienced a recurrence of aHUS (Table 8.3). Due to close mon-
itoring and rapid reinitiation of eculizumab therapy, no chronic sequelae were detected 
in these patients (Table 8.3). After clinical remission was reached, eculizumab was 
again withdrawn in two patients (Figure 8.1). The rate of relapses differed between the 
patient groups with various genetic variants: respectively four out of the eight patients 
with a CFH mutation and one out of the four patients with C3 mutation experienced 
a relapse, In patients with identified genetic variants in respectively, CFB (n=1), CFI 
(n=1), CFH-CHFR1 (n=3), patients with auto-antibodies against CFH (n=1) or patients 
were no pathogenic mutation was detected (n=2), no aHUS recurrence was detected 
after therapy adjustment. 
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Table 8.1 Patient Characteristics
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
1 F Yes, multiple aHUS 
episodes, PT dependent 
and received eculizumab 
in Alexion trial C08-
002A 
No 3 19 CFB: c.967A>G 
(p.(Lys323Glu))
Pathogenic 
Gain of function 
mutation143
No 5.6 No When Alexion trial ended patient 
received eculizumab 5.6 months 
before therapy was discontinued.
2 F No No 21 21 CFH:c.2572T>A 
(p.(Trp858Arg))
Variant of 
unknown 
significance
Yes, no 
response
43.2 Yes, after 3 
and twelve 
months
Two relapses :
1.Three months after therapy 
discontinuation, occurred in parallel 
with decreasing the beta blocker and 
an increase of blood pressure.
2. At eculizumab interval of 8 weeks, 
triggered by gastro-enteritis
3 F Yes, First episode of TMA 
in October 2012, for which 
PT, however patient was 
PT dependent 
No 43 43 CFH: c.2120delC 
(p.(Pro707fs))
Pathogenic
Frameshift
Yes, plasma 
dependent
28.3 Yes, after 12 
months
Relapse most likely triggered by viral 
infection
4 F No No 31 31 C3: c.481C>T 
(p.(Arg161Trp))
Pathogenic
Gain of function 
mutation143
Yes, no 
response
4 No
5 F No No 27 27 CFH: c.1778T>A 
(p.(Leu593*)) 
Pathogenic
Nonsense 
mutatie
Yes, plasma 
dependent
9.6 No Interval between eculizumab 
administrations was gradually 
extended before eculizumab 
discontinuation due to variable 
serum creatinine values
6 F Yes, pre-eclampsia after 
which ESRD for which 
peritoneal dialysis
Two kidney 
transplan-
tations
31 44 CFH: c.1520-1G>A 
(p.(?))
Variant of 
unknown 
significance
Splice site 
mutation
No 34.5 Yes, at 
moment of 
extended 
interval
Decline in kidney function 
for which kidney biopsy was 
performed. Signs of TMA activity 
for which eculizumab treatment was 
intensified.
7 F No No 62 62 C3: c.481C>T 
(p.(Arg161Trp)) 
Pathogenic
Gain of function 
mutation 143
Yes, no 
response
6.8 No Eculizumab was stopped 
after extended period due to 
unresponsiveness
8 F No No 21 21 CFI: c.685T>C 
(p.(Cys229Arg)) 
Variant of 
unknown 
significance
Yes, no 
response
1.3 No After six eculizumab infusions 
patient was admitted to the ICU 
with a severe pneumonia. Due to 
this severe infection and the lack 
of ongoing TMA, eculizumab was 
discontinued
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discontinuation due to variable 
serum creatinine values
6 F Yes, pre-eclampsia after 
which ESRD for which 
peritoneal dialysis
Two kidney 
transplan-
tations
31 44 CFH: c.1520-1G>A 
(p.(?))
Variant of 
unknown 
significance
Splice site 
mutation
No 34.5 Yes, at 
moment of 
extended 
interval
Decline in kidney function 
for which kidney biopsy was 
performed. Signs of TMA activity 
for which eculizumab treatment was 
intensified.
7 F No No 62 62 C3: c.481C>T 
(p.(Arg161Trp)) 
Pathogenic
Gain of function 
mutation 143
Yes, no 
response
6.8 No Eculizumab was stopped 
after extended period due to 
unresponsiveness
8 F No No 21 21 CFI: c.685T>C 
(p.(Cys229Arg)) 
Variant of 
unknown 
significance
Yes, no 
response
1.3 No After six eculizumab infusions 
patient was admitted to the ICU 
with a severe pneumonia. Due to 
this severe infection and the lack 
of ongoing TMA, eculizumab was 
discontinued
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Table 8.1 Continued
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
9 F Unknown Two kidney 
transplan-
tations
42 42 No pathogenic 
mutation found 
in: CFH, CFI, CFB, 
C3, MCP, CFH/
CFHR region
NA No 1.7 No TMA developed as complication 
of her first pregnancy. Caesarian 
was performed. Due to incomplete 
recovery of hemolysis and renal 
function eculizumab was started. 
After 1.7 months it was considered 
safe to withdrawn eculizumab due to 
elimination of the initial trigger and 
no signs of active TMA.
10 F Yes, hypertension and 
eclampsia
One kidney 
transplan-
tation
51 51 CFH: c.2669G>T 
(p.(Ser890Ile))
Variant of 
unknown 
significance141
No 2.4 No
11 F Yes, malignant 
hypertension
One kidney 
transplan-
tation
21 28 CFH:c.1548T>A 
(p.Asn516Lys) 
Variant of 
unknown 
significance267
No 4.7 No
12 M No No 33 33 C3: c.481C>T 
(p.(Arg161Trp)) 
Pathogenic
Gain of function 
mutation143
Yes ,no 
respons
3.2 No
13 F Yes, multiple aHUS 
episodes
Two kidney 
transplan-
tation
31 41 CFH: c.2034g>t 
(p.Trp678Cys)
Variant of 
unknown 
significance
No 5.4 Yes, after 2 
weeks
Patient had a complicated 
disease course with changes in 
immunosuppressive therapy. First, 
calcineurin inhibitor nephrotoxicity 
was considered likely, and patient 
was switched to belatacept with 
calcineurin inhibitor withdrawal. 
Two weeks after the last eculizumab 
administration patient presented with 
fever,an increase of serum creatinine, 
mildy decreased thrombocytes and 
high LDH values. Although kidney 
biopsy showed no signs of active 
TMA, eculizumab was restarted. 
However, after eculizumab initiation 
serum creatinine did not decline, 
questioning the presence of TMA.
CH
A
PTER 8
Restrictive eculizumab regimen   |   153
Table 8.1 Continued
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
9 F Unknown Two kidney 
transplan-
tations
42 42 No pathogenic 
mutation found 
in: CFH, CFI, CFB, 
C3, MCP, CFH/
CFHR region
NA No 1.7 No TMA developed as complication 
of her first pregnancy. Caesarian 
was performed. Due to incomplete 
recovery of hemolysis and renal 
function eculizumab was started. 
After 1.7 months it was considered 
safe to withdrawn eculizumab due to 
elimination of the initial trigger and 
no signs of active TMA.
10 F Yes, hypertension and 
eclampsia
One kidney 
transplan-
tation
51 51 CFH: c.2669G>T 
(p.(Ser890Ile))
Variant of 
unknown 
significance141
No 2.4 No
11 F Yes, malignant 
hypertension
One kidney 
transplan-
tation
21 28 CFH:c.1548T>A 
(p.Asn516Lys) 
Variant of 
unknown 
significance267
No 4.7 No
12 M No No 33 33 C3: c.481C>T 
(p.(Arg161Trp)) 
Pathogenic
Gain of function 
mutation143
Yes ,no 
respons
3.2 No
13 F Yes, multiple aHUS 
episodes
Two kidney 
transplan-
tation
31 41 CFH: c.2034g>t 
(p.Trp678Cys)
Variant of 
unknown 
significance
No 5.4 Yes, after 2 
weeks
Patient had a complicated 
disease course with changes in 
immunosuppressive therapy. First, 
calcineurin inhibitor nephrotoxicity 
was considered likely, and patient 
was switched to belatacept with 
calcineurin inhibitor withdrawal. 
Two weeks after the last eculizumab 
administration patient presented with 
fever,an increase of serum creatinine, 
mildy decreased thrombocytes and 
high LDH values. Although kidney 
biopsy showed no signs of active 
TMA, eculizumab was restarted. 
However, after eculizumab initiation 
serum creatinine did not decline, 
questioning the presence of TMA.
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Table 8.1 Continued
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
14 M No No 49 49 CFH:c.2850C>T 
(p.(Gln950His)) 
Variant of 
unknown 
significance
Yes, PT 
dependent 
3.2 No
15 M Yes, multiple aHUS 
episodes, treated with 
PT and eculizumab in 
Alexion trial C10-003
No 5 
months
2 de novo 
rearrangement 
CFH- CFHR1a
Pathogenic148 No 44 NA Experienced relapse three months 
after eculizumab withdrawal due to 
end of Alexion trial. Eculizumab was 
restarted.
16 M Yes, multiple aHUS 
episodes, patient was PT 
dependent
No 4 
months
11 Hybrid CFH-
CFHR1 geneb
Pathogenic148 Yes, PT 
dependent
41.7 NA
17 M Yes, multiple aHUS 
episodes, patient was PT 
dependent
No 6 9 Auto-antibodies 
against CFH
Pathogenic47 Yes, PT 
dependent
37.2 No The auto-antibody CFH remained 
high, for which rituximab and 
mycophenolate mofetil was 
administered. The titer was 
successfully reduced after which 
eculizumab was withdrawn according 
recently published guidelines4
18 M No No 16 
months
16 months No pathogenic 
mutation found 
in CFH, CFI, CFB, 
C3, MCP, PLG, 
THBD, DGKε, 
CFHR1-5, CFH/
CFHR region
NA No 13.4 No Patient received eculizumab for over 
a year with an extended interval up 
to four weeks, after which therapy 
since patient showed no signs of 
TMA.
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Table 8.1 Continued
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
14 M No No 49 49 CFH:c.2850C>T 
(p.(Gln950His)) 
Variant of 
unknown 
significance
Yes, PT 
dependent 
3.2 No
15 M Yes, multiple aHUS 
episodes, treated with 
PT and eculizumab in 
Alexion trial C10-003
No 5 
months
2 de novo 
rearrangement 
CFH- CFHR1a
Pathogenic148 No 44 NA Experienced relapse three months 
after eculizumab withdrawal due to 
end of Alexion trial. Eculizumab was 
restarted.
16 M Yes, multiple aHUS 
episodes, patient was PT 
dependent
No 4 
months
11 Hybrid CFH-
CFHR1 geneb
Pathogenic148 Yes, PT 
dependent
41.7 NA
17 M Yes, multiple aHUS 
episodes, patient was PT 
dependent
No 6 9 Auto-antibodies 
against CFH
Pathogenic47 Yes, PT 
dependent
37.2 No The auto-antibody CFH remained 
high, for which rituximab and 
mycophenolate mofetil was 
administered. The titer was 
successfully reduced after which 
eculizumab was withdrawn according 
recently published guidelines4
18 M No No 16 
months
16 months No pathogenic 
mutation found 
in CFH, CFI, CFB, 
C3, MCP, PLG, 
THBD, DGKε, 
CFHR1-5, CFH/
CFHR region
NA No 13.4 No Patient received eculizumab for over 
a year with an extended interval up 
to four weeks, after which therapy 
since patient showed no signs of 
TMA.
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Table 8.1 Continued
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
19 F Yes, multiple aHUS 
episodes treated with PT
No 9 11 C3: c.481C>T 
(p.(Arg161Trp)) 
Pathogenic
Gain of function 
mutation143
No 5.3 Yes, after 12 
months
At start maintenance phase 
(1200mg) patient showed signs 
indicative of an anaphylactic 
reaction after eculizumab infusion. 
Temperature increased up to 38.7 
Celsius, patient experienced shivers, 
and erythematous spots were seen 
at the face and shoulders. The 
reaction was observed during four 
consecutive infusions and patient 
responded good at anti-histamine 
treatment.
Twelve months after therapy 
discontinuation, patient experienced 
a relapse, wherefore patient was 
treated again with eculizumab for 3 
months
20 M No No 10 10 Hybrid CFH-
CFHR1 geneb
Pathogenic148 No 2.5 No
aHUS, atypical hemolytic uremic syndrome; C3, complement component C3; CFB, complement factor B; CFH, com-
plement factor H; CFHR, complement factor H related protein; CFI, complement factor I; CMV, cytomegalovirus; 
DGKε; diacylglycerol kinase-ε; ESRD, end stage renal disease; ICU, intensive care unit; F, female; LDH, lactate 
dehydrogenase; M, male; MCP, membrane cofactor protein; NA, not applicable; PCR, polymerase chain reaction; 
PLG, plasminogen; PT, plasma therapy; THBD, thrombomodulin; TMA, thrombotic microangiopathy
a identified genetic variants in CFH: c.3572C>T (p.(Ser1191Leu)) and c.3590T>C (p.(Val1197Ala)). b Caused by dele-
tion CFH exon 23, CFHR3 and CFHR1 exon 1-5
CH
A
PTER 8
Restrictive eculizumab regimen   |   157
Table 8.1 Continued
Patient 
number
Gender Previous TMA 
episodes
History of 
kidney 
transplan-
tation
Age 
first 
onset 
(years)
Age 
eculizumab 
initiation 
(years)
Identified 
genetic 
variant
Mutation 
classification
Initial PT Total 
duration 
eculizumab 
treatment 
(months)
Relapse 
after 
eculizumab 
withdrawal?
Remarks
19 F Yes, multiple aHUS 
episodes treated with PT
No 9 11 C3: c.481C>T 
(p.(Arg161Trp)) 
Pathogenic
Gain of function 
mutation143
No 5.3 Yes, after 12 
months
At start maintenance phase 
(1200mg) patient showed signs 
indicative of an anaphylactic 
reaction after eculizumab infusion. 
Temperature increased up to 38.7 
Celsius, patient experienced shivers, 
and erythematous spots were seen 
at the face and shoulders. The 
reaction was observed during four 
consecutive infusions and patient 
responded good at anti-histamine 
treatment.
Twelve months after therapy 
discontinuation, patient experienced 
a relapse, wherefore patient was 
treated again with eculizumab for 3 
months
20 M No No 10 10 Hybrid CFH-
CFHR1 geneb
Pathogenic148 No 2.5 No
aHUS, atypical hemolytic uremic syndrome; C3, complement component C3; CFB, complement factor B; CFH, com-
plement factor H; CFHR, complement factor H related protein; CFI, complement factor I; CMV, cytomegalovirus; 
DGKε; diacylglycerol kinase-ε; ESRD, end stage renal disease; ICU, intensive care unit; F, female; LDH, lactate 
dehydrogenase; M, male; MCP, membrane cofactor protein; NA, not applicable; PCR, polymerase chain reaction; 
PLG, plasminogen; PT, plasma therapy; THBD, thrombomodulin; TMA, thrombotic microangiopathy
a identified genetic variants in CFH: c.3572C>T (p.(Ser1191Leu)) and c.3590T>C (p.(Val1197Ala)). b Caused by dele-
tion CFH exon 23, CFHR3 and CFHR1 exon 1-5
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Table 8.2 Laboratory values at start of treatment and after recovery
Patient number 
(genetic variant in)
Values at start of eculizumab Values at start of eculizumab Lowest values at recovery
Screat (µmol/l) Hemoglobin (mmol/l) Trombocytes (x109/l) LDH (U/l) Haptoglobin (g/l) Screat (µmol/l) Days until recovery creatinine
1 (CFB) * 159 6.9 277 151 0.31 132 NA
2 (CFH) ª 648 5.5 125 360 <0.10 159 83
3 (CFH) b 270 6.9 129 420 <0.10 124 11
4 (C3) ª 605 5.2 78 1368 - 154 99
5 (CFH) b 164 5.2 138 231 0.82 160 NA
6 (CFH) 275 4.9 150 331 <0.10 160 15
7 (C3) 291 6.1 135 260 <0.10 NA NA
8 (CFI) ª 817 5.1 130 338 0.89 146 65
9 (-) 224 5.9 177 395 0.42 149 20
10 (CFH) ª 376 5.0 84 1329 <0.10 147 50
11 (CFH) ª 1063 4.5 46 1701 <0.10 203 132
12 (C3) 341 5.1 45 1905 <0.10 88 54
13 (CFH) 163 6.8 165 426 <0.10 111 21
14 (CFH) b 250 6.2 181 230 0.45 166 39
15 (CFH-CFHR1) 95 3.4 109 982 <0.10 29 48
16 (CFH-CFHR1) b 81 7.0 180 244 0.48 84 NA
17 (αCFH) b 46 7.4 288 186 0.28 47 NA
18 (-) ª 200 5.2 514 632 <0.10 39 19
19 (C3) 122 4.8 12 - 0.43 56 15
20 (CFH-CFHR1) ª 552 6.0 76 2490 <0.10 45 32
Total, median (IQR) 260 (160-508) 5.5 (5-6.8) 135 (84-180) 377 (241-1069) 0.01 (0.01-0.43) 139 (77-159) 39 (19-65)
Table 8.2. Values indicating TMA at start of eculizumab are depicted. Serum creatinine value at recovery and days 
until recovery of creatinine are given. For a detailed description of the genetic variants per patient, see Table 8.1.
αCFH; auto-antibodies directed against complement factor H, C3; complement component C3, CFB; complement 
factor B, CFH; complement factor H, CFHR; complement factor H related protein, CFI; complement factor I, 
LDH; lactate dehydrogenase, NA; not applicable, Screat; creatinine
* patient received already eculizumab as participant in a clinical trial conducted by Alexion Pharmaceuticals, Inc.
ª patient was on dialysis at start of eculizumab
b patient was PT dependent at start of eculizumab
Table 8.3 Follow up of patients with aHUS recurrence after eculizumab withdrawal
Patient (genetic variant in)  2 (CFH) 3 (CFH) 6 (CFH) 13 (CFH) 19 (C3)
Value Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Initial presentation 1860 2.5 628 7.5 275 0.6 175 0.3 121 14.4
Recovery 143 0.24 122 <0.10 160 <0.10 98 0.2 56 <0.01
First Relapse 1022 7.7 305 1.7 225 <0.10 128 0.2 136 8.8
Recovery first relapse 146 <0.10 118 <0.10 150 <0.10 116* <0.10 55 <0.01
Second Relapse 330 0.8 NA NA NA NA NA NA NA NA
Recovery second relapse 141 <0.10 NA NA NA NA NA NA NA NA
Last follow up 138 <0.10 100 <0.10 150 <0.10 120 <0.10 52 <0.01
Table 8.3 Five patients with recurrence of aHUS after eculizumab discontinuation are presented in this table with 
serum creatinine (Screat) and protein-to-creatinine ratio (PCR) as value for the proteinuria during this period. 
C3; complement component C3, CFH; complement factor H
*The disease course of this patients is described in Table 8.1.
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Table 8.2 Laboratory values at start of treatment and after recovery
Patient number 
(genetic variant in)
Values at start of eculizumab Values at start of eculizumab Lowest values at recovery
Screat (µmol/l) Hemoglobin (mmol/l) Trombocytes (x109/l) LDH (U/l) Haptoglobin (g/l) Screat (µmol/l) Days until recovery creatinine
1 (CFB) * 159 6.9 277 151 0.31 132 NA
2 (CFH) ª 648 5.5 125 360 <0.10 159 83
3 (CFH) b 270 6.9 129 420 <0.10 124 11
4 (C3) ª 605 5.2 78 1368 - 154 99
5 (CFH) b 164 5.2 138 231 0.82 160 NA
6 (CFH) 275 4.9 150 331 <0.10 160 15
7 (C3) 291 6.1 135 260 <0.10 NA NA
8 (CFI) ª 817 5.1 130 338 0.89 146 65
9 (-) 224 5.9 177 395 0.42 149 20
10 (CFH) ª 376 5.0 84 1329 <0.10 147 50
11 (CFH) ª 1063 4.5 46 1701 <0.10 203 132
12 (C3) 341 5.1 45 1905 <0.10 88 54
13 (CFH) 163 6.8 165 426 <0.10 111 21
14 (CFH) b 250 6.2 181 230 0.45 166 39
15 (CFH-CFHR1) 95 3.4 109 982 <0.10 29 48
16 (CFH-CFHR1) b 81 7.0 180 244 0.48 84 NA
17 (αCFH) b 46 7.4 288 186 0.28 47 NA
18 (-) ª 200 5.2 514 632 <0.10 39 19
19 (C3) 122 4.8 12 - 0.43 56 15
20 (CFH-CFHR1) ª 552 6.0 76 2490 <0.10 45 32
Total, median (IQR) 260 (160-508) 5.5 (5-6.8) 135 (84-180) 377 (241-1069) 0.01 (0.01-0.43) 139 (77-159) 39 (19-65)
Table 8.2. Values indicating TMA at start of eculizumab are depicted. Serum creatinine value at recovery and days 
until recovery of creatinine are given. For a detailed description of the genetic variants per patient, see Table 8.1.
αCFH; auto-antibodies directed against complement factor H, C3; complement component C3, CFB; complement 
factor B, CFH; complement factor H, CFHR; complement factor H related protein, CFI; complement factor I, 
LDH; lactate dehydrogenase, NA; not applicable, Screat; creatinine
* patient received already eculizumab as participant in a clinical trial conducted by Alexion Pharmaceuticals, Inc.
ª patient was on dialysis at start of eculizumab
b patient was PT dependent at start of eculizumab
Table 8.3 Follow up of patients with aHUS recurrence after eculizumab withdrawal
Patient (genetic variant in)  2 (CFH) 3 (CFH) 6 (CFH) 13 (CFH) 19 (C3)
Value Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Screat 
(µmol/l)
PCR 
(g/10mmol)
Initial presentation 1860 2.5 628 7.5 275 0.6 175 0.3 121 14.4
Recovery 143 0.24 122 <0.10 160 <0.10 98 0.2 56 <0.01
First Relapse 1022 7.7 305 1.7 225 <0.10 128 0.2 136 8.8
Recovery first relapse 146 <0.10 118 <0.10 150 <0.10 116* <0.10 55 <0.01
Second Relapse 330 0.8 NA NA NA NA NA NA NA NA
Recovery second relapse 141 <0.10 NA NA NA NA NA NA NA NA
Last follow up 138 <0.10 100 <0.10 150 <0.10 120 <0.10 52 <0.01
Table 8.3 Five patients with recurrence of aHUS after eculizumab discontinuation are presented in this table with 
serum creatinine (Screat) and protein-to-creatinine ratio (PCR) as value for the proteinuria during this period. 
C3; complement component C3, CFH; complement factor H
*The disease course of this patients is described in Table 8.1.
160   |   Chapter 8
Discussion 
Although eculizumab is recommended as lifelong therapy for patients with aHUS, this 
study shows that a short treatment period with eculizumab is feasible and more impor-
tantly: safe and effective. Of the twenty patients, only two patients currently receive 
eculizumab, according SPC advise, continuously at two weeks interval. In total, eculi-
zumab has been discontinued without aHUS recurrence, in thirteen patients of which 
five are event free for over a year now. 
Our local restrictive treatment is effective, with 19 out of the 20 patients showing 
TMA remission and improvement of kidney function. The duration of treatment in our 
center deviates from the current international guideline and is based on the follow-
ing principles: first, there is no proof that lifelong eculizumab therapy is needed and/or 
associated with improved survival. Moreover, in former times PT could be withdrawn in 
a substantial amount of aHUS patients without disease recurrence. Additionally, most 
relapses occurred during the first year after disease onset. This risk decreased from over 
80% to approximately 25% in almost all aHUS patients, after the first year.261 Secondly, 
treatment with eculizumab is not without risk, with as most prominent one the risk of 
developing meningococcal meningitis. Finally, the risk of aHUS recurrence is depending 
on risk factors such as age of onset, genetic background of the patient, disease history 
(prior recurrence) and the presence of triggers, such as the use of calcineurin inhibitors 
after kidney transplantation, or the presence of rejection.1,8,44,57,267
Based on these principles we have pursued eculizumab withdrawal in all aHUS patients. 
In adults with a primary aHUS episode in their native kidney, therapy withdrawal was con-
sidered after three months of therapy. In patients considered of high risk for relapse, such 
as: adults who received kidney transplantation, or patients with disease recurrence after 
eculizumab withdrawal, treatment was gradually extended. Extending the dose interval of 
eculizumab dosage may seem irrational. However, we recently showed that the standard treat-
ment regimen often leads to eculizumab serum levels that largely exceed the target level.158
In pediatric patients it can be difficult to differentiate between complaints possibly 
related to the use of eculizumab, such as infections due to their immune compromised 
status or possible side effects of the drug itself. The optimal treatment schedule of eculi-
zumab in pediatric aHUS patients has yet to be established. Because children, especially 
young children, tend to experience more infections which are an important trigger 
for aHUS recurrence, in most of our pediatric patients eculizumab treatment was first 
tapered before discontinuation.44,57 
Other studies have reported the successful discontinuation of eculizumab in patients 
with aHUS. 160,161,165,190,192,265 The largest cohort was recently described by Fakhouri et al.165 
This study included 108 patients who were treated with eculizumab for aHUS. Eculizumab 
was withdrawn in 38 patients (35%) after a median duration of treatment of 17.5 months. 
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Follow up after eculizumab withdrawal amounted 22 months. During follow up 12 patients 
(32%) experienced a relapse. Retreatment with eculizumab was successful. Although this 
and other studies thus provide evidence that eculizumab treatment can be stopped in 
some patients, there are some limitations. Most patients were treated with eculizumab for 
a long period of time. Most importantly, withdrawal of eculizumab was only attempted 
in a limited amount of patients, which may have introduced selection bias. 
Our study adds important new information. We have tried to withdrawn eculizumab 
in all patients as early as three months after start of therapy. Clearly, outcome in our 
patients was favorable with approximately 30% of patients experiencing a relapse which 
could be reversed with re-introduction of eculizumab. Obviously, we cannot exclude that 
patients with a relapse after eculizumab withdrawal are at risk for more severe chronic 
kidney disease later in life. Therefore, it is important to be able to predict early relapses. 
Based on theoretical considerations, we have been reluctant to withdrawn eculizumab in 
young children or in patients who had received a kidney transplantation. In these patients 
we have extended the treatment interval to allow evaluation of TMA signs in a period of 
less intensive complement blockade.
 Literature data suggest that knowledge of the genetic defect may also add in pre-
dicting relapses. Indeed, in the study of Fakhouri et al.165 and Ardissino et al.160,192 most 
relapsing patients had a mutation in CFH. Likewise, four of five patients with a relapse 
in our study had a mutation in CFH. Still, in our view predictive accuracy is too low: four 
patients in our cohort with a mutation in CFH did not experience a relapse after eculi-
zumab discontinuation. Well designed, prospective, multicenter, international studies 
may allow the identification of high risk mutations which could guide individual therapy. 
A restrictive treatment regimen is important in reducing possible long-term side 
effects and lowering the burden of lifelong eculizumab treatment. Furthermore, another 
important issue in our society comprises healthcare expenses. Eculizumab is known as 
one of world’s most expensive drugs at this moment and treatment of one patient can 
cost up to half a million euro’s.263 A restrictive treatment strategy will reduce costs con-
siderably. Recently, a cost-effectiveness analysis concerning treatment of aHUS in kidney 
transplant recipients was published.268 Van den Brand et al. showed that induction ther-
apy with eculizumab followed by a lifelong treatment was inferior to eculizumab upon 
recurrence. This restrictive treatment strategy appeared cost-effective. In addition, our 
data provides important information to allow cost-effectiveness analyses of treatment 
of patients with aHUS in the native kidney. 
Our treatment strategy allowed early eculizumab withdrawal and hereby reduced drug 
costs in our patients. The total costs of treatment with eculizumab in these twenty patients 
were approximately €7.3 million. This comprises a cost reduction of 62% when compared 
to the treatment regimen according the SPC of EMA, which would have cost around €18.7 
million. Obviously, we have not performed a formal cost-effectiveness analysis. 
162   |   Chapter 8
One important limitations of our observational study is that eculizumab withdrawal 
was not protocolized but rather based on clinical information and the assessment of 
the treating physician. Furthermore, it remains important to consider the importance of 
early recognition of symptoms indicating aHUS recurrence, which is sometimes difficult 
in young children. Future studies should help to identify a reliable predictor of disease 
recurrence. The most reliable markers may reflect complement activation in blood and 
on the cell surface as previously suggested.173,269
Prospective studies are needed to determine optimal duration of treatment with 
eculizumab and evaluate prediction markers. Recently, a national, prospective study called 
CUREiHUS (NTR5988) has started in the Netherlands. This study will include all aHUS 
patients and will monitor and evaluate the restrictive treatment regimen according the 
new Dutch guideline. With the CUREiHUS study we hope to show that a restrictive 
treatment regimen is feasible. Moreover, we want to investigate the potential efficacy 
of this new treatment regimen from a societal perspective with the design of a cost-ef-
fectiveness analysis. In conclusion, discontinuation of eculizumab treatment in patients 
with aHUS is safe and effective, with close monitoring for signs of disease recurrence. 
This restrictive eculizumab regimen reduces costs considerably. 
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Eculizumab in atypical 
hemolytic uremic syndrome:  
strategies toward restrictive use
Abstract
With the introduction of the complement C5-inhibitor eculizumab, a new era was entered 
for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very 
effectively reversed thrombotic micro-angiopathy and reduced mortality and morbidity. 
Initial guidelines suggested lifelong treatment and recommended prophylactic use of ecu-
lizumab in aHUS patients receiving a kidney transplant. However, there is little evidence 
to support lifelong therapy or prophylactic treatment in kidney transplant recipients. 
Worldwide there is an ongoing debate regarding the optimal dose and duration of treat-
ment, particularly in view of the high costs and potential side effects of eculizumab. An 
increasing but still limited number of case reports and small cohort studies suggest that 
a restrictive treatment regimen is feasible. We review the current literature and focus on 
the safety and efficacy of restrictive use of eculizumab. Our current treatment protocol is 
based on restrictive use of eculizumab. Prospective monitoring will provide more definite 
proof of the feasibility of such restrictive treatment.
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Introduction
Over the last decade, the knowledge of the pathogenesis of atypical hemolytic uremic 
syndrome (aHUS) has increased substantially.1,5,57 Atypical HUS is a rare and severe form of 
thrombotic microangiopathy (TMA) which predominantly affects the renal vasculature. 
The disease course is characterized by relapses and both onset and recurrence are often 
triggered by a gastro-intestinal or pulmonary infection or pregnancy.1,57 Atypical HUS is 
caused by dysregulation of the alternative complement pathway, resulting in excessive 
production of the terminal complement complex C5b-9, and subsequently endothelial 
cell injury. In up to 60% of the aHUS patients pathogenic mutations in complement (reg-
ulatory) genes, such as complement factor H (CFH), membrane cofactor protein (MCP), and 
C3, can be detected. Additionally, about 10% of the patients, predominantly adolescents, 
have auto-antibodies directed against CFH.1 Atypical HUS is associated with increased 
mortality, although the reported mortality varies in the different cohort studies. Mor-
tality, largely dependent on the underlying pathogenic mutation, seems to be higher in 
children than in adults, and could be estimated at 2-4% in adults and 8-14% in children at 
3-5 years of follow up.53,54 In the absence of effective treatment approximately one third 
of the pediatric patients and half of adult patients with aHUS who did not died in the 
acute phase required, often permanent, dialysis treatment.53,54 The risk of recurrent dis-
ease after kidney transplantation was estimated to be 50 to 80%, with a overall five year 
graft survival of 36 ± 7% in patients with a recurrence compared to 70 ± 8% in patients 
without a recurrence.10,58,267 
Plasmatherapy (PT), either plasma exchange (PE) or in some cases plasma infusions, 
became the cornerstone of treatment in aHUS in the early nineties, despite the lack of 
randomized clinical trials and most information being based on retrospective studies 
with variable treatment protocols.. In 2009, the European Pediatric Study Group for HUS 
was the first who published a guideline to promote standardized high volume and early 
initiated PT in aHUS patients.156 The results of an audit analysis of this guideline were 
published in 2014 by Johnson et al. who evaluated 71 pediatric patients treated with PT.262 
Only 59 (83%) patients received some form of PT, and of these 59 patients 13 patients 
received early high volume PT as recommended by the guideline. Median (range) time 
until hematological remission in all patients was 11.5 (0-119) days and 83% of the patients 
reached hematological remission within 33 days. After 33 days, renal function had not 
fully recovered in most patients: 17% of the patients were still dialysis dependent, 46% 
suffered from persistent renal impairment and 11% had either residual proteinuria and/or 
hypertension.262 Of note, PT is not without risks: in most studies various adverse events 
were noted, more in the pediatric population (up to 80%, especially young patients with 
low body weight had an increased risk) than in adults (26%), mostly catheter infections 
(50%) and thrombosis (19%).57,58,262,270 
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By unraveling the role of complement in aHUS, novel therapeutic options emerged.8 
With the introduction of eculizumab in 2011, a new era was entered for treatment of 
aHUS patients. Eculizumab is a humanized, chimeric monoclonal antibody directed 
against complement component C5. By blocking the cleavage of C5 into C5a and C5b 
and subsequently the assembly of C5b-C9, endothelial injury is prevented.8 Based on 
two prospective open label phase two pivotal trials (including adults and adolescents) 
and a retrospective analysis of aHUS cohort (including pediatric, adolescent and adult 
patients) who received eculizumab outside the trials, eculizumab gained marketing 
approval and was adopted as first line therapy in patients with aHUS.8,57,185 In these 
trials eculizumab was administered following a standard treatment scheme, which is 
currently recommended by the European Medicines Agency (EMA) and Food and Drug 
Administration (FDA) (Table 9.1). In the prospective studies TMA event free status and 
complete TMA response was observed in respectively >92% and 50-85% of the aHUS 
patients who were respectively resistant to PT or PT dependent.8 PT could be discon-
tinued in all patients. Overall eculizumab treatment was well tolerated. Efficacy of 
eculizumab in the pediatric population was confirmed in a prospective open label phase 
2 trial conducted in 22 children below 18 years of age.166 Complete TMA response was 
achieved after a median of 8.6 (1-22) weeks.166 In the pivotal trials eculizumab treatment 
was continued for at least two years.8,185 No advice was given how to proceed when a 
patient was stable and in remission. Of note, TMA event free status and complete TMA 
response should not be interpreted as complete remission or full renal recovery (see 
also table 6 in the manuscript of Loirat et al. for an extensive overview of definitions 
and attainment of endpoints).57
Although these trials showed excellent results of treatment with eculizumab, the 
introduction of the drug initiated a worldwide debate regarding the optimal treatment 
strategy. Different questions were raised such as: what is the optimal duration of ther-
apy? How can therapy be monitored? Is it safe to stop eculizumab therapy? Is there a 
need for prophylactic use of eculizumab in case of kidney transplantation? Guidelines, 
written by Kidney Disease Improving Global Outcome (KDIGO) or clinical recommen-
dations generated by HUS international (a group of HUS experts), are inconclusive.57,233 
This review will focus on the safety, effectiveness and feasibility of restrictive eculi-
zumab treatment. 
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Eculizumab therapy: a none-ending story
Although no official document or international guideline directly addresses the duration 
of eculizumab therapy, it is assumed (and advocated in various scientific meetings and 
publications) that standard therapy is eculizumab in two-weekly dosages lifelong.57,233 
Indeed approval reports of both EMA and FDA emphasize the risks of withdrawal of 
eculizumab.169,194,233 In most guidelines, both treatment duration and dosage of eculizumab 
are debated.57,233 There are reasonable arguments against the advised standard therapy. 
Table 9.1 Eculizumab dosage regimen, standard therapy according to EMA/FDA 
Weight 
category
Induction 
phase
Maintenance 
phase
Above 40 kg 900mg, every week, for 4 weeks 1200mg, in fifth week, every 14 days thereafter
30 to < 40 kg 600mg, every week, for 2 weeks 900mg, in third week, every 14 days thereafter
20 to < 30 kg 600mg every week, for 2 weeks 600mg, in third week, every 14 days thereafter
10 to < 20 kg 300mg once 300mg, in second week, every 14 days thereafter
5 to < 10 kg 300mg once 300mg, in second week, every 21 days thereafter
Eculizumab has to be administrated intravenously.
EMA; European medicines agency, FDA; food and drug administration
First of all, there is little evidence to support lifelong therapy in every patient with 
aHUS. Before introduction of eculizumab, when PT was the mainstay therapy, renal out-
come of aHUS patients was poor. However, some patients responded well to PT with 
hematological remission and recovery of kidney function and were not in need of chronic 
PT. Geerdink et al. evaluated a Dutch cohort of 45 pediatric aHUS patients.44 Of these, 12 
patients (25%) were not in need of chronic PT and did not relapse after the first aHUS 
episode. Fremeaux-Bacchi et al. reported 214 patients (89 children and 125 adults) with 
aHUS, of which 146 were treated with PT and followed for 4-5 years.54 In 42% of the 
children and 34% of the adults outcome was favorable, the remaining patients relapsed, 
reached ESRD after the first aHUS episode or died. In 2006 Caprioli et al. reported the 
outcome of 60 aHUS patients with a mutation in CFH, MCP or complement factor I (CFI). 
The majority of the patients was treated with PT for a period of 2 days to 6 weeks. After 
long-term follow up renal function had normalized in 38% of the patients, including 
in 22.5% of the patients with a CFH mutation.141 Jamme et al. evaluated the outcome of 
156 adult aHUS patients treated with 5-20 sessions of PE. Overall outcome was poor as 
14 patients died from aHUS or complications of treatment. After 1-year follow up renal 
function (according to Modification of Diet in Renal Disease equation (MDRD)) had 
recovered to an estimated glomerular filtration rate (eGFR) of ≥60ml/min/1.73m² in 19% 
of the patients.271 Some authors argue in favor of lifelong therapy while referring to the 
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underlying genetic abnormality. However, many patients only present with disease in 
adulthood, and have been free of disease in childhood despite contact with triggers such 
as vaccinations or infections.1
Secondly, eculizumab treatment is not without risks. Although eculizumab is safe 
and well tolerated, potential (serious) adverse events need to be taken into account. The 
most prominent risk factor is the susceptibility to infections with encapsulated bacteria, 
especially meningogoccal disease. By blocking the complement system, which is part 
of innate immunity, patients are more prone to infections with encapsulated bacteria, 
especially Neisseria meningitidis. The risk of invasive meningococcal disease is estimated 
at >2000-fold increased compared to the normal population.272,273 To minimize the risk, 
patients are vaccinated against serotypes A,C,W, Y and recently B and receive prophylactic 
antibiotics.272 Furthermore, booster vaccinations every five years are highly recommended, 
since it is unknown what degree of protection is reached in patients with complement 
deficiencies.272 Yet, a few cases have been described of fulminant meningogoccal disease 
despite extensive vaccination and adequate antibodies titers, questioning the effective-
ness of the vaccines.155,274 The protective efficacy of vaccinations is less potent in patients 
who are treated with immunosuppressive drugs. Hence, a higher risk of infections can be 
expected in patients with aHUS after kidney transplantation. Furthermore, there is a risk 
of developing human anti human antibodies (HAHA) which could neutralize eculizumab. 
Thus far, all case reports described non-neutralizing HAHA, which did not interfere with 
eculizumab efficacy.166 Other (long term) chronic sequelae of eculizumab therapy are not 
yet fully comprehended. Only recently, emerging evidence appeared regarding the hep-
atotoxicity caused by eculizumab.99,184,275 In retrospect, hepatotoxicity was already noted 
in 10 patients during the pivotal trials as described in the approval package of the FDA.194 
Liver enzyme abnormalities were observed 10-29 days following initiation of eculizumab. 
In most cases liver enzyme derangement was transient, however in some patients eculi-
zumab was withdrawn due to suspicion of drug induced liver injury.99,184,275
Thirdly, pharmacokinetic and pharmacodynamic data are only sparsely described 
in the pivotal trials and are insufficient to endorse the current treatment scheme.169,208 
The recommended trough level of 50-100 µg/ml is based on a meta-analysis of patients 
with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab. Some PNH 
patients showed residual complement activity (based on a hemolytic assay to asses total 
complement activity; CH50) at targeted eculizumab trough levels of 35 µg/ml. Hence, 
trough levels of 50-100 µg/ml were advised for aHUS patients to minimize the risk of 
residual complement activation.169,208,276
And last but not least, with costs up to €500,000 per year per patient, eculizumab 
is unaffordable in many countries, or can only be afforded with specific restrictions. For 
example, The UK National Institute for Health and Care Excellence (NICE), located in the 
United Kingdom, stated in 2015 that eculizumab could only be reimbursed if the following 
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arrangements were in place: coordination of eculizumab use through an expert centre, a 
registry to monitor these patients, a national protocol with start and stop criteria and a 
research program to evaluate a restrictive treatment regimen.263,265 These criteria are under 
development and have not been published. 
In this review we discuss the available evidence and address the unanswered ques-
tions regarding eculizumab therapy, its prophylactic use, treatment dose and duration 
of treatment. Prospective studies are needed to answer the open questions. Prospective 
evaluation of our current treatment protocol will provide some answers and expand the 
evidence.
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Strategies towards a restrictive use of 
eculizumab in patients with native kidneys
When to start eculizumab therapy?
Early initiation of treatment (<24-48 hours) is highly recommended to stop TMA activity 
and to prevent chronic sequelae.57,189,262 In pediatric patients treatment with eculizumab 
is the preferred option, also in view of the high complication rate of PE in children.262,270 
In adults, initial therapy with PE for five days is recommended. This will allow a detailed 
diagnostic work-up to exclude secondary causes of TMA, such as hypertension, drugs 
or auto-immune diseases. This is in agreement with the pivotal study protocol, which 
included patients with progressive TMA after four or more sessions of PE and showed 
favorable outcomes. Of note, actual median (range) time to start eculizumab therapy in 
PE resistant patients was 0.8 months (0.2-3.7) in this study.8,277 A similar approach may also 
be feasible in adolescents, who have high prevalence of CFH auto-antibodies. 
If the suspected diagnosis of complement mediated aHUS is not refuted and patient 
did not respond to PE, eculizumab therapy should be initiated. Of note, TMA activity may 
disappear either spontaneously or with PE only in some patients with aHUS. In the latter 
cases, eculizumab therapy is not needed and PE can be gradually withdrawn as described 
by the European Pediatric Study Group for HUS.156,262 
Can we reduce eculizumab dosage?
Following the summary of product characteristics, eculizumab should be administered as 
two- or three-weekly infusions during the maintenance phase (Table 9.1).169 The pivotal 
trials aimed at reaching a trough level between 50-100 µg/ml considered necessary to 
fully block complement (CH50<10%). Therapeutic drug monitoring was not done, and 
all patients were treated with the advised fixed dose. It became clear that often serum 
eculizumab levels above target were reached, with reported trough levels up to 700 µg/
ml in adults and up to 1100 µg/ml in children.194 This has stimulated clinical investiga-
tors to adapt the treatment schedule, by either increasing the interval or decreasing the 
dosage to maintain trough levels between 50-100 µg/ml.167 Volokhina et al. evaluated 11 
aHUS patients in whom treatment intervals were prolonged. Eculizumab concentrations 
ranged from 40-772 µg/ml, 61-367 µg/ml, 11-256 µg/ml and 13-161 µg/ml after respectively 
2, 3, 4 or 5 weeks interval. At intervals of 4-5 weeks, 80% of the patients had eculizumab 
trough levels > 50 µg/ml. All patients with trough levels above 50 µg/ml had a fully 
blocked complement system as measured by CH50 (<10%).182 Willrich et al. showed com-
plete complement blockade with eculizumab trough levels of 100 µg/ml, confirming the 
target levels as established in the pivotal trials.276 Ardissino et al. reported that a median 
dose of 0.75 mg/kg/day (IQR 0.67-0.95) eculizumab was sufficient to block complement 
up to four weeks.259 In comparison, the recommended dose of 1200 mg two-weekly for a 
CH
A
PTER 9
Strategies toward restrictive eculizumab use   |   173
70 kg adult provides 1.2 mg/kg/day and a 900 mg dose in a 40 kg child provides 1.6 mg/
kg/day. Gatault et al. developed a one-compartment model to predict pharmacokinetics 
and pharmacodynamics of eculizumab using the data of seven patients. Following their 
model, it would be possible to extend the interval to four weeks in patients less than 90kg 
and even to six weeks in patients with body weight below 70kg.167 Of note, eculizumab 
trough levels are quite variable between patients with an inter-individual variation coef-
ficient of 45%.167,182
The added value of therapeutic drug monitoring in patients treated with eculizumab 
is still unproven. Interpretation of eculizumab levels is difficult since the assays differ and 
all detect (to a variable degree) both bound and unbound eculizumab (Table 9.2). Instead 
of measuring eculizumab levels, the pharmacodynamic effect (total complement activity 
expressed as CH50) could also be used to monitor therapy. Most authors target a fully 
blocked complement system (CH50<10%). In contrast, a recent study evaluated efficacy 
of reduced dose of eculizumab, targeting CH50<30%. In a substantial amount of patients 
this resulted even in less effective complement blockade with CH50 between of 10-70%. 
All 38 patients remained in remission.259 Indeed, various studies reported relapse free 
remissions in patients treated with eculizumab at extended intervals and incompletely 
blocked complement. 182,190,259 This suggest that complete complement blockade may not 
be necessary. Other markers of eculizumab activity and endothelial damage have been 
proposed. However, inconclusive and conflicting results have been published regarding 
the correlation between C3, C3d, C5, C5a, soluble C5b-C9, ex vivo endothelial cell assay, 
alternative pathway (AP50) activity, and efficacy of eculizumab therapy.168,182,252,269 Also, 
although treatment with eculizumab reduced the levels of markers of endothelial damage, 
their value in clinical practice is not proven.278
Is withdrawal of eculizumab therapy possible?
Evidence to support lifelong therapy, as suggested shortly after the introduction of ecu-
lizumab, is limited.8,233 In the past years, an increasing number of case reports and small 
cohort studies have provided information on eculizumab withdrawal. Nine reports have 
summarized the data of both children and adult patients in which therapy was either 
tapered and/or withdrawn (Table 9.3). In these studies, eculizumab was withdrawn in 
171 patients after a median (range) of 6 (0.5-50) months. Median (range) follow up was 
12 (0-47) months. In the individual studies relapse rate ranged from 20-67%.160,165,192,258,265
,279,280 Overall, 44 (27%) patients developed disease relapse. The median (range) time to 
relapse was 3 (1-29.5) months. This is in agreement with earlier reports, dating from the 
pre-eculizumab era, indicating that 57-82% of relapses occurred in the first year of follow 
up.54 Due to close monitoring (among others screening for proteinuria and hematuria, 
and rigorous control of blood pressure) and rapid re-initiation of eculizumab at the time 
of relapse, chronic sequelae could be prevented.160,165,192,258,265,279,280 
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Table 9.2 Monitoring of eculizumab therapy and complement activity in aHUS
Parameter Interpretation Remarks
Serum eculizumab 
level
Target is set at trough levels of 50-100 µg/ml to fully block complement Reports differ regarding the measurement of only the free proportion of eculizumab182 versus 
measurement of eculizumab both free and bound to C5 8,166 Furthermore, eculizumab can bind a 
maximum of 2 C5 molecules per eculizumab molecule and is able to bind both C5 as C5b incorporated 
in C5b-C9 complex. Hence, measurement of eculizumab can comprise free (excess) eculizumab, 
eculizumab bound to 1 C5, eculizumab bound to 2 C5, or in combination with C5b-C9 complexes.281 The 
assay used in the trials to determine the trough levels measured both bound and free proportion.193,194 
Eculizumab-C5 
complex
In contrast to serum eculizumab levels, one could also determine eculizumab 
bound to C5, hence only the bound proportion of eculizumab is determined.
It is known that eculizumab can also bind C5b-C9. Furthermore one eculizumab molecule could bind 
respectively 1 or 2 C5 molecules, hence the remaining capacity is unknown.158 Clinical use is unknown
Total complement 
activity (CH50)
CH50 levels correlated nicely with eculizumab serum trough levels, and 
suppressed CH50 (<10%) is reached with trough levels >30-50 µg/ml.182,193,208,252
There are different assays to measure CH50. With this test total complement activity (also known 
as CH50) is tested to determine the capacity of patient serum to lyse sheep or chicken erythrocytes 
coated with antibodies. In case of a functional complement system, the CP will be activated, 
consequently leading to C5b-C9 deposition on the erythrocytes and consequently cause hemolysis. 
With the Wieslab test, CH50 can be measured withC5b-C9 formation, detected using a C9 neoantigen, 
as read-out.252 Recently, Willrich et al. reported CH50 measurement during eculizumab treatment with 
liposome immunoassay with stable and reliable results.276
Alternative pathway 
activity (AP50)
AP50 levels can be suppressed by eculizumab, however ongoing activation has 
been noted despite adequate eculizumab levels.168,252
There are different assays to measure AP50. Specific assessment of alternative pathway activation 
is possible with a hemolytic assay based on untreated rabbit erythrocytes (AP50). Puissant-Lubrano 
et al. compared both the hemolytic assays as used in all trials with the Wieslab ELISA in 16 patients 
treated with eculizumab, and found conflicting results.252 Residual activity of the AP was observed 
with the hemolytic assay, in the presence of (sufficient) eculizumab levels. In contrast to the Wieslab 
ELISA which showed complete blockade of the AP. Moreover, they assessed sensitivity of all assays 
and concluded that the Wieslab ELISA is less sensitive, hence the residual activity measured with the 
hemolytic assay is most accurate.252
C3d C3d is a breakdown product of C3, hence elevated C3d complement levels 
reflect activation at level of C3 is present.
C3d levels are elevated in acute phase of aHUS and decreased in the majority of patient with 
eculizumab therapy42,168
C3 Can be both normal as decreased in aHUS patients during acute phase and 
remission
269
C5 Eculizumab binds to C5. Eculizumab trough levels correlate with C5 levels C5 levels fluctuate between and within patients due to among others disease activity.276
C5a C5a is released after cleavage of C5. In case of eculizumab therapy, C5 cannot 
be cleaved, hence less C5a is present.
Interestingly, values of C5a do not decrease to zero, although no C5a should be present in light of 
sufficient eculizumab.168 Furthermore, C5a has a very short half-life of approximately 1 minute. 
Ex vivo endothelial 
cell assay
By determining the C5b-C9 deposition after adding patient serum on 
activated endothelial cells, complement blockade could be assessed with good 
reproducibility
This assay has one major drawback since it is a highly specialized technique which cannot be easily 
performed in any laboratory.269 Although Noris et al. advocates that persistent complement activation 
tested ex vivo (whereas CH50 remained low) is a reason to increase eculizumab dosage or decrease 
interval, Merril et al. showed different results using a ham test.269,280
Ham test The Ham test is modified from the assay used to detect PNH. By acidifying the 
patient serum, AP is activated and results in erythrocyte lysis in PNH. In the 
modified Ham test, PNH like cells are incubated with serum of aHUS patients 
and depending on AP dysregulation present in the serum, will be lysed.282
Merril et al. showed no correlation was seen between positive or negative Ham test, hence the presence 
of complement activation, and aHUS recurrence. Moreover, various patients remained positive with 
the Ham test without disease recurrence and withdrawal of eculizumab therapy.280
Soluble 
C5b-C9 (TCC)
Soluble C5b-C9 should decrease during eculizumab therapy Various studies report different results. Due to the ability of eculizumab to bind C5b-C9, it could be 
possible that these complexes have a lower clearance, hence are elevated during remission. 168,182,252,269,276
AP; Alternative complement pathway,CP; Classical complement pathway, ELISA;Enzyme linked immunoabsorbent assay, PNH; paroxysmal nocturnal hemoglobinuria, TCC;terminal complement complex
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Table 9.2 Monitoring of eculizumab therapy and complement activity in aHUS
Parameter Interpretation Remarks
Serum eculizumab 
level
Target is set at trough levels of 50-100 µg/ml to fully block complement Reports differ regarding the measurement of only the free proportion of eculizumab182 versus 
measurement of eculizumab both free and bound to C5 8,166 Furthermore, eculizumab can bind a 
maximum of 2 C5 molecules per eculizumab molecule and is able to bind both C5 as C5b incorporated 
in C5b-C9 complex. Hence, measurement of eculizumab can comprise free (excess) eculizumab, 
eculizumab bound to 1 C5, eculizumab bound to 2 C5, or in combination with C5b-C9 complexes.281 The 
assay used in the trials to determine the trough levels measured both bound and free proportion.193,194 
Eculizumab-C5 
complex
In contrast to serum eculizumab levels, one could also determine eculizumab 
bound to C5, hence only the bound proportion of eculizumab is determined.
It is known that eculizumab can also bind C5b-C9. Furthermore one eculizumab molecule could bind 
respectively 1 or 2 C5 molecules, hence the remaining capacity is unknown.158 Clinical use is unknown
Total complement 
activity (CH50)
CH50 levels correlated nicely with eculizumab serum trough levels, and 
suppressed CH50 (<10%) is reached with trough levels >30-50 µg/ml.182,193,208,252
There are different assays to measure CH50. With this test total complement activity (also known 
as CH50) is tested to determine the capacity of patient serum to lyse sheep or chicken erythrocytes 
coated with antibodies. In case of a functional complement system, the CP will be activated, 
consequently leading to C5b-C9 deposition on the erythrocytes and consequently cause hemolysis. 
With the Wieslab test, CH50 can be measured withC5b-C9 formation, detected using a C9 neoantigen, 
as read-out.252 Recently, Willrich et al. reported CH50 measurement during eculizumab treatment with 
liposome immunoassay with stable and reliable results.276
Alternative pathway 
activity (AP50)
AP50 levels can be suppressed by eculizumab, however ongoing activation has 
been noted despite adequate eculizumab levels.168,252
There are different assays to measure AP50. Specific assessment of alternative pathway activation 
is possible with a hemolytic assay based on untreated rabbit erythrocytes (AP50). Puissant-Lubrano 
et al. compared both the hemolytic assays as used in all trials with the Wieslab ELISA in 16 patients 
treated with eculizumab, and found conflicting results.252 Residual activity of the AP was observed 
with the hemolytic assay, in the presence of (sufficient) eculizumab levels. In contrast to the Wieslab 
ELISA which showed complete blockade of the AP. Moreover, they assessed sensitivity of all assays 
and concluded that the Wieslab ELISA is less sensitive, hence the residual activity measured with the 
hemolytic assay is most accurate.252
C3d C3d is a breakdown product of C3, hence elevated C3d complement levels 
reflect activation at level of C3 is present.
C3d levels are elevated in acute phase of aHUS and decreased in the majority of patient with 
eculizumab therapy42,168
C3 Can be both normal as decreased in aHUS patients during acute phase and 
remission
269
C5 Eculizumab binds to C5. Eculizumab trough levels correlate with C5 levels C5 levels fluctuate between and within patients due to among others disease activity.276
C5a C5a is released after cleavage of C5. In case of eculizumab therapy, C5 cannot 
be cleaved, hence less C5a is present.
Interestingly, values of C5a do not decrease to zero, although no C5a should be present in light of 
sufficient eculizumab.168 Furthermore, C5a has a very short half-life of approximately 1 minute. 
Ex vivo endothelial 
cell assay
By determining the C5b-C9 deposition after adding patient serum on 
activated endothelial cells, complement blockade could be assessed with good 
reproducibility
This assay has one major drawback since it is a highly specialized technique which cannot be easily 
performed in any laboratory.269 Although Noris et al. advocates that persistent complement activation 
tested ex vivo (whereas CH50 remained low) is a reason to increase eculizumab dosage or decrease 
interval, Merril et al. showed different results using a ham test.269,280
Ham test The Ham test is modified from the assay used to detect PNH. By acidifying the 
patient serum, AP is activated and results in erythrocyte lysis in PNH. In the 
modified Ham test, PNH like cells are incubated with serum of aHUS patients 
and depending on AP dysregulation present in the serum, will be lysed.282
Merril et al. showed no correlation was seen between positive or negative Ham test, hence the presence 
of complement activation, and aHUS recurrence. Moreover, various patients remained positive with 
the Ham test without disease recurrence and withdrawal of eculizumab therapy.280
Soluble 
C5b-C9 (TCC)
Soluble C5b-C9 should decrease during eculizumab therapy Various studies report different results. Due to the ability of eculizumab to bind C5b-C9, it could be 
possible that these complexes have a lower clearance, hence are elevated during remission. 168,182,252,269,276
AP; Alternative complement pathway,CP; Classical complement pathway, ELISA;Enzyme linked immunoabsorbent assay, PNH; paroxysmal nocturnal hemoglobinuria, TCC;terminal complement complex
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Obviously, the abovementioned studies have a relative short follow up time of 
12 months. Furthermore, they could be biased, since eculizumab was withdrawn in 
selected patients and not per protocol. Also, the duration of eculizumab therapy 
before withdrawal was quite variable. This selection process could have led to a more 
favorable outcome. However, a comparable relapse rate was noted in a study where 
eculizumab therapy was stopped per protocol at 3-6 months after start of therapy in 
adolescent and adults patients in remission.258 In pediatric patients eculizumab could 
be stopped in 4 patients and tapered in the remaining two children. A recurrence 
developed in one out of the six pediatric patients. Still, long term follow up is needed 
to provide more information regarding chronic sequelae of treatment withdrawal. It 
is also important to study possible predictors of relapse. In this respect, information 
regarding the presence and type of genetic mutation could be relevant. 
Due to still limited data on eculizumab withdrawal in children and adults with 
various pathogenic mutations, evaluating data deriving from the pre-eculizumab era is 
the best alternative up till now to estimate risk of relapse. Several large cohort studies 
have been published which looked at disease relapse in patients with different patho-
genic mutations.53,54 Patients were treated with various protocols of PE or received only 
conservative therapy. In respectively children and adults the risk of relapse was esti-
mated at 43% and 35% respectively, mostly within the first year after presentation.53,54 
The risk of recurrence seemed to be higher in patients with pathogenic mutation in 
CFH (31-55%), MCP (18-52%) and C3 (50%).53,54 Long term outcome in general was more 
favorable, despite the frequently reported relapses, in patients with a mutation in 
MCP.160,165,192,258,265,279,280 Before the introduction of eculizumab, relapse rates were approx-
imately 30% in patients without a known pathogenic mutation.54 
The risk of relapse in the nine mentioned studies is 27% after withdrawal of ecu-
lizumab. This compares favorably with the above mentioned relapse rates. Notably, 
since the introduction of eculizumab, to our knowledge, only one case of disease 
relapse after eculizumab withdrawal is reported in a patient without a proven patho-
genic mutation.265 In contrast, the risk of relapse is reported to be higher (up to 75%) in 
patients with a genetic variant in CFH.165 In patients with a MCP mutation a relative 
high risk up till 50% is reported after eculizumab withdrawal.165 Our own data showed 
a relapse rate of 50% in patients with a CFH mutation, which is lower than previ-
ously reported in literature.258 Limited data are published regarding the relapse rate 
after discontinuation of eculizumab in children, which ranges between 16-50%.156,262 In 
conclusion, the risk of relapse after eculizumab withdrawal is estimated at 30% and 
most relapses occurred within the first year after withdrawal. Pathogenic mutations 
in CFH and MCP seem to be associated with higher chance of recurrence. In con-
trast, withdrawal of eculizumab in patients without a proven pathogenic mutation 
was associated with a low risk of disease recurrence. In all reported cases of relapse, 
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rapid re-initiation of eculizumab treatment allowed remission of aHUS and full renal 
recovery. 165,258
Future studies should provide more insight in the relation between specific patho-
genic mutations and risk of relapse and chronic sequelae. 
Is withdrawal of eculizumab therapy possible after relapse of aHUS?
There are very limited data on eculizumab withdrawal in patients with relapse of disease. 
In total, 17 patients were described who had a recurrence after eculizumab withdrawal. 
In three patients, with respectively pathogenic mutations in CFH, MCP and C3, eculi-
zumab was again discontinued after 3 to 20 months of treatment. No relapses have been 
reported.165,258 This suggests that even in a proportion of patients with disease recurrence, 
lifelong treatment is not necessary. However, future studies should provide more insight 
in the risks of multiple relapses and ability of eculizumab therapy to prevent chronic 
damage when given “on demand” (i.e. during active TMA episodes).
178   |   Chapter 9
Table 9.3 Studies describing a restrictive eculizumab regimen in aHUS patients 
Author
& year 
of 
publication
Number 
of 
participants
Age 
(years) 
Duration 
standard 
eculizumab 
therapy
(months)
Number of 
participants 
with 
tapered 
therapy
Number of 
participants 
in whom 
therapy was 
discontinued
Follow up 
period after 
therapy 
adjustment 
(months)
Recurrence, 
number (%)
Time 
until 
recurrence 
(months)
Outcome 
283 Cugno et al. 
2014
18 Mean 21 
(range 2-40) 
Up till 40 months 18; interval was extended 
up to 4 weeks based on 
CH50
0 Up till 43 
months
0 NA No chronic sequelae
160,192 Ardissino et 
al. 2014-2015
22 18 (1-53) 4.3 (0.5-14.4) months 0 16 Up till 40 
months
5/16 (31%) 1.2 (0.7-16.3) 
months
No chronic sequelae after restart of 
eculizumab. Serum creatinine and 
proteinuria returned to baseline 
values
265 Sheerin et al. 
2016
43 Unknown 6 (0.5-8.5) months 0 12 12 months 3/12 (25%) 2.5 (1.5-9) 
months
Full renal recovery was seen in 1 
patient. The remaining two patient 
were still dialysis dependent on time 
of withdrawal and presented with 
hemolysis and hyperkalaemia which 
resolved quickly with reintroduction 
of eculizumab.
165 Fakhouri et 
al. 2017
108 30 (2-79) 17.5 (2-50) months 0 38 22 (5-23) 
months
12/38 (31%) 7.5 (3-29) 
months
No chronic sequelae after restart of 
eculizumab
280 Merril et al. 
2017
17 46 (19-69) 3 (0.5-18.2) months NA 15 10.2 (1.2-46.3) 
months
3/15 (20%) 2 (1.8-3.3) 
months
Two patients received eculizumab 
after which kidney function was 
restored .One patient died during PE 
for recurrence after non adherence 
with antihypertensive drugs. 
279 Macia et al. 
2017 Summary 
of authors’ case 
reports
6 37 (16-39) 6 (1-14) months 1; patient received 900mg 
every 4 weeks
5 Unknown 4/6 (67%) 3 (2-12) 
months
Unknown
258 Wijnsma et 
al. 2017
20 28 (1-62) 3.8 (1.3-14.7) months 5 15 27.4 (6-47) 
months
5/20 (25%) 7.5 (1-12) 
months
No chronic sequelae after restart of 
eculizumab. One relapse occurred 
during tapering eculizumab. 
259 Ardissino et 
al. 2017
47 25 (0.5-60) 2.6 (0.4-24.6) months 38 9 26.9 (0.8-80.9) 
months
0 NA No chronic sequelae after restart of 
eculizumab 
279 Macia et al. 
2017 Summary 
of clinical series
130 26 (0-80) 6.3 (0.2-53.7) months 0 61 5.6 (0-35.1) 
months
12/61 (20%) 3 (1-29.5) 
months
Limited data available. One patient 
progressed to ESRD despite re-
initiation of therapy.
Numbers are expressed as median (range) unless otherwise specified
The different cohort studies and case reports include patients with aHUS after kidney transplantation and patients 
with aHUS due to auto-antibodies directed against complement component factor H. 
ESRD; end stage renal disease, NA; not applicable, PE; plasma exchange
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Table 9.3 Studies describing a restrictive eculizumab regimen in aHUS patients 
Author
& year 
of 
publication
Number 
of 
participants
Age 
(years) 
Duration 
standard 
eculizumab 
therapy
(months)
Number of 
participants 
with 
tapered 
therapy
Number of 
participants 
in whom 
therapy was 
discontinued
Follow up 
period after 
therapy 
adjustment 
(months)
Recurrence, 
number (%)
Time 
until 
recurrence 
(months)
Outcome 
283 Cugno et al. 
2014
18 Mean 21 
(range 2-40) 
Up till 40 months 18; interval was extended 
up to 4 weeks based on 
CH50
0 Up till 43 
months
0 NA No chronic sequelae
160,192 Ardissino et 
al. 2014-2015
22 18 (1-53) 4.3 (0.5-14.4) months 0 16 Up till 40 
months
5/16 (31%) 1.2 (0.7-16.3) 
months
No chronic sequelae after restart of 
eculizumab. Serum creatinine and 
proteinuria returned to baseline 
values
265 Sheerin et al. 
2016
43 Unknown 6 (0.5-8.5) months 0 12 12 months 3/12 (25%) 2.5 (1.5-9) 
months
Full renal recovery was seen in 1 
patient. The remaining two patient 
were still dialysis dependent on time 
of withdrawal and presented with 
hemolysis and hyperkalaemia which 
resolved quickly with reintroduction 
of eculizumab.
165 Fakhouri et 
al. 2017
108 30 (2-79) 17.5 (2-50) months 0 38 22 (5-23) 
months
12/38 (31%) 7.5 (3-29) 
months
No chronic sequelae after restart of 
eculizumab
280 Merril et al. 
2017
17 46 (19-69) 3 (0.5-18.2) months NA 15 10.2 (1.2-46.3) 
months
3/15 (20%) 2 (1.8-3.3) 
months
Two patients received eculizumab 
after which kidney function was 
restored .One patient died during PE 
for recurrence after non adherence 
with antihypertensive drugs. 
279 Macia et al. 
2017 Summary 
of authors’ case 
reports
6 37 (16-39) 6 (1-14) months 1; patient received 900mg 
every 4 weeks
5 Unknown 4/6 (67%) 3 (2-12) 
months
Unknown
258 Wijnsma et 
al. 2017
20 28 (1-62) 3.8 (1.3-14.7) months 5 15 27.4 (6-47) 
months
5/20 (25%) 7.5 (1-12) 
months
No chronic sequelae after restart of 
eculizumab. One relapse occurred 
during tapering eculizumab. 
259 Ardissino et 
al. 2017
47 25 (0.5-60) 2.6 (0.4-24.6) months 38 9 26.9 (0.8-80.9) 
months
0 NA No chronic sequelae after restart of 
eculizumab 
279 Macia et al. 
2017 Summary 
of clinical series
130 26 (0-80) 6.3 (0.2-53.7) months 0 61 5.6 (0-35.1) 
months
12/61 (20%) 3 (1-29.5) 
months
Limited data available. One patient 
progressed to ESRD despite re-
initiation of therapy.
Numbers are expressed as median (range) unless otherwise specified
The different cohort studies and case reports include patients with aHUS after kidney transplantation and patients 
with aHUS due to auto-antibodies directed against complement component factor H. 
ESRD; end stage renal disease, NA; not applicable, PE; plasma exchange
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Strategies towards a restrictive use of 
eculizumab in kidney transplant recipients
Kidney transplantation is associated with an estimated risk of aHUS recurrence of 50% 
to 80%.58,284,285 Most recurrences occur early in the post-transplant period. Recurrent aHUS 
usually leads to graft loss and curative PE does not improve graft survival.267,284 The risk 
of recurrence depends on the genetic variant, and especially patients with a pathogenic 
mutation in genes that encode circulating complement components, such as CFH, CFI, 
complement factor B (CFB) or C3, have a high risk of recurrence (50-80%). In contrast, the 
recurrence rate is low (8%) in patients with a single genetic variant in MCP, a membrane 
bound factor. This is not unexpected since the endothelium of the graft expresses a func-
tional variant.58,284,285 In patients without a pathogenic mutation the risk of recurrence is 
reported to be moderate (18-28%).53,141 A lower percentage of aHUS recurrence (20%) and 
graft failure was reported in children286,287, however, presumably in most of these studies 
patients with STEC HUS were included.288-291 Sellier-Leclerc et al. more accurately diag-
nosed aHUS and reported a higher recurrence rate of 53% among pediatric patients, and 
even of 80% in patients with a mutation in the gene encoding CFH. Graft survival at one 
year was 62%.292 The recurrence risk is influenced by transplantation related factors such 
as pre-donation kidney injury, ischemia reperfusion injury, acute rejections, infections, 
the use of mammalian target of rapamycin (mTOR) inhibitors and calcineurin inhibitors 
(CNI).284,285,290,293,294
Prophylactic eculizumab therapy in kidney transplantation
Effectiveness of prophylactic eculizumab therapy 
The reported high recurrence rate and absence of effective treatment urged many trans-
plantation centers to be very restrictive with offering a kidney graft to aHUS patients 
with end stage renal disease (ESRD). After the introduction of eculizumab many centers 
started to perform kidney transplantation using eculizumab prophylaxis in various dif-
ferent schemes.295 The first case series of aHUS patients treated prophylactically with 
eculizumab was published by Zuber et al. in 2012.295 Since then, in total, 53 patients, includ-
ing 14 pediatric patients have been reported in literature (Supplementary Table 9.1). 
As expected, the overall outcome of transplantation with prophylactic eculizumab ther-
apy was favorable. In most patients allograft function remained well preserved. Median 
(range) serum creatinine values, available in 38 patients, was 88 (44-187) µmol/l at 15 
months (1.5-44 months) after transplantation. Four patients had signs of TMA after trans-
plantation, which resolved after increase of eculizumab dose.265,296-298 One patient lost its 
allograft due TMA and a renal artery thrombosis, while on eculizumab therapy. No biopsy 
was performed.299 
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Discontinuing prophylactic eculizumab therapy 
In the patients who were treated prophylactically, eculizumab was discontinued in eight, 
all adults, at 1 to 28 months after transplantation.192,279,300-303 Two patients, both recipients 
of a living donor kidney, developed aHUS recurrence after discontinuation of eculizumab 
(Supplementary Table 9.1).279,303 The remaining patients did well, without aHUS recur-
rence and serum creatinine ranged from 67 to 118 µmol/l after a follow up of 4 to 26 
months (Supplementary Table 9.1 and Table 9.4). These data indicate that continued 
eculizumab treatment is not needed in all adults patients after kidney transplantation.
Kidney transplantation in aHUS patients without eculizumab prophylaxis
The reported high incidence of recurrent aHUS after kidney transplantation was based on 
studies that mainly included patients who received a deceased donor kidney, were treated 
with high dose CNI, and often experienced rejection episodes. Small studies suggested 
better outcomes after living donor kidney transplantation.300,304,305 Based on these data, 
we hypothesized that kidney transplantation without eculizumab prophylaxis should be 
feasible and developed a transplantation protocol to limit endothelial cell injury of the 
allograft and subsequent complement activation. (Supplementary Table 9.5). Initial 
data analysis showed a low aHUS recurrence rate. 305 Meanwhile, we have transplanted 19 
adult patients with a living donor kidney. Eighteen patient had a high risk of recurrence 
according to the KDIGO classification, in seven patients a mutation in the gene encoding 
CFH was present. After a median follow-up of 42 (4-78) months, two patients (one patient 
with a CFH mutation and one patients with a C3 mutation) developed aHUS recurrence, 
respectively after two and four months after transplantation, for which eculizumab was 
restarted. In these 19 patients median (range) serum creatinine concentration at last 
follow-up is 138 (79 -185) µmol/l. 
Effectiveness of rescue therapy with eculizumab 
The pivotal trials included 25 patients who received eculizumab for aHUS recurrence after 
kidney transplantation. The median (range) interval between onset of aHUS recurrence 
and start of eculizumab was relatively long: 1.25 months (0.03-36.7). In 88% of the patients 
a TMA event-free status was reached. In twenty patients who completed the 18 months 
follow-up mean eGFR was 44 ml/min/1.73m² (SD 27).306 After extended follow-up two 
patients lost their grafts: one never responded to eculizumab and the second reportedly 
experienced TMA after a reduction in eculizumab dosage leading to ESRD.279 In addition, 
we identified 56 patients, including five children (5,10, 13, 15 and 17 years old), from liter-
ature who had been treated with rescue therapy (Supplementary Table 9.2). Patients 
with a known genetic mutation more often had experienced a recurrence in a previous 
allograft (Supplementary Table 9.3). In the majority of the patients (68%) the onset 
of recurrence was within three months after transplantation. The interval between the 
182   |   Chapter 9
onset of aHUS and initiation of eculizumab varied between 0 days and 279 days. Eculi-
zumab was started within seven days after onset of recurrence in only 22 (39%) patients. 
Of note, late initiation of eculizumab is associated with less recovery of kidney function.295 
Graft function was maintained in 47 (84%) patients. The remaining patients experienced 
graft loss despite rescue therapy (n=9;16%), in three patients caused by aHUS of which 
one had received insufficient eculizumab treatment 186,300,307and six patients lost their graft 
due to non-TMA related causes (rejection, infectious complications, acute tubular necro-
sis.186,300,302,308-310 Graft function after aHUS recurrence was reported in 38 patients: median 
(range) serum creatinine was 137 µmol/L (48-486) with a median (range) follow up of 14 
months (2- 82) after onset of aHUS. Serum creatinine values exceeded 200 µmol/L in five 
patients.186,311-314 In all of them eculizumab therapy had been suboptimal (late initiation 
of therapy or too early discontinuation) and/or renal function had been compromised 
before the onset of aHUS. We identified 10 patients305,315-324, with at least four patients at 
high risk of recurrence, 305,317,318,323 in whom eculizumab was initiated within seven days 
after onset of aHUS. Early treatment resulted in full recovery of renal function: median 
(range) serum creatinine was 113 µmol/L (53-159) before aHUS recurrence and 116 µmol/L 
(53-180) after treatment of recurrence. 
These data seemingly contrast with those reported by Legendre et al. These authors 
suggested that the recovery of kidney function in transplant patients treated with eculi-
zumab was limited.306 In a pooled post hoc analysis, which included 26 kidney transplant 
patients and 74 patients with a native kidney, recovery of kidney function was less 
pronounced in kidney transplant patients compared to patients with a native kidney: 
respectively a mean eGFR after 26 weeks of 37 ml/min/1.73m2 (SD 36), mean change from 
baseline 11 ml/min/1.73m2 (SD 20) versus 61 ml/min/1.73m2 (SD 41) and 38 ml/min/1.73m2 
(SD 36) (P=0.0092). These differences may partly be explained by the type of renal injury 
which differed between the groups: patients with aHUS in the native kidney had expe-
rienced a more rapid decrease of eGFR in the time interval compared to patients with 
post transplant aHUS which showed a more gradual renal function deterioration. In addi-
tion, the time from aHUS diagnosis to introduction of eculizumab was in both patients 
groups much longer than currently accepted: in transplant patients median 1.25 months 
(range 0.03-36.7 months) versus 0.69 months (0.03-47.4 months) in patients with native 
kidneys. The above data suggest that rescue therapy with eculizumab in adult patients 
may result in acceptable recovery of renal function, however early initiation of therapy 
is of paramount importance.
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Discontinuing rescue therapy 
In the above mentioned 56 patients eculizumab was discontinued in sixteen adult patients 
(29%) (Supplementary Table 9.2). A new recurrence occurred in 11 of 16 patients (63%).294
,300,302,305,307,309,310,314,319,325 The recurrence rate in this group is higher compared to the recurrence 
rate reported in patients who stopped eculizumab prophylaxis after transplantation (2/8 
patients; 25%). Of note, in all patients (n=4)with mutation in the gene encoding CFH dis-
continuation of eculizumab led to a recurrence (Supplementary Table 9.3).300,302,305,307 In 
nine of 11 patients eculizumab was restarted. In six patients renal function improved, how-
ever not to baseline values. 294,300,305,314,319,325 Graft failure occurred in the other three, but was 
not attributed to aHUS by the authors300,302,310 In contrast, a remarkably lower recurrence 
rate was described by Macia et al. in 2017.279 In their study 16 patients from the pivotal 
trials, who had been treated with eculizumab for aHUS recurrence after transplantation, 
discontinued therapy. During a median follow up of 24 weeks one patient (without iden-
tified genetic variant) experienced aHUS recurrence for which eculizumab was restarted 
resulting in improvement of kidney function.306 The high recurrence rate calculated from 
the case reports may be the consequence of publication bias. Otherwise, Macia et al. may 
have included several patients with de novo TMA after transplantation, not caused by 
aHUS, but by transplantation related factors, explaining the low recurrence rate after 
discontinuation of eculizumab. Future studies are necessary to determine recurrence risk 
after discontinuation of rescue therapy and the consequences for renal outcome. 
Reduction of eculizumab dosage after kidney transplantation
No systematic data are available on the safety of tapering eculizumab therapy after 
transplantation to reach trough levels of 50 to 100 µg/ml. However, patients have been 
described who were successfully treated with eculizumab at extended intervals.152,321,326,327In 
contrast, several patients developed aHUS activity after interval prolongation.295,328 
Furthermore, patients have been reported with TMA while on standard maintenance 
therapy.265,296-298 In two of the latter cases eculizumab trough levels were above target 
range and/or complement was completely blocked.297,298 Therefore, it has been suggested 
that higher eculizumab levels are necessary in patients after kidney transplantation when 
exposed to strong triggers of complement activation.297 Alternatively, other causes of TMA 
in kidney transplant patients, such as infections, antiphospholipid antibodies, antibody 
mediated rejection or immunosuppressive drugs, must be considered in these situations. 
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Monitoring
After therapy withdrawal strict monitoring is essential, therefore we would recommend 
to see the patient regularly in the outpatient clinic under supervision of an physician with 
expertise in aHUS (Table 9.4). Since signs indicative of a subclinical or early phase of 
TMA can be subtle, and aHUS is a rare disease, it can be difficult to recognize and adjust 
treatment appropriately. Especially in kidney transplant recipient, aHUS can present as a 
smoldering disease. A allograft biopsy may discloses only subtle changes, mostly limited 
to swelling of vascular endothelial cells in capillaries and small arterioles.293 
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Time for a paradigm shift
in the treatment of aHUS with eculizumab 
Based on literature we have developed a treatment protocol of restrictive eculizumab 
therapy (Figure 9.1). Our protocol is founded on the principle that eculizumab can be 
withdrawn in patients with aHUS in remission after a first episode in native kidneys, 
routine eculizumab prophylaxis is not needed in adult patients before kidney transplan-
tation, and that reducing the eculizumab dose is often possible in patients who need 
long term therapy. Of note, decisions concerning individualization are based on age, 
disease history, co-morbidities, renal function, and patient and physicians preferences. 
Many restrictive treatment strategies can be considered (Figure 9.2). Obviously, the best 
strategy is currently unknown. Prospective studies are needed to allow comparisons and 
to compose evidence based recommendations.
In the Netherlands national guideline was drafted based on our restrictive treatment 
protocol. The guideline was composed by the Dutch aHUS working group, comprising 
a nephrologist and pediatric nephrologist from every academic hospital in the Neth-
erlands. The guideline was approved by the professional societies and implemented in 
January 2016. In the Netherlands several criteria must be met before orphan drugs can 
be (re)imbursement by the National Healthcare Institute: the presence of an indication 
committee, the definition of clear start and stop criteria, monitoring of this process and 
performing a cost effectiveness analysis. In accordance with this policy start of eculi-
zumab therapy in the Netherlands must be approved by the national aHUS working group 
(with four members being available on a daily basis) and treatment should follow the 
new guideline. Furthermore, a national prospective, observational study (abbreviated as 
CUREiHUS, NTR5988) was designed to monitor the guideline and eculizumab therapy. 
The study will be closed in august 2020 Analysis of our study data will provide evidence 
to develop optimized treatment protocols.
Because the optimal treatment strategy in aHUS is currently under investigation and 
our treatment scheme was designed as a study protocol we recommend that all aHUS 
patients who are withdrawn of eculizumab will be included in a registry or national study 
to allow comparison and to aid future research. Furthermore, due to the rarity of aHUS 
and because treatment can be complicated, we believe monitoring of eculizumab therapy 
requires consultation with a aHUS referral center and access to a specialized laboratory 
capable of performing eculizumab and complement assays.
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Table 9.4 Monitoring disease activity in aHUS patients
Characteristics aHUS Regular 
workup during 
eculizumab 
therapya
Regular workup 
after therapy 
withdrawal
Recurrence aHUSb,c
1. (acute) Kidney injury Serum creatinine Serum creatinine Serum creatinine greater than 
upper limit of normal per age 
or increase of >15% compared 
to baseline
Proteinuria 
(protein – 
creatinine ratio)
Proteinuria(protein 
– creatinine ratio)
Increase of >25% in proteinuria
Dipstick analyses 
twice per week at 
home
Bloodpressure 
(aim for P50)
Bloodpressure 
measurement twice 
per week at home
NA
2. Thrombocytopenia Platelets Platelets Platelet count < 150,000 x 103 µl
3. Mechanical 
hemolytic anemia
Mechanical hemolysis is defined 
by the presence of at least 2 or 
more of the following criteria:
Hemoglobin Hemoglobin Below lowest limit of normal 
per age
LDH LDH Greater than upper limit of 
normal
Haptoglobin Haptoglobin Undetectable
Schizocytes Schizocytes Appearance of schizocytes
Table 9.4 After therapy withdrawal strict monitoring is essential. Regular workup after at least 1,2, 3, 6, 9 and 12 
months is required. We would advise to monitor blood pressure at home. We aim for blood pressures around P50 for 
height and age (children) or <130/80 mmHg (adults). Urine dipstick analysis at home could be considered, especially 
in children. Moreover, comprehensible instructions to the patient (and caregivers) when and how to contact their 
treating physician are essential. In case of signs indicating aHUS recurrence such as high blood pressure, petechiae, 
fatigue, oliguria, jaundice, or a possible triggering event like infection, the patient has to seek contact immediately. 
Of note, recurrent aHUS after kidney transplantation can present as a smouldering disease, with a slow increase 
in serum creatinine without overt systemic hemolysis. A allograft biopsy may disclose only subtle changes, mostly 
limited to swelling of vascular endothelial cells in capillaries and small arterioles.293
a Consider to monitor liver enzymes in light of potential hepatotoxicity, especially in patients with pre-existing 
liver disease. b Recurrece of aHUS is defined by the occurrence of all 3 characteristics of aHUS; acute kidney injury, 
thrombocytopenia, and mechanical hemolytic anemia. c a kidney biopsy to detect (smoldering) TMA can be of 
additional value. LDH; lactate dehydrogenase NA: not applicable, P50; median percentile for height and age, 
TMA;thrombotic microangiopathy
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Figure 9.1 Treatment algorithm 
Patient with TMA 
Eculizumab treatmentb 
Standard protocol, dose therapy depending on body weight. 
Evaluation therapy after 3 monthsc 
In case the patient is in remission (normalized hematological parameters, normalized 
and/or stabilized kidney function and proteinuria, normal blood) adjustment of 
eculizumab therapy can be considered 
In anticipation of diagnostics to rule out other causes of TMAa  
& 
Strong suspicion aHUS 
Withdrawal or taperingd: 
Scenario 1-5 figure 9.2 
Monitoring after therapy adjustment 
Regular workup at every hospital visit is required or in case of discontinuation after 1,2,3,6,9 &12 
months after withdrawal. Between hospital visits, dipstick analysis and/or blood pressure (aim for p50 
in children or below 130/80mmHg in adults) monitoring 3 times per week at home is advised. 
Figure 9.1 After adequate exclusion of other causes of TMA such as TTP, STEC-HUS or secondary TMA and in 
patients with strong suspicion of aHUS, eculizumab treatment should be started within 24 hours after presenta-
tion. When the patient is stable and in remission, withdrawal or tapering can be considered, depending on patient 
characteristics (see Figure 9.2). After therapy adjustment, strict monitoring is essential. NB in case of antibodies 
against complement factor H a different treatment protocol has to be initiated as described by Loirat et al.57 
a For extensive overview of practical diagnostics approach for TMA see Fakhouri et al. 2017 Lancet.5 b Treatment 
should preferably be started within 24 hours after presentation. In adults with first episode of aHUS in native kidney, 
treatment with plasma exchange for 4 days (high volume PE with 1.5 plasma volume) is advised to allow diagnosis 
of secondary causes of aHUS. Adolescents may be considered as adults. 277 After exclusion of secondary causes of 
aHUS and if the patient does not show a favorable response after four days of PE, treatment should be switched 
to eculizumab. Starting treatment with eculizumab within seven days after presentation in PE resistant patients 
was effective in the clinical trials.189 In case the patient is PE sensitive, PE should be tapered and discontinued in the 
course of one month.156,262 c Improvement of platelets and LDH is expected within 2-4 weeks. If no response, consider 
alternative diagnosis or inefficacy of eculizumab (C5 polymorphism p.Arg885His).254 d See figure 2 for the different 
scenario’s to withdrawn or taper eculizumab, depending on patient characteristics.
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Other studies of eculizumab discontinuation
To our knowledge there are two other, registered, studies which evaluate safety and effi-
cacy of eculizumab discontinuation. The first is a prospective study conducted in France 
(STOPECU, NCT02574403). The study protocol is well described, with criteria when and 
how to withdraw eculizumab. According to the protocol, eculizumab will be discontinued 
after six months of therapy. The primary end-point is the incidence of aHUS recurrence in 
follow-up period of two years. The study will end inclusion in November 2019. The second 
study is conducted by Alexion Pharmaceuticals (EVIDENCE studie, NCT02614898) with 
a planned end date of April 2020. This study is observational, without defined protocol, 
and will document TMA events and outcome of all included patients. 
Since aHUS is a rare disease, and disease course is quite variable, we feel that a 
prospective study with inclusion of all treated patients and used of defined treatment 
algorithms is the best option to gain more insight in the pros and cons of different 
treatment options. We realize that withdrawal of eculizumab is not without risks. Still, 
lifelong therapy will expose many patients unnecessary to a drug which can cause side 
effects. Strict monitoring of the patients and rapid re-initiation of eculizumab therapy 
should limit risks. Obviously, the enormous costs of eculizumab cannot be disregarded. 
For a societal perspective, the health care budget is not infinite. Therefore, we must 
aim to develop cost-effective treatment strategies. The data provided by the CUREiHUS 
and STOPECU studies should help to develop cost-effective scenario’s which may vary 
per country depending on the local willingness to pay per quality adjusted life year. 
We have calculated cost-effectiveness of prophylactic eculizumab therapy after kidney 
transplantation and showed that the costs exceeded the willingness to pay threshold in 
the Netherlands.268
Conclusions
Eculizumab therapy has changed the lives of patients with aHUS. The optimal treatment 
strategy is unknown. There is no evidence to support the need for lifelong therapy and 
untargeted treatment. Limiting the initial treatment period to three months in incident 
carefully evaluated patients with native kidney aHUS and withholding prophylactic ther-
apy in patients with aHUS at transplantation is the first step toward restrictive use of 
eculizumab. Future studies, preferably at a multinational level, should evaluate the best 
strategies to prevent, predict and treat relapsing disease. This includes targeted therapy 
aiming at complete and incomplete complement blockade, and development of biomark-
ers that predict preclinical TMA activity. 
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Figure 9.2 Scenario’s for the treatment of aHUS patients with eculizumab
 Time on eculizumab therapy (months) 
Standard therapy Target eculizumab 
Ctrough 50-100 µg/ml 
Withdrawal 2. 
Standard therapy 6. 
1. Standard therapy Withdrawal 
0 3 
Standard therapy 3. Withdrawal Tapering without full 
complement blockade 
Standard therapy Target eculizumab Ctrough 50-100 µg/ml 5. 
Target eculizumab 
Ctrough 50-100 µg/ml 
Standard therapy 4. 
Tapering without full 
complement blockade 
Target eculizumab 
Ctrough 50-100 µg/ml 
Figure 9.2 The current standard regime is reflected by scenario 6, lifelong therapy with standard dose eculizumab 
at biweekly intervals. 
Scenario’s 1-5 illustrate options of restrictive eculizumab therapy. According scenario 1 eculizumab is given at 
standard dose, at biweekly intervals, with withdrawal after 3 months. According to scenario 2 eculizumab dose 
will be adapted to target trough levels of 50-100 µg/ml with complete blockade of the complement system. After an 
observation period eculizumab therapy will be withdrawn. In scenario 3, drug withdrawal is preceded by a period 
of eculizumab therapy at reduced dose and incomplete complement blockade (CH50 < 30%). For logistical reasons 
dose reduction will be done by extending the dose interval. In scenario 4 and 5, treatment with eculizumab will 
continue for undefined period (“lifelong”, waiting for more data), either aiming at incomplete (scenario 4) or com-
plete complement blockade (scenario 5). Of note, the observations periods are not strictly defined. The choice for a 
scenario as well as the length of the observation period will be dependent on patient characteristics, disease history, 
renal function and patient or physician preferences. In patients with uncontrolled blood pressure, active (viral or 
bacterial) infection, reduced eGFR with evidence of continuous improvement (i.e. the nadir of serum creatinine has 
not been reached), or evidence of ongoing (extra-renal) TMA activity, eculizumab treatment should be continued 
until stable remission is reached.
Typical examples of the patient profiles which may best fit a proposed scenario are presented below. To aid the 
choice for a certain scenario a score can be calculated based on patient characteristics. The sum of the points will 
guide the selection of a scenario (Supplementary table 9.6). 
Scenario 1. This is the proposed scenario used in adults patients with a first episode of aHUS in the native kidneys, 
who have adequately responded to treatment, with well controlled blood pressure, stable renal function and no 
signs of TMA.
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Figure 9.2 Continued
Scenario 2. This is the proposed scenario used in adults with a first relapse of aHUS in native kidneys, occurring 
more than 12 months after treatment withdrawal, who have adequately responded to treatment with recovery of 
eGFR, well controlled blood pressure, and no signs of TMA. This scenario is also suitable for pediatric patients 
above 6 years of age and kidney transplant recipients with no pathogenic mutation.
Scenario 3. This is the proposed scenario used in adults with first relapse of aHUS in native kidneys, occurring within 
3 – 12 months after treatment withdrawal, who have adequately responded to treatment with recovery of eGFR, 
well controlled blood pressure, and no signs of TMA. This scenario is also suitable for kidney transplant patients 
with a aHUS recurrence, successfully treated with eculizumab and pathogenic mutations in other genes than CFH.
Scenario 4. This is the proposed scenario for patients with multiple relapses and kidney transplant recipients with 
a relapse (and CFH mutation) in which lifelong therapy is necessary.
Scenario 5. This scenario is proposed for adult patients with relapse occurring during treatment with incomplete 
complement blockade, or with early (< 3 months) relapse after eculizumab withdrawal. This scenario is also used 
in pediatric patients below 6 years of age. They have an increased risk for frequent relapse since they are exposed 
to various infectious triggers during childhood. Therefore withdrawal of eculizumab is not advised, but tapering of 
therapy to target serum trough levels could be beneficial to limit potential side effects and prevent overtreatment. 
Scenario 6. This scenario is proposed for patients with relapsing disease while receiving eculizumab therapy at 
doses targeted to levels of 50-100 µg/ml. This scenario may also apply to patients with ESRD due to aHUS, with a 
history of graft failure due to disease recurrence, CFH mutations, or other high risk factors. In these patients any 
risk of recurrence should be avoided. 
** These scenario’s illustrate the treatment with eculizumab, as induction therapy for new-onset aHUS, either as 
first episode in incident patients or as relapse in prevalent patients. Prophylactic therapy with eculizumab in kidney 
transplant patients is not illustrated. We do not advise prophylactic therapy with eculizumab in each patients with 
aHUS. Still, we do not exclude the use of prophylactic therapy, in particular in children, in adult patient with a 
severe disease history, previous graft loss due to recurrence aHUS, genetic mutations in CFH, comorbidity (prior 
vascular events, known macrovascular disease), or highly sensitized patients. When prophylaxis is considered we 
suggest to start with the induction dose 7-10 days before the kidney transplantation with a second dose 0-3 days 
before transplantation as eculizumab through levels of 50-100 µg/ml (and CH50 <10%) may not yet be reached 
after the first dose. We would consider continued treatment with eculizumab after successful transplantation 
according scenario’s 4-6.
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Supplementary Table 9.1 Prophylactic eculizumab therapy in patients with aHUS receiving a 
kidney transplantation 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic variant
Discontinuation 
of Ecu
Time (in 
months) on 
Ecu before 
discontinuation 
Recurrence 
(time in 
months 
after Tx)
Restart 
of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
329Nieto-Ríos et 
al.2018
No 38 DD CFH: p. Arg257Cys No NA No NA 18 71 
279Macia et 
al.2017 
No 38 LD Negative Yes 14 Yes (26) Yes Unknown Unknown ¹
279Macia et al.2017 Unknown 37 LD MCP No NA No NA Unknown Unknown 
303Krishnan et 
al.2017
No 54 LURD CFH Yes 12 Yes (17) Yes 18 150 
321Manani et 
al.2017
No 45 DD THBD: 
p.Pro501Leu
CFHR1-3 del with 
anti CFH ab
No NA No NA 7 81 
302Levi et al. 2017 Unknown 32 DD CFI No NA No NA 4.4 124 
302Levi et al. 2017 Unknown 44 DD Anti CFH ab No NA No NA 11.7 93 
302Levi et al. 2017 Unknown 37 DD CFI: p.Ile357Met No NA No NA 14 157 
302Levi et al.2017 Unknown 56 ABOi LD Anti CFH ab No NA No NA 14.7 133 
302Levi et al. 2017 Unknown 48 DD CFI: p.Gly243Val No NA No NA 20.2 121 
302Levi et al. 2017 Unknown 39 DD C3: p.Arg161Trp No NA No NA 21.9 97 
302Levi et al. 2017 Unknown 18 DD CFH: 
p.Asn767LysfsX7
CFI: p.His183Arg
No NA No NA 27.4 187 
302Levi et al. 2017 Unknown 40 DD Unknown Yes 28.7 No NA 32.5 77 
302Levi et al. 2017 Unknown 38 LD CFH: p.Gln81Pro No NA No NA 35 171 
302Levi et al. 2017 Unknown 50 DD CFH: p.Tyr1177Cys No NA No NA 44.3 178 
299de Andrade et 
al. 2017
Unknown 29 DD CFH No NA Yes, 
recurrence 
while on 
eculizumab 
(4)
NA 4 Graft loss Graft loss (while 
experiencing endovascular 
problems) due to aHUS 
while on maintenance 
therapy (1200 mg, every 15 
days) despite additional 
dosage of Ecu. 
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Supplementary Table 9.1 Prophylactic eculizumab therapy in patients with aHUS receiving a 
kidney transplantation 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic variant
Discontinuation 
of Ecu
Time (in 
months) on 
Ecu before 
discontinuation 
Recurrence 
(time in 
months 
after Tx)
Restart 
of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
329Nieto-Ríos et 
al.2018
No 38 DD CFH: p. Arg257Cys No NA No NA 18 71 
279Macia et 
al.2017 
No 38 LD Negative Yes 14 Yes (26) Yes Unknown Unknown ¹
279Macia et al.2017 Unknown 37 LD MCP No NA No NA Unknown Unknown 
303Krishnan et 
al.2017
No 54 LURD CFH Yes 12 Yes (17) Yes 18 150 
321Manani et 
al.2017
No 45 DD THBD: 
p.Pro501Leu
CFHR1-3 del with 
anti CFH ab
No NA No NA 7 81 
302Levi et al. 2017 Unknown 32 DD CFI No NA No NA 4.4 124 
302Levi et al. 2017 Unknown 44 DD Anti CFH ab No NA No NA 11.7 93 
302Levi et al. 2017 Unknown 37 DD CFI: p.Ile357Met No NA No NA 14 157 
302Levi et al.2017 Unknown 56 ABOi LD Anti CFH ab No NA No NA 14.7 133 
302Levi et al. 2017 Unknown 48 DD CFI: p.Gly243Val No NA No NA 20.2 121 
302Levi et al. 2017 Unknown 39 DD C3: p.Arg161Trp No NA No NA 21.9 97 
302Levi et al. 2017 Unknown 18 DD CFH: 
p.Asn767LysfsX7
CFI: p.His183Arg
No NA No NA 27.4 187 
302Levi et al. 2017 Unknown 40 DD Unknown Yes 28.7 No NA 32.5 77 
302Levi et al. 2017 Unknown 38 LD CFH: p.Gln81Pro No NA No NA 35 171 
302Levi et al. 2017 Unknown 50 DD CFH: p.Tyr1177Cys No NA No NA 44.3 178 
299de Andrade et 
al. 2017
Unknown 29 DD CFH No NA Yes, 
recurrence 
while on 
eculizumab 
(4)
NA 4 Graft loss Graft loss (while 
experiencing endovascular 
problems) due to aHUS 
while on maintenance 
therapy (1200 mg, every 15 
days) despite additional 
dosage of Ecu. 
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Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic variant
Discontinuation 
of Ecu
Time (in 
months) on 
Ecu before 
discontinuation 
Recurrence 
(time in 
months 
after Tx)
Restart 
of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
299de Andrade et 
al. 2017
No 17 DD CFHR5: 
p.Arg356His
No NA No NA 4 84 
265Sheerin et al. 
2016
8 pts
Unknown Unknown Unknown Unknown No NA No NA Unknown Unknown 
(“good 
transplant 
function”)
²
330Sun et al.2016 No 42 DBD CFH No NA No NA 6 66 
331Akchurin et 
al.2015
No 10 LURD CFH: p.Trp920Arg No NA No NA Unknown Unknown 
(“stable 
renal 
function”)
301Kasapoǧlu et 
al.2015
No 18 LRD CFH: p. 
Asp268Asn 
CFH: p.Tyr271stop
Yes 1 No NA 12 67 
186Mallet et al.2015 Yes 18 LRD Negative No NA No NA 29 116 
332Alasfar et 
al.2015
Yes 35 DD CFH: int20br-
CFHR3
CFH: CFHR1int4-
CFHR4 block 7/2 
prime
No NA No NA Unknown 44 
332Alasfar et 
al.2015
No 27 LURD CFH No NA No NA Unknown 97 
296Riddell et 
al.2015
No 33 LURD CFH: p.Arg1251Gly No NA Yes, 
subclinical 
TMA in 
biopsy 
while on 
eculizumab 
(9) 
NA ± 24 150 Incomplete complement 
blockade with 1200 mg 
Ecu every two weeks. 
Increase of dosage to 1500 
mg every two weeks.
298Parikova et 
al.2015
No 43 LUR CFH: p.Ser451Stop No NA Yes, TMA in 
peripheral 
blood (0.5)
NA 18 150 TMA in peripheral 
blood on day 14 despite 
therapeutic through 
levels of Ecu (293 µg/ml). 
Treatment scheme was 
intensified 
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previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic variant
Discontinuation 
of Ecu
Time (in 
months) on 
Ecu before 
discontinuation 
Recurrence 
(time in 
months 
after Tx)
Restart 
of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
299de Andrade et 
al. 2017
No 17 DD CFHR5: 
p.Arg356His
No NA No NA 4 84 
265Sheerin et al. 
2016
8 pts
Unknown Unknown Unknown Unknown No NA No NA Unknown Unknown 
(“good 
transplant 
function”)
²
330Sun et al.2016 No 42 DBD CFH No NA No NA 6 66 
331Akchurin et 
al.2015
No 10 LURD CFH: p.Trp920Arg No NA No NA Unknown Unknown 
(“stable 
renal 
function”)
301Kasapoǧlu et 
al.2015
No 18 LRD CFH: p. 
Asp268Asn 
CFH: p.Tyr271stop
Yes 1 No NA 12 67 
186Mallet et al.2015 Yes 18 LRD Negative No NA No NA 29 116 
332Alasfar et 
al.2015
Yes 35 DD CFH: int20br-
CFHR3
CFH: CFHR1int4-
CFHR4 block 7/2 
prime
No NA No NA Unknown 44 
332Alasfar et 
al.2015
No 27 LURD CFH No NA No NA Unknown 97 
296Riddell et 
al.2015
No 33 LURD CFH: p.Arg1251Gly No NA Yes, 
subclinical 
TMA in 
biopsy 
while on 
eculizumab 
(9) 
NA ± 24 150 Incomplete complement 
blockade with 1200 mg 
Ecu every two weeks. 
Increase of dosage to 1500 
mg every two weeks.
298Parikova et 
al.2015
No 43 LUR CFH: p.Ser451Stop No NA Yes, TMA in 
peripheral 
blood (0.5)
NA 18 150 TMA in peripheral 
blood on day 14 despite 
therapeutic through 
levels of Ecu (293 µg/ml). 
Treatment scheme was 
intensified 
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Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic variant
Discontinuation 
of Ecu
Time (in 
months) on 
Ecu before 
discontinuation 
Recurrence 
(time in 
months 
after Tx)
Restart 
of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
333Ažukaitis et 
al.2014
No 6 DD C3: p.Pro1640Leu No NA No NA 9 days 
after Tx
Patient 
deceased
Patient deceased due to 
iCVA possibly extrarenal 
manifestation of aHUS, no 
signs of peripheral blood 
TMA.
334Ardissino et 
al.2014
No 19 Type 
unknown
Anti CFH ab Yes ± 5.5 No NA 31.4 118 
297Ranch et al.2014 No 3 DD CFH: p.Ser1191Trp No NA Yes, TMA in 
peripheral 
blood (2 
days)
NA Unknown Unknown 
(“stable 
kidney 
function”) 
Maintenance therapy with 
Ecu (dosage of 300 mg 11 
days before and on day 0 
of Tx). TMA in peripheral 
blood on day 2 after Tx for 
which treatment scheme 
was intensified. 
335Román-Ortiz et 
al.2014
No 9 DD CFH: p.Ser890Ile
CFH: p.Val1007Leu
CFH/CFHR1 
hybrid gene
No NA No NA 36 80 
300Matar et al. 
2014
Yes 51 LRD Negative Yes 6 No NA 12 88 
300Matar et al. 
2014
No 38 LRD Negative Yes 6 No NA 12 97 
300Matar et al. 
2014
Yes 40 LURD Negative Yes 6 No -NA 12 115 
300Matar et al. 
2014
Yes 27 LURD CFH: p.Ser1191L
CFH: p.Val1197Ala
No NA No NA 12 80 
336 Békássy et 
al.2013
Yes 11 DD CFI: p.Gly261Asp
CFB: p.Leu433Ser
No NA No NA 12 (79 ml/
min/1.73m²)
337Pelicano et 
al.2013
No 27 LRD CFH: p.Pro116Leu No NA No NA 15 76 
152Zuber et al.2012 No 17 DD CFH-CFHR1 
hybrid gene
No NA No NA 14 87 
152Zuber et al.2012 No 10 months DD C3: p.Arg161Trp No NA No NA 4.5 44 
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source
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after Tx)
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of Ecu 
Last FU 
(time in 
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after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
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333Ažukaitis et 
al.2014
No 6 DD C3: p.Pro1640Leu No NA No NA 9 days 
after Tx
Patient 
deceased
Patient deceased due to 
iCVA possibly extrarenal 
manifestation of aHUS, no 
signs of peripheral blood 
TMA.
334Ardissino et 
al.2014
No 19 Type 
unknown
Anti CFH ab Yes ± 5.5 No NA 31.4 118 
297Ranch et al.2014 No 3 DD CFH: p.Ser1191Trp No NA Yes, TMA in 
peripheral 
blood (2 
days)
NA Unknown Unknown 
(“stable 
kidney 
function”) 
Maintenance therapy with 
Ecu (dosage of 300 mg 11 
days before and on day 0 
of Tx). TMA in peripheral 
blood on day 2 after Tx for 
which treatment scheme 
was intensified. 
335Román-Ortiz et 
al.2014
No 9 DD CFH: p.Ser890Ile
CFH: p.Val1007Leu
CFH/CFHR1 
hybrid gene
No NA No NA 36 80 
300Matar et al. 
2014
Yes 51 LRD Negative Yes 6 No NA 12 88 
300Matar et al. 
2014
No 38 LRD Negative Yes 6 No NA 12 97 
300Matar et al. 
2014
Yes 40 LURD Negative Yes 6 No -NA 12 115 
300Matar et al. 
2014
Yes 27 LURD CFH: p.Ser1191L
CFH: p.Val1197Ala
No NA No NA 12 80 
336 Békássy et 
al.2013
Yes 11 DD CFI: p.Gly261Asp
CFB: p.Leu433Ser
No NA No NA 12 (79 ml/
min/1.73m²)
337Pelicano et 
al.2013
No 27 LRD CFH: p.Pro116Leu No NA No NA 15 76 
152Zuber et al.2012 No 17 DD CFH-CFHR1 
hybrid gene
No NA No NA 14 87 
152Zuber et al.2012 No 10 months DD C3: p.Arg161Trp No NA No NA 4.5 44 
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Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic variant
Discontinuation 
of Ecu
Time (in 
months) on 
Ecu before 
discontinuation 
Recurrence 
(time in 
months 
after Tx)
Restart 
of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
152Zuber et al.2012 No 1 DD CFH: Gln1137X No NA No NA 4 58 
152Zuber et al.2012 Yes 3 DD CFH: p.Ser1191Leu No NA No NA 1 day after 
Tx
Graft loss Graft loss due to arterial 
thrombosis, transplant 
nephrectomy at day 3.
152Zuber et al.2012 Yes 33 DD CFH: p.Tyr1177Cys No NA No NA 1.5 176 6 weeks after Tx mixed 
rejection.
338Xie et al.2012 No 31 LURD CFH: 
p.Gluc625Stop
No NA No NA 12 78 
295,326Krid et al.2012 No 7 DD CFH-CFHR1 
hybrid gene
No NA No NA 15 48 
295,339Nester et 
al.2011
Yes 12 LURD CFH-CFHR1 
hybrid gene
No NA No NA 16 70 
295,327Weitz et 
al.2011
No 7 DD CFH: 
p.Glu1189Stop
No NA No NA 23 44 
295,340Zimmerhackl 
et al. 2010
No 9 DD CFH: p.Trp1183Cys No NA No NA 39 46 
Supplementary table 9.1 Case reports and case series found in literature with prophylactic use of eculizumab in 
aHUS patients receiving a kidney transplantation. In several case reports serum creatinine (or follow up time) is not 
described in text but depicted in a figure, the approximate values were used in this table and designated as ± . Eight 
patients discontinued eculizumab after transplantation and are indicated in red. The patients printed in bold had 
a recurrence after discontinuation. 
LRD; living related donor, LD; living donor, DD; deceased donor, DBD; donation after brain death, DCD; donation 
after cardiac death, LURD; living unrelated donor, ABMR; antibody mediated rejection, CFH; complement factor 
H, CFI; complement factor I, CFB;complement factor B, C3; complement factor 3, MCP; membrane cofactor protein, 
THBD; thrombomodulin, CFHR; complement factor H related protein, del; deletion, Tx ; kidney transplantation,
MDRD ; modification of diet in renal disease, ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies,  
Ecu;eculizumab, NA; not applicable, Bx;kidney biopsy, TMA ; thrombotic microangiopathy, PE ; plasma exchange, 
GL ;graft loss, ATN ; acute tubular necrosis, GI ; gastro-intestinal, IVIG ; intravenous immunoglobulins, Scr; serum 
creatinine, HD ; hemodialysis, iCVA ; ischemic cerebrovasculair accident, FU ; follow-up. 
¹ after six months eculizumab was discontinued again, resulting in a recurrence 4 months later, possibly triggered 
by a urine tract infection. Eculizumab was restarted as lifelong therapy. The renal outcome is unknown.
² one patient with a CFH mutation showed deterioration of renal function, incomplete complement blockade and 
low-grade TMA on renal biopsy during treatment with eculizumab (1200 mg every two weeks). Eculizumab treat-
ment was intensified to 1500 mg every two weeks. Trough levels of eculizumab are unknown. No details on the 
post-transplantation period of the other patients were reported.
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discontinuation 
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(time in 
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after Tx)
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of Ecu 
Last FU 
(time in 
months 
after Tx)
Serum 
creatinine 
(µmol/L) 
(MDRD) at 
last FU 
Remarks
152Zuber et al.2012 No 1 DD CFH: Gln1137X No NA No NA 4 58 
152Zuber et al.2012 Yes 3 DD CFH: p.Ser1191Leu No NA No NA 1 day after 
Tx
Graft loss Graft loss due to arterial 
thrombosis, transplant 
nephrectomy at day 3.
152Zuber et al.2012 Yes 33 DD CFH: p.Tyr1177Cys No NA No NA 1.5 176 6 weeks after Tx mixed 
rejection.
338Xie et al.2012 No 31 LURD CFH: 
p.Gluc625Stop
No NA No NA 12 78 
295,326Krid et al.2012 No 7 DD CFH-CFHR1 
hybrid gene
No NA No NA 15 48 
295,339Nester et 
al.2011
Yes 12 LURD CFH-CFHR1 
hybrid gene
No NA No NA 16 70 
295,327Weitz et 
al.2011
No 7 DD CFH: 
p.Glu1189Stop
No NA No NA 23 44 
295,340Zimmerhackl 
et al. 2010
No 9 DD CFH: p.Trp1183Cys No NA No NA 39 46 
Supplementary table 9.1 Case reports and case series found in literature with prophylactic use of eculizumab in 
aHUS patients receiving a kidney transplantation. In several case reports serum creatinine (or follow up time) is not 
described in text but depicted in a figure, the approximate values were used in this table and designated as ± . Eight 
patients discontinued eculizumab after transplantation and are indicated in red. The patients printed in bold had 
a recurrence after discontinuation. 
LRD; living related donor, LD; living donor, DD; deceased donor, DBD; donation after brain death, DCD; donation 
after cardiac death, LURD; living unrelated donor, ABMR; antibody mediated rejection, CFH; complement factor 
H, CFI; complement factor I, CFB;complement factor B, C3; complement factor 3, MCP; membrane cofactor protein, 
THBD; thrombomodulin, CFHR; complement factor H related protein, del; deletion, Tx ; kidney transplantation,
MDRD ; modification of diet in renal disease, ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies,  
Ecu;eculizumab, NA; not applicable, Bx;kidney biopsy, TMA ; thrombotic microangiopathy, PE ; plasma exchange, 
GL ;graft loss, ATN ; acute tubular necrosis, GI ; gastro-intestinal, IVIG ; intravenous immunoglobulins, Scr; serum 
creatinine, HD ; hemodialysis, iCVA ; ischemic cerebrovasculair accident, FU ; follow-up. 
¹ after six months eculizumab was discontinued again, resulting in a recurrence 4 months later, possibly triggered 
by a urine tract infection. Eculizumab was restarted as lifelong therapy. The renal outcome is unknown.
² one patient with a CFH mutation showed deterioration of renal function, incomplete complement blockade and 
low-grade TMA on renal biopsy during treatment with eculizumab (1200 mg every two weeks). Eculizumab treat-
ment was intensified to 1500 mg every two weeks. Trough levels of eculizumab are unknown. No details on the 
post-transplantation period of the other patients were reported.
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Supplementary Table 9.2 Efficacy of eculizumab rescue therapy in patients with aHUS after 
kidney transplantation 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
341Devresse et al. 
2018
No 23 LRD CFI: 
p.Pro50Ala
MCP
CFHR1-3 del
40 days ± 4 months 107 ±486 177; ± 17 Yes No NA
312Zwang et 
al.2018 *
Unknown 39 DD CFI: p. 
Ile398Leu
CFHR1-3 del
7 months ± 15 days 300 1043 486; 10 No No NA Poor renal 
function before 
aHUS recurrence 
due to persistent 
borderline 
rejection.
342 Vondrak et 
al. 2018
No 13 DD CFH/CFHR1 /
CFHR3 hybrid 
gene
2 months 5 days Unknown 322 109; 84 No No NA
299de Andrade et 
al.2017
No 30 LD Negative 4 days Max 2 days Unknown ¹ 141; 42 No No NA
299de Andrade et 
al. 2017
Unknown 20 DD CFH: 
p.Asn1050Tyr
CFH: del in 
exon 23
CFRH1-3 del
30 days Max 2 days Unknown ¹ 80; 42 No No  NA
299de Andrade et 
al.2017
No 36 DD Negative 2 months Max 2 days Unknown ¹ 185; 7 No No NA
299de Andrade et 
al.2017
No 32 DD CFI: 
p.Ile416Leu
CFRH1-3 del
1 month and 
20 days
Max 2 days Unknown ¹ 194; 9 No No  NA
299de Andrade et 
al.2017
No 44 DD Unknown 1 day Max 2 days Unknown ¹ 141; 6 No No NA Patient died with 
functioning graft 
6 months after 
transplantation 
due to aspergillus 
infection.
CH
A
PTER 9
Strategies toward restrictive eculizumab use   |   201
Supplementary Table 9.2 Efficacy of eculizumab rescue therapy in patients with aHUS after 
kidney transplantation 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
341Devresse et al. 
2018
No 23 LRD CFI: 
p.Pro50Ala
MCP
CFHR1-3 del
40 days ± 4 months 107 ±486 177; ± 17 Yes No NA
312Zwang et 
al.2018 *
Unknown 39 DD CFI: p. 
Ile398Leu
CFHR1-3 del
7 months ± 15 days 300 1043 486; 10 No No NA Poor renal 
function before 
aHUS recurrence 
due to persistent 
borderline 
rejection.
342 Vondrak et 
al. 2018
No 13 DD CFH/CFHR1 /
CFHR3 hybrid 
gene
2 months 5 days Unknown 322 109; 84 No No NA
299de Andrade et 
al.2017
No 30 LD Negative 4 days Max 2 days Unknown ¹ 141; 42 No No NA
299de Andrade et 
al. 2017
Unknown 20 DD CFH: 
p.Asn1050Tyr
CFH: del in 
exon 23
CFRH1-3 del
30 days Max 2 days Unknown ¹ 80; 42 No No  NA
299de Andrade et 
al.2017
No 36 DD Negative 2 months Max 2 days Unknown ¹ 185; 7 No No NA
299de Andrade et 
al.2017
No 32 DD CFI: 
p.Ile416Leu
CFRH1-3 del
1 month and 
20 days
Max 2 days Unknown ¹ 194; 9 No No  NA
299de Andrade et 
al.2017
No 44 DD Unknown 1 day Max 2 days Unknown ¹ 141; 6 No No NA Patient died with 
functioning graft 
6 months after 
transplantation 
due to aspergillus 
infection.
202   |   Chapter 9
Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
302Levi et al. 2017 Yes 26 DD CFH
CFH/CFHR1 
hybrid gene
Within 25 
days
Unknown 
(Ecu started 
d25 after Tx)
Unknown Unknown Graft loss; 55 Yes Yes (56) Unknown Graft loss due 
to chronic graft 
dysfunction and 
sepsis, resulting 
in restart of HD. 
After subsequent 
withdrawal 
of Ecu aHUS 
recurrence.
302Levi et al. 2017 Yes 23 DD CFH: 
p.Ser1191Leu
CFH: 
p.Val1197Ala
Within 6 
days
Unknown 
(Ecu started 
d6 after Tx)
Unknown Unknown  NA No No NA
294Munch et 
al.2017
Yes 58 DD CFHR1-3 del 
Anti CFH ab
21 days Unknown 
(after 6 ses-
sions of PT)
Unknown ± 270 
(incomplete 
respons to 
PT)
±150; 3.8 Yes Yes (4.7) Yes Scr after 2nd 
recurrence ± 
140µmol/L 18 
months after Tx.
314Shochet et 
al.2017 *
No 45 DD 
(pancreas-
kidney)
Unknown 7 days 17 days 315 HD 267; ±2.3 Yes Yes (±2.8) Yes Renal function 
compromised 
due to infectious 
complications 
before and after 
transplantation. 
Scr after 2nd 
recurrence ± 
182µmol/L 6 
months after Tx.
343Asif et al.2017 No 37 LRD Negative 8 days Unknown 80 HD 150; 6 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
302Levi et al. 2017 Yes 26 DD CFH
CFH/CFHR1 
hybrid gene
Within 25 
days
Unknown 
(Ecu started 
d25 after Tx)
Unknown Unknown Graft loss; 55 Yes Yes (56) Unknown Graft loss due 
to chronic graft 
dysfunction and 
sepsis, resulting 
in restart of HD. 
After subsequent 
withdrawal 
of Ecu aHUS 
recurrence.
302Levi et al. 2017 Yes 23 DD CFH: 
p.Ser1191Leu
CFH: 
p.Val1197Ala
Within 6 
days
Unknown 
(Ecu started 
d6 after Tx)
Unknown Unknown  NA No No NA
294Munch et 
al.2017
Yes 58 DD CFHR1-3 del 
Anti CFH ab
21 days Unknown 
(after 6 ses-
sions of PT)
Unknown ± 270 
(incomplete 
respons to 
PT)
±150; 3.8 Yes Yes (4.7) Yes Scr after 2nd 
recurrence ± 
140µmol/L 18 
months after Tx.
314Shochet et 
al.2017 *
No 45 DD 
(pancreas-
kidney)
Unknown 7 days 17 days 315 HD 267; ±2.3 Yes Yes (±2.8) Yes Renal function 
compromised 
due to infectious 
complications 
before and after 
transplantation. 
Scr after 2nd 
recurrence ± 
182µmol/L 6 
months after Tx.
343Asif et al.2017 No 37 LRD Negative 8 days Unknown 80 HD 150; 6 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
305 Duineveld et 
al. 2017
Yes 41 LURD CFH: 
p.Trp678Cys
64 days 1 day 94 145 110; 5 Yes Yes (±5.2) Yes Possible 
recurrence 
after Tx with 
peripheral 
blood hemolysis 
without TMA in 
Bx or alternative 
cause TMA. Scr 
after 2nd relapse 
143µmol/L 14 
months after 
Tx. ²
344Dedhia et 
al.2017 *
No 28 LURD CFHR1-3 del ± 40 days 0 days 221 486 132; 30 No No NA Poor renal 
function before 
aHUS recurrence 
due to rejection 
and bacteremia.
279,306Legendre 
et al. Macia et 
al. 2017
25 pts
Unknown Median 41.5 
(17-69) 
Unknown 13 (50%) with 
complement 
mutation or 
autoantibody
Unknown 1.25 months 
(range 0.03-
36.7 months)
Unknown Median 
eGFR 
22.2 ml/
min/1.73m² 
(range 10-
72.3) 
Mean eGFR 44 
ml/min/1.73m² 
(SD 27); 18 
months 
after start of 
eculizumab
Yes, 16 pt Yes, in 3 
patients 
(including 
1 patient 
during 
a dose 
reduction) 
Yes, 
restart in 1 
patient
In patient who 
restarted Ecu 
renal function 
improved. Graft 
loss occurred in 
the other two 
patients due to 
aHUS. A forth 
patient died, not 
due to aHUS. 
324Yamamoto et 
al. 2017
No 35 LD Negative 15 days 22 days ± 136 Unknown 116; 36 Unknown No NA Treated 
for ABMR 
before aHUS 
recurrence.
265Sheerin et al. 
2016
Unknown Unknown Unknown Unknown Early post-
operative 
period 
Unknown Unknown Unknown Unknown ( 
“good transplant 
function”)
Unknown No NA Further details 
are missing.
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
305 Duineveld et 
al. 2017
Yes 41 LURD CFH: 
p.Trp678Cys
64 days 1 day 94 145 110; 5 Yes Yes (±5.2) Yes Possible 
recurrence 
after Tx with 
peripheral 
blood hemolysis 
without TMA in 
Bx or alternative 
cause TMA. Scr 
after 2nd relapse 
143µmol/L 14 
months after 
Tx. ²
344Dedhia et 
al.2017 *
No 28 LURD CFHR1-3 del ± 40 days 0 days 221 486 132; 30 No No NA Poor renal 
function before 
aHUS recurrence 
due to rejection 
and bacteremia.
279,306Legendre 
et al. Macia et 
al. 2017
25 pts
Unknown Median 41.5 
(17-69) 
Unknown 13 (50%) with 
complement 
mutation or 
autoantibody
Unknown 1.25 months 
(range 0.03-
36.7 months)
Unknown Median 
eGFR 
22.2 ml/
min/1.73m² 
(range 10-
72.3) 
Mean eGFR 44 
ml/min/1.73m² 
(SD 27); 18 
months 
after start of 
eculizumab
Yes, 16 pt Yes, in 3 
patients 
(including 
1 patient 
during 
a dose 
reduction) 
Yes, 
restart in 1 
patient
In patient who 
restarted Ecu 
renal function 
improved. Graft 
loss occurred in 
the other two 
patients due to 
aHUS. A forth 
patient died, not 
due to aHUS. 
324Yamamoto et 
al. 2017
No 35 LD Negative 15 days 22 days ± 136 Unknown 116; 36 Unknown No NA Treated 
for ABMR 
before aHUS 
recurrence.
265Sheerin et al. 
2016
Unknown Unknown Unknown Unknown Early post-
operative 
period 
Unknown Unknown Unknown Unknown ( 
“good transplant 
function”)
Unknown No NA Further details 
are missing.
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
265Sheerin et al. 
2016
Unknown Unknown Unknown C3 29 months Unknown Unknown Unknown Unknown ( 
“improvement 
in transplant 
function”)
Unknown No NA Further details 
are missing.
265Sheerin et al. 
2016
Unknown Unknown Unknown CFH Early after 
Tx
Unknown Unknown Unknown Unknown ( 
“stable transplant 
function”)
Unknown No NA Further details 
are missing.
265Sheerin et al. 
2016
Unknown Unknown Unknown Unknown Early after 
Tx
Unknown Unknown Unknown Unknown ( 
“stable transplant 
function”)
Unknown No NA Further details 
are missing.
345Ikeda et 
al.2016
No 27 LRD Not 
investigated
 1 day 2 days Unknown ± 681 117; 8 Yes No NA -
345Ikeda et 
al.2016
No 66 LURD Not 
investigated
1 day 5 days Unknown ± 575 120; 12 Yes No NA -
346Okumi et 
al.2016
Nov 30 LRD CFH: 
p.Arg1215Gln
3 weeks ± 8 months 133 Unknown 158; 60 No No NA -
317Salameh et 
al.2016
No 48 DD CFH: 
p.Arg1215Gln
3 months Unknown 
(after 7 
session of 
PT)
133 >353 133; 9 No NA NA -
320Juega-Marino 
et al.2016
No 46 DD 
(pancreas-
kidney)
Negative 7 months >10 days 110 438 180; >10 Yes No NA -
347 Fan et al. 2015 No 30 LRD CFH: 
p.Arg1251Glu
21 days Unknown Unknown Unknown 199; specific 
time after Tx 
unknown
No No NA -
313Iqbal et al.2015 No 49 DD C3: 
p.Asp1093Asn
29 months ±2 months 100 396 (±20 ml/min/
1.73m2); ± 39 
No No NA -
186Mallet et 
al.2015
No 40 DD Negative Within 2 
days
2 days Unknown 620 (PT 
resistant) 
Graft loss; 12 NA NA NA Graft loss 1 
year after Tx 
due to anti-
body mediated 
rejection, 
ongoing aHUS 
remission.
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
265Sheerin et al. 
2016
Unknown Unknown Unknown C3 29 months Unknown Unknown Unknown Unknown ( 
“improvement 
in transplant 
function”)
Unknown No NA Further details 
are missing.
265Sheerin et al. 
2016
Unknown Unknown Unknown CFH Early after 
Tx
Unknown Unknown Unknown Unknown ( 
“stable transplant 
function”)
Unknown No NA Further details 
are missing.
265Sheerin et al. 
2016
Unknown Unknown Unknown Unknown Early after 
Tx
Unknown Unknown Unknown Unknown ( 
“stable transplant 
function”)
Unknown No NA Further details 
are missing.
345Ikeda et 
al.2016
No 27 LRD Not 
investigated
 1 day 2 days Unknown ± 681 117; 8 Yes No NA -
345Ikeda et 
al.2016
No 66 LURD Not 
investigated
1 day 5 days Unknown ± 575 120; 12 Yes No NA -
346Okumi et 
al.2016
Nov 30 LRD CFH: 
p.Arg1215Gln
3 weeks ± 8 months 133 Unknown 158; 60 No No NA -
317Salameh et 
al.2016
No 48 DD CFH: 
p.Arg1215Gln
3 months Unknown 
(after 7 
session of 
PT)
133 >353 133; 9 No NA NA -
320Juega-Marino 
et al.2016
No 46 DD 
(pancreas-
kidney)
Negative 7 months >10 days 110 438 180; >10 Yes No NA -
347 Fan et al. 2015 No 30 LRD CFH: 
p.Arg1251Glu
21 days Unknown Unknown Unknown 199; specific 
time after Tx 
unknown
No No NA -
313Iqbal et al.2015 No 49 DD C3: 
p.Asp1093Asn
29 months ±2 months 100 396 (±20 ml/min/
1.73m2); ± 39 
No No NA -
186Mallet et 
al.2015
No 40 DD Negative Within 2 
days
2 days Unknown 620 (PT 
resistant) 
Graft loss; 12 NA NA NA Graft loss 1 
year after Tx 
due to anti-
body mediated 
rejection, 
ongoing aHUS 
remission.
208   |   Chapter 9
Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
186Mallet et 
al.2015
No 23 LRD Unknown 10 months 4 months Unknown 450 (PT 
dependent) 
328; specific 
time after Tx 
unknown 
No NA NA
186Mallet et 
al.2015
No 36 DD Negative 5 years 9.1 months 80-90 130 (PT 
resistant)
469; specific 
time after Tx 
unknown 
NA NA NA No renal or 
hematological 
respons to ecu. 
Visual and 
GI symptoms 
attributed to 
aHUS. Pt died 114 
days after start 
of Ecu.
319Garlo et 
al.2015
No 30 LURD Unknown 2 years Unknown 
(after 9 
sessies of 
PT)
71 618 71; specific 
time after Tx 
unknown (two 
week after 
start of ecu)
Yes Yes Yes Patient presented 
26 weeks 
pregnant with 
pre-eclampsia 
for which a 
caesarian section 
was performed. 
Two days later 
she developed 
aHUS recurrence. 
Scr after 2nd 
recurrence ± 106 
µmol/L ± 3 years 
after Tx
318Broeders et 
al. 2014
Yes 41 DCD CFH: 
p.His860His 
6 months 1 week 141 168 (respons 
to PT 
unknown)
141; 18 No NA NA 13 days after Tx 
also episode of 
TMA diagnosed 
as TMA due to 
ABMR, treated 
with steroids, 
IVIG and 3 
sessions of PT 
leading to full 
recovery of 
kidney function
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
186Mallet et 
al.2015
No 23 LRD Unknown 10 months 4 months Unknown 450 (PT 
dependent) 
328; specific 
time after Tx 
unknown 
No NA NA
186Mallet et 
al.2015
No 36 DD Negative 5 years 9.1 months 80-90 130 (PT 
resistant)
469; specific 
time after Tx 
unknown 
NA NA NA No renal or 
hematological 
respons to ecu. 
Visual and 
GI symptoms 
attributed to 
aHUS. Pt died 114 
days after start 
of Ecu.
319Garlo et 
al.2015
No 30 LURD Unknown 2 years Unknown 
(after 9 
sessies of 
PT)
71 618 71; specific 
time after Tx 
unknown (two 
week after 
start of ecu)
Yes Yes Yes Patient presented 
26 weeks 
pregnant with 
pre-eclampsia 
for which a 
caesarian section 
was performed. 
Two days later 
she developed 
aHUS recurrence. 
Scr after 2nd 
recurrence ± 106 
µmol/L ± 3 years 
after Tx
318Broeders et 
al. 2014
Yes 41 DCD CFH: 
p.His860His 
6 months 1 week 141 168 (respons 
to PT 
unknown)
141; 18 No NA NA 13 days after Tx 
also episode of 
TMA diagnosed 
as TMA due to 
ABMR, treated 
with steroids, 
IVIG and 3 
sessions of PT 
leading to full 
recovery of 
kidney function
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
300Matar et 
al.2014
Yes 38 LRD CFH:p.
Leu1189Phe
6 years Unknown Unknown Unknown Unknown Yes Yes (84) Yes After 2nd 
recurrence life-
long Ecu therapy. 
Graft is still 
functioning. 
300Matar et 
al.2014
Yes 33 LURD Negative 3 months Unknown Unknown Unknown Unknown Yes Yes (17) Yes After restart 
of Ecu respons 
was seen. At 23 
months after 
Tx graft loss 
due to contrast 
nephropathy and 
ATN.
300Matar et 
al.2014
Yes 57 DD CFH: p. 
Ile059Thre
CFH: 
p.Gln1143Glu 
3 months Unknown Unknown Unknown Graft loss; 6 NA NA NA Graft loss due to 
aHUS recurrence 
, no respons to 
Ecu.
348Commereuc 
et al.2013
No 22 DD 
(combined 
lung-
kidney)
Negative 3 days 12 days 72 HD Unknown 
(“hemodialysis 
could be 
stopped”)
Unknown No NA Unknown 
recovery of renal 
function, yet 
hemodialysis 
could be stopped.
308Sinibaldi et 
al.2013
Yes 19 DD THBD: 
p.Pro501Leu
11 weeks 5 days ± 88 ± 177 ± 110-120; 4.5 No NA NA Graft loss 7 
months after 
Tx due to 
cellular rejection 
unresponsive to 
steroids.
322Reuter et 
al.2013
No 24 LRD MCP: 
p.Tyr54Cys
9 days ± 14 days 159 ± 290 159; 44 No NA NA -
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Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
300Matar et 
al.2014
Yes 38 LRD CFH:p.
Leu1189Phe
6 years Unknown Unknown Unknown Unknown Yes Yes (84) Yes After 2nd 
recurrence life-
long Ecu therapy. 
Graft is still 
functioning. 
300Matar et 
al.2014
Yes 33 LURD Negative 3 months Unknown Unknown Unknown Unknown Yes Yes (17) Yes After restart 
of Ecu respons 
was seen. At 23 
months after 
Tx graft loss 
due to contrast 
nephropathy and 
ATN.
300Matar et 
al.2014
Yes 57 DD CFH: p. 
Ile059Thre
CFH: 
p.Gln1143Glu 
3 months Unknown Unknown Unknown Graft loss; 6 NA NA NA Graft loss due to 
aHUS recurrence 
, no respons to 
Ecu.
348Commereuc 
et al.2013
No 22 DD 
(combined 
lung-
kidney)
Negative 3 days 12 days 72 HD Unknown 
(“hemodialysis 
could be 
stopped”)
Unknown No NA Unknown 
recovery of renal 
function, yet 
hemodialysis 
could be stopped.
308Sinibaldi et 
al.2013
Yes 19 DD THBD: 
p.Pro501Leu
11 weeks 5 days ± 88 ± 177 ± 110-120; 4.5 No NA NA Graft loss 7 
months after 
Tx due to 
cellular rejection 
unresponsive to 
steroids.
322Reuter et 
al.2013
No 24 LRD MCP: 
p.Tyr54Cys
9 days ± 14 days 159 ± 290 159; 44 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
310Alachkar et 
al.2012
Yes 32 LD Negative 3.5 months Unknown 
(after 8 
sessions of 
PT)
Unknown 
(“excellent 
function”)
HD 159; 8 Yes Yes (13) Yes Scr after 2nd 
recurrence 282 
µmol/L. Graft 
loss, 2 years 
after Tx, due 
to complicated 
endovascular 
procedure with 
ATN, no signs 
of TMA in 
peripheral blood.
152 Zuber et al. 
2012
Yes Unknown Unknown CFHR1-3 del
Anti CFH ab
5 years 3 months Unknown 89 
(incomplete 
respons PT)
80; ± 72 No Yes, relapse 
while on 
eculizumab 
therapy (± 
86)
NA  During Ecu 
therapy fresh 
TMA lesions 
on renal biopsy, 
possible also due 
to chronic active 
ABMR. CH50 
below detection 
threshold. 
Unknown renal 
function after 2nd 
relapse. 
152 Gueutin by 
Zuber et al. 2012
Yes Unknown Unknown CFI: p. 
Gly101Arg
± 36 months 9 weeks ± 156 190 (PT 
resistant)
Unknown No Yes, relapse 
while on 
eculizumab 
therapy
During Ecu 
therapy TMA in 
peripheral blood 
after interval 
prolongation. Scr 
after 2nd relapse 
156 µmol/L ± 
40,5months after 
Tx.
152 Zuber et al. 
2012
Yes Unknown Unknown CFH: 
p.Ser1191Leu
CFH: 
p.Val1197Ala
3 days 3 days Unknown 627 (PT 
resistant)
65; 17 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
310Alachkar et 
al.2012
Yes 32 LD Negative 3.5 months Unknown 
(after 8 
sessions of 
PT)
Unknown 
(“excellent 
function”)
HD 159; 8 Yes Yes (13) Yes Scr after 2nd 
recurrence 282 
µmol/L. Graft 
loss, 2 years 
after Tx, due 
to complicated 
endovascular 
procedure with 
ATN, no signs 
of TMA in 
peripheral blood.
152 Zuber et al. 
2012
Yes Unknown Unknown CFHR1-3 del
Anti CFH ab
5 years 3 months Unknown 89 
(incomplete 
respons PT)
80; ± 72 No Yes, relapse 
while on 
eculizumab 
therapy (± 
86)
NA  During Ecu 
therapy fresh 
TMA lesions 
on renal biopsy, 
possible also due 
to chronic active 
ABMR. CH50 
below detection 
threshold. 
Unknown renal 
function after 2nd 
relapse. 
152 Gueutin by 
Zuber et al. 2012
Yes Unknown Unknown CFI: p. 
Gly101Arg
± 36 months 9 weeks ± 156 190 (PT 
resistant)
Unknown No Yes, relapse 
while on 
eculizumab 
therapy
During Ecu 
therapy TMA in 
peripheral blood 
after interval 
prolongation. Scr 
after 2nd relapse 
156 µmol/L ± 
40,5months after 
Tx.
152 Zuber et al. 
2012
Yes Unknown Unknown CFH: 
p.Ser1191Leu
CFH: 
p.Val1197Ala
3 days 3 days Unknown 627 (PT 
resistant)
65; 17 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
152 Zuber et al. 
2012
Yes Unknown Unknown CFH-CRFH1 
hybrid gene
3 days 1 month Unknown 237 
(incomplete 
respons PT)
Unknown No Yes, relapse 
while on 
eculizumab 
therapy 
(± 4)
NA During 
eculizumab 
therapy fresh 
TMA lesions 
on renal biopsy, 
possible partly 
due to high 
tacrolimus 
trough levels. 
CH50 below 
detection 
threshold. Serum 
creatinine after 
2nd relapse 204 
µmol/L ± 15 
months after Tx.
349Zlamy et 
al.2012
No 10 DD CFH 6 days 4 days Unknown GFR 45 ml/
min/m²
48; 27 No NA NA -
315Hodgkins et 
al.2012
No 5 DD Negative 4 years and 
6 months
2 days 44-53 751 ± 53; 84 No NA NA -
152,350Duran et al. 
2012
No 32 DCD CFH: 
p.Glu1172Stop
2.5 months 1 month 159 Hemo-
dialysis
168; ± 20 No NA NA -
152,325Heyne et 
al. 2011
Yes Unknown Unknown Not 
investigated
8 days 1 day Unknown 176 114; specific 
time after Tx 
unknown
Yes Yes (±11) Yes Scr after 2nd 
relapse 123 
µmol/L; ± 25 
months after Tx
351Wilson et 
al.2011
No 46 DD 
(pancreas-
kidney)
Negative 41 days 3 weeks Unknown Unknown (40 ml/
min/1.73m²); 24 
Yes No NA -
316Chandran et 
al.2011
No 34 DD 
(pancreas-
kidney)
Unknown 10 days 4 days 88 HD 63; 4 Yes No No -
152,323Al-Akash et 
al. 2010
Yes 15 DD C3: 
p.Arg570Trp
9 weeks 3 weeks 115 202 
(incomplete 
respons PT)
115; ±42 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
152 Zuber et al. 
2012
Yes Unknown Unknown CFH-CRFH1 
hybrid gene
3 days 1 month Unknown 237 
(incomplete 
respons PT)
Unknown No Yes, relapse 
while on 
eculizumab 
therapy 
(± 4)
NA During 
eculizumab 
therapy fresh 
TMA lesions 
on renal biopsy, 
possible partly 
due to high 
tacrolimus 
trough levels. 
CH50 below 
detection 
threshold. Serum 
creatinine after 
2nd relapse 204 
µmol/L ± 15 
months after Tx.
349Zlamy et 
al.2012
No 10 DD CFH 6 days 4 days Unknown GFR 45 ml/
min/m²
48; 27 No NA NA -
315Hodgkins et 
al.2012
No 5 DD Negative 4 years and 
6 months
2 days 44-53 751 ± 53; 84 No NA NA -
152,350Duran et al. 
2012
No 32 DCD CFH: 
p.Glu1172Stop
2.5 months 1 month 159 Hemo-
dialysis
168; ± 20 No NA NA -
152,325Heyne et 
al. 2011
Yes Unknown Unknown Not 
investigated
8 days 1 day Unknown 176 114; specific 
time after Tx 
unknown
Yes Yes (±11) Yes Scr after 2nd 
relapse 123 
µmol/L; ± 25 
months after Tx
351Wilson et 
al.2011
No 46 DD 
(pancreas-
kidney)
Negative 41 days 3 weeks Unknown Unknown (40 ml/
min/1.73m²); 24 
Yes No NA -
316Chandran et 
al.2011
No 34 DD 
(pancreas-
kidney)
Unknown 10 days 4 days 88 HD 63; 4 Yes No No -
152,323Al-Akash et 
al. 2010
Yes 15 DD C3: 
p.Arg570Trp
9 weeks 3 weeks 115 202 
(incomplete 
respons PT)
115; ±42 No NA NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
152,309Larrea et al. 
2010
No 22 DCD Negative 12 days 9 days 97 415 (PT 
resistant)
70; specific 
time after Tx 
unknown
Yes Yes (11) Yes Discontinuation 
after 1 dosage 
of ecu; after 2nd 
relapse Scr of 175 
µmol/L. After 4 
months Ecu was 
stopped because 
of infection; 
GL loss due to 
ABMR.
295,352Châtelet et 
al.2010
Yes >36 DD C3: 
p.Arg570Gln
4 years 5 weeks ± 160 320 (PT 
dependent)
Unknown No Yes, 2 x 
mild relapse 
while on 
eculizumab
NA First aHUS 
recurrence after 
current Tx was 
successfully 
treated with 
PE. Second 
recurrence is 
described here. 
During Ecu 
therapy TMA in 
peripheral blood 
after interval 
prolongation. 
CH50 below 
detection 
threshold. Serum 
creatinine 
after relapse 
230 µmol/L 68 
months after Tx.
295,353Davin et 
al.2010
Yes 17 Unknown CFH: 
p.Ser1191Leu
4 months 6 months 130 131 (PT 
dependent)
120; ± 49 No NA NA -
152Ardissino et 
al. 2010
No Unknown Unknown CFH 2 months 2 days Unknown 442 
(incomplete 
respons PT)
48; ± 27 No NA  NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
152,309Larrea et al. 
2010
No 22 DCD Negative 12 days 9 days 97 415 (PT 
resistant)
70; specific 
time after Tx 
unknown
Yes Yes (11) Yes Discontinuation 
after 1 dosage 
of ecu; after 2nd 
relapse Scr of 175 
µmol/L. After 4 
months Ecu was 
stopped because 
of infection; 
GL loss due to 
ABMR.
295,352Châtelet et 
al.2010
Yes >36 DD C3: 
p.Arg570Gln
4 years 5 weeks ± 160 320 (PT 
dependent)
Unknown No Yes, 2 x 
mild relapse 
while on 
eculizumab
NA First aHUS 
recurrence after 
current Tx was 
successfully 
treated with 
PE. Second 
recurrence is 
described here. 
During Ecu 
therapy TMA in 
peripheral blood 
after interval 
prolongation. 
CH50 below 
detection 
threshold. Serum 
creatinine 
after relapse 
230 µmol/L 68 
months after Tx.
295,353Davin et 
al.2010
Yes 17 Unknown CFH: 
p.Ser1191Leu
4 months 6 months 130 131 (PT 
dependent)
120; ± 49 No NA NA -
152Ardissino et 
al. 2010
No Unknown Unknown CFH 2 months 2 days Unknown 442 
(incomplete 
respons PT)
48; ± 27 No NA  NA -
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
152,311Legault et 
al. 2009
No 34 LRD Unknown 1 month ± 8 months 106 321 
(incomplete 
respons PT)
238; ± 15 No NA NA -
152,307Nürnberger 
et al.2009
Yes 37 DD CFH: 
p.Tyr475Ser
6 weeks 5 days ±107 132 (PT 
resistant) 
97; specific 
time after Tx 
unknown 
Yes Yes (21) No Discontinuation 
after 1 dosage 
of Ecu; second 
recurrence, not 
treated with 
eculizumab, led 
to graft loss 22 
months after Tx.
Supplementary table 9.2 Case reports and case series found in literature with the use of eculizumab in case of aHUS 
recurrence after kidney transplantation. In several case reports serum creatinine (or follow up time) is not described in 
text but depicted in a figure, the approximate values were used in this table and designated as ± . For the ten patients 
indicated in red a serum creatinine before the onset of aHUS and after the recurrence was available and these patients 
had started eculizumab therapy within 28 days after onset of aHUS. Three patients (indicated with *) were excluded 
as these patients had a poor renal function before the onset of aHUS due of infectious complications or a rejection. 
LRD; living related donor, LD; living donor, DD; deceased donor, DBD; donation after brain death, DCD; donation after 
cardiac death, LURD; living unrelated donor, ABMR; antibody mediated rejection, CFH; complement factor H, CFI; 
complement factor I, CFB;complement factor B, C3; complement factor 3, MCP; membrane cofactor protein, THBD; 
thrombomodulin, CFHR; complement factor H related protein, del; deletion, Tx ; kidney transplantation, 
MDRD ; modification of diet in renal disease, ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies, Ecu;ecu-
lizumab, NA; not applicable, Bx;kidney biopsy, TMA ; thrombotic microangiopathy, PE ; plasma exchange, GL ;graft 
loss, ATN ; acute tubular necrosis, GI ; gastro-intestinal, IVIG ; intravenous immunoglobulins, Scr; serum creatinine, 
HD ; hemodialysis, iCVA ; ischemic cerebrovasculair accident, FU ; follow-up. 
¹individual improvement in kidney function is depicted in a figure in article by Andrade et al. The mean serum creatinine 
for all 5 patients was 362 µmol/L ± 62 µmol/L at start of eculizumab and 168 µmol/L ± 53 µmol/L after 6 months of 
treatment with eculizumab. 
² Eculizumab was discontinued 170 days after the second recurrence. A third recurrence was suspected based on slow 
increase in serum creatinine and confirmed, almost a year after discontinuation, by kidney biopsy. No signs of peripheral 
blood TMA were seen. Eculizumab was restarted and improvement of kidney function was seen. 
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Supplementary Table 9.2 Continued 
Reference aHUS in 
previous 
transplant
Recipients 
age (yrs) 
at Tx
Donor 
source
Reported 
genetic 
variant
Time 
from Tx to 
recurrence
Time from 
recurrence 
to start of 
Ecu
SCr ( 
µmol/L) 
(MDRD) 
before 
aHUS
Scr 
(µmol/L) 
(MDRD) 
at start 
of ecu
Nadir Scr 
(µmol/L) after 
1st recurrence; 
follow-up 
(in months) 
after Tx
Disconti-
nuation 
of Ecu
Second 
recurrence 
(time in 
months 
after Tx)
Restart 
ecu
Remarks 
152,311Legault et 
al. 2009
No 34 LRD Unknown 1 month ± 8 months 106 321 
(incomplete 
respons PT)
238; ± 15 No NA NA -
152,307Nürnberger 
et al.2009
Yes 37 DD CFH: 
p.Tyr475Ser
6 weeks 5 days ±107 132 (PT 
resistant) 
97; specific 
time after Tx 
unknown 
Yes Yes (21) No Discontinuation 
after 1 dosage 
of Ecu; second 
recurrence, not 
treated with 
eculizumab, led 
to graft loss 22 
months after Tx.
Supplementary table 9.2 Case reports and case series found in literature with the use of eculizumab in case of aHUS 
recurrence after kidney transplantation. In several case reports serum creatinine (or follow up time) is not described in 
text but depicted in a figure, the approximate values were used in this table and designated as ± . For the ten patients 
indicated in red a serum creatinine before the onset of aHUS and after the recurrence was available and these patients 
had started eculizumab therapy within 28 days after onset of aHUS. Three patients (indicated with *) were excluded 
as these patients had a poor renal function before the onset of aHUS due of infectious complications or a rejection. 
LRD; living related donor, LD; living donor, DD; deceased donor, DBD; donation after brain death, DCD; donation after 
cardiac death, LURD; living unrelated donor, ABMR; antibody mediated rejection, CFH; complement factor H, CFI; 
complement factor I, CFB;complement factor B, C3; complement factor 3, MCP; membrane cofactor protein, THBD; 
thrombomodulin, CFHR; complement factor H related protein, del; deletion, Tx ; kidney transplantation, 
MDRD ; modification of diet in renal disease, ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies, Ecu;ecu-
lizumab, NA; not applicable, Bx;kidney biopsy, TMA ; thrombotic microangiopathy, PE ; plasma exchange, GL ;graft 
loss, ATN ; acute tubular necrosis, GI ; gastro-intestinal, IVIG ; intravenous immunoglobulins, Scr; serum creatinine, 
HD ; hemodialysis, iCVA ; ischemic cerebrovasculair accident, FU ; follow-up. 
¹individual improvement in kidney function is depicted in a figure in article by Andrade et al. The mean serum creatinine 
for all 5 patients was 362 µmol/L ± 62 µmol/L at start of eculizumab and 168 µmol/L ± 53 µmol/L after 6 months of 
treatment with eculizumab. 
² Eculizumab was discontinued 170 days after the second recurrence. A third recurrence was suspected based on slow 
increase in serum creatinine and confirmed, almost a year after discontinuation, by kidney biopsy. No signs of peripheral 
blood TMA were seen. Eculizumab was restarted and improvement of kidney function was seen. 
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Supplementary Table 9.3 Characteristics and outcome of rescue therapy according to genetics 
in aHUS renal transplantation patients
Mutation aHUS in 
previous 
transplant
Donor source 
(%)
Median Time 
from Tx to 
recurrence in 
days (range)
Start of 
Ecu ≤ 7 
days after 
recurrence
Time from 
recurrence 
to Ecu in 
days (range)
Nadir median 
Scr (µmol/L) 
after 1st recurrence 
² (range)
Discontin-
uation 
of Ecu
Second r
ecurrence 
after 
discontinuation
Graft loss 
(due to 
aHUS)
CFH mutation (including 3 patients 
with CFH/CFHR hybrid genes) 
(n=19)
265,295,299,300,302,305,307,317,318,342,346,347,349,350,353
9 (47%) 10 (53%) DD
4 (21%) LD
5 (26%) unknown 
42 (0-2190) 9 (47%) 5 (1-244) 110 (48-199) 4 (21%) 4 (100%) 3/19 (2) ³
Other mutation¹
(n=13)
265,294,295,299,308,312,313,322,323,328,341,344
6 (46%) 7 (54%) DD
3 (23%) LD
3 (23%) unknown
77 (9-1825) 3 (23%) 21 (0-120) 154 (80-486) 2 (15%) 1 (50%) 1/13 (0)
Negative 
(n=13)
186,299,300,309,310,315,320,324,343,348,351
2 (15%) 8 (62%) DD
5 (38%) LD
41 (2-1825) 4 (31%) 10 (2-279) 150 (53-185) 5 (42%) 3 (60%) 4/13 (0)
Unknown
(n=11) 
186,265,299,311,314,316,319,325,345
0 (0%) 3 (27%) DD
5 (45%) LD
3 (27%) unknown
7 (0-730) 5 (45%) 5 (1-244) 120 (63-328) 6 (50%) 3 (50%) 1/11 (1)
P- value⁴ P=0.075 P=0.313 P=0.016 P=0.889 P=0.628 P=0.156
Supplementary table 9.3 Characteristics and outcome of rescue therapy according to genetic mutation. The patients 
are divided into groups: CFH or CFH/CFHR hybrid gene, other mutation, no mutation or unknown mutational 
status. LD; living donor, DD; deceased donor, CFH; complement factor H, CFI; complement factor I, CFB;com-
plement factor B, C3; complement factor 3, MCP; membrane cofactor protein, THBD; thrombomodulin, CFHR; 
complement factor H related protein, del; deletion, Tx ; kidney transplantation, MDRD ; modification of diet in 
renal disease, ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies, Ecu;eculizumab, Scr; serum creatinine. 
¹Other mutation: 4 mutations in the gene coding for CFI, 2 mutations in the gene coding for MCP, 4 mutations in
the gene coding for C3, 2 CFHR1-3 deletions with anti-CFH antibodies, 1 mutation in the gene coding for THBD and 
4 patients with CFHR1-3 deletions without anti CFH antibodies. ² Excluding the patients who died (n=1), suffered 
from graft loss (n=9) and the patients without a reported nadir serum creatinine (n=11).³ Two patients lost their 
grafts due to aHUS. One patient had not responded to eculizumab treatment and the second patient discontinued 
eculizumab therapy after one dose, leading to a second recurrence, which was not treated with eculizumab. 265,307
⁴Statistical method: Kruskal-Wallis test
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Supplementary Table 9.3 Characteristics and outcome of rescue therapy according to genetics 
in aHUS renal transplantation patients
Mutation aHUS in 
previous 
transplant
Donor source 
(%)
Median Time 
from Tx to 
recurrence in 
days (range)
Start of 
Ecu ≤ 7 
days after 
recurrence
Time from 
recurrence 
to Ecu in 
days (range)
Nadir median 
Scr (µmol/L) 
after 1st recurrence 
² (range)
Discontin-
uation 
of Ecu
Second r
ecurrence 
after 
discontinuation
Graft loss 
(due to 
aHUS)
CFH mutation (including 3 patients 
with CFH/CFHR hybrid genes) 
(n=19)
265,295,299,300,302,305,307,317,318,342,346,347,349,350,353
9 (47%) 10 (53%) DD
4 (21%) LD
5 (26%) unknown 
42 (0-2190) 9 (47%) 5 (1-244) 110 (48-199) 4 (21%) 4 (100%) 3/19 (2) ³
Other mutation¹
(n=13)
265,294,295,299,308,312,313,322,323,328,341,344
6 (46%) 7 (54%) DD
3 (23%) LD
3 (23%) unknown
77 (9-1825) 3 (23%) 21 (0-120) 154 (80-486) 2 (15%) 1 (50%) 1/13 (0)
Negative 
(n=13)
186,299,300,309,310,315,320,324,343,348,351
2 (15%) 8 (62%) DD
5 (38%) LD
41 (2-1825) 4 (31%) 10 (2-279) 150 (53-185) 5 (42%) 3 (60%) 4/13 (0)
Unknown
(n=11) 
186,265,299,311,314,316,319,325,345
0 (0%) 3 (27%) DD
5 (45%) LD
3 (27%) unknown
7 (0-730) 5 (45%) 5 (1-244) 120 (63-328) 6 (50%) 3 (50%) 1/11 (1)
P- value⁴ P=0.075 P=0.313 P=0.016 P=0.889 P=0.628 P=0.156
Supplementary table 9.3 Characteristics and outcome of rescue therapy according to genetic mutation. The patients 
are divided into groups: CFH or CFH/CFHR hybrid gene, other mutation, no mutation or unknown mutational 
status. LD; living donor, DD; deceased donor, CFH; complement factor H, CFI; complement factor I, CFB;com-
plement factor B, C3; complement factor 3, MCP; membrane cofactor protein, THBD; thrombomodulin, CFHR; 
complement factor H related protein, del; deletion, Tx ; kidney transplantation, MDRD ; modification of diet in 
renal disease, ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies, Ecu;eculizumab, Scr; serum creatinine. 
¹Other mutation: 4 mutations in the gene coding for CFI, 2 mutations in the gene coding for MCP, 4 mutations in
the gene coding for C3, 2 CFHR1-3 deletions with anti-CFH antibodies, 1 mutation in the gene coding for THBD and 
4 patients with CFHR1-3 deletions without anti CFH antibodies. ² Excluding the patients who died (n=1), suffered 
from graft loss (n=9) and the patients without a reported nadir serum creatinine (n=11).³ Two patients lost their 
grafts due to aHUS. One patient had not responded to eculizumab treatment and the second patient discontinued 
eculizumab therapy after one dose, leading to a second recurrence, which was not treated with eculizumab. 265,307
⁴Statistical method: Kruskal-Wallis test
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Supplementary Table 9.4 Characteristics and outcome of prophylactic therapy according to 
genetics in aHUS renal transplantation patients
Mutation aHUS in 
previous 
transplant
Donor 
source (%)
Discontin-
uation 
of Ecu ²
Recurrence 
after 
discontin-
uation
Graft loss 
(due to 
aHUS)
CFH mutation (including 3 
patients with CFH/CFHR 
hybrid genes) 
(n=25)
295-303,326,327,329-332,335,337-340
4 (16%) 14 (56%) DD
11(44%) LD
2 (8%) 1 (50%) 2 (1)
Other mutation¹
(n=14)
192,279,295,299,302,321,332,333,336
2 (14%) 11(79%) DD
2 (14%) LD
1 (7%) 
unknown
1 (7%) 0 (0%) 0³
Negative 
(n=5)
186,279,300
3 (60%) 0 (0%) DD
5 (100%) LD
4 (80%) 1 (25%) 0 
Unknown
(n=9)
 265,302
0 (0%) 1(1%) DD
0 (0%) LD
8 (89%) 
unknown
1(11%) 0 (0%) 0
P- value⁴ P=0.000 P=0.000 P=0.000 P=0.761 P=1.000
Supplementary table 9.4 Characteristics and outcome of prophylactic therapy according to genetic mutation. The 
patients are divided into groups: CFH or CFH/CFHR hybrid gene, other mutation, no mutation or unknown muta-
tional status.
LD; living donor, DD; deceased donor, CFH; complement factor H, CFI; complement factor I, CFB;complement 
factor B, C3; complement factor 3, MCP; membrane cofactor protein, THBD; thrombomodulin, CFHR; complement 
factor H related protein, del; deletion, Tx ; kidney transplantation, MDRD ; modification of diet in renal disease, 
ABOi; ABO incompatible, anti CFH ab; anti CFH antibodies, Ecu;eculizumab, Scr; serum creatinine. 
¹Other mutation: 5 mutations in the gene coding for CFI, 1 mutation in the gene coding for CFB, 1 mutation in the 
gene coding for MCP, 3 mutations in the gene coding for C3, 3 patients with anti CFH antibodies, 1 mutation in 
the gene coding for THBD and 2 other mutations in the genes coding for CFHR.
² The amount of patients who discontinued eculizumab (not according to donor source). 
³ One patient died of a cerebrovascular incident, possibly an extrarenal manifestation of aHUS.333
⁴ Statistical method: Kruskal-Wallis test
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Supplementary Table 9.5 Kidney transplantation protocol to minimize endothelial injury 
in aHUS patients 
Treatment Dosage / targets
Living donor kidney
Basiliximab 20 mg day 1 and day 4
Tacrolimus Starting dose 0.03 mg/kg twice daily; target blood levels of 4-5 
µg/L first 30 days, thereafter 5-7 µg/L
Prednisone Starting dose 100 mg/day on days 1-3, thereafter 25 mg/
day and tapering to 0.1 mg/kg/day at 3 months after 
transplantation
Mycophenolate mofetil Starting dose 1000 mg twice daily; target area under the curve 
40-60 mg/mL/hour
Blood pressure Target <130/80 mmHg
Early introduction of ACE inhibitor 
Early introduction of statins 
Supplementary table 9.5 Transplantation protocol for adults aHUS patients aimed to minimize endothelial injury. 
This protocol was used previously by Duineveld et al. and Verhave et al.266,305Transplantation from a living related 
donor can be considered if the causative genetic factor is identified in the recipient and is absent in the donor. 233 After 
transplantation close monitoring is advised: daily for the first two week, twice weekly for the next two to four weeks 
and weekly thereafter until four months after transplantation, followed by gradual extension of the interval to every 
six weeks at 12 months and every three months after two years. Home blood pressure measurements are advised.
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Supplementary Table 9.6 Proposed guidance for the selection of restrictive treatment 
scenarios based on patient characteristics
Characteristics Points 
Age ≤ 6 5
6-12 years 1
> 12 years 0
Native kidney
First episode 0
Any relapse , never treated with eculizumab 0
First relapse >12 months after eculizumab withdrawal 1
First relapse >3- <12 months after eculizumab withdrawal 2
First relapse <3 months after eculizumab withdrawal 4
Multiple relapses after eculizumab withdrawal 3
Relapse while on eculizumab (with incomplete complement blockade) 4
Relapse while on eculizumab (with complete complement blockade) 14
Kidney transplantation
First episode of recurrence > 1-3 months after transplantation 2
First episode of recurrence < 1-3 months after transplantation 3
Second relapse > 12 months after eculizumab withdrawal 3
Second relapse < 12 months after eculizumab withdrawal 4
Relapse while on eculizumab (with incomplete complement blockade) 4
Relapse while on eculizumab (with complete complement blockade) 14
Having received prophylactic treatment because of anticipated high risk 8
Genetic analysis
No mutation 0
Mutation not in complement factor H 1
Mutation in complement factor H 2
Supplementary table 9.6 To assist in the selection of a certain scenariowe have tried to describe patient characteris-
tics and attribute a score; points can be added for age, aHUS in a native kidney or allograft and for the presence of 
a genetic mutation. The total score (sum of points)provides guidance forthe selection of a scenario, however based 
on additional clinical characteristics and/or physicians or patients preference a different choice can be made. A 
total score of 1 points corresponds with scenario 1, a total score of 2 points corresponds with scenario 2, a total score 
of 3 points corresponds with scenario 3, a total score of 4 points corresponds with scenario 4, a total score of 5-13 
points corresponds to scenario 5 and a score >13 points corresponds with scenario 6. 
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Abstract
Introduction
With the introduction of eculizumab, a new era began for patients with atypical hemo-
lytic uremic syndrome (aHUS); a rare but severe form of thrombotic microangiopathy 
(TMA). Although eculizumab proved very effective, a worldwide debate started regarding 
optimal treatment strategy. Lifelong treatment with a standard dose (1200mg in adults) 
biweekly was advised, despite any evidence. However, treatment is not without risks. 
Moreover, high trough levels were measured in many patients, suggestive that we may 
need less drug for effective treatment in most patients. Finally, eculizumab is considered 
one of world’s most expensive drugs, leading to both political and ethical discussions 
regarding reimbursement and affordability of gained life years in patients with aHUS. 
In the Netherlands, this led to the development of a new Dutch guideline, drafted by 
the National Working Group aHUS, which proposes a restrictive eculizumab regimen. 
When patients are stable and in remission, eculizumab therapy is tapered or withdrawn 
after three months. In a nationwide, observational prospective study, called CUREiHUS, 
treatment with eculizumab will be monitored and evaluated after four years.
Methods and analysis
In this national prospective, observational, cohort study, all pediatric and adult patients 
suspected of or previously diagnosed with aHUS ,who start treatment with eculizumab 
between 2016 and 2020 will be asked for informed consent. Participating centers are 
instructed to use the national guideline. At hospital visits, two blood tubes will be 
collected to study complement activation, biomarkers and eculizumab serum levels. 
Furthermore, every three months all patients will receive two questionnaires to assess 
quality of life and productivity losses to perform a cost-effectiveness analysis. Separate 
informed consent is requested for two add-on studies, one regarding pharmacokinetics 
and pharmacodynamics of eculizumab and the other on patient experience and satisfac-
tion with expensive drugs like eculizumab.
Ethics and dissemination
This study will be conducted according the principles of the declaration of Helsinki and 
in accordance with the Medical Research Involving Human Subjects Act. Medical ethical 
approval was obtained. After completion of the study the results will be submitted for 
publication in international peer-reviewed scientific journals. Registered in the Dutch 
Trial Registry with number NTR5988.
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Introduction
Atypical hemolytic uremic syndrome (aHUS) is a rare, but severe form of thrombotic micro-
angiopathy (TMA), that is characterized by the triad hemolytic anemia, thrombocytopenia, 
and acute renal failure. It is considered the consequence of dysregulation of the alternative 
pathway of the complement system.5 Mutations in genes encoding complement (regulat-
ing) proteins can result in dysregulation of the complement system, eventually leading 
to TMA.1,57 Atypical HUS has an estimated prevalence 1-2/1,000,000 cases per year in the 
Netherlands. The disease affects patients at all ages and is characterized by its recurrent 
character.1,57 Until 2011, plasma therapy (PT) was the cornerstone of treatment in aHUS, 
yet with limited success. In the pre-eculizumab era aHUS was associated with poor out-
come with mortality in 5-15% and development of end stage renal disease in 30-50% of the 
patients at 3-5 year follow up.1,53,54,58 Moreover, the risk of recurrence in kidney transplant 
recipients was estimated as high as 80%, resulting in poor graft survival.58,267
With the introduction of eculizumab, the field of complement therapeutics experi-
enced a watershed moment.8,9,281,354 Eculizumab is a chimeric monoclonal antibody directed 
against complement component C5. It inhibits the cleavage of C5 into C5a and C5b, 
subsequently blocking formation of the terminal complement complex (TCC). Since 2011, 
eculizumab forms the cornerstone of treatment in aHUS and has improved morbidity and 
mortality significantly. Treatment consists of and induction phase of weekly infusions 
(up to four weeks) followed by a maintenance phase of eculizumab infusions every 14-21 
days depending on the body weight of the patient, potentially lifelong.8 Although eculi-
zumab improves the health-related quality of life, the burden of this lifelong treatment 
is tremendous. Moreover, eculizumab is considered one of world’s most expensive drugs 
with costs as high as €500,000 per patient per year. The high costs of such orphan drugs 
have stimulated political and ethical discussions regarding costs of healthcare.354
Therefore, the introduction of eculizumab as lifelong treatment for aHUS patients 
sparked a debate. Roughly, there are four important arguments to take into account. His-
torically, PT could be tapered and stopped in a significant proportion of patients, therefore 
questioning the need for lifelong duration of therapy. Since the introduction in 2011, 
numerous and often confliction opinions have been postulated concerning the proposed 
treatment scheme.43,58,162,165,182,192,258,265 Secondly, recent studies and our own data indicate that 
we may sometimes exceed the recommended trough levels by a tenfold with the current 
treatment schedules. This offers hope that we may need less drug for effective treatment 
in most patients.158,182 Thirdly, treatment is not without risks, with as most prominent risk 
factor the susceptibility of infections and especially meningococcal disease.155 Lastly, since 
eculizumab is a highly expensive drug, the costs of lifelong treatment quickly exceed 
the willingness to pay thresholds per quality adjusted life year (QALY) thus impeding 
reimbursement policies and hereby patient benefit in the Netherlands.
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To guarantee healthcare access for everyone in the Netherlands, specific arrange-
ments were implemented. The aim was to promote efficient and purposeful usage of 
orphan drugs, to optimize (costs)effectiveness of orphan drugs like eculizumab. Three 
criteria have to be met before a drug can be (re)imbursed. The first criteria is the presence 
of an indication committee which has to give advice to physicians regarding start and 
withdrawal of treatment. Secondly, clear start and stop criteria have to be defined. Finally, 
patients have to be monitored in a registry to evaluate efficacy of the drug and to perform 
a costs effectiveness analysis.60
In the Netherlands this led to the development of a new Dutch guideline, drafted by 
the National aHUS Working Group, which proposes restrictive eculizumab regimen.4 The 
national aHUS working group consists of one nephrologists and one pediatric nephrol-
ogists of each university center in the Netherlands and meet every three months to 
discuss all the patients. Patients are divided into different groups and will either receive 
PT or eculizumab depending on age and their risk profile. After three months therapy 
is accessed and in case patients are stable and shows no signs of active TMA, therapy 
is withdrawn (Figure 10.1). Only recently, the Ministry of Health, Wellfare and Sport of 
the Netherlands declined reimbursement of eculizumab as lifelong therapy. This deci-
sion derived mainly from the lack of clear insight in costs effectiveness as provided by 
the pharmaceutical company. Still, the introduction of the guideline offered hope for 
restrictive and costs-effective therapy. Therefore, the ministry allowed reimbursement 
of eculizumab, when treatment is started after approval by the committee, treatment is 
done according to the guideline, and patient data are monitored, with a planned evalu-
ation after four years.
In the nationwide prospective study, called CUREiHUS, all pediatric and adult 
patients with aHUS treated with eculizumab between 2016 and 2020 will be included. 
This registry is independent of the pharmaceutical company as also suggested by Karp-
man et al.354 In this prospective, observational, cohort study we will monitor eculizumab 
treatment of patients with aHUS in the Netherlands strictly adhere to the guideline and 
investigate the efficiency. Furthermore, we will perform a cost-effectiveness analysis. 
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Method and analysis
Trial design and setting
CUREiHUS is a national prospective, observational, cohort study. All pediatric and adult 
patients with a (suspected) diagnosis of aHUS and who are receiving treatment with 
eculizumab, in any of the eight Dutch academic centers, between 2016 and 2020 will be 
asked for informed consent to participate in this study. The study is coordinated by the 
research team instituted in the Radboud university medical center (Radboudumc).
Clinical evaluation at the start and during treatment of the patients will be per-
formed by the local nephrologist or pediatric nephrologist, who participates in the 
national working group aHUS. The working group forms a platform for medical discus-
sions and evaluation of individual cases concerning diagnosis and treatment of patients 
with TMA and suspected aHUS. 
 All patients with TMA and suspected aHUS, considered for eculizumab therapy 
are presented in the working group. Approval for start of therapy can be obtained within 
24 hours after discussion by four representatives. Figure 10.1 illustrates the treatment 
algorithm. In adults without a disease history of TMA, initial treatment consists of PT for 
a period of five days to allow proper diagnostics to exude secondary TMA. Eculizumab is 
started immediately in children, patients with a disease recurrence and in kidney trans-
plant recipients. Eculizumab is given at the standard dose, as advised by the EMA and 
FDA for a period of three months. After three months treatment is stopped or continued 
at reduced doses, depending among others on age, previous disease history, underlying 
complement abnormality and kidney function. Of note, patients with TMA who do not 
receive eculizumab are not represented in the CUREiHUS study.
Eligibility criteria
A subject has to fulfill all of the following inclusion criteria without presence of any exclu-
sion criteria before entering the CUREiHUS study. In order to be eligible to participate in 
this study, a subject must meet all of the following criteria: 
· Patients of all ages, suspected of or diagnosed with aHUS, who are treated with 
eculizumab.
· Furthermore, subject and/or parents is/are able and willing to sign the informed 
consent before screening evaluations. 
A potential subject who meets any of the following criteria will be excluded from par-
ticipation in this study: 
· Patients with other etiological forms of TMA than aHUS. 
· Subject and/or his parents is/are not able or willing to sign the informed consent 
before screening evaluations. 
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If a patient does not want to enter the CUREiHUS study, this patient will still receive 
the restrictive treatment with eculizumab. Furthermore, separate informed consent is 
gathered for two add-on studies, however patients can still participate in the CUREiHUS 
study without informed consent for these two add-on studies.
Figure 10.1 Treatment algorithm following the new Dutch Guideline
Prevalent patient with aHUS 
Previous episode: 
Spontaneous 
remission or  
PT sensitive 
 
PT dependent, 
PT resistant or 
previous need 
for eculizumab 
Evaluation after 3 months 
In case the patient is in remission (normalized hematological parameters, normalized and/or stabilized kidney function and proteinuria, normal blood) 
consider discontinuation or tapering of eculizumab 
Patient with aHUS  
in native kidney 
Patient with aHUS  
in kidney transplant 
Incident patient with aHUS 
Plasmatherapy 
High volume daily plasma therapy  
1.5x plasma volume; 60-75 ml/kg  
Start within 24-48 hours 
Plasmatherapy sensitive 
Evaluation of plasmatherapy after 4 days 
Plasmatherapy resistant 
Plasmatherapy dependent 
Taper plasmatherapyb 
In anticipation of diagnostics to rule out other causes of TMA 
Children Adultsa 
Eculizumab treatment  
Following standard treatment scheme 
Figure 10.1 In 2016 a new Dutch guideline was implemented promoting a restrictive eculizumab regimen in patients 
with aHUS. Patients who present with first episode of TMA (incident patient) will receive plasmatherapy (PT) as 
first line treatment for four days to rule out other causes of TMA (e.g. STEC-HUS, TTP, secondary causes of TMA). 
In case no other cause of TMA is found and the patient does not respond to PT or is PT dependent, eculizumab 
treatment is started. In children with a strong suspicion of aHUS, eculizumab is the first choice of treatment. In 
patients who present with disease recurrence (prevalent patients) in native kidneys PT or eculizumab could be 
started depending on medical history. In patients with aHUS recurrence after kidney transplantation eculizumab 
should be started directly to preserve graft function. After three months, when the patient is stable and in remission, 
therapy is evaluated and when possible therapy is tapered or discontinued. Strict monitoring is essential to prevent 
chronic sequelae and for early detection of disease recurrence.
a Adolescents may be considered adults and treated accordingly.
b Taper PT 5x per week first two weeks, than, 3x per week for two weeks.
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Study objectives
The primary study objective of the CUREiHUS study is to monitor and evaluate restric-
tive use of eculizumab in patients with aHUS according the new national guideline. An 
overview of the primary and secondary objectives is given in Figure 10.2.
National aHUS registry
Data from all aHUS patients treated with eculizumab will be gathered to evaluate out-
come. Clinical information such as the first presentation, duration of illness, pathology 
reports, complement analysis and pathogenic mutations, family history, and treatment 
received in the past will be collected. The considerations and argumentations of the 
working group for start and/or stop treatment will be carefully described as well as lab-
oratory values at time of presentation and during follow up. All data will be gathered in 
the online webbased database Castor. In addition to regular care, patients will be asked 
for additional collection of one serum tube (minimum of 1ml) and one EDTA plasma tube 
(minimum of 1ml) at every hospital visits for additional analysis. Samples are collected 
at time of venipuncture/intravenous access as part of standard care, so patients do not 
need extra invasive procedures. Directly after blood collection, the tubes will be placed 
on ice to prevent complement activation. Blood samples will be processed within 30-60 
minutes within the university hospital where patient is treated. Plasma and serum 
aliquots will be stored on -80°C immediately after centrifugation (2000g, 10 min at 
4 ºC). Strict adherence to the protocol for sample collection is critical to prevent in 
vitro complement activation. All samples will be send to the department of Laboratory 
Medicine of the Radboudumc, where specialized assays will be performed. For a detailed 
overview of time points to collect blood see Figure 10.3.
Cost-effectiveness analysis
To perform a costs-effectiveness and budget impact analysis two questionnaires will be 
sent to all participants via email and automatically linked to the online Castor database. 
The first is to measure the quality of the health status of the patients, with a validated 
so-called health-related quality of life (HRQoL) instrument, the EQ-5D. This HRQoL 
instrument is available in a validated Dutch translation and will be completed by the 
patients. The EQ-5D is a generic HRQoL instrument comprising five domains: mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D index is 
obtained by applying predetermined weights to the five domains. This index gives a soci-
etal-based global quantification of the patient’s health status on a scale that is (upper)
anchored at 1 (perfect health). Patients will also be asked to rate their overall HRQoL on 
a visual analogue scale (EQ- 5D VAS) consisting of a vertical line ranging from 0 (worst 
imaginable health status) to 100 (best imaginable). For children between eight and 11 
years of age the EQ-5D-youth will be used. Since the EQ-5D-youth is only available in 3 
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level (three answer options per question), we will use the EQ-5D-3L for children above 
12 age and adults as well to generate as much as possible uniform data. After the start of 
inclusion patients will receive the EQ-5D-3L questionnaire every four weeks, for a period 
of three months, after which the patient will be asked to complete the questionnaire every 
three months. In case the patient experiences disease recurrence or in case of another 
serious adverse event the of the EQ-5D-3L will be sent every four weeks for three months 
again to fully document the effect on quality of life during these periods (Figure 10.3).
To measure health-care related productivity losses, we will use the Medical Tech-
nology Assessment Productivity Costs Questionnaire (iPCQ) questionnaire. All patients 
≥ 18 years of age will receive the iPCQ and all parents of patients below 18 years of age 
will receive the iPCQ adapted to measure productively losses in families of patients with 
aHUS. Patients will receive the iPCQ questionnaire at start of inclusion and then every 
three months until the end of the study.
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Add-on studies:
Pharmacokinetics and pharmacodynamics of eculizumab
All participants will be asked separate informed consent to participate in add-on study 
one. To develop a protocol for therapeutic drug monitoring (TDM) in patients with eculi-
zumab, a thorough understanding of pharmacokinetics (PK) and pharmacodynamics (PD) 
is required. In this study we want to investigate the PK in an actual clinical setting, under 
the tailored regimens and link this to complement inhibition, or PD in aHUS patients 
treated with eculizumab.
In consenting patients, additional blood samples are collected between two ecu-
lizumab administrations, during the maintenance phase (Figure 10.3). For this study, 
a patient will visit the hospital on four additional days for collection of blood. With 
the use of the program POPED which uses D-optimal approach, the optimal sampling 
design is determined, hereby maximizing the PK information gathered in this patient 
group.355 PK of eculizumab depends on the clearance (CL) and volume of distribution 
(Vd).240 The best moments to sample according our optimal sampling design, were 
respectively, 6, 16, 72, 100, 364 and 464 hours after eculizumab administration, to 
determine CL with 3% coefficient of variance (CV) and Vd with 4% CV. Taking into 
account the patient effort and the most convenient time schedule, we choose to 
spread the moments of sampling over two separate study periods between eculizumab 
infusions. Secondly, not all patients will receive eculizumab with a set interval of two 
weeks. Therefore, next to the optimal sampling design, we will determine the Ctrough 
level, regardless of the dosing interval, instead of the time point set at 100 hours 
after administration, in all patients. Although, CV concerning the estimated CL and 
Vd shall increase when using these time points in patients in whom the interval 
between infusions exceeds 14 days, it will remain below 10%. The chosen time points 
to collect samples in study period one are: 2-4 hours after administration depending 
at the moment the patient will receive eculizumab, one day after infusion, three days 
after infusion and just prior to the new infusion. In study period two, samples will be 
collected one and five days after infusions.
Patient related outcome measures
All participants, aged ≥ 15 years, will be asked separate informed consent to participate 
in add-on study two: Patient Experiences and Satisfaction with Medications (PESaM-) 
questionnaire. In 2015, after literature review, focus group interviews, expert opinion, and 
face validity tests, a patient-reported outcome measure (PROM) was developed to gain 
insight into patient experiences and satisfaction with medications. The PROM consists of 
a generic module (for any medication) and a disease- specific module, specifically focused 
on experiences and satisfaction with eculizumab. In the PROM there are multiple items 
in the following domains: effectiveness, side-effects, ease of use, and overall satisfaction 
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(only for the generic module). Participants will receive the PESaM-questionnaire at four 
weeks after the first eculizumab gift; and every three months hereafter, either up to 
three months after the last eculizumab gift or when the maximum of five measurements 
are reached. In addition, participants in whom eculizumab is started or resumed will 
receive the expectation measure at baseline (week 0). If eculizumab is resumed (e.g. due 
to recurrence of disease) the participant will receive the questionnaire again following 
the scheme indicated above.
Assays
Eculizumab levels together with measurement of classical pathway activation (CH50) will 
be determined as described previously by Volokhina et al.182 By quantifying the amount 
of the complement activation in our patients, we will be able to correlate serum concen-
trations of eculizumab to optimal inhibition of complement activity and subsequent 
optimal therapy. In addition to CH50, other measurements of complement will be evalu-
ated. Methods to detect C3b/c, C3bBbP, and TCC have been developed previously and are 
available at the department of Laboratory Medicine, as is C3d assay.158 Alternative pathway 
(AP) activity and C5 levels assays are commercially available (from Eurodiagnostica and 
Abcam, respectively). C3 and C4 concentration will be determined by nephelometry (BN™ 
II System of Siemens Healthcare Diagnostics).
Sample size
No official sample size calculation was performed since the CUREiHUS study is an obser-
vational study and it is intended to include all aHUS patients treated with eculizumab in 
the Netherlands. With an estimated incidence of 3 pediatric and 10 adult aHUS patients 
per year in Netherlands it is expected to enroll 52 patients until 2020. 
Data analysis
For this descriptive study, clinical information such as the therapy followed, reported 
side effects, correlation between relapse and genetic profile are presented as qualita-
tive data. Laboratory values are presented as quantative data. For continuous variables 
within normal distribution, values are expressed using the mean and standard deviation 
(SD), otherwise median and interquartile range 25-75 (IQR) is used. After four years of 
monitoring the guideline, the evaluation will take place. Differences will be measured 
using two sided t-test or mann-whitney test for non-parametric data as appropriate. For 
multiple analysis ANOVA with posthoc analysis or Kruskall Wallis followed by wilcoxon 
and bonferroni correction to control the alfa will be used.
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Cost-effectiveness analysis
This study investigates the potential efficacy of a new safe and effective treatment regime 
of eculizumab in patients with aHUS from a societal perspective. The comparator is 
treatment as prescribed by the pharmaceutical company. The time frame of evaluation for 
the cost-effectiveness analyses (CEA) exceeds the follow-up of the cohort as it evaluates 
lifelong provision of eculizumab. Therefore, the CEA will follow an empirical approach 
as far as it concerns the cohort follow-up and a decision analytical approach to evaluate 
cost-effectiveness beyond the cohort follow-up period of four years. The design of the 
economic evaluation follows the principles of a cost-effectiveness analysis and adheres 
to the Dutch manual for costing research.356 
Outcome measures specific for the CEA will be QALYs based on EQ-5D-3L. The direct 
(medical) costs of both eculizumab treatment regimens will be determined on a per 
patient basis. Further, on patient level, volumes of care will be measured prospectively 
using medical records and provider information systems. Resource utilization, such as 
medical specialist visits, general physician visits, medication, dialysis, and hospital admis-
sions, as well as out-of-pocket expenses such as for over-the-counter drugs and travel 
costs will be collected. For units of care/resources where no guideline or standard prices 
are available, real prices will be determined. The effect of uncertainty in model parame-
ters will be estimated through scenario analyses and a probabilistic sensitivity analysis 
Cost-effectiveness acceptability curves will be derived that are able to evaluate the proba-
bility that the new treatment regime is efficient against different thresholds (Willingness 
To Pay) for a QALY gained in different scenarios.
Productivity losses will be measured using the friction cost approach described in 
the Dutch manual for costing research.356 All this input will be used in a decision analytic 
model with a lifelong horizon taking into account discounting. The discount rate follows 
the Dutch guidelines for pharmaco-economic evaluation. 
Budget impact analysis
The budget impact analysis (BIA) will be conducted as outlined in Mauskopf et al.357 The 
aim of this BIA is to assess the financial consequences of the introduction of the gender 
sensitive risk classification approach in the Dutch health care system in the short-to-
medium term from the budget holders perspective. Also a more broad perspective i.e., the 
societal scenario (for example including productivity gains/losses) will be determined. 
It is obvious that if the new guideline is successful, the bulk of the budgetary savings 
comes from reduced eculizumab use. For the base case BIA perspective, within the health 
care domain, only costs associated with this perspective will be taken into account. Most 
of these cost are collected in the CEA. Deterministic uncertainty concerning BIA input 
such as perspective, pricing parameters, time horizon, uptake, etc. will be dealt with by 
generating the budget impact as a series of scenario analyses covering a relevant range 
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of costs. Both annual resource use (in terms of volumes consumed) and cost (volumes 
multiplied by prices) will be presented. The BIA will be assessed through more or less the 
same decision analytic model as the CEA.
Pharmacokinetic and pharmacodynamic properties
Individual and median plasma concentrations will be presented. Overlay presentations 
will be given to illustrate inter-subject variability. Descriptive statistics will be calculated 
for the plasma concentrations at each sampling time. The primary outcome measurement 
will be AUC0-tau values of eculizumab. PK parameters will be derived using a compart-
mental analysis with Phoenix version 7.0 (Pharsight Inc). Peak plasma concentrations 
(Cmax) will be directly observed from the data.
Patient reported outcome measure
The psychometric properties of the PESaM-questionnaire will be explored, including 
its construct validity and reliability. Existing standards and guidelines for evaluating 
reliability and validity of PROMs will be used.358,359 In addition to testing psychometric 
properties, initial descriptive outcomes will be produced for the items and domains of 
the generic and disease-specific module.
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Ethics and dissemination
Ethics approval
Ethical approval was obtained in the Netherlands from the medical ethical committee of 
Arnhem-Nijmegen at 15th of June 2016. The registration number of the CUREiHUS study 
is NL52817.091.15. This study will be conducted according the principles of the declaration 
of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and in accor-
dance with the Medical Research Involving Human Subjects Act (WMO). Any substantial 
amendments and modifications will first be presented at the medical ethical committee 
before implemented in the CUREiHUS study protocol.
Consent
Patients will be approached for participation in this study by their physicians, mostly the 
head investigator at the site and member of the national working group aHUS. From all 
patients and/or their parents or legal representatives depending on age of the patient, 
informed consent will be obtained prior to the inclusion in the study. Patients have to give 
separate consent for all add-on studies. Patients and/or parents will receive an information 
letter and informed consent form. For the two add-on studies separate informed consent is 
obtained. Resistance of children to study procedures will be handled following the ‘code of 
conduct involving minors’ as established by the Pediatric Association of the Netherlands. 
Subjects can leave the study at any time for any reason if they wish to do so without any 
consequences. After withdrawal, subjects will continue treatment as prescribed by the 
physician. Data gathered up to point of withdrawal can be used for further analysis.
Confidentiality
All patients receive an unique encoded study ID as composed in Castor. The study ID is 
composed of the country and hospital where the patient presented, followed by a number, 
based on the order of inclusion, for example NL-Rad-001. The blood that will be collected 
after inclusion will be labeled with this study ID numbers together with time and date 
of acquisition. The investigators per academic centre safeguard the key of the study IDs 
assigned to the participants of that centre.
The hosting of Castor, the online database, is by ISO:27001 and NEN7510, certified 
datacenters. The system of the database enables an audit trail after each modification and 
login events. Login actions can only be with a personal (role and center specific) authori-
zation with qualified passwords. Castor has a monitor function whereby data controls will 
be executed. The members of the national working group aHUS from the Radboudumc 
are responsible for this database. The investigator (together with their database manager) 
of each centre will enter the data in this online database. The handling of personal data 
is in accordance with the Dutch Personal Data Protection Act. 
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Data will be stored until fifteen years after publication. After the study is finished 
and scientifically published, subject material from the study will only be stored and pos-
sibly used for future studies when subjects agree with this, as included in the informed 
consent. Without agreement of the medical ethical committee, materials will not be used 
for future studies that will not have a direct relation to the current study and not for 
studies that involve the chance of finding additional outcomes. If subjects do not give 
permission to use their material for future studies, the material will be discarded after 
this study has been finished and scientifically published.
Safety
Based on the checklist risk classification of the Dutch Federation of University Medical 
Center (NFU) workgroup, there is no risk for participants of this study. For this obser-
vational study, the national working group aHUS will form the safety committee. The 
working group gathers every three month to discuss all patients with aHUS who receive 
eculizumab and the possibility of therapy adjustment and/or discontinuation. It forms 
a platform for medical discussions and evaluation of individual cases concerning the 
diagnosis, advising and interpretations diagnostic tests.
For this observational study, (serious) adverse events ((S)AEs), serious adverse 
reactions (SAR) and Suspected Unexpected Serious Adverse Reaction (SUSARs) as a 
consequence of our study are not applicable. However, information about side-effects 
or adverse reactions which occur at therapy adjustment/discontinuation of eculizumab 
during this observational study will be collected in the database.
Dissemination policy
Trial is registered with the Dutch Trial Registry NTR5988. After completion of this study 
the results will be published in (inter)national peer-reviewed scientific journals. A final 
report will be distributed to all stakeholders and the article and summary of results will 
be published on the website of the CUREiHUS study for all participants.
Trial status
The study started recruitment in August 2016 and is currently still recruiting.
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“Now this is not the end. It is not even the beginning of the end. 
But it is, perhaps, the end of the beginning.” 
Winston Churchill
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Summary and general discussion
A new era has commenced for patients with a thrombotic microangiopathy (TMA). 
TMA is an umbrella term and characterized by hemolytic anemia, thrombocytopenia 
and ischemia of end organs. It can be a manifestation of a wide variety of diseases, often 
associated with significant mortality and morbidity. Both primary and secondary causes 
of TMA have been described (Figure 11.1). The introduction of eculizumab, the first 
drug to inhibit the complement system, not only provoked a renewed interest in com-
plement involvement, but also increased the need to properly diagnose the underlying 
cause of TMA. The recent discovery of mutations in complement regulatory genes in 
presumed secondary causes of TMA, demonstrated that primary and secondary forms 
of TMA do overlap (Figure 11.1).360,361 An accurate diagnosis to start the appropriate 
treatment is essential.
The scope of this thesis comprised two causes of TMA: Shiga toxin producing Esch-
erichia coli (STEC) hemolytic uremic syndrome (HUS) and atypical HUS (aHUS). Over 
the last decade, increasing awareness for aHUS, has been raised by defining the role of 
complement dysregulation as the primary cause in aHUS.5,57 By unraveling the pathophys-
iology, eculizumab became the first choice of treatment in patients with aHUS.8 Thus 
far there is no proof that eculizumab is also effective in STEC-HUS, leading to divergent 
treatment strategies. Consequently, optimizing treatment requires accurate differentia-
tion between STEC-HUS and aHUS. This may be difficult, since the clinical presentation 
shows a high degree of resemblance. Moreover, since aHUS is a diagnosis per exclusionem 
establishing STEC infections with high accuracy is indispensible. 
Eculizumab as standard therapy for aHUS aroused a worldwide debate regarding 
the optimal treatment scheme and duration. Initial guidelines suggested lifelong treat-
ment with a fixed dose for all patients. However, there is no evidence to support such 
strategy. Reducing the cumulative eculizumab dose is important, not the least in view 
of the enormous costs of this expensive orphan drug. In part I of this thesis we focused 
on STEC-HUS, aiming at determining new possible mediators of TMA and improving 
the diagnostics of STEC-HUS. In part II we focused on strategies to reduce eculizumab 
dosage, and implement individualized treatment strategies for patients with aHUS. 
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Part I: New aspects of pathophysiology 
and diagnosis in STEC-HUS
Diagnosis 
The current gold standard to detect STEC infection involves fecal examination by detec-
tion of Stx encoding genes by polymerase chain reaction (PCR) and subsequent feces 
culture in case PCR is positive.20,22,79,362 Of note, some laboratories use enzyme immunoassay 
(EIA) to detect Stx in the feces. However, since only a low inoculum is needed to cause 
disease, the detection of Stx can be difficult. Therefore it is strongly recommended to 
perform EIA only on enriched broth cultures.19 Historically, feces culture was the gold 
standard to establish STEC infection and this was mainly based on the fact that the 
most common STEC serotype O157 could not ferment sorbitol, leading to colorless col-
onies on the Sorbitol MacConkey agar (SMAC) plate. Although STEC serotype O157 is 
still the predominant cause of HUS, non-O157 serotypes are increasingly associated with 
STEC-HUS.30 Moreover, many non-O157 and even some O157 STEC strains are capably of 
fermenting sorbitol, making SMAC culture unreliable. Nowadays, only ˜40% of the feces 
samples which tested positive with PCR, can be cultivated on SMAC plates.20 Hence, the 
detection of STEC in the feces is limited. Due to the natural course of the disease and low 
inoculums, the detection of STEC in the feces becomes increasingly difficult as the disease 
progresses. New and upcoming techniques such as molecular virulence and serotyping 
assays seem promising, however all rely on culture of the pathogenic strains.20 Currently, 
solely use of fecal diagnostics is not yet sufficient to establish an STEC infection.20 
In CHAPTER 2 and CHAPTER 3 we described the additional value of serology to 
detect antibodies against STEC O157. In CHAPTER 2 we evaluated the role of a serolog-
ical antibody assay to detect IgM antibodies against lipopolysaccharide (LPS) of STEC 
serotype O157 in addition to fecal diagnostics in a cohort of pediatric patients with STEC-
HUS. In patients with suspected STEC-HUS, fecal diagnostics was positive in 54% of the 
patients. The LPS enzyme-linked immunosorbent assay (ELISA; LPS-ELISA), allowed 
establishing a diagnosis of STEC-HUS in 63% of the patients. This is an added value of 23% 
when serological antibody assay is used in addition to standard fecal diagnostics tests to 
confirm the diagnosis STEC-HUS. The added value of serology became especially apparent 
when the tests was performed more than seven days after the initial manifestation of 
the gastrointestinal symptoms.
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Figure 11.1 Thrombotic microangiopathy (TMA) has a broad differential diagnosis which can be divided into dif-
ferent subgroups. Primary and secondary causes of TMA are described and can be further divided into primary 
hereditary and primary acquired TMA and secondary TMA due to infection or with other coexisting diseases. Yet, 
the field of TMA keeps evolving and in an increasing amount of cases the subdivision appears to be ambiguous. In 
presumed secondary causes (e.g. malignant hypertension or pregnancy-HUS) pathogenic mutations in complement 
regulatory genes have been found. In the end leading to genetic predisposition to develop TMA concordant with 
atypical HUS. Adapted from Brocklebank et al.361 (Clin J Am Soc Neph 2018;13:300-317) Copyright the American 
Society of Nephrology
aHUS; Atypical hemolytic uremic syndrome, cblC; cobolamine C, CFH; complement factor H, DGKε; diacylglycerol 
kinase e, HUS; hemolytic uremic syndrome, STEC; Shiga toxin producing E. coli, TMA; Thrombotic microangiop-
athy, TTP; Thrombotic thrombocytopenic purpura, 
a TMA is described both after bone marrow transplant or solid organ transplant. Especially de novo onset of TMA 
after solid transplant is related to genetic predisposition for TMA such as aHUS.
b Various autoimmune diseases have been described in association with TMA such as systemic lupus erythematosus, 
antiphospholipid syndrome and scleroderma.
c Various drugs have been reported to induce TMA; e.g. calcineurin inhibitors, quinine, gemcitabine, oral contra-
ceptives, heroin, cocaine
d A broad range of infectious agents have been described to cause TMA; e.g. Influenza H1/N1, Haemophilus influ-
enzae, Coxsackie B virus, Epstein-Barr virus, Hepatitis A or C, Bordetella pertussis.
Although LPS-ELISA cleary improved the diagnosis of STEC-HUS, this conven-
tional LPS-ELISA (in which ELISA plates are coated with purified LPS) has various 
drawbacks. The most important limitation is the presence of cross-reactivity with the 
conserved lipid A part of the LPS molecule.29,31,81 The LPS structure consists of a lipid 
A part, an outer and inner core and an O-antigen, of which the latter has the highest 
immunogenic activity. Since the lipid A part is also present in other strains of STEC 
and even other gram-negative bacteria, this could lead to cross-reactivity. Potentially 
causing false positive results (in case of cross-reactivity with other bacteria than STEC) 
or incorrect determination of the STEC serotype causing HUS.29,82,83 In CHAPTER 3 we 
described a new ELISA technique (glyco-iELISA) to tackle the aforementioned issues. 
Via bacterial glyco-engineering, glycoproteins with engineered O-polysaccharides could 
be produced. In the glyco-iELISA recombinant serotype specific glycoproteins are used, 
consisting of the O157 polysaccharide attached to the protein carrier acceptor AcrA 
(O157-Acr). Due to the absence of the lipid A structure, potential cross-reactivity is 
counteracted.81 We tested the added value of this new glyco-iELISA in two cohorts. The 
first cohort comprised pediatric patients with clinical suspected STEC-HUS (largely 
the same cohort as described in chapter 2). Of these patients 43% had a positive fecal 
diagnosis for STEC, 65% had positive serology based on the LPS-ELISA against O157, 
and 78% had positive serology based on the glyco-iELISA. Overall, the glyco-iELISA 
yielded 10 additional patients who tested negative with LPS-ELISA. Furthermore, the 
LPS-ELISA seemed false-positive in three patients in contrast to the glyco-iELISA. Fur-
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thermore, by combining the glyco-iELISA with fecal diagnostics, STEC infection was 
detected in 89% of the patients. In a second nationwide cohort of 212 patients with TMA, 
in respectively 48 (23%) and 60 (38%) patients with TMA, confirmation of STEC O157 
infection was found with LPS-ELISA and glyco-iELISA. Furthermore, the glyco-iELISA 
appeared highly sensitive, no cross-reactivity was observed with the glyco-iELISA and 
IgM could be detected for a long period of time. 
STEC serotype O157 is still the most prominent serotype associated with STEC-HUS 
in the Netherlands. Yet, non-O157 serotypes are emerging as cause of HUS. Obviously, a 
diagnostic assay to determine anti-O157 antibodies will miss an infection with non-O157 
STEC strain. Therefore, it remains highly important to perform both fecal diagnostics 
(PCR and culture) together with serology. With fecal diagnostics, one could establish 
STEC infection based on the presence of Shiga toxin (Stx) genes (and other virulence fac-
tors) in the feces with PCR. In case the pathogenic strain has been harvested with culture, 
molecular serotyping could help to further determine the STEC serotype and additional 
virulence factors. In CHAPTER 4 the importance of thorough fecal diagnostics in the 
differential diagnosis of HUS is illustrated. We described the case of a 16-month old boy 
with an aggressive course of STEC-HUS due to a rare STEC serotype: Stx2d producing 
E.coli O80:H2. The clinical course of this patient mimicked aHUS due to the severity of 
the disease and the absence of a recent history of diarrhea. Consequently, eculizumab 
was administered. However,the next day PCR was positive for Stx2 and intimin-encoding 
eae genes, confirming STEC infection as the cause of HUS. In addition, fecal isolates were 
used for molecular serotyping using whole genome sequencing (WGS) and revealed the 
rare STEC serotype O80:H2, which contained the Stx2d gene and the eae ξ gene variant, 
which is rarely seen in humans.91 This report underlines the importance of STEC diag-
nostic tests in all children with HUS, including those with an atypical presentation, and 
emphasizes the importance of molecular and serotyping assays to estimate the virulence 
of an STEC strain.
Pathophysiology
Although STEC-HUS is one of the most common causes of acute kidney injury in 
children, the exact pathogenesis leading to TMA is still not well defined.5,363,364 Besides 
the released Stx which undoubtedly plays a pivotal role, other virulence factors might 
contribute to the development of TMA, possibly explaining the broad range in clinical 
presentation and outcome. The development of anti-complement therapies has stimu-
lated research into the role of complement activation in STEC-HUS.39,41,42 As part of the 
host response to bacterial infections, the complement system is activated during the 
acute phase of disease in patients with STEC-HUS. Some patients exhibit low levels of 
C3 in combination with high levels of soluble C5b-C9.39,41,42 Yet, it remains controver-
sial if complement activation as seen in STEC-HUS contributes to the development 
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of endothelial damage in STEC-HUS. In rare cases, mutations in complement genes 
(both pathogenic mutations and mutations of unknown significance) have been found 
in patients who present with TMA associated with a STEC infection. Of note, many 
mutations need still to be confirmed by functional analysis. Most likely, these patients 
with STEC-associated HUS and pathogenic mutations might actually represent aHUS 
triggered by STEC infection.42,365 Up till now, it seems highly unlikely that complement 
involvement could explain the wide variability in clinical presentation and outcome 
in STEC-HUS, ranging from no chronic sequelae to hypertension, proteinuria, chronic 
renal failure, end stage renal disease or even death.5
Several studies have been published regarding the role of the noxious molecule 
heme in relation to tissue injury in various forms of hemolytic anemias. During hemo-
lytic anemia, heme is released and scavenged by hemopexin extracellularly under 
normal conditions . Yet, in case of massive hemolysis this system will be overwhelmed. 
Free heme is associated with endothelial activation and vaso-occlusion in among others 
patients with sickle cell disease.100,104,129 We hypothesized that heme contributes to the 
development of TMA. In CHAPTER 5 the contributing effect of heme in the evolve-
ment of STEC-HUS is described. Significantly elevated heme levels were found in 48 
STEC-HUS patients compared to controls. Moreover, the observed heme levels had a 
strong inverse correlation with hemopexin levels, making hemopexin a reliable bio-
marker for toxic levels of heme present in vivo. Furthermore, a pro-inflammatory and 
pro-thrombotic response was observed when primary human glomerular microvascular 
endothelial cells were incubated with heme. Moreover, upregulation of the cytopro-
tective enzyme heme oxygenase 1 (HO-1) was impaired by Stx. Consequently, heme as 
released during hemolysis could contribute, amplify and even drive the detrimental 
cascade leading to STEC-HUS.
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Conclusions and future perspectives part I
The research field of STEC-HUS is constantly evolving. Although the role of complement 
in STEC-HUS is extensively studied, other factors like heme are relatively disregarded. 
With our study we showed the oxidative stress and pro-thrombotic effect caused by 
heme on glomerular endothelial cells. Moreover, STEC-HUS patients are more suscep-
tible for these effects since Stx inhibits the production of the protective HO-1 enzyme. 
Furthermore, we have shown that serological assays have a place in the diagnostic work 
up of patients with TMA. We advocate to always combine fecal diagnostics together with 
serological diagnostics. Moreover, the optimal assay to determine serological antibodies 
against STEC serotype O157 is the glyco-iELISA. As discussed in chapter 2 and 3, children 
who present with HUS in the absence of positive fecal diagnostics should not be diag-
nosed as aHUS. One could even argue to exclude STEC infection in all patients (children 
and adults) who present with a first episode of TMA. Especially since the clinical presen-
tation of STEC-HUS can be quite atypical in adults and is often accompanied by a delay 
in diagnosis.366,367 Of note, in patients without stool production at time of presentation, 
the use of rectal swabs (performed on multiple occasions) is a sensitive alternative to 
detect STEC in the feces and therefore highly recommended.368 
Until today it remains unclear why only ˜15% of all patients infected with STEC 
develops HUS. Most likely, due to a complex interplay of host, pathogen and environment 
factors some patients are more prone to develop HUS. The susceptibiliy for heme toxicity 
could be one of these host factors. Heme is released during hemolysis, as present in vari-
ous degrees in these patients. Subsequently, heme is degraded intracellularly by HO-1. The 
activity of this important degrading enzyme is influenced by known polymorphisms in 
the promoter region.126 Moreover, one study even showed a relation between the length 
of repeats in the promoter of HO-1 and the development of acute kidney injury.369 Hence, 
future studies need to focus on the role of polymorphisms in HO-1 in patients with STEC-
HUS. Ultimately, leading to a better prediction and prevention model for patients who 
develop STEC-HUS.
The case as described in chapter 4 emphasizes the importance to rule out STEC 
infection, even in patients with an atypical presentation of HUS. Similar as in our patient, 
in 6-10% of the children with STEC-HUS there is no (bloody) diarrhea, whereas aHUS is 
preceded by diarrhea in 25% of cases.44 Clinical features can thus be misleading. Further-
more, it underlines the importance to look for non-O157 serotypes as well as to estimate 
the virulence of an STEC strain, by molecular and serotyping assays using WGS. More 
research is needed to further characterize this emerging and highly diverse group of 
non-O157 serotypes which are increasingly detected due to improved diagnostics.6,18,30,32,80 
Molecular serotyping assays are also critical in public health as they can determine the 
source of an outbreak and establish transmission pathways.20 
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Speed is essential to rapidly distinguish between STEC-HUS and other forms of TMA. 
Future studies should focus on improving diagnostic assays for bedside use. For example, 
with the use of lateral flow technology one could develop a point of care test for patients 
presenting with TMA. This would be of great additional value since the current gly-
co-iELISA takes at least 24 hours to perform. Even with the new techniques like WGS, it 
takes at least 48 hours if not longer to complete the diagnostic workup since a cultivated 
STEC strain is necessary to perform WGS.20 Recently, the role of metagenomic charac-
terization of STEC is described, by applying shot gun sequencing on the collected feces 
(result within 24 hours).370 Hereby excluding STEC culture as major limitation. Of note, 
due to the low inoculum needed to cause disease, also metagenomics can fail to detect 
STEC infection. Moreover, with the recent developement of a miniaturized sequence 
device (Oxford Nanopore Technology MiniION) bedside diagnosis of STEC-HUS comes 
within reach. Since these techniques will generate enormous amount of data, adequate 
bioinformatic analysis is needed to interpretate these data. Furthermore, with help of 
international genome databases for E.coli one could join forces to interpretate the large 
bulk of information. Although these techniques are most likely the future for STEC detec-
tion, for now PCR, culture and serology remain the gold standard. 
Up till now, treatment of STEC-HUS is merely symptomatic and no specific treatment 
targeting STEC is validated yet. With temporary dialysis (in 50-60%) and erythrocyte 
transfusions (in over 70%), STEC-HUS usually is a self-limiting disease.6,18 Furthermore, 
increasing evidence is emerging that early and generous intravenous fluid administra-
tion reduces the risk of development of oligo- or anuria, neurological complications and 
decreases the need for renal replacement therapy.121,122 Overall, the use of antibiotics to 
treat STEC infection is discouraged as some antibiotics are associated with increased 
release of Stx.96,371,372 A logical therapeutic approach would be to target Stx itself to neu-
tralize the noxious effects. However, thus far no drug targeting Stx has proceeded past a 
phase II trial.373 Urtoxazumab appeared safe and well tolerated in both healthy adults as 
pediatric patients with STEC-HUS. Yet, the effect of urtoxazumab on clinical outcome 
in STEC-HUS patients is not reported.374 Furthermore, one could wonder if antibodies 
targeting Stx would be effective, since endothelial damage has already occurred when a 
patient presents itself with symptoms of HUS. Another approach could be to neutralize 
the noxious effect of heme and hereby increase the chance on a favorable outcome with 
minimized chronic sequelae. Hemopexin infusions would be the first choice as scavenger 
of heme. Although promising results with hemopexin infusions were obtained in animal 
models, the first human trials need still to be conducted.129
The use of the complement inhibitor eculizumab is still controversial in STEC-HUS. 
Simultaneously with the implementation of eculizumab as standard treatment of aHUS 
in 2011, a catastrophic outbreak with STEC serotype O104 was reported in Germany. The 
decision to administer eculizumab during this outbreak was primarily funded on one 
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case report of three patients with STEC-HUS with serotype O157 and rapid (neurological) 
improvement after eculizumab treatment.375 However, in a retrospective analysis of a large 
adult STEC-HUS cohort during the outbreak, no effect was observed from eculizumab 
treatment on renal and neurological outcome.376 Since then, several small studies report 
better outcome in STEC-HUS patients with neurological involvement, after eculizumab 
treatment.98,377,378 Of note, one study conducted with 11 pediatric STEC-HUS patients with 
among others neurological involvement, suggested a potential negative effect in patients 
with simultaneous multi-organ failure.98 Since spontaneous recovery (both renal as neu-
rological improvement) is seen in nearly all patients with STEC-HUS, placebo-controlled 
trials are needed to study the additional effect of eculizumab on recovery. At this moment, 
the ECULISHU trial (NCT02205541) in France and the ECUSTEC trial in the United King-
dom are the first randomized double-blind placebo-controlled trials to study the effect 
of eculizumab in STEC-HUS. The ECULISHU trial was completed in June 2018, however 
the results are not yet published. The expected end date of the ECUSTEC trial is March 
2022. To date, STEC-HUS is still treated symptomatically and eculizumab remains only 
eligible to treat patients with an atypical form of HUS.
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Part II Strategies towards personalized
treatment of aHUS
In patients with aHUS due to complement dysregulation outcome has improved dra-
matically after the introduction of eculizumab. Eculizumab very effectively inhibits 
complement activation, thus allowing to restore endothelial cell integrity, and induc-
ing hematological remission. Subsequently, renal function improves or stabilizes in the 
majority of patients, including patients who were plasma therapy dependent or resistant 
previously.8,185,379 Overall, treatment is well tolerated with few side effects. The severity 
of the disease together with the underlying genetic defect in the majority of patients 
and the risk of disease recurrence, has stimulated the use of lifelong eculizumab therapy 
with standard dosages. However, the need for lifelong therapy is not evidence based, and 
debated not the least because of the enormous costs of the drug. One year of therapy 
with eculizumab in an adult patient would cost approximately €500,000. Thus, there is 
an unmet need to optimize eculizumab therapy, specifically by limiting treatment dose 
(discussed in chapter 6 and 7) or duration (discussed in chapter 8 and 9), and hereby 
further personalize treatment in patients with aHUS. 
In CHAPTER 6 we described 11 aHUS patients, both children and adults, who received 
eculizumab according the standard dosage regimen and with an extended interval vary-
ing between 3-8 weeks. Eculizumab serum trough levels were measured. We showed that 
eculizumab levels increased over time when given at weekly intervals in the induction 
phase (depending on the body weight and possibly initial soluble C5b-9 concentration). 
Eculizumab levels remained stable when dosed at two weekly intervals during the main-
tenance phase, and decreased when the intervals were longer. However, even with an 
extended interval up till four weeks, sufficient complement inhibition was reached in a 
considerable subset of pediatric and adult patients. Moreover, during the standard treat-
ment regimen, eculizumab trough levels up to 772 µg/ml were detected, far exceeding the 
therapeutic target of 50-100 µg/ml. Hence, the current treatment scheme (as approved 
by the european medicines agency and food and drug administration) resulted in a large 
variation in drug concentrations per aHUS patient and an excess of eculizumab could be 
noted in the majority of patients.
Besides aHUS, eculizumab is registered as therapy for two other diseases. Further-
more, numerous cases have been reported regarding patients with a wide variety of 
diseases who received eculizumab off-label. In CHAPTER 7 the pharmacokinetic and 
pharmacodynamic properties of eculizumab, both for reported on- (paroxysmal noc-
turnal hemoglobinuria, aHUS, generalized myasthenia gravis) and off-label indications 
(hematopoietic stem cell transplantation associated TMA), were reviewed. We concluded 
that there were large differences in measured serum trough levels between the various 
patients groups. As a consequence, both the advised trough level targets as the pursued 
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effects were different per indication. To provide the best tailored care, we advocated an 
individualized approach and highlighted the importance of therapeutic drug monitoring, 
as foundation for personalized medicine, in patients treated with eculizumab. 
Next to tapering of eculizumab therapy, another option would be to treat patients 
with a restrictive eculizumab regimen; withdrawal of eculizumab when the patient is 
stable and in remission. In CHAPTER 8 we described the course in 20 aHUS patients, 
both children as adults, who were treated with restrictive eculizumab therapy. Eculi-
zumab therapy could be tapered in all patients. Furthermore, in 17 patients eculizumab 
was withdrawn. Subsequently, recurrence of aHUS occurred in five patients. Due to close 
monitoring, recurrence was detected early and eculizumab was restarted. No clinical 
sequelae such as proteinuria or progressive kidney dysfunction were detected. In total, 
eculizumab has been discontinued in 13 patients without aHUS recurrence, of which five 
were event free for over a year. With this strategy approximately €11.4 million has been 
saved.
An increasing, but still limited, amount of case reports has been published over 
the years describing aHUS patients who received a restrictive eculizumab regimen. In 
CHAPTER 9 we reviewed all literature regarding a restrictive eculizumab regimen in 
patients with a first episode of TMA, patients with aHUS relapse in their native kidneys 
and transplant recipients who experienced disease recurrence. Overall, withdrawal of 
eculizumab seemed possible in a large group of patients with strict monitoring for disease 
recurrence. Approximately 27% of the patients experienced disease relapse, mostly within 
one year after therapy withdrawal. After rapid reinitiation of eculizumab, no chronic 
sequelae were detected. Strategies to taper and withdraw therapy were extensively dis-
cussed and a treatment algorithm was proposed. 
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Conclusions and future perspectives part II
Although eculizumab therapy has dramatically improved the prognosis of patients with 
aHUS, the optimal treatment regimen is yet unknown. Most importantly, there is no 
evidence to support the current treatment protocol which advocates lifelong therapy, 
leaving room to develop strategies to personalize treatment. Within this thesis, we have 
proposed an alternative and unique approach to treat patients with aHUS. This strategy 
is based on the hypothesis that a restrictive eculizumab regimen in aHUS appears safe 
and (cost) effective. 
As described in chapter 6 and 7, trough levels often exceed the set target of 50-100 
µg/ml required to block the complement system. As extensively discussed in chapter 7, 
by applying therapeutic drug monitoring one could adjust therapy and minimize unnec-
essary use of eculizumab. Moreover, it is unknown if a completely blocked complement 
system is required to halt disease activity, or that merely a suppressed complement system 
would be sufficient, as described by Ardissino et al.259 Of note, potential side effects of ecu-
lizumab, like high susceptibility for meningococcal disease, could be reduced if patients 
are still able to form C5b-C9 complexes upon infection. Therefore, targeted therapy 
aiming at complete and/or incomplete complement blockade should be further explored. 
The introduction of eculizumab in clinical care in the Netherlands has created aware-
ness for the difficulties in discussing treatment for rare diseases with expensive orphan 
drugs. Upon market approval of eculizumab, a national aHUS working group was formed, 
including one nephrologists and one pediatric nephrologists of every university hospital 
in the Netherlands.4 Together they implemented a new guideline to diagnose and treat 
patients who present with TMA. Moreover, a restrictive eculizumab regimen was pro-
posed, in which aHUS patients are treated with eculizumab for three months after which 
therapy is evaluated. The study protocol for the nationwide prospective observational 
study to monitor and eventually evaluate this new guideline is described in CHAPTER 10. 
This study, called CUREiHUS, includes all aHUS patients who are treated conform the 
new Dutch guideline. Questionnaires are sent to assess quality of life and productivity 
losses to perform a cost-effectiveness analysis and budget impact analysis. Furthermore, 
blood is collected to study complement activation, biomarkers for disease recurrence and 
eculizumab serum levels. The study will close in October 2020. 
Our study and other ongoing international studies will evaluate the best strategies 
to prevent, predict and treat disease recurrence. As discussed in chapter 9, approximately 
27% of the aHUS patients in which eculizumab therapy is withdrawn will suffer disease 
recurrence. Although with close monitoring eculizumab can be reinitiated rapidly upon 
recurrence, hereby preventing chronic sequelae, it remains important to predict disease 
recurrence. Unfortunately, no biomarkers that predict disease recurrence are yet discov-
ered. The use of routine complement assays do not allow differentiation since normal 
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C3 and soluble C5b-C9 levels are often reported in patients with aHUS. More specialized 
assays have been proposed, however need to be tested in prospective studies to prove 
their value.269,282 Especially the ex vivo serum complement activation assay on human 
microvascular endothelial cells gained a lot of attention.269,360 The intensity of C3 and 
C5b-C9 deposition on endothelial cells was a reflection of the amount of complement 
activation. This assay could have clinical implications to help to differentiate between 
active disease and remission, to monitor and adjust eculizumab therapy and finally help 
to predict relapses after eculizumab withdrawal. Although the results are promising of 
this assay, a specialized and dedicated laboratory to perform this assay is required. Hence, 
hereby decreasing the accessibility and availability of this assay. 
One could question if merely one biomarker would be sufficient to monitor such 
a complex and heterogeneous disease as aHUS. Increasing evidence suggests that the 
pathogenic mutation underlying the development of aHUS could guide duration of 
treatment. For example, patients with complement independent forms of aHUS will not 
respond to this therapy. Not all mutations associated with aHUS are located in genes 
encoding for complement proteins. For example, mutations in thrombomodulin, DGKε 
and plasminogen have been described in relation to the development of aHUS.308,380-382 
However, all these mutations appear to comprises genes involved in the coagulation 
system and hereby leading to coagulation mediated TMA in contrast to complement 
mediated TMA. Although there is bidirectional crosstalk between these two systems, 
the exact mechanisms and clinical implications still needs to be unraveled.364 By default, 
these mutations have been described in relation to aHUS. Yet, in this case aHUS is defined 
as non-typical (hence STEC-HUS) rather than complement mediated aHUS such as dis-
cussed in this thesis. Some pathogenic mutations in complement regulatory genes are 
thought to be associated with worse outcome such as genetic alternations in comple-
ment factor H including complement factor H related hybrid proteins. More research is 
needed to study the potential influence of pathogenic mutations on disease course and 
treatment outcome.
Furthermore, the aHUS patient population is highly heterogeneous with patients 
who present with a first episode, patients who have encountered previous episodes of 
aHUS and even some patients who reached en stage renal disease and received a kidney 
transplant. This poses a new dilemma, since the optimal treatment for one individual 
can change over time, depending the response to previous treatment episodes. Instead 
of merely looking at one aspect, an extended algorithm should be developed to include 
all above mentioned topics, ultimately guiding tailored patient care (Figure 11.2). As 
discussed in chapter 9, by developing for example a scoring system, including gathered 
data on therapeutic drug monitoring, one could integrate all this information. 
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Figure 11.2 Personalized treatment of aHUS
Eculizumab treatment 
Standard treatment scheme Personalized medicine 
Eculizumab treatment 
Clinical reality 
? 
Figure 11.2 In the current standard treatment scheme as described by the pharmaceutical company, eculizumab 
dosage recommendations are depending on the body weight of the patient (categories: 5-10kg, 10-20kg, 20-30kg, 
30-40kg, >40kg) and all patients receive a fixed dose with a set interval, potentially lifelong (black arrow). Yet, 
in clinical reality, some patients need less drug to achieve the target range of eculizumab in blood, or do not need 
lifelong treatment at all. Depending age, pathogenic mutation causing aHUS, medical history and previous epi-
sodes of disease relapse, each patient should receive a different and personalized treatment regimen. For example, 
in transplant recipients prophylactic eculizumab may not be necessary to prevent disease relapse (white arrow). 
Furthermore, patients could receive a short period of eculizumab after which therapy is withdrawn, or eculizumab 
therapy could be tapered before withdrawal. In only a small subset of patients, ongoing eculizumab therapy would 
be needed. Yet, instead of a fixed dose, therapeutic drug monitoring should be applied to achieve target levels.
The successful implementation of eculizumab let to a renaissance of complement-tar-
geted drug developments. More than 20 drugs that target the complement system at some 
stage are nowadays being evaluated in clinical trials, with a dozens other agents in the 
pipeline.9 Most candidate drugs in development to treat aHUS focus on blockade at C5 
level, resembling eculizumab. For example, a phase III trial using a long-acting C5 inhibitor 
(Ravulizumab, or ALXN1210) produced by the same pharmaceutical company as eculizumab, 
is currently running. In this trial, intravenous administration of eculizumab is compared 
to ALXN1210 which has to be administered every eight weeks instead of every fortnight. 
Furthermore, with the patent protection of eculizumab expiring in May 2020 within Europe, 
various trials using a biosimilar of eculizumab are conducted (ABP959 and Tesidolumab).
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In contrast to these antibodies who need to be administrated intravenously, Cover-
sin is a small peptide blocking the splicing of C5 with the advantage of subcutaneous 
administration. Yet, no study results in patients with aHUS are published up till now. 
Blockade at the level of C3 would be less favorable considering the key role of C3 in all 
complement pathways. A phase III trial is currently running, with a novel therapeutic 
targeting the mannan binding lectin associated serine protease 2 (MASP2), an enzyme of 
the lectin pathway.9 Although they report promising results in patients with aHUS, the 
interplay of the lectin pathway in the development of aHUS needs yet to be elucidated. 
Taking into account the pathophysiological mechanisms of aHUS with dysregulation of 
the alternative pathway of the complement system and excessive deposition of C5b-C9 
on endothelial cells, C5 inhibition seems the most logical choice. Future studies should 
focus on blockade of the formation of the terminal complement complex (C5b-C9), pref-
erably with drugs who have oral bioavailability or could be administered subcutaneously 
instead of parenteral administration. 
Eculizumab as treatment for the rare disease aHUS is just one of the many exam-
ples of a highly expensive orphan drugs which gained market approval the last decade. 
With the sharp increase in orphan drugs entering the market and even more in the 
development pipelines, various governments install interventions and regulations to 
control these expenses and secure economic health-care resources.9,383 To smoothen the 
implementation process, a lot can be learned from our experience with eculizumab and 
the orphan drug arrangement as implemented in the Netherlands. The first step after 
market approval, would be to develop a guideline with clear start and stop criteria, drafted 
by experts in the field. Furthermore, studies have to be conducted regarding the optimal 
treatment regimen with each orphan drug. To facilitate policy making and translate the 
preclinical data into clinical benefits, monitoring of patients in a independent registry is 
imperative. With this gained knowledge, the proposed guidelines need to be re-evaluated 
after some years and adjusted accordingly. Imbursement policies vary from country to 
country, but overall countries tend to put a threshold on the affordability of drugs, despite 
its effectiveness. With the performance of an independent cost-effectiveness analysis 
decision making regarding reimbursement can be supported. Although informed con-
sent is always obliged, one could argue on the moral duty of patients who receive such 
expensive treatment to participate in a registry study to monitor and evaluate (cost-) 
effectiveness. Ultimately, government, healthcare insurances, researchers, physicians and 
patients have to join forces to achieve optimal and affordable healthcare.
It remains important to optimize, evolve and innovate treatment of aHUS patients. 
With among others the results obtained from the CUREiHUS study, expected in the fall 
of 2020, the Dutch guideline regarding treatment of aHUS patients should be critically 
evaluated. With the learned experiences, further improvements should be implemented 
to pursue the best tailored care for patients with aHUS.
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Research data presented in this thesis and obtained during this PhD at the department 
of pediatric nephrology were achived according the Findable, Accessible, Interoperable 
and Reusable (FAIR) principles. All studies were conducted according the principles of 
the declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) 
and in accordance with the Medical Research Involving Human Subjects Act (WMO), 
Dutch Code of conduct, Dutch Personal Data Protection Act and the Medical Treatment 
Agreement Act. Research data management was conducted according Good Clinical Prac-
tice (GCP) requirements. 
Both chapter 2 and chapter 3 contain data which were collected using the webbased 
database Castor. Furthermore, patient data gathered for the ongoing CUREiHUS study 
(as described in chapter 10) are stored in Castor. The hosting of Castor is by ISO:27001 and 
NEN7510, certified datacenters. The system of the database enables an audit trail after 
each modification and login events. Login actions can only be with a personal (role and 
center specific) authorization with qualified passwords. Castor has a monitor function 
whereby data controls will be executed. 
All laboratory experiments were described in paper lab journals and stored appro-
priately. With the introduction of Labguru, a digital labjournal with backup facilities, all 
experiments were registered in Labguru. Remaining data is stored at the research server of 
the department of pediatrics in an encrypted subdirectory. Furthermore, all data regarding 
the CUREiHUS study are stored in the digital research environment (DRE) facilitating the 
FAIR principles. DRE offers researchers a safe and well equipped research environment 
for analysis, storage and sharing of data and is supported by the Executive Board of the 
Radboudumc. Both servers can be accessed by associated scientific staff members.
All data generated or analyzed in this thesis was included in published articles and 
its additional files are available from the associated corresponding authors on request. 
Data will be kept until fifteen years after publication. After the study was finished and 
scientifically published, subject material from the study will only be stored and possibly 
used for future studies when subjects agree with this, as included in the informed con-
sent. Without agreement of the medical ethical committee, materials will not be used for 
future studies that do not have a direct relation to the current study and not for studies 
that involve the chance of finding additional outcomes. If subjects do not give permission 
to use their material for future studies, the material will be discarded after this study has 
been finished and scientifically published.
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List of abbreviations
ABMR Antibody mediated rejection
ABOi ABO incompatible
ADAMTS13 A disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13
aHUS Atypical hemolytic uremic syndrome
anti-CFH Autoantibodies against complement factor H
AP Alternative pathway
AP50 Alternative pathway activity
AU Arbitrary units
AUC Area under the curve
BIA Budget impact analysis
BSA Bovine serum albumin
Bx Kidney biopsy
CEA Cost-effectiveness analysis 
CFB Complement factor B
CFH Complement factor H
CFHR Complement factor H related protein
CFI Complement factor I 
CH50 Total hemolytic complement activity
CI Confidence interval
CL Clearance
Cmax Peak plasma concentration 
CNI Calcineurin inhibitor
CP Classical complement pathway
Ctrough Trough level
CV Coefficient of variance 
DAF Decay acceleration factor
DBD Donation after brain death
DCD Donation after cardiac death
DD Deceased donor
DGKε Diacylglycerol kinase epsilon
eae Attaching and effacing
Ecu Eculizumab
eGFR Estimated glomerular filtration rate 
ELISA Enzyme-linked immunosorbent assay
EMA European Medicines Agency
ESRD End stage renal disease
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FDA Food and Drug Administration 
FStx Free fecal shiga toxin test 
FU Follow up
Gb3 Globotriaosyl ceramide
glyco-iELISA Glycoprotein based ELISA
gMG Generalized myasthenia gravis 
HAHAs human antihuman antibodies 
HGMVECs Human glomerular microvascular endothelial cells 
HO-1 Heme oxygenase 1
HRQoL Health-related quality of life 
HSCT Hematopoietic stem cell transplantation 
HUS Hemolytic uremic syndrome
IC Informed consent
ICU Intensive care unit 
IgM Immunoglobulin M 
IMG Idiopathic membranous glomerulopathy 
iPCQ Productivity Costs Questionnaire 
IQR Interquartile range
IVIG Intravenous immunoglobulin
KDIGO Kidney Disease Improving Global Outcome
LD Living donor
LDH Lactate dehydrogenase
LP Lectin pathway
LPS Lipopolysaccharide
LRD Living related donor
LURD Living unrelated donor
MAC Membrane attack complex
MASP2 Mannose-binding lectin-associated serine protease 2
MBL Mannose binding lectin
MCP Membrane cofactor protein
RD Modification of Diet in Renal Disease equation
MLPA Multiplex ligation-dependent probe amplification 
MRI Magnetic resonance imaging 
mTOR Mammalian target of rapamycin
NA Not applicable
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells
NICE National Institute for Health and Care Excellence
OD Optical density
OR Odds ratio
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P/N ratio Positive/negative ratio
P50 Median percentile for height and age
PBS Phosphate buffered saline
PBST Phosphate buffered saline and tween
PCR Polymerase chain reaction
PCR protein-to-creatinine ratio
PD Pharmacodynamic
PE Plasma exchange
PESaM Patient Experiences and Satisfaction with Medications
PI Plasma infusion
PK Pharmacokinetic
PLG Plasminogen
PNH Paroxysmal nocturnal hemoglobinuria
PREMs Patient-reported experience measures
pRIFLE pediatric Risk, Injury, Failure, Loss, End-stage renal disease
PT Plasmatherapy
QALY Quality adjusted life year 
qPCR quantitative polymerase chain reaction
RA Rheumatoid arthritis 
Radboudumc Radboud university medical center
RIVM Dutch National Institute for Public Health and Environment 
ROS Reactive oxygen species 
RT Room themperature
sC5b-9 Soluble C5b-C9
Screat serum creatinine
SD standard deviation
SLE Systemic lupus erythematosus
SMAC Sorbitol MacConky agar 
SPC Summary of Product Characteristics 
STEC Shiga toxin producing Escherichia coli
Stx Shiga toxin
TCC Terminal complement complex
TDM Therapeutic drug monitoring 
TF Tissue factor
THBD Thrombomodulin
TMA Thrombotic microangiopathy 
TMB Tetramethylbenzidine
TTP Thrombocytopenic purpura 
Tx Kidney transplantation
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Vd Volume of distribution
WGS Whole genome sequencing
WMO Medical Research Involving Human Subjects Act

“Wanneer je je reis naar Ithaca aanvangt, 
bid dan dat de weg lang mag zijn, 
vol avontuur, 
rijk aan stof tot kennis. 
Wees niet bang.” 
Konstantínos P. Kavákis
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Het leven van de patiënten met een atypische vorm van het hemolytisch uremisch syn-
droom (HUS) veranderde drastisch met de implementatie van het weesgeneesmiddel 
eculizumab in 2011. Door de komst van dit geneesmiddel is de prognose van patiënten 
met atypische HUS (aHUS) enorm verbeterd: daar waar deze patiënten vroeger vaak niet 
herstelden met de standaard behandeling en vaak aangewezen waren op levenslange nier-
functievervangende therapie, treedt nu meestal herstel van de nierfunctie op, en hebben 
de patiënten een vrijwel normaal leven. Ondanks dat eculizumab een zeer effectief en 
potent geneesmiddel is, wordt eculizumab beschouwd als een van de duurste medicamen-
ten ter wereld. Het beschikbaar komen van dit effectieve, maar ook dure geneesmiddel 
heeft geleid tot vele nieuwe vragen, o.a. met betrekking tot het diagnosticeren van aHUS 
en het optimale gebruik van eculizumab. 
Atypische HUS is een zeldzame en ernstige vorm van trombotische microangio-
pathie (TMA). TMA is een verzameling van verschijnselen welke ontstaan als gevolg 
van vaatwandschade hetgeen leidt tot trombose in de kleine bloedvaten. TMA wordt 
gekenmerkt door een trias aan symptomen: hemolyse (afbraak van rode bloedcellen), 
trombocytopenie (tekort aan bloedplaatjes) en perfusie stoornis (zuurstoftekort) lei-
dend tot eind orgaanschade. De nieren in het bijzonder zijn vatbaar voor deze effecten 
en TMA leidt dan ook vaak tot acuut nierfalen. Vele verschillende oorzaken kunnen ten 
grondslag liggen aan het ontwikkelen van TMA. Om TMA adequaat te kunnen behan-
delen is het van groot belang de onderliggende oorzaak te diagnosticeren. Grofweg 
wordt TMA in vier subgroepen onderverdeeld (Figuur 1). Echter is er veel overlap in 
symptomatologie tussen deze vier subgroepen, wat het klinisch onderscheid bemoei-
lijkt. De meest voorkomende vorm van TMA wordt bij kinderen veroorzaakt door een 
infectie met de shiga-toxine producerende E.coli (STEC), resulterend in STEC-HUS. Bij 
volwassenen wordt met name trombotische trombocytopenische purpura (TTP), ver-
oorzaakt door verminderde activiteit van het ADAMTS13 eiwit, als oorzaak van TMA 
gezien. Snelle en goede diagnostiek is nodig om de juiste diagnose te stellen en adequate 
behandeling te kunnen starten. Het onderzoek zoals beschreven in dit proefschrift richt 
zich op twee subgroepen van TMA. In sectie I van dit proefschrift wordt de diagnose 
en pathofysiologie van STEC-HUS besproken. In sectie II van dit proefschrift wordt 
ingegaan op de behandeling van patiënten met aHUS.
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Sectie I Nieuwe inzichten in de 
pathofysiologie en diagnose van STEC-HUS
Meer dan 90% van de kinderen die zich presenteren met het beeld van HUS, heeft STEC-
HUS. STEC-HUS komt met name op de kinderleeftijd voor (vooral tussen 1-5 jaar) en 
ontstaat na een darminfectie met de STEC-bacterie. Bij de overgrote meerderheid van de 
patiënten is er sprake van diarree die in de meeste gevallen bloederig is. Slechts een deel 
(15%) van de mensen met een darminfectie veroorzaakt door de STEC-bacterie ontwikkelt 
uiteindelijk HUS.
De shiga toxines welke geproduceerd worden door de STEC-bacterie veroorzaken 
vermoedelijk schade aan de vaatwand, resulterend in TMA. Er zijn verschillende seroty-
pes van STEC die STEC-HUS kunnen veroorzaken. Ondanks dat STEC-O157 nog steeds 
het meest voorkomende serotype is bij patiënten met STEC-HUS, worden er steeds meer 
non-O157 serotypes (zoals O26, O103, O104 etc.) gevonden. Om STEC-HUS te diagnosti-
ceren wordt ontlasting en bloed onderzocht. Het ontlastingsonderzoek bestaat uit een 
feceskweek en polymerase-kettingreactie (PCR) waarmee gekeken wordt naar de aanwe-
zigheid van shiga toxine in de ontlasting. Helaas is vaak het ontlastingsonderzoek alleen 
niet toereikend om de diagnose STEC-HUS te kunnen stellen. Bij meer dan 30% van de 
patiënten met een sterke klinische verdenking op STEC-HUS kan geen STEC worden 
aangetoond in de ontlasting. 
In het bloed kunnen antistoffen aanwezig zijn tegen het lipopolysaccharide, de bui-
tenmembraan van de STEC-bacterie. Deze antistoffen kunnen worden aangetoond met 
behulp van een lipopolysaccharide enzyme-linked immuno sorbent assay (LPS-ELISA). 
Serologisch onderzoek in het kader van de diagnostiek van STEC-HUS wordt in Nederland 
alleen in het Radboudumc in Nijmegen uitgevoerd. In hoofdstuk 2 hebben we onder-
zocht wat de toegevoegde waarde is van de LPS-ELISA voor detecteren van STEC-O157 
infectie in relatie tot ontlastingsonderzoek. Bij een groep kinderen met een klinische 
verdenking op STEC-HUS werd de diagnose STEC-HUS in 54% van de gevallen bevestigd 
door ontlastingsonderzoek. De diagnose STEC-HUS werd in 63% bevestigd door de LPS-
ELISA specifiek gericht tegen het meest voorkomende serotype bij STEC-HUS, serotype 
O157. Bovendien, wanneer ontlastingsonderzoek gecombineerd werd met serologie voor 
STEC-O157 ( met de LPS-ELISA) kon in maar liefst 77% van de patiënten met verdenking 
op STEC-HUS, de diagnose worden bevestigd. Bij de overige 23% van de patiënten kan 
STEC-HUS veroorzaakt zijn door een ander serotype dan STEC-O157. Ook kan er sprake 
zijn van een andere oorzaak van HUS.
Echter heeft de LPS-ELISA ook enkele nadelen. Door de structuur van de LPS die 
gebruikt wordt in deze test kan er eventuele kruisreactiviteit ontstaan tussen verschil-
lende serotypes van STEC (o.a. O157, O26, O103) en zelfs tussen verschillende gram 
negatieve bacteriën. Hierdoor kan de uitslag vals positief zijn. In hoofdstuk 3 wordt 
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een nieuwe serologische assay beschreven die dit probleem verhelpt door gebruik te 
maken van recombinante glycoproteïnes (glyco-iELISA). In vergelijking met de oude test 
(LPS-ELISA) kon de glyco-iELISA STEC-HUS op basis van STEC-O157 vaststellen bij 10 
patiënten waarbij de uitslag negatief was met de LPS-ELISA. Daarnaast bleek dat bij 
drie patiënten de test vals positief was met de LPS-ELISA. Door ontlastingsonderzoek te 
combineren met de glyco-iELISA voor STEC-O157 kon in 89% van de patiënten STEC-HUS 
worden gediagnosticeerd. Patiënten zijn alleen getest op de aanwezigheid van antistof-
fen tegen het serotype STEC-O157. Het plan is om de glyco-iELISA in de toekomst uit te 
breiden voor de meest voorkomende serotypes van STEC.
In hoofdstuk 2 en 3 ligt de focus vooral op STEC serotype O157, echter er worden 
steeds meer gevallen beschreven van patiënten met STEC-HUS die veroorzaakt worden 
door andere STEC-serotypes dan O157. In hoofdstuk 4 wordt een casus van een 16 
maanden oude jongen beschreven met een ernstig en atypisch beloop van STEC-HUS, 
veroorzaakt door het zeldzame STEC serotype O80. Initieel, mede gezien de afwezigheid 
van diarree, werd er gedacht aan aHUS, derhalve heeft de patiënt een gift eculizumab 
ontvangen. Echter de volgende dag werd door een positieve PCR uitslag voor de aanwe-
zigheid van shiga toxine in de ontlasting de diagnose STEC-HUS bevestigd. Vervolgens 
is met behulp van moleculaire serotypering door middel van whole genome sequencing 
de STEC-bacterie verder getypeerd. Deze patiënt bleek STEC-HUS te hebben op basis van 
het zeldzame O80 serotype welke bekend staat vanwege de potente virulentie factoren. 
Deze casus onderstreept het belang van adequate diagnostiek en virulentie bepaling 
van de STEC-bacterie bij patiënten met HUS, juist ook bij patiënten met een atypische 
presentatie van HUS, om zo de juiste behandeling te kunnen starten.
Ondanks dat STEC-HUS een veelvoorkomende oorzaak is van acuut nierfalen bij 
kinderen is er nog steeds weinig bekend over de exacte pathofysiologie waardoor een 
STEC-infectie kan leiden tot HUS. Zo ontwikkelt slechts 15% van de patiënten met een 
STEC-infectie HUS. In hoofdstuk 5 onderzochten we het effect van de toxische stof 
heem op het ontstaan en verergeren van HUS. Heem komt vrij als erytrocyten (rode bloed-
cellen) vervallen, bijvoorbeeld bij hemolyse zoals aanwezig bij patiënten met TMA. Heem 
is schadelijk als het in grote hoeveelheden tegelijk vrijkomt in de bloedbaan. In een groep 
van 48 STEC-HUS patiënten werd er een statistisch significant hogere heem-concentratie 
in het bloed gevonden in vergelijking met gezonde controles. Deze heem-concentraties 
werden vervolgens aangebracht op endotheelcellen (vaatwandcellen) in vitro. Toediening 
van heem op endotheelcellen cellen leidde tot een verhoogde stollings- en ontstekingsre-
actie, zoals ook aanwezig bij patiënten met HUS. Dit effect werd versterkt door het tegelijk 
aanbrengen van heem en shiga toxine op de cellen. Heem, wat vrijkomt bij patiënten met 
HUS door het verval van erytrocyten, kan dus bijdragen aan het ontstaan van STEC-HUS.
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Conclusie sectie I
Het vaststellen van een STEC-infectie heeft vergaande behandelconsequenties voor pati-
enten die zich presenteren met HUS. Aangezien aHUS niet direct middels een test aan 
te tonen is, wordt het onderscheid tussen STEC-HUS en aHUS gemaakt op basis van 
het aantonen dan wel uitsluiten van een STEC-infectie. Zoals aangetoond in hoofdstuk 
2 en 3 is serologie, in combinatie met ontlastingsonderzoek, van essentieel belang in de 
diagnostiek van STEC-HUS. In de toekomst moeten deze serologische assays uitgebreid 
worden met andere STEC serotypes om zo de groeiende groep van non-O157 STEC-bacte-
riën te kunnen detecteren. Daarnaast worden moleculaire assays steeds belangrijker niet 
alleen voor de diagnostiek maar mede ook om virulentie factoren van de STEC-bacterie 
te bepalen. Dit is niet alleen van belang voor de behandeling en prognose van patiënten 
met STEC-HUS, maar geeft ook inzichten over de epidemiologie van STEC in Nederland.
Het is tot op heden onbekend waarom maar 15% van de patiënten een HUS ontwik-
kelt na een STEC-infectie. Waarschijnlijk heeft dit te maken met een complexe interactie 
tussen patiëntkarakteristieken, omgevingsfactoren en specifieke kenmerken van de 
STEC-bacterie. Een van de mogelijk factoren die een rol kan spelen is heem. Aangezien 
heem een pro-trombotisch effect heeft kan een verhoogde heem-concentratie een rol 
spelen in het ontstaan dan wel verergeren van TMA. Vervolgonderzoek moet aantonen 
of deze bevinding behandelconsequenties kan hebben voor patiënten met STEC-HUS.
Voor patiënten met STEC-HUS is er tot op heden geen specifieke behandeling, 
en worden patiënten alleen symptomatisch behandeld. STEC-HUS gaat bij de meeste 
patiënten vanzelf over mits de patiënt tijdig herkend wordt en op tijd symptomatische 
therapie (onder andere nierfunctie vervangende therapie, adequaat vochtbeleid en bloed-
transfusies) ontvangt. Het gebruik van eculizumab als behandeling voor patiënten met 
STEC-HUS is tot op heden omstreden. Echter lopen er momenteel twee studies om het 
effect van eculizumab behandeling voor patiënten met STEC-HUS te onderzoeken. Deze 
studies zullen uitsluitsel geven of eculizumab behandeling van toegevoegde waarde is 
voor de behandeling van patiënten met STEC-HUS. 
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Sectie II Op weg naar een gepersonaliseerde 
behandeling voor iedere patiënt met aHUS
Atypische HUS is een ernstige en zeldzame vorm van HUS en kan voorkomen op alle 
leeftijden. In tegenstelling tot STEC-HUS kan aHUS een chronische ziekte zijn met een 
recidiverend karakter. Atypische HUS wordt ook wel complement gemedieerde HUS 
genoemd. Het complement systeem is een belangrijk onderdeel van het aangeboren 
afweersysteem en speelt een zeer belangrijke rol bij de afweer tegen micro-organismen. 
De belangrijkste functies van het complement systeem zijn opsonisatie door C3b, che-
motaxis door C3a en C5a en het lyseren van cellen door de vorming van het zogenoemd 
membrane attack complex. Eigen lichaamscellen, zoals de vaatwand, zijn beschermd 
tegen het complement systeem door de aanwezigheid van verschillende complement 
regulatoren. Deze complement regulatoren spelen een belangrijke rol in het in balans 
houden van het complement systeem en voorkomen ontregeling. Veranderingen in de 
genetische codering van een aantal van deze eiwitten uit het complement systeem maken 
dat het complementsysteem te actief is en/of te actief blijft. Een overactief en niet goed 
gereguleerd complement systeem kan leiden tot vaatwand beschadiging, waardoor pati-
enten aHUS kunnen ontwikkelen. Op dit moment wordt in 40 tot 60% van de patiënten 
met aHUS een erfelijke aanleg in het complement systeem gevonden, dan wel antistoffen 
gericht tegen de complement eiwitten.
Atypische HUS is een ernstig ziektebeeld met hoge morbiditeit en mortaliteit. Daar-
naast ontstaat er vaak schade, waardoor een patiënt chronisch nierfalen kan ontwikkelen. 
Bij deze groep patiënten is dialyse noodzakelijk en in sommige gevallen een niertrans-
plantatie. Indien geen specifieke maatregelen genomen worden, krijgt helaas de overgrote 
meerderheid van aHUS patiënten een recidief aHUS in de nieuwe getransplanteerde 
nier. Sinds 2011 is eculizumab de standaard behandeling voor aHUS en zijn deze lange 
termijn gevolgen sterk verbeterd. Eculizumab is een gehumaniseerd monoklonaal anti-
lichaam gericht tegen complement C5 en blokkeert de splitsing van C5 in zijn actieve 
bestandsdelen: C5a en C5b. C5b is noodzakelijk is voor de vorming van het membrane 
attack complex. Door de remming van het membrane attack complex kan er geen schade 
meer door het overactieve complement systeem ontstaan aan de vaatwand. Volgens een 
vastgesteld schema (één dosis per twee weken in de onderhoudsfase bij volwassenen) 
wordt eculizumab via het infuus in het ziekenhuis toegediend. De farmaceut raadt aan 
het medicament levenslang te geven. Ondanks dat de ziekte meestal goed reageert op 
de behandeling met eculizumab, zitten er ook nadelen aan de behandeling. Zo hebben 
patiënten onder andere een sterk verhoogde kans op het ontwikkelen van meningitis en 
zijn er enkele studies die leverschade door eculizumab beschrijven. Daarnaast is er nog 
weinig bekend over het beste behandelschema en behandelduur, de precieze werking van 
eculizumab, en mogelijke overige risico’s en bijwerkingen. Bovendien is eculizumab een 
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van de duurste medicamenten ter wereld, met kosten oplopend tot 500.000 euro per jaar 
per patiënt. Kortom, er is ruimte voor het optimaliseren van de behandeling van aHUS.
In hoofdstuk 6 worden eculizumab spiegels in het bloed gerapporteerd. Deze spie-
gels zijn gemeten bij elf aHUS patiënten gedurende een standaard behandeling en tijdens 
het uitbreiden van het interval tussen de eculizumab toedieningen. Om een adequate 
onderdrukking van het complement systeem te waarborgen, wordt gestreefd naar een 
dalspiegel van 50-100 µg/ml. In deze studie lieten we zien dat de eculizumab spiegels vele 
malen hoger waren dan de streefwaardes (tot 772 µg/ml) bij patiënten die eculizumab 
elke twee weken ontvingen. Bovendien had een substantieel aantal van de patiënten die 
eculizumab ontvingen met een uitgebreid interval (tot vier weken) ook nog adequate 
dalspiegels. Hieruit kan worden geconcludeerd dat er minder eculizumab gegeven hoeft 
te worden om adequate spiegels te bereiken.
Om meer inzicht te krijgen in de optimale dosering en het effect van eculizumab, is 
er een uitgebreide literatuurstudie uitgevoerd welke staat beschreven in hoofdstuk 7. 
Hierin wordt alle literatuur besproken omtrent de eculizumab behandeling geïndiceerd 
voor verschillende aandoeningen waaronder aHUS en pleiten we voor therapeutische 
drug (medicatie) monitoring. Door zowel de spiegels als het effect van eculizumab te 
monitoren bij elke patiënt, kan de behandeling worden aangepast naar het individu. 
Naast het aanpassen van het interval tussen de eculizumab toedieningen kan de 
behandeling ook gestaakt worden. In hoofdstuk 8 worden twintig aHUS patiënten 
besproken waarbij de eculizumab behandeling bij zeventien patiënten werd gestaakt en 
bij drie patiënten aangepast werd door middel van een verlengd interval. Bij vijf patiënten 
(25%) resulteerde de aangepaste behandeling in een recidief aHUS, waarna de eculizumab 
behandeling is herstart zonder chronische schade. Naar schatting is er 11.4 miljoen euro 
bespaard dankzij deze aanpassingen.
Afgezien van onze studie, zoals beschreven in hoofdstuk 8, zijn er enkele andere studies 
gepubliceerd die het aanpassen en staken van eculizumab beschrijven. In hoofdstuk 9 
wordt alle literatuur betreffende het aanpassen en staken van eculizumab therapie bij 
aHUS patiënten besproken. Over het algemeen is het veilig en effectief om eculizumab 
behandeling te staken, mits er strikte monitoring voor een mogelijk recidief plaatsvindt. 
Ongeveer 27% van de patiënten beschreven in de literatuur ontwikkelde een recidief, 
meestal binnen het eerste jaar na staken. Er werd geen duidelijke chronische schade 
gevonden na het herstarten van eculizumab behandeling. In dit hoofdstuk worden ver-
schillende strategieën beschreven om de behandeling aan te passen dan wel te staken.
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Conclusie sectie II
De introductie van eculizumab heeft geleid tot een sterke verbetering van de prognose 
van patiënten met aHUS. In veel landen wordt eculizumab volgens een standaard schema 
voorgeschreven, in potentie levenslang. Echter is er weinig tot geen bewijs voor de nood-
zaak van deze levenslange duur. Door het toepassen van therapeutische drug monitoring 
kan de dosering van eculizumab worden geoptimaliseerd per patiënt. Daarnaast lijkt ˜ 70% 
van de patiënten ziektevrij voor minimaal 1 jaar na het staken van eculizumab behande-
ling. Kortom, er is ruimte voor verbetering (Figuur 2). In dit proefschrift wordt een uniek 
en aangepast behandelschema besproken voor patiënten met aHUS.
Om de zorg te optimaliseren, en om betaalbare en toegankelijke gezondheidszorg te 
waarborgen, is er in Nederland sinds januari 2016 een nieuwe richtlijn voor de behandeling 
van aHUS geïntroduceerd. Deze richtlijn is opgesteld door de landelijke werkgroep aHUS, 
bestaande uit een nefroloog en een kindernefroloog uit elk universitair medisch cen-
trum in Nederland. In hoofdstuk 10 beschrijven we het studieprotocol van de landelijke, 
observationele studie om de nieuwe richtlijn te monitoren en evalueren. Deze studie, ook 
wel CUREiHUS studie genoemd, includeert alle aHUS patiënten die behandeld worden 
volgens de nieuwe richtlijn. Patiënten worden gevraagd vragenlijsten in te vullen en er 
wordt bloed afgenomen om te kijken naar complement activatie, eculizumab spiegels 
en biomarkers voor het voorspellen van een recidief. Met behulp van twee vragenlijsten 
om de kwaliteit van leven en productiviteitsverliezen te meten zal aan het einde van 
studie een kosteneffectiviteitanalyse worden uitgevoerd. De CUREiHUS studie zal naar 
verwachting aflopen in oktober 2020. Aan de hand van de resultaten kan de behandeling 
van aHUS patiënten verder worden geoptimaliseerd.
Eculizumab is slechts één voorbeeld van de vele dure weesgeneesmiddelen die op de 
markt zijn gekomen. Door de scherpe toename in dure geneesmiddelen komt de toegan-
kelijkheid en betaalbaarheid van de Nederlandse zorg onder druk te staan. Daarnaast is 
door het zeldzame karakter van veel ziektebeelden de beschikbare informatie omtrent de 
grootte van het effect, de kosteneffectiviteit en de klinische relevantie vaak beperkt. In 
Nederland is er een weesgeneesmiddelen arrangement geïmplementeerd door het Zor-
ginstituut om zo de vergoeding van weesgeneesmiddelen te optimaliseren. Eculizumab 
was het eerste medicament welke volgens dit weesgeneesmiddelen arrangement werd 
geïmplementeerd. De CUREiHUS studie kan als voorbeeld dienen voor het opzetten en 
inrichten van dergelijke initiatieven om de (kosten)effectiviteit van weesgeneesmiddelen, 
onafhankelijk van de farmaceutische industrie, te evalueren.
Met het onderzoek gepresenteerd in dit proefschrift hoop ik een aanzet te geven 
tot het verder optimaliseren van de diagnostiek van STEC-HUS en de behandeling van 
patiënten met aHUS. Het is van groot belang om de zorg voor HUS patiënten te blijven 
evalueren en aan de hand hiervan passende en innovatieve maatregelen te bedenken én 
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te implementeren. Als artsen, patiënten, onderzoekers, politici, zorgverzekeraars en far-
maceutische bedrijven de handen ineen te slaan, kunnen we samen bouwen aan goede, 
betaalbare en toegankelijke gezondheidszorg.
Figuur 2. Gepersonaliseerde behandeling voor patiënten met aHUS
Duur en intensiteit eculizumab behandeling 
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Figuur 2. Volgens het standaard behandelschema zoals beschreven door de farmaceut, ontvangt elke aHUS pa- 
tiënt een vaste dosis eculizumab volgens een vast interval (zwarte balk). Echter de realiteit is weerbarstiger. Aan 
de hand van specifieke patiëntkarakteristieken (weergegeven door de verschillende kleuren) kan een gepersonali-
seerd behandelschema worden opgesteld. Zo kan het mogelijk zijn om de eculizumab therapie te staken, dan wel 
de behandeling af te bouwen op geleide van spiegels. Naar verwachting zal maar in een beperkte groep patiënten 
levenslange therapie noodzakelijk zijn.
“Be yourself, everyone else is already taken” 
Oscar Wilde
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werd geboren op 8 november 1990 te Utrecht waar zij samen met haar zusje Uzume 
Zoë opgroeide. In 2008 behaalde zij haar VWO diploma aan het Sint Bonifatius College 
in Utrecht waarna ze startte met de studie Geneeskunde aan de Radboud Universiteit 
Nijmegen. Naast haar studie heeft ze via het excellent student program van het Amalia 
kinderziekenhuis onderzoek gedaan naar kinderen met een respiratoir syncytieel virus 
infectie, onder begeleiding van Dr. I.M.L. Ahout en Dr. J.G. Ferwerda van 2010 t/m 2014 
op het laboratorium kinderinfectiologie. In 2014 werd ze aangenomen voor het dedica-
ted schakeljaar kindergeneeskunde bij de kindernefrologie in het Radboudumc Amalia 
kinderziekenhuis en bij de algemene kindergeneeskunde in het Canisius Wilhelmina 
Ziekenhuis te Nijmegen. Gedurende het schakeljaar heeft ze onder begeleiding van Dr. 
N.C.A.J. van de Kar onderzoek gedaan naar de diagnostiek van het hemolytisch uremisch 
syndroom, welke preliminaire resultaten ze mocht presenteren in december 2014 op het 
One Health symposium Focus on STEC-HUSEC te Groningen. 
Na het succesvol afronden van haar studie Geneeskunde in februari 2015 startte 
Kioa haar promotieonderzoek omtrent diagnostiek en behandeling van het hemoly-
tisch uremisch syndroom op de afdeling kindernefrologie in het Radboudumc Amalia 
kinderziekenhuis onder dagelijkse begeleiding van Dr. N.C.A.J. van de Kar, mede onder 
begeleiding van Prof.dr. L.P. van den Heuvel, Prof.dr. J.F.M. Wetzels en Dr. E.B. Volokhina. 
Dit onderzoek heeft geresulteerd in meerdere artikelen, verscheidende presentaties op 
(inter)nationale congressen en dit proefschrift. Gedurende haar promotieonderzoek heeft 
Kioa deelgenomen aan verschillende cursussen waaronder de Da Vinci Challenge en heeft 
zij meerdere studenten begeleid (zie ook PhD portfolio). Met hulp van het Sengers-Sti-
pendium van Stichting Kindergeneeskunde heeft ze voor enkele maanden een student 
assistent kunnen aannemen om het onderzoek naar de rol van heem in kinderen met het 
hemolytisch uremisch syndroom voort te zetten.
Per 1 Januari 2019 is Kioa in opleiding tot kinderarts in het Canisius Wilhelmina Zie-
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TRAINING ACTIVITIES (Continued) Year(s) ECTS
c) (Inter)national Symposia & Congresses (Continued)
- Patient organization Nephrology (NVN), patient day, Lunteren & 
Bunnik, the Netherlands^^
- Amalia Science Day, Nijmegen, the Netherlands *#
- Dutch Federation of Nephrology (NfN) Fall symposium, Bunnik, 
the Netherlands #
- American Society of Nephrology, Chicago, USA #
- Bessensap, NOW, Amsterdam, the Netherlands *
- International symposium on VTEC, Florence, Italy*
2016, 2017
2016, 2018
2017
2017
2017
2018
1 
1
0.5
1.25
0.5
1.25
d) Other
- Committee member of excellent student programme, among 
others chair of symposium yearly
- PLAN (Platform for PhD students and postdocs within 
nephrology) board member and chair (2017-2018)
- Organizing PLAN symposium in Nijmegen
- Travel grant, Stichting Kindergeneeskunde
- Kidney STAR Award, American Society of Nephrology
- Price for best poster presentation, NfN, Fall symposium
- March of Dimes Award, IPNA
- Sengers Stipendium, Stichting kindergeneeskunde, to set up 
project entitled “New kid on the block: free heme and its role in 
HUS”
- Reviewing various scientific publications
- Best presentation of 2017-2018 Amalia Childrens Hospital 
Research Round
- Price best abstract at conference of European Society for 
Pediatric Nephrology 2018
2015-2018
2015-2018
2016
2015, 2018
2016
2016
2016
2017
2016-2018
2018
2018
2
2
2
0.5
TEACHING ACTIVITIES Year(s) ECTS
e) Lecturing
- Transferable skills (weekly 1 hour education for students)
- Education for interns; Hematuria & Proteinuria, Monthly
- Education MM2TR
- Capita Selecta
2017-2018
2015-2018
2016-2017
2018
1
1
0.5
0.5
f) Supervision of internships/other
- Supervision of 6 students: medical biology first and second 
master internship, twice supervision of scientific research 
internship medical students for 3 months, supervision internship 
of student of Saxion, supervision of 2 excellent students for 10 
hours per week
2015-2018 9
TOTAL 58.55
Invited, oral and poster presentations are indicated with a ^, * and # respectively after the name of the 
activity, respectively.


List of publications   |   317
PU
BLICATIO
N
S
List of publications
Wijnsma KL, Duineveld C, van de Wetering J, Dorresteijn E, van der Heijden JW, van Wijk 
JAE, Gracchi V, Berger SP, de Vries APJ, Bouts AHM, Bemelman FJ, Keijzer-Veen MG, van 
Zuilen AD, Horuz FAPT, van Paassen P, Kimman ML, Adang E, Brüggemann RJ, Storm M, 
Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ. National observational 
study to monitor the new Dutch guideline concerning treatment of patients with atypical 
hemolytic uremic syndrome. Unpublished
Wijnsma KL, Veissi ST, de Wijs S, van der Velden TJAM, Volokhina EB, Wagener FADTG, 
van de Kar NCAJ, van den Heuvel LP. Heme as contributing factor in the evolvement of 
Shiga toxin E.coli induced hemolytic uremic syndrome. Submitted
Wijnsma KL, ter Heine R, Moes DJ, Langemeijer S, Schols SEM, Volokhina EB, van den 
Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, pharmaco-
kinetics and pharmacodynamics of eculizumab and possibilities for an individualized 
approach to eculizumab. Submitted
Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemo-
lytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2018; doi:10.1007/
s00467-018-4091-3
Kimman ML, Wijsenbeek M, van Kuijk SMJ, Wijnsma KL, van de KAR NCAJ, Storm M, 
van Jaarsveld F, Dirksen CD. Validity of the Patient Experiences and Satisfaction with 
Medications (PESaM-) questionnaire. Patient 2018; doi: 10.1007/s40271-018-0340-6
Wijnsma KL, Vessi ST, van Bommel SAM, Heuver R, Volokhina EB, Comerci DJ, Ugalde JE, 
van de Kar NCAJ, van den Heuvel LP. Glyco-iELISA: a highly sensitive and unambiguous 
serological method to diagnose STEC-HUS caused by serotype O157. Pediatric Nephrol 2018; 
doi:10.1007/s00467-018-4118-9
Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels 
JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical hemolytic 
uremic syndrome. Nephrol Dial Transplant 2017; doi:10.1093/ndt/gfx196
Wijnsma KL, Schijvens AM, van de Vegt J, Rossen JWA, Kooistra-Smid A, Schreuder MF, 
van de Kar NCAJ. Unusual presentation of a severe case of STEC serotype O80:H2 induced 
hemolytic uremic syndrome. Pediatr Nephrol 2017; 32(7):1263-1268
318   |   Appendices
Volokhina EB, Wijnsma KL, van der Molen R, Roeleveld N, van der Velden T, Goertz J, 
Sweep F, Brüggemann RJ, Wetzels JFM, van de Kar NCAJ, van den Heuvel LP. Eculizumab 
dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol 
Ther 2017; 102(4):671-678
Rotteveel AH, Wijsenbeek M, Mostard R, Tak N, van Jaarsveld F, Storm M, Wijnsma KL, 
Gelens M, van de Kar NCAJ, Wetzels JFM, Dirksen CD. Development and pre-testing of 
a questionnaire to assess patient experiences and satisfaction with medications. Patient 
2017; 10(5):629-642
Wijnsma KL, van Bommel SA, van der Velden T, Volokhina EB, Schreuder MF, van den 
Heuvel LP, van de Kar NCAJ. Fecal diagnostics in combination with serology: best test to 
establish STEC–HUS. Pediatr Nephrol 2016; 31(11):2163-2170
Binkhorst M, Wijnsma KL, Steenbergen EJ, van de Kar NCAJ, Schreuder MF. A young girl 
with an unusual cause of acute kidney injury: Answers. Pediatr Nephrol 2016; 31(11):2075-2078
Binkhorst M, Wijnsma KL, Steenbergen EJ, van de Kar NCAJ, Schreuder MF. A young 
girl with an unusual cause of acute kidney injury: Questions. Pediatr Nephrol 2016; 
31(11):2071–2073 

“Veni, Vidi, Amavi”
Appendices
Dankwoord

Dankwoord   |   323
D
A
N
KW
O
O
RD
Dankwoord
In de afgelopen jaren heb ik me ondergedompeld in de onderzoekswereld. Met vallen 
en opstaan en vooral veel plezier heb ik een hoop geleerd en presenteer ik met trots dit 
proefschrift. Naast de inhoudelijke verdieping was mijn persoonlijke ontwikkeling ook 
een belangrijk thema in de afgelopen jaren. Graag wil ik iedereen bedanken die betrokken 
is geweest bij het tot stand komen van dit proefschrift en bijgedragen heeft aan mijn 
groei als onderzoeker én persoon.
Lieve Nicole, beste baas, wat een fantastische jaren heb ik achter de rug. In het begin 
heb je mij een tikje moeten aansporen om aan dit promotietraject te beginnen. Het lijkt 
nu onvoorstelbaar dat ik ooit heb getwijfeld. In de afgelopen jaren is mijn bewondering 
en respect voor jou als onderzoeker en persoon alleen maar toegenomen. Ik heb je leren 
kennen als een nieuwsgierige, intelligente, warme en bescheiden vrouw die tot grootse 
zaken in staat is. Je hebt mij onder je vleugels genomen en ik ben dankbaar dat ik van jou 
heb mogen leren. In de loop der jaren hebben we samen heel wat meegemaakt. Zo kwam 
je mij elke dag thuis ophalen met de auto na mijn skiongeluk, zodat ik toch naar het werk 
kon komen. Het feit dat je dit als gangbaar beschouwt, onderstreept jouw persoonlijkheid. 
Dankjewel voor je zorgzaamheid. Daarnaast zijn we meerdere malen samen op congres 
geweest. Naast de inhoud van deze congressen zijn de “buitenschoolse” activiteiten mij 
goed bijgebleven. Juist tijdens deze congressen kreeg ik een kijkje achter de schermen bij 
jou. Hoe graag ik ook zou uitweiden over onze ervaringen, de stelregel blijft staan “ What 
happens in Innsbruck /Chicago /Glasgow /San Diego stays in Innsbruck /Chicago /Glas-
gow /San Diego”. Maar als klein aandenken zodat we het allebei niet vergeten: een muis 
als kamergenoot, bier gooien op het vliegveld en obers die cappuccino komen brengen. 
Heel graag wil ik betrokken blijven bij het onderzoek en van jou blijven leren. Wat mij 
betreft nemen we geen afscheid, maar luiden we samen een nieuw hoofdstuk in. Zoals 
Pippi eens wijs zei: “Ik heb het nog nooit gedaan, dus ik denk dat ik het wel kan”.
Beste Bert, je gaf mij de kans om mezelf te blijven ontwikkelen. Naast de CUREiHUS 
studie hebben we ook nauw samengewerkt voor het opzetten van de glyco-iELISA en 
het onderzoek naar heem. Ondanks je drukke agenda heb ik altijd het gevoel gehad dat 
de deur open stond. Door ons samen te buigen over de struikelblokken zorgde je dat ik 
genoeg handvaten had om weer door te kunnen. Dank voor de goede zorgen.
Beste Jack, het was een aanwinst voor het team toen jij als mijn tweede promotor werd 
aangesteld. De afgelopen jaren heb ik veel geleerd van jouw scherpe analytisch vermogen 
en innovatieve ideeën. Jouw verbluffend snelle reacties op mails en manuscripten, correc-
ties immer handgeschreven, zorgden voor een positieve stimulans. Ik hoop dat ik in de 
toekomst nog mag blijven leren van jouw visie op de behandeling van aHUS.
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Beste Elena, onze vruchtbare samenwerking heeft geresulteerd in een aantal translati-
onele studies. Hopelijk kunnen we in de toekomst samen verder bouwen aan deze brug 
tussen laboratorium en kliniek.
Lieve Michiel, ik reken me rijk met naast mijn officiële supervisoren ook nog een mentor 
die vanaf de zijlijn mee coacht. Persoonlijke ontwikkeling is een van de thema’s die we 
vaak hebben besproken, zeker nu jij mijn mentor bent voor de Da Vinci Challenge. Geno-
ten heb ik van onze gesprekken de afgelopen jaren, de chocolade in Brussel, de gekkigheid 
op vrijdagmiddag en de Whisky(‘s) in Glasgow. Dankjewel dat je altijd tijd vrij maakte 
voor mij (ook al ben ik niet een van de tien). Op naar de volgende memorabele jaren!
Lieve Marlies, Linda, Charlotte, Jacqueline en Femke, mijn jaren binnen het nefro 
team, als schakelco en promovenda, heb ik ervaren als een warm bad. Hopelijk eindigt 
onze samenwerking niet hier, maar mag ik nog wat langer genieten van jullie team! 
Marlies, het vertrouwen wat je mij schonk heb ik als zeer fijn ervaren. Linda, wat was 
ik trots als jij mij bestempelde als “complement expert” en om advies vroeg. Charlotte, 
je eerlijke en recht door zee houding waardeer ik erg. Ik hoop dat we tijd blijven vinden 
om af en toe bij te kletsen. Jacqueline, ik heb genoten van je hartelijkheid. Ties, en ik 
stiekem toch ook, zijn erg blij met jouw kattenconnecties, die ons Noet en Tibbie hebben 
opgeleverd!
Een van de sterke punten van dit onderzoeksteam is het translationele karakter, wat niet 
zou kunnen zonder jullie: Andrei, Thea, Joop, Annelies, Sanne, Monique en Marloes. 
Dank dat jullie altijd klaar stonden voor mij, en bovenal mijn studenten, voor advies, tips 
en tricks. Andrei, het was een feestje toen jij het CUREiHUS team kwam versterken! Met 
jouw secure houding, van aanpakken weten en hart voor de zaak ben je een aanwinst voor 
ons team en heb ik ervan genoten met jou samen te werken. 
Caroline, al snel kwam jij ons team versterken. Ik vond het fijn met jou te kunnen sparren 
over studiezaken en ingewikkelde patiënten. Door jouw opleiding tot internist-nefroloog 
bracht je veel achtergrond kennis mee, waar ik dankbaar gebruik van kon maken. Met alle 
vertrouwen leg ik de studie nu in de handen van jou en Romy en ga ik ervan uit dat we 
elkaar nog zeker zullen tegenkomen in het veld.
Graag wil ik de ZonMw projectgroep bedanken voor het mogelijk maken van de CUREi-
HUS studie. Beste Roger en Rob, wat heb ik veel geleerd van jullie! Door jullie (geduldige) 
uitleg omtrent farmacokinetiek en farmacodynamiek hebben we samen een mooi review 
geschreven. Roger, jouw visie op de behandeling met eculizumab heeft een stempel 
gedrukt op de CUREiHUS studie en was van onmisbare waarde. Rob, met jouw enthou-
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siasme en innovatieve blik ben je een aanwinst voor het team. Ik ben heel benieuwd naar 
de nieuwe farmacologische ontwikkelingen voor eculizumab en ongetwijfeld zal jij daar 
een sleutelrol in vervullen.
Beste Eddy, in de afgelopen jaren ben ik toenemend geïnteresseerd geraakt in Health 
Technology Assessment, en de kosteneffectiviteitanalyse zoals ook gepland staat voor de 
CUREiHUS studie. Ik kijk ernaar uit om me meer te kunnen verdiepen hierin en nauw 
betrokken te zijn bij de analyses aan het einde van de studie. Dank voor je inzet en betrok-
kenheid bij de CUREiHUS studie.
Beste Marjolein Storm en Wim Altena, jullie input vanuit de patiëntenvereniging 
heeft veel betekend voor het onderzoek naar aHUS en het huidige behandelschema. Door 
onze krachten te bundelen vormen we een sterk team. Francine Kruitwagen, ook jij hebt je 
met hart en ziel ingezet voor het onderzoek rondom aHUS. Dank voor je zeer waardevolle 
input bij het jaarlijkse onderwijs. Ik hoop in de toekomst met jullie samen te blijven werken 
om de diagnostiek en behandeling van patiënten met aHUS te optimaliseren. Daarnaast 
wil ik graag alle patiënten die deelnemen aan de studie bedanken voor hun kostbare inzet. 
Jullie maken het mogelijk om wetenschappelijk onderzoek te doen en samen verder te 
bouwen aan het optimaliseren van de diagnostiek en behandeling voor patiënten met HUS.
De kracht van de CUREiHUS studie zit hem in de nationale samenwerking binnen de 
landelijke werkgroep aHUS. Dank jullie wel Eiske, Jacqueline, Antonia, Frederike, 
Mandy, Arjan, Aiko, Ans, Joost, Valentina, Stefan, Flore en Pieter dat ik een kijkje 
in de keuken mocht nemen tijdens de vergaderingen. Door jullie krachten te bundelen 
hebben jullie samen een unieke richtlijn opgesteld die veel invloed heeft gehad op de 
vergoeding van eculizumab. Ik wil jullie graag bedanken voor jullie inzet, flexibiliteit en 
geduld, waardoor we samen de CUREiHUS studie hebben kunnen opstarten. Gelukkig 
werd ieder van jullie ook gesteund door een groep databasemanagers/research verpleeg-
kundigen. Superfijn om zo de studie achter te kunnen laten in de betrouwbare handen 
van Katinka, Caro, Marja, Helma, Marieke, Anneke en Dorien. 
De studie had niet kunnen bestaan zonder de inzet van het RCT-CS Team Vrouw en 
Kind: Jos, Yvet, Nienke, Karin en Regine. Beste Jos, vanaf het begin ben je betrokken 
geweest bij het opzetten en uitrollen van de studie. De organisatie van zo’n landelijke 
studie heeft behoorlijk wat voeten in de aarde, waarbij jouw hulp en inzicht welkom was. 
Yvet en Nienke, jullie waren mijn steun en toeverlaat voor de CUREiHUS database. In 
de afgelopen jaren hebben jullie steeds meer taken gekregen binnen de studie en hebben 
we samen een succesvol draaiend systeem opgezet. Dank jullie wel dat ik altijd op jullie 
kon rekenen (zelfs voor de data extracties in de late uurtjes als ik weer eens met spoed 
data moest hebben). Samen hebben we de CUREiHUS studie opgebouwd (letterlijk) en 
reken ik op jullie om samen met Romy de studie voort te zetten!
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Dear prof. dr. Juan Ugalde and dr. Diego Comerci, I want to thank you both for your 
hospitality to welcome Susan in your lab for several weeks and our fruitful collabora-
tion. By combining our knowledge, patient material and the glycoproteins you so kindly 
supplied, we improved diagnostics in patients with HUS. Hopefully we will meet again 
the future.
Beste prof. dr. Frans Russel en dr. Frank Wagener, graag wil ik jullie hartelijk bedank 
voor jullie inzet binnen het heem project. Dankzij jullie medewerking en inzet hebben 
we dit project kunnen opzetten. Beste Frank, je was op een zeer prettige manier actief 
betrokken bij het project. We hebben dankbaar gebruik gemaakt van jouw kennis om zo 
samen onze krachten te bundelen. 
 
In de afgelopen jaren heb ik een aantal studenten mogen begeleiden. Sheila, Susan, 
Rik, Sem en Roos, dank voor jullie inzet en hulp bij het tot stand komen van dit boekje. 
Sheila, letterlijk vanaf dag 1 ben jij betrokken geweest bij de opzet van hoofdstuk 2 van 
dit proefschrift: serologische diagnostiek bij STEC-HUS. Ik heb je leren kennen als een 
betrouwbare, hardwerkende dokter en heb bewondering voor je doorzettingsvermogen 
om al die jaren naast je studie betrokken te blijven bij dit project. Op jou kon ik bouwen. 
Hopelijk treffen we elkaar in de toekomst als collega’s. 
Susan, it is only appropriate that I write this in English. Although it seems that 
in the past couple of years your Dutch has become flawless, old habbits die hard. I 
want to thank you for all your hard work, insights, discussions in the cave and com-
pany. You did a great job and already have a successful career with two papers and a 
PhD position at out Pediatric Nephrology research group. Chapter 3 and 5 would not 
exist if it was not for you, we are a golden couple! It is with a smile that I think back 
at our years of collaborations with me as the big boss ofcourse. Hopefully you have 
forgiven me by now for all my“ mierenneukerij”. What do you think: shall we set up 
a new project together?
Gerben, na mijn avontuur als ESP student op jullie afdeling hebben we ons contact warm 
gehouden door jouw rol als mentor gedurende mijn promotietraject. Ondanks dat het niet 
nodig was om elkaar meer dan 1x per jaar te zien, staan een aantal van je rake opmerkingen 
mij nog scherp voor de geest. Zo heb ik je advies opgevolgd: niet wachten met dat doen 
waar je gelukkig van wordt, in het begin overal ja op zeggen en me (soms) niet tegen alles 
aan bemoeien. Ik hoop dat we elkaar in de toekomst nog eens tegenkomen.
Wouter, helaas zien we elkaar (te) weinig als mede PhDs op hetzelfde onderwerp. Maar 
zo af en toe krijg ik de kans even mee te genieten van jouw humor. Ons verblijf in Florence 
tijdens de VTEC staat nog in mijn geheugen gegrift (samen met de baas in een airbnb, de 
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door jouw verzorgde ontbijtjes, en natuurlijk pinokkio). Hopelijk blijven we elkaar tegen 
komen in het veld (VTEC in Toronto?) enne als die smurf eindelijk onder je voet vandaan 
komt hoor ik het graag.
Lieve Daan, ondanks onze valse start (iets met rotti en Amsterdamse attitude) was het 
al snel duidelijk dat wij naast een dosis flauwe humor meer interesses delen. Door de Da 
Vinci Challenge is onze vriendschap in een stroomversnelling gekomen. Ik heb je leren 
kennen als een oprechte, betrokken en lieve man met oog voor de ander. De week in 
Malaga zal me zeker bij blijven, mede door ons contact, heel veel jambonnetjes, biertjes 
drinken, samen koken en goede gesprekken. Heel fijn om iemand te leren kennen die 
voorbij het eerste rookgordijn kan kijken. Op naar het volgende biertje!
Roel en Anouk, het zou onvoorstelbaar zijn om jullie niet in dezelfde zin als Daan 
te noemen. Ik heb vaak mee mogen genieten van jullie interactie met zijn drieën. Samen 
zetten jullie een heerlijke sfeer neer waar bovenal heel veel gelachen wordt. Ik houd 
me aanbevolen voor alle (gênante) foto’s, verhalen en anderszins gekkigheid die jullie 
meemaken.
Manon, we startten bijna tegelijk aan onze promotie, en zaten toevallig bij elkaar in de 
kantoortuin. Wat was het een opluchting dat ik jou heb leren kennen! Samen sparren 
over we zaken moesten aanpakken, samen lunchen en een rondje wandelen als we het 
even gehad hadden. Ik ben blij dat onze bureaus aan elkaar grensde.
Sanne, je attente cadeautjes en gezellige babbel zijn de eerste dingen waar ik aan denk 
bij jou. Onze levens volgen elkaar goed op: safari in Tanzania, promoveren en trouwen! 
Heel veel plezier met al deze mijlpalen.
Per toeval werd ik bestuurslid van PLAN, maar mijn promotietijd zou zeker niet hetzelfde 
geweest zijn zonder jullie: Hessel, Niki, Eliane, Maarten, Sjoerd, Laura, Tineke en 
Dominique. Het was super om jullie op elk congres weer te zien en de befaamde borrels zijn 
natuurlijk onvergetelijk. Dominique, ik durf niet te zeggen wanneer wij hebben besloten 
dat het een goed idee was om naast PLAN ook eens samen af te spreken, maar een goed 
idee was het zeker! Openhartige gesprekken (en een heleboel speciaal biertjes natuurlijk) 
kenmerkt ons contact. Hopelijk weten we deze memorabele avonden te behouden.
Lieve Anne Dittrich, als een rode draad loop jij door mijn kindergeneeskunde carrière 
heen! Van begeleider als kernco, tot mentor als schakelco, tot vriendin als promovenda. 
Je hebt altijd je vertrouwen in mij uitgesproken en jouw warme persoonlijkheid maakt 
dat ik me snel op mijn gemak voel bij jou. Hopelijk stop je nooit met mensen knuffelen 
en in je hart sluiten.
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Lieve schoon opa en oma, Eva en Hendrik, weinig mensen hebben zo meegeleefd met 
mijn onderzoek als jullie. Met enige regelmaat kreeg ik krantenknipsels toegestuurd met 
betrekking tot het onderzoek naar weesgeneesmiddelen en kosten in de zorg. Nooit zijn 
jullie vergeten te informeren naar de voortgang en resultaten. Daarnaast mocht ik altijd 
gebruik maken van de Uiterton om in alle rust te kunnen schrijven aan mijn proefschrift. 
De rust en reinheid in Friesland gaven mij de kans om me een week af te zonderen van 
alle hectiek en me heerlijk te kunnen verdiepen in de manuscripten. Dank jullie wel voor 
jullie betrokkenheid, gastvrijheid en goede zorgen. 
Lieve Hiske, menig gesprek hebben we gevoerd over mijn carrière en welk pad ik zou 
kiezen. Ik waardeer je eerlijke houding daarin waarbij je er altijd vanuit ging dat niks 
“zomaar” genoeg zou zijn voor mij. Samen ontsnappen van het werk en even ontspannen 
deden we met enige regelmaat tijdens de skivakanties, Vietnam en Londen. Ik kijk uit 
naar jouw verdediging!
Lieve Joris, vaak hebben we gesproken over mijn promotie. Als copromotor van velen 
kon je mij ook een beetje coachen vanaf de zijlijn. Ondanks dat het leven niet altijd loopt 
zoals je hoopt, wens ik je toe dat je een (lang en) gelukkig leven kan opbouwen in Nij-
megen. Wij waarderen jouw nabije aanwezigheid erg en hopen er nog lang van te mogen 
genieten. Op naar de toekomst.
Laura, heerlijk om na het werk bij jou aan te kunnen schuiven voor een culinair hoog-
standje. Je sleept me altijd mee voor een goed feestje, huizen bekijken (zeer geslaagd 
gezien onze beide koophuizen!) en nieuwe eettentjes proberen. Of het nou om een 
avondje bier drinken, culinair uit eten, of op de bank hangen met een kop thee gaat, je 
bent overal voor in. Fijn dat je er altijd gewoon was.
Pippa, met jouw quote #promoverenkanjeleren brak een nieuw tijdperk aan binnen mijn 
promotietraject. Al snel was ik verhuisd naar ons huidige kantoor waar we samen hebben 
geprobeerd de banden met mede kindergeneeskunde PhDs aan te halen. Dat deze avon-
den vaak eindigden met ons drieën was geen toeval. Ik heb veel steun ervaren in het 
samen lachen (en huilen) en natuurlijk kwijlen op de muismat. Ik reken erop dat we in 
de toekomst weer collega’s worden.
Jelle, alles wat wij nodig hadden was een Woezel en Pip kamer in Groningen. Toen je 
ook nog eens van koken bleek te houden kon het ook niet anders dan dat ons contact 
uitgroeide tot een goede vriendschap. Je hebt mee geholpen met het organiseren van 
de PLAN dag in Nijmegen, maar bovenal hebben we elkaar leren kennen tijdens onze 
gesprekken in de Aesculaaf. De diners bij een van ons met Kirsten en Ties erbij zijn een 
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groot succes en aanleiding tot extra inspiratie voor nieuwe gerechten. Ik hoop nog lang 
mee te mogen genieten van je open en hartelijke houding.
Lieve Emmy, samen zijn we aan het avontuur “Nijmegen” begonnen. De wetenschap dat 
jij om de hoek woonde en ik altijd bij jou terecht kon, heeft mij heel veel steun geboden de 
afgelopen jaren. Onvoorwaardelijke steun, slappe lach, the special two, durven vragen wat 
ik nodig heb en vooral heel veel etentjes, is waar ik bij jou aan denk. Het is even wennen 
dat jij nu niet meer binnen fietsafstand woont, maar nu hebben we weer een excuus om 
onze logeerpartijen een nieuw leven in te blazen! Met jou aan mijn zijde als getuige en 
paranimf kan ik alles aan.
Lieve Pieter, in de afgelopen vijf jaar heb ik een hoop geleerd: bijvoorbeeld wat een 
paranimf is en dat je altijd direct naar het dankwoord moet bladeren in elke thesis. Als 
ik terugblik op de afgelopen vijf jaar zie ik jou als constante factor. Zowel privé als werk 
wisten we goed te combineren tijdens onze schrijfweken waar we overdag hard werkten 
en ’s avonds tijd hadden om onze immer uitgebreide agenda aan gesprekspunten af te 
werken. Het ontleden van een onderwerp hebben we verheven tot wetenschap, waarbij 
we met een kritische blik en gezonde dosis introspectie een dilemma deduceren. Het 
vooruitblikken naar de komende vijf jaar bewaar ik voor onze geplande sessie “vijf jaar 
later” in November 2019, maar één ding is zeker: jij bent en blijft mijn beste vriend, hoeveel 
jaren er ook zullen volgen. 
Lieve Anne, de dag dat ik jou ontmoette (8 september 2015, for the record) veranderde 
mijn promotietraject voorgoed. Gedurende de maanden dat jij je wetenschappelijke stage 
deed bij mij bloeide onze vriendschap op en het was feest toen bleek dat jij ook als pro-
movendus werd aangenomen bij de kindernefrologie! We hebben teveel onvergetelijke 
momenten meegemaakt om hier allemaal op te sommen, maar graag wil ik er een paar 
uitlichten: ons kamernummer versturen op de NND, zoek-de-verschillen foto’s versturen 
naar de bazen, DE foto tijdens New Frontiers symposium, je beruchte uitspraak “nu is 
het klaar hoor baas”, schrijfweken in Friesland, de ESPN in Glasgow waar we samen een 
Airbnb deelden en hebben rondgetrokken door het schitterende Schotland, en onze jaar-
lijkse etentjes bij Vesters. Je bent mijn steun en toeverlaat en ik kan altijd op je rekenen. 
Naast dat we natuurlijk vriendinnen blijven, ben ik niet bereid afscheid te nemen van 
jou als collega. Wat mij betreft is dit dus geen afscheid, maar juist het begin van onze 
carrière als (toekomstige) collega’s!
Lieve Uzume, ondanks dat ik weinig (lees:niks) snap van jouw promotieonderzoek (ik 
zat er schijnbaar grofweg 2000 jaar naast als ik iedereen trots probeerde te vertellen wat 
jij onderzoekt) vind ik het onwijs leuk en stoer dat wij beide een promotietraject doen! 
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Zoals weerspiegeld in onze promotieonderwerpen verschillen wij behoorlijk in karakter, 
maar juist de overeenkomsten brengen ons dichter bij elkaar. Zo hebben we dezelfde 
humor, bezitten we nul algemene kennis, houden we allebei van de winterse dagen met 
sinterklaas, kaarsjes en kerstmuziek, weten we goed wat we willen (a.k.a. eigenwijs en 
koppig) en zijn we gepassioneerd in datgene wat we doen. Ik geniet erg van onze zussen 
quality time, en wil die graag uitbouwen in de toekomst. En niet vergeten: als grote zus 
ben ik onwijs trots op je zumie.
Lieve Papa, zo vader zo dochter, dat blijkt maar weer. Vanaf jongs af aan was het al 
twee handen op een buik, maar de afgelopen jaren bleek dat we ook op werkgebied veel 
gemeen hebben. Ons debuut als de Wijnsma’s hebben we gemaakt op de NND in 2016 
waar we samen een workshop over kosten in de zorg hebben verzorgd. Daarnaast was 
het een nek aan nek race wie als eerst zou promoveren. Ik ben trots op je dat jij jouw 
jongensdroom hebt weten te verwezenlijken en vind het erg bijzonder dat Uzume en ik 
jouw paranimfen mogen zijn. Zoals Winston Churchill al eens zei “Now this is not the end. 
It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”. Ik kijk uit naar 
je volgende boek.
Lieve Mama, als een trotse leeuwin waak jij over je dochters. Als eerste wist jij perfect 
aan iedereen uit te leggen waar mijn promotie over ging en heb je als kers op de taart ook 
nog de naam CUREiHUS verzonnen! Ondanks dat ik nu bijna doctor ben, zal ik altijd jouw 
meisje blijven die een knuffel krijgt ook al doe ik nog zo alsof ik hem niet nodig heb. Het 
meisje dat verwend wordt met een attent cadeautje als het even tegen zit en waar jij aan 
haar stem alleen al hoort dat het niet goed zit en degene voor wie je altijd in de bres zult 
springen, ongeacht wie er tegenover je zal staan. Ik hoop dat ik ooit net zo krachtig zal zijn. 
Allerliefste Ties, wie zou ik zijn zonder jou? Je steunt me, je maakt me aan het lachen, 
je luistert naar me, en je spreekt me streng toe als ik doordraaf. Ruim 9 jaar later ben ik 
nog steeds smoorverliefd op je. Vol verlangen kijk ik uit naar ons volgende avontuur in 
Italië: met niemand liever wil ik de rest van mijn leven delen. “In your arms, where all my 
journeys end”
